0001493152-22-022006.txt : 20220811 0001493152-22-022006.hdr.sgml : 20220811 20220811130123 ACCESSION NUMBER: 0001493152-22-022006 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 93 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220811 DATE AS OF CHANGE: 20220811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Agape ATP Corp CENTRAL INDEX KEY: 0001713210 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] IRS NUMBER: 364838886 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-220144 FILM NUMBER: 221154764 BUSINESS ADDRESS: STREET 1: 1705-1708 LEVEL 17, TOWER 2, FABER TOWER STREET 2: JALAN DESA BAHAGIA, TAMAN DESA CITY: KUALA LUMPUR STATE: N8 ZIP: 58100 BUSINESS PHONE: (603) 27325716 MAIL ADDRESS: STREET 1: 1705-1708 LEVEL 17, TOWER 2, FABER TOWER STREET 2: JALAN DESA BAHAGIA, TAMAN DESA CITY: KUALA LUMPUR STATE: N8 ZIP: 58100 10-Q 1 form10-q.htm
0001713210 false --12-31 Q2 36,636 Purchases of beauty products 0001713210 2022-01-01 2022-06-30 0001713210 2022-08-09 0001713210 2022-06-30 0001713210 2021-12-31 0001713210 2022-04-01 2022-06-30 0001713210 2021-04-01 2021-06-30 0001713210 2021-01-01 2021-06-30 0001713210 us-gaap:CommonStockMember 2020-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001713210 us-gaap:RetainedEarningsMember 2020-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001713210 us-gaap:NoncontrollingInterestMember 2020-12-31 0001713210 2020-12-31 0001713210 us-gaap:CommonStockMember 2021-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001713210 us-gaap:RetainedEarningsMember 2021-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001713210 us-gaap:NoncontrollingInterestMember 2021-03-31 0001713210 2021-03-31 0001713210 us-gaap:CommonStockMember 2021-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001713210 us-gaap:RetainedEarningsMember 2021-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001713210 us-gaap:NoncontrollingInterestMember 2021-12-31 0001713210 us-gaap:CommonStockMember 2022-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001713210 us-gaap:RetainedEarningsMember 2022-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001713210 us-gaap:NoncontrollingInterestMember 2022-03-31 0001713210 2022-03-31 0001713210 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001713210 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001713210 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001713210 2021-01-01 2021-03-31 0001713210 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001713210 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001713210 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001713210 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001713210 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001713210 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001713210 2022-01-01 2022-03-31 0001713210 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001713210 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001713210 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001713210 us-gaap:CommonStockMember 2021-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001713210 us-gaap:RetainedEarningsMember 2021-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001713210 us-gaap:NoncontrollingInterestMember 2021-06-30 0001713210 2021-06-30 0001713210 us-gaap:CommonStockMember 2022-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001713210 us-gaap:RetainedEarningsMember 2022-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001713210 us-gaap:NoncontrollingInterestMember 2022-06-30 0001713210 AATP:AgapeATPInternationalHoldingLimitedMember 2022-06-30 0001713210 AATP:ShareExchangeAgreementMember AATP:MrHowKokChoongMember 2020-05-07 2020-05-08 0001713210 AATP:SubsidiaryCompanyTwoMember 2020-05-08 0001713210 AATP:SubsidiaryCompanyFiveMember 2021-11-11 0001713210 AATP:SubsidiaryCompanyMember 2022-01-01 2022-06-30 0001713210 AATP:SubsidiaryCompanyMember 2022-06-30 0001713210 AATP:SubsidiaryCompanyOneMember 2022-01-01 2022-06-30 0001713210 AATP:SubsidiaryCompanyOneMember 2022-06-30 0001713210 AATP:SubsidiaryCompanyTwoMember 2022-01-01 2022-06-30 0001713210 AATP:SubsidiaryCompanyTwoMember 2022-06-30 0001713210 AATP:SubsidiaryCompanyThreeMember 2022-01-01 2022-06-30 0001713210 AATP:SubsidiaryCompanyFourMember 2022-01-01 2022-06-30 0001713210 AATP:SubsidiaryCompanyFourMember 2022-06-30 0001713210 AATP:SubsidiaryCompanyFiveMember 2022-01-01 2022-06-30 0001713210 AATP:SubsidiaryCompanyFiveMember 2022-06-30 0001713210 2021-01-01 2021-12-31 0001713210 AATP:HealthAndWellnessServicesMember 2022-01-01 2022-06-30 0001713210 AATP:HealthAndWellnessServicesMember 2022-04-01 2022-06-30 0001713210 AATP:HealthAndWellnessServicesMember 2021-04-01 2021-06-30 0001713210 AATP:HealthAndWellnessServicesMember 2021-01-01 2021-06-30 0001713210 us-gaap:ShippingAndHandlingMember 2022-04-01 2022-06-30 0001713210 us-gaap:ShippingAndHandlingMember 2021-04-01 2021-06-30 0001713210 us-gaap:ShippingAndHandlingMember 2022-01-01 2022-06-30 0001713210 us-gaap:ShippingAndHandlingMember 2021-01-01 2021-06-30 0001713210 AATP:SocialSecurityOrganizationMember 2022-01-01 2022-06-30 0001713210 AATP:SocialSecurityOrganizationMember AATP:MYRCurrencyMember 2022-01-01 2022-06-30 0001713210 AATP:EmployeesProvidentFundMember 2022-01-01 2022-06-30 0001713210 AATP:EmploymentInsuranceSystemMember 2022-01-01 2022-06-30 0001713210 AATP:EmploymentInsuranceSystemMember AATP:MYRCurrencyMember 2022-01-01 2022-06-30 0001713210 AATP:HumanResourceDevelopmentFundMember 2022-01-01 2022-06-30 0001713210 us-gaap:ComputerEquipmentMember srt:MinimumMember 2022-01-01 2022-06-30 0001713210 us-gaap:ComputerEquipmentMember srt:MaximumMember 2022-01-01 2022-06-30 0001713210 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2022-01-01 2022-06-30 0001713210 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2022-01-01 2022-06-30 0001713210 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-06-30 0001713210 us-gaap:VehiclesMember 2022-01-01 2022-06-30 0001713210 us-gaap:ComputerSoftwareIntangibleAssetMember 2022-01-01 2022-06-30 0001713210 AATP:SurvivorSelectMember 2022-04-01 2022-06-30 0001713210 AATP:SurvivorSelectMember 2021-04-01 2021-06-30 0001713210 AATP:SurvivorSelectMember 2022-01-01 2022-06-30 0001713210 AATP:SurvivorSelectMember 2021-01-01 2021-06-30 0001713210 AATP:EnergizedMineralConcentrateMember 2022-04-01 2022-06-30 0001713210 AATP:EnergizedMineralConcentrateMember 2021-04-01 2021-06-30 0001713210 AATP:EnergizedMineralConcentrateMember 2022-01-01 2022-06-30 0001713210 AATP:EnergizedMineralConcentrateMember 2021-01-01 2021-06-30 0001713210 AATP:IonizedCalMagMember 2022-04-01 2022-06-30 0001713210 AATP:IonizedCalMagMember 2021-04-01 2021-06-30 0001713210 AATP:IonizedCalMagMember 2022-01-01 2022-06-30 0001713210 AATP:IonizedCalMagMember 2021-01-01 2021-06-30 0001713210 AATP:OmegaBlendMember 2022-04-01 2022-06-30 0001713210 AATP:OmegaBlendMember 2021-04-01 2021-06-30 0001713210 AATP:OmegaBlendMember 2022-01-01 2022-06-30 0001713210 AATP:OmegaBlendMember 2021-01-01 2021-06-30 0001713210 AATP:BetaMaxxMember 2022-04-01 2022-06-30 0001713210 AATP:BetaMaxxMember 2021-04-01 2021-06-30 0001713210 AATP:BetaMaxxMember 2022-01-01 2022-06-30 0001713210 AATP:BetaMaxxMember 2021-01-01 2021-06-30 0001713210 AATP:IronMember 2022-04-01 2022-06-30 0001713210 AATP:IronMember 2021-04-01 2021-06-30 0001713210 AATP:IronMember 2022-01-01 2022-06-30 0001713210 AATP:IronMember 2021-01-01 2021-06-30 0001713210 AATP:YoungFormulaMember 2022-04-01 2022-06-30 0001713210 AATP:YoungFormulaMember 2021-04-01 2021-06-30 0001713210 AATP:YoungFormulaMember 2022-01-01 2022-06-30 0001713210 AATP:YoungFormulaMember 2021-01-01 2021-06-30 0001713210 AATP:OrganicYouthCarCleansingBarMember 2022-04-01 2022-06-30 0001713210 AATP:OrganicYouthCarCleansingBarMember 2021-04-01 2021-06-30 0001713210 AATP:OrganicYouthCarCleansingBarMember 2022-01-01 2022-06-30 0001713210 AATP:OrganicYouthCarCleansingBarMember 2021-01-01 2021-06-30 0001713210 AATP:ATPRMITOPlusMember 2022-04-01 2022-06-30 0001713210 AATP:ATPRMITOPlusMember 2021-04-01 2021-06-30 0001713210 AATP:ATPRMITOPlusMember 2022-01-01 2022-06-30 0001713210 AATP:ATPRMITOPlusMember 2021-01-01 2021-06-30 0001713210 AATP:LipomaskMember 2022-04-01 2022-06-30 0001713210 AATP:LipomaskMember 2021-04-01 2021-06-30 0001713210 AATP:LipomaskMember 2022-01-01 2022-06-30 0001713210 AATP:LipomaskMember 2021-01-01 2021-06-30 0001713210 AATP:HyaluronicAcidSerumMember 2022-04-01 2022-06-30 0001713210 AATP:HyaluronicAcidSerumMember 2021-04-01 2021-06-30 0001713210 AATP:HyaluronicAcidSerumMember 2022-01-01 2022-06-30 0001713210 AATP:HyaluronicAcidSerumMember 2021-01-01 2021-06-30 0001713210 AATP:MousseFacialCleanserMember 2022-04-01 2022-06-30 0001713210 AATP:MousseFacialCleanserMember 2021-04-01 2021-06-30 0001713210 AATP:MousseFacialCleanserMember 2022-01-01 2022-06-30 0001713210 AATP:MousseFacialCleanserMember 2021-01-01 2021-06-30 0001713210 AATP:TrimPlusMember 2022-04-01 2022-06-30 0001713210 AATP:TrimPlusMember 2021-04-01 2021-06-30 0001713210 AATP:TrimPlusMember 2022-01-01 2022-06-30 0001713210 AATP:TrimPlusMember 2021-01-01 2021-06-30 0001713210 AATP:ProductHealthTherapiesMember 2022-04-01 2022-06-30 0001713210 AATP:ProductHealthTherapiesMember 2021-04-01 2021-06-30 0001713210 AATP:ProductHealthTherapiesMember 2022-01-01 2022-06-30 0001713210 AATP:ProductHealthTherapiesMember 2021-01-01 2021-06-30 0001713210 AATP:OthersMember 2022-04-01 2022-06-30 0001713210 AATP:OthersMember 2021-04-01 2021-06-30 0001713210 AATP:OthersMember 2022-01-01 2022-06-30 0001713210 AATP:OthersMember 2021-01-01 2021-06-30 0001713210 us-gaap:ProductMember 2022-04-01 2022-06-30 0001713210 us-gaap:ProductMember 2021-04-01 2021-06-30 0001713210 us-gaap:ProductMember 2022-01-01 2022-06-30 0001713210 us-gaap:ProductMember 2021-01-01 2021-06-30 0001713210 AATP:PeriodEndMYRMember 2022-06-30 0001713210 AATP:PeriodEndMYRMember 2021-12-31 0001713210 AATP:PeriodEndHKDMember 2022-06-30 0001713210 AATP:PeriodEndHKDMember 2021-12-31 0001713210 AATP:PeriodAverageMYRMember 2022-04-01 2022-06-30 0001713210 AATP:PeriodAverageMYRMember 2021-04-01 2021-06-30 0001713210 AATP:PeriodAverageMYRMember 2022-01-01 2022-06-30 0001713210 AATP:PeriodAverageMYRMember 2021-01-01 2021-06-30 0001713210 AATP:PeriodAverageHKDMember 2022-04-01 2022-06-30 0001713210 AATP:PeriodAverageHKDMember 2021-04-01 2021-06-30 0001713210 AATP:PeriodAverageHKDMember 2022-01-01 2022-06-30 0001713210 AATP:PeriodAverageHKDMember 2021-01-01 2021-06-30 0001713210 AATP:SubsidiaryCompanyThreeMember 2022-06-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2022-06-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2021-12-31 0001713210 us-gaap:VariableIncomeInterestRateMember 2022-04-01 2022-06-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2021-04-01 2021-06-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2022-01-01 2022-06-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2021-01-01 2021-06-30 0001713210 srt:MinimumMember 2022-06-30 0001713210 srt:MaximumMember 2022-06-30 0001713210 srt:MinimumMember 2021-06-30 0001713210 srt:MaximumMember 2021-06-30 0001713210 AATP:ComputerAndOfficeEquipmentMember 2022-06-30 0001713210 AATP:ComputerAndOfficeEquipmentMember 2021-12-31 0001713210 us-gaap:FurnitureAndFixturesMember 2022-06-30 0001713210 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001713210 us-gaap:LeaseholdImprovementsMember 2022-06-30 0001713210 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001713210 AATP:VehicleMember 2022-06-30 0001713210 AATP:VehicleMember 2021-12-31 0001713210 AATP:GreenproCapitalCorpMember 2018-05-17 0001713210 AATP:GreenproCapitalCorpMember 2018-07-30 0001713210 AATP:GreenproCapitalCorpMember 2018-10-16 0001713210 AATP:DSwissIncMember 2020-11-03 0001713210 AATP:DSwissIncMember 2020-12-09 0001713210 AATP:SEATechVenturesCorpMember 2021-09-27 0001713210 AATP:PhoenixPlusCorpMember 2019-04-03 0001713210 us-gaap:CommonStockMember AATP:PhoenixPlusCorpMember 2019-04-03 0001713210 AATP:PhoenixPlusCorpMember 2022-06-30 0001713210 AATP:PhoenixPlusCorpMember 2021-12-31 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2022-01-01 2022-06-30 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2021-01-01 2021-12-31 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2022-06-30 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2021-12-31 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdMember 2022-01-01 2022-06-30 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdMember 2021-01-01 2021-12-31 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdMember 2022-06-30 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdMember 2021-12-31 0001713210 AATP:AgapeATPAsiaLimitedMember 2022-01-01 2022-06-30 0001713210 AATP:AgapeATPAsiaLimitedMember 2021-01-01 2021-12-31 0001713210 AATP:AgapeATPAsiaLimitedMember 2022-06-30 0001713210 AATP:AgapeATPAsiaLimitedMember 2021-12-31 0001713210 AATP:HostastaySdnBhdMember 2022-01-01 2022-06-30 0001713210 AATP:HostastaySdnBhdMember 2021-01-01 2021-12-31 0001713210 AATP:HostastaySdnBhdMember 2022-06-30 0001713210 AATP:HostastaySdnBhdMember 2021-12-31 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdOneMember 2022-01-01 2022-06-30 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdOneMember 2021-01-01 2021-12-31 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdOneMember 2022-06-30 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdOneMember 2021-12-31 0001713210 AATP:DSYBeautySdnBhdMember 2022-01-01 2022-06-30 0001713210 AATP:DSYBeautySdnBhdMember 2021-01-01 2021-12-31 0001713210 AATP:DSYBeautySdnBhdMember 2022-06-30 0001713210 AATP:DSYBeautySdnBhdMember 2021-12-31 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2022-04-01 2022-06-30 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2021-04-01 2021-06-30 0001713210 AATP:DSYBeautySdnBhdMember 2022-04-01 2022-06-30 0001713210 AATP:DSYBeautySdnBhdMember 2021-04-01 2021-06-30 0001713210 AATP:DSYWellnessandLongevityCenterSdnBhdTwoMember 2022-04-01 2022-06-30 0001713210 AATP:DSYWellnessandLongevityCenterSdnBhdTwoMember 2021-04-01 2021-06-30 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2021-01-01 2021-06-30 0001713210 AATP:DSYBeautySdnBhdOneMember 2022-01-01 2022-06-30 0001713210 AATP:DSYBeautySdnBhdOneMember 2021-01-01 2021-06-30 0001713210 AATP:DSYWellnessandLongevityCenterSdnBhdTwoMember 2022-01-01 2022-06-30 0001713210 AATP:DSYWellnessandLongevityCenterSdnBhdTwoMember 2021-01-01 2021-06-30 0001713210 AATP:DSYBeautySdnBhdMember 2021-01-01 2021-06-30 0001713210 AATP:HowKokChoongMember 2022-04-01 2022-06-30 0001713210 AATP:HowKokChoongMember 2021-04-01 2021-06-30 0001713210 AATP:HowKokChoongMember 2022-01-01 2022-06-30 0001713210 AATP:HowKokChoongMember 2021-01-01 2021-06-30 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdThreeMember 2022-04-01 2022-06-30 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdThreeMember 2021-04-01 2021-06-30 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdThreeMember 2022-01-01 2022-06-30 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdThreeMember 2021-01-01 2021-06-30 0001713210 AATP:HostastaySdnBhdHostastayMember 2022-04-01 2022-06-30 0001713210 AATP:HostastaySdnBhdHostastayMember 2021-04-01 2021-06-30 0001713210 AATP:HostastaySdnBhdHostastayMember 2021-01-01 2021-06-30 0001713210 AATP:HostastaySdnBhdHostastayMember 2022-01-01 2022-06-30 0001713210 AATP:ShareForfeitureAgreementsMember AATP:HowKokChoongTalentLimitedMember 2022-01-01 2022-06-30 0001713210 AATP:ShareForfeitureAgreementsMember 2022-01-01 2022-06-30 0001713210 country:MY 2022-04-01 2022-06-30 0001713210 country:MY 2021-04-01 2021-06-30 0001713210 country:MY 2022-01-01 2022-06-30 0001713210 country:MY 2021-01-01 2021-06-30 0001713210 country:HK 2022-04-01 2022-06-30 0001713210 country:HK 2021-04-01 2021-06-30 0001713210 country:HK 2022-01-01 2022-06-30 0001713210 country:HK 2021-01-01 2021-06-30 0001713210 us-gaap:StateAndLocalJurisdictionMember 2022-01-01 2022-06-30 0001713210 us-gaap:ForeignCountryMember 2022-01-01 2022-06-30 0001713210 country:US 2022-06-30 0001713210 country:US 2021-12-31 0001713210 AATP:LabuanMember 2018-12-28 2019-01-02 0001713210 country:MY 2022-06-30 0001713210 country:MY 2021-12-31 0001713210 AATP:UnutilizedMember 2022-06-30 0001713210 AATP:UnutilizedMember 2021-12-31 0001713210 AATP:UnutilizedMember 2022-01-01 2022-06-30 0001713210 AATP:NoCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001713210 AATP:NoCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001713210 AATP:NoCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001713210 AATP:NoCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001713210 us-gaap:AccountsReceivableMember AATP:ECommerceCompanyMember us-gaap:CustomerConcentrationRiskMember AATP:OneIndividualCustomersMember 2022-01-01 2022-06-30 0001713210 AATP:VendorOneMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-04-01 2022-06-30 0001713210 AATP:VendorTwoMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-04-01 2022-06-30 0001713210 AATP:VendorThreeMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-04-01 2022-06-30 0001713210 AATP:VendorOneMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001713210 AATP:VendorTwoMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001713210 AATP:VendorOneMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-04-01 2021-06-30 0001713210 AATP:VendorOneMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-06-30 0001713210 AATP:VendorOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001713210 AATP:VendorTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001713210 AATP:VendorThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001713210 AATP:VendorMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001713210 us-gaap:SupplierConcentrationRiskMember us-gaap:AccountsPayableMember AATP:OneVendorMember 2021-01-01 2021-12-31 0001713210 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember AATP:OneSalesDistributorMember 2022-04-01 2022-06-30 0001713210 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember AATP:OneSalesDistributorMember 2021-04-01 2021-06-30 0001713210 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember AATP:NoSalesDistributorMember 2022-01-01 2022-06-30 0001713210 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember AATP:OneSalesDistributorMember 2021-01-01 2021-06-30 0001713210 AATP:AgapeSuperiorLivingMember 2020-04-01 0001713210 2021-05-30 2021-05-31 0001713210 AATP:TrainingCenterMember 2021-05-30 2021-05-31 0001713210 2021-05-31 0001713210 AATP:AgapeSuperiorLivingMember 2021-05-31 0001713210 AATP:AgapeSuperiorLivingMember 2022-06-30 0001713210 AATP:COVIDNineteenImpactMember 2022-01-01 2022-06-30 0001713210 us-gaap:SubsequentEventMember 2022-07-18 2022-07-19 0001713210 AATP:GreenproCapitalCorpMember 2022-06-30 0001713210 us-gaap:SubsequentEventMember AATP:GreenproCapitalCorpMember 2022-07-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:MYR

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

For The Quarterly Period Ended June 30, 2022

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______________ to _______________

 

Commission File Number 333-220144

 

AGAPE ATP CORPORATION

(Exact name of registrant issuer as specified in its charter)

 

Nevada   36-4838886

(State or other jurisdiction

of incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

1705 - 1708, Level 17, Tower 2, Faber Tower, Jalan Desa Bahagia,
Taman Desa, 58100 Kuala Lumpur, Malaysia.

(Address of principal executive offices, including zip code)

 

Registrant’s phone number, including area code (60) 192230099

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding twelve months (or shorter period that the registrant was required to submit and post such files).

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-accelerated Filer ☒ Smaller reporting company

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes ☐ No

 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

 

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

 

Yes ☐ No ☐

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class   Outstanding at August 9, 2022
Common Stock, $0.0001 par value   75,452,012

 

 

 

 
 

 

TABLE OF CONTENTS

 

      Page
PART I   FINANCIAL INFORMATION  
ITEM 1.   UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:  
    Unaudited Condensed Consolidated Balance Sheets F-1
    Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss F-2
    Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity F-3
    Unaudited Condensed Consolidated Statements of Cash Flows F-4
    Notes to Unaudited Condensed Consolidated Financial Statements F-5 - F-31
ITEM 2.   MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 3
ITEM 3.   QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 12
ITEM 4.   CONTROLS AND PROCEDURES 12
PART II   OTHER INFORMATION  
ITEM 1   LEGAL PROCEEDINGS 15
ITEM 2   UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 15
ITEM 3   DEFAULTS UPON SENIOR SECURITIES 15
ITEM 4   MINE SAFETY DISCLOSURES 15
ITEM 5   OTHER INFORMATION 15
ITEM 6   EXHIBITS 16
    SIGNATURES 17

 

2
 

 

PART I FINANCIAL INFORMATION

 

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

   June 30,   December 31, 
   2022   2021 
         
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents (Included $7,626 and $17,493 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of June 30, 2022 and December 31, 2021, respectively)  $1,807,437   $2,597,848 
Accounts receivable   214    - 
Amount due from related parties   4,548    7,004 
Inventories   346,744    375,535 
Prepaid taxes (Included $1,744 and $1,357 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of June 30, 2022 and December 31, 2021, respectively)   339,999    636,218 
Prepayments and deposits   178,697    295,517 
Total Current Assets   2,677,639    3,912,122 
           
OTHER ASSETS          
Property and equipment, net   169,915    215,799 
Intangible assets, net   2,601    3,660 
Operating right-of-use assets   158,630    237,718 
Investment in marketable securities   35,707    89,001 
Investment in non-marketable securities   1,500    1,500 
Deferred offering costs   443,661    264,735 
Total Other Assets   812,014    812,413 
           
TOTAL ASSETS  $3,489,653   $4,724,535 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
CURRENT LIABILITIES          
Accounts payable  $21,519   $13,715 
Accounts payable – a related party   14,407    - 
Customer deposits   89,606    279,689 
Operating lease liabilities   150,573    157,094 
Other payables and accrued liabilities ($787 and $1,548 are included in the consolidated VIE that are without recourse to the credit of Agape ATP Corporation as of June 30, 2022 and December 31, 2021, respectively)   637,033    858,355 
Other payable – a related party   2,082    - 
Income tax payable   9,249    3,988 
Total Current Liabilities   924,469    1,312,841 
           
NON-CURRENT LIABILITIES          
Operating lease liabilities   10,812    83,484 
Deferred tax liabilities   17,975    15,574 
Total Non-current Liabilities   28,787    99,058 
           
TOTAL LIABILITIES   953,256    1,411,899 
           
STOCKHOLDERS’ EQUITY          
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; None issued and outstanding   -    - 
Common Stock, par value $0.0001; 1,000,000,000 shares authorized, 75,452,012 and 290,460,047 shares issued and outstanding as of June 30, 2022 and December 31, 2021 respectively   7,545    29,046 
Additional paid in capital   6,470,716    6,449,215 
Accumulated deficit   (3,972,684)   (3,258,687)
Accumulated other comprehensive income   20,219    93,398 
TOTAL AGAPE CORPORATION STOCKHOLDERS’ EQUITY   2,525,796    3,312,972 
           
NON-CONTROLLING INTERESTS   10,601    (336)
           
TOTAL EQUITY   2,536,397    3,312,636 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $3,489,653   $4,724,535 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-1
 

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

                     
   For the three months ended   For the six months ended 
   June 30,   June 30, 
   2022   2021   2022   2021 
                 
REVENUE  $396,707   $303,786   $805,667   $605,566 
                     
COST OF REVENUE   (109,383)   (35,623)   (182,814)   (113,214)
                     
GROSS PROFIT   287,324    268,163    622,853    492,352 
                     
SELLING   (79,587)   (100,838)   (194,198)   (216,952)
COMMISSION   (62,557)   (92,774)   (176,666)   (181,213)
GENERAL AND ADMINISTRATIVE   (451,363)   (361,862)   (830,404)   (724,008)
PROVISION FOR DOUBTFUL ACCOUNTS   -    (121,686)   -    (121,686)
TOTAL OPERATING EXPENSES   (593,507)   (677,160)   (1,201,268)   (1,243,859)
                     
LOSS FROM OPERATIONS   (306,183)   (408,997)   (578,415)   (751,507)
                     
OTHER (EXPENSES) INCOME                    
Other income (expenses), net   1,341    11,770    12,826    (48,546)
Interest income   3,526    -    8,251    - 
Unrealized holding loss on marketable securities   (35,219)   (241,027)   (52,889)   (165,731)
Exchange loss, net   (67,417)   -    (83,883)   - 
TOTAL OTHER EXPENSES, NET   (97,769)   (229,257)   (115,695)   (214,277)
                     
LOSS BEFORE INCOME TAXES   (403,952)   (638,254)   (694,110)   (965,784)
                     
PROVISION FOR INCOME TAXES   (392)   (3,971)   (8,680)   (10,091)
                     
NET LOSS   (404,344)   (642,225)   (702,790)   (975,875)
                     
LESS: NET INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS   10,556    -    11,207    - 
                     
NET LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION  $(414,900)  $(642,225)  $(713,997)  $(975,875)
                     
NET LOSS  $(404,344)  $(642,225)  $(702,790)  $(975,875)
                     
OTHER COMPREHENSIVE LOSS                    
Foreign currency translation adjustment   (61,156)   (36,347)   (73,179)   (74,631)
                     
TOTAL COMPREHENSIVE LOSS   (465,500)   (678,572)   (775,969)   (1,050,506)
                     
Less: Comprehensive loss attributable to non-controlling interests   (271)   -    (270)   - 
                     
COMPREHENSIVE LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION  $(465,229)  $(678,572)  $(775,699)  $(1,050,506)
                     
LOSS PER SHARE                    
Basic and diluted  $(0.01)  $0.00   $(0.01)  $0.00 
                     
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING                    
Basic and diluted   75,452,012    376,452,047    100,397,696    376,452,047 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-2
 

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF

CHANGES IN STOCKHOLDERS’ EQUITY

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

                               
   COMMON STOCK   ADDITIONAL      

ACCUMULATED

OTHER

   TOTAL 
  

Number of

shares

  

Par

value

  

PAID IN

CAPITAL

  

ACCUMULATED

DEFICIT

  

COMPREHENSIVE

INCOME

  

STOCKHOLDERS’

EQUITY

 
Balance as of December 31, 2020   376,452,047   $37,645   $6,440,616   $(734,443)  $      181,016 - $      5,924,834 
Net loss   -    -    -    (333,650)   -   (333,650)
Foreign currency translation adjustment   -    -    -    -    (38,284)-  (38,284)
Balance as of March 31, 2021   376,452,047   $37,645   $6,440,616   $(1,068,093)  $142,732 - $5,552,900 
Net loss   -    -    -    (642,225)   -   (642,225)
                               
Foreign currency translation adjustment   -    -    -    -    (36,347)-  (36,347)
Balance as of June 30, 2021   376,452,047   $37,645   $6,440,616   $(1,710,318)  $106,385 - $4,874,328 

 

                                    
   COMMON STOCK   ADDITIONAL      

ACCUMULATED

OTHER

   NON-   TOTAL 
  

Number of

shares

  

Par

value

  

PAID IN

CAPITAL

  

ACCUMULATED

DEFICIT

  

COMPREHENSIVE

INCOME

  

CONTROLLING

INTERESTS

  

STOCKHOLDERS’

EQUITY

 
Balance as of December 31, 2021   290,460,047   $29,046   $6,449,215   $(3,258,687)  $          93,398   $          (336)  $            3,312,636 
Forfeiture of common stock   (215,008,035)   (21,501)   21,501    -    -    -    - 
Net loss   -    -    -    (299,097)   -    651    (298,446)
Foreign currency translation adjustment   -    -    -    -    (12,023)   1    (12,022)
Balance as of March 31, 2022   75,452,012   $7,545   $6,470,716   $(3,557,784)  $81,375   $316   $3,002,168 
Net loss   -    -    -    (414,900)   -    10,556    (404,344)
Foreign currency translation adjustment   -    -    -    -    (61,156)   (271)   (61,427)
Balance as of June 30, 2022   75,452,012   $7,545   $6,470,716   $(3,972,684)  $20,219   $10,601   $2,536,397 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-3
 

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”)

 

           
  

For the six months ended

June 30,

 
   2022   2021 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(702,790)  $(975,875)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   36,661    38,179 
Amortization   897    1,006 
Amortization of operating right-of-use assets   75,241    75,387 
Unrealized holding loss on marketable securities   52,889    165,731 
Deferred tax provision (benefit)   2,401    (53,299)
Inventory write-downs   -    36,636 
Provision for doubtful accounts   -    121,686 
Changes in operating assets and liabilities:          
Accounts receivables   (214)   169,393 
Amount due from related parties   2,201    - 
Inventories   28,790    80,969 
Prepaid taxes   296,219    448,054 
Prepayments and deposits   102,099    (15,120)
Accounts payable   7,804    - 
Accounts payable – a related party   14,407    - 
Customer deposits   (175,936)   (60,618)
Operating lease liabilities   (75,200)   (74,399)
Other payables and accrued liabilities   (166,137)   (129,355)
Amount due to a related party   2,081    - 
Income tax payable   5,261    36,877 
Net cash used in operating activities   (493,326)   (134,748)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of equipment   (750)   (1,220)
Net cash used in investing activities   (750)   (1,220)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Deferred offering costs   (178,926)   (14,160)
Advances to related parties   -    (2,428)
Net cash used in financing activities   (178,926)   (16,588)
           
EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS   (117,409)   (64,244)
           
DECREASE IN CASH AND CASH EQUIVALENTS   (790,411)   (216,800)
           
CASH AND CASH EQUIVALENTS, beginning of period   2,597,848    3,517,600 
           
CASH AND CASH EQUIVALENTS, end of period  $1,807,437   $3,300,800 
           
SUPPLEMENTAL CASH FLOWS INFORMATION          
Income taxes paid  $77,117   $249,583 
           
SUPPLEMENTAL NON-CASH FLOWS INFORMATION          
Changes in right-of-use assets and lease liabilities due to lease modifications  $-   $3,286 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-4
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

1. ORGANIZATION AND BUSINESS BACKGROUND

 

Agape ATP Corporation, a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016.

 

Agape ATP Corporation operates through its subsidiaries, namely, Agape ATP Corporation, a company incorporated in Labuan, Malaysia, and Agape Superior Living Sdn. Bhd. (“ASL”), a company incorporated in Malaysia. .

 

Agape ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with 100% equity interest in Agape ATP International Holding Limited, a company incorporated in Hong Kong.

 

On May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in Agape Superior Living Sdn. Bhd., a network marketing entity incorporated in Malaysia.

 

Agape Superior Living Sdn. Bhd. is a limited company incorporated on August 8, 2003, under the laws of Malaysia.

 

On September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn, Bhd. (“WATP”), a wholly owned subsidiary under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle.

 

On November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (“DSY Wellness”) with an independent third party which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies.

 

The Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs.

 

The accompanying consolidated financial statements reflect the activities of the Company, AATP LB, AATP HK, WATP, ASL and its variable interest entity (“VIE”), Agape S.E.A. Sdn. Bhd. (“SEA”) (See Note 3), and DSY Wellness.

 

Details of the Company’s subsidiaries:

 

  

Subsidiary

company name

 

Place and date of

incorporation

 

Particulars of

issued capital

  Principal activities 

Proportional of

ownership interest

and voting power

held

 
                 
1.  Agape ATP Corporation  Labuan,
March 6, 2017
  100 shares of ordinary share of US$1 each  Investment holding   100%
                  
2.  Agape ATP International Holding Limited  Hong Kong,
June 1, 2017
  1,000,000 shares of ordinary share of HK$1 each  Wholesaling of health and wellness products; and health solution advisory services   100%
                  
3.  Agape Superior Living Sdn. Bhd.  Malaysia,
August 8, 2003
  9,590,598 shares of ordinary share of RM1 each  Health and wellness products and health solution advisory services via network marketing   99.99%
                  
4.  Agape S.E.A. Sdn. Bhd.  Malaysia,
March 4, 2004
  2 shares of ordinary share of RM1 each  VIE of Agape Superior Living Sdn. Bhd.   VIE 
                  
5.  Wellness ATP International Holdings Sdn, Bhd  Malaysia,
September 11, 2020
  100 shares of ordinary share of RM1 each  The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns   100%
                  
6.  DSY Wellness International Sdn Bhd.  Malaysia,
November 11, 2021
  1,000 shares of ordinary share of RM1 each  Provision of complementary health therapies   60%

 

F-5
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

1. ORGANIZATION AND BUSINESS BACKGROUND (Continued)

 

Business Overview

 

Agape ATP Corporation is a company that provides health and wellness products and health solution advisory services to our clients. The Company primarily focus its efforts on attracting customers in Malaysia. Its advisory services center on the “ATP Zeta Health Program”, which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.

 

In order to strengthen the Company’s supply chain, on May 8, 2020, the Company has successfully acquired approximately 99.99% of ASL, with the goal of securing an established network marketing sales channel that has been established in Malaysia for the past 15 years. ASL has been offering the Company’s ATP Zeta Health Program as part of its product lineup. As such, the acquisition creates synergy in the Company’s operation by boosting the Company’s retail and marketing capabilities. The newly acquired subsidiary allows the Company to fulfill its mission of “helping people to create health and wealth” by providing a financially rewarding business opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle.

 

Via ASL, the Company offers three series of programs which consist of different services and products: ATP Zeta Health Program, ÉNERGÉTIQUE and BEAUNIQUE.

 

The ATP Zeta Health Program is a health program designed to promote health and general wellbeing designed to prevent health diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity through a combination of modern health supplements, proper nutrition and advice from skilled dieticians as well as trained members and distributors.

 

The ÉNERGÉTIQUE series aims to provide a total dermal solution for a healthy skin beginning from the cellular level. The series is comprised of the Energy Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.

 

The BEAUNIQUE product series focuses on the research of our diet’s impact on modifying gene expressions in order to address genetic variations and deliver a nutrigenomic solution for every individual.

 

The Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution advisory services; and therefore, incorporated WATP. Upon its establishment, WATP started collaborating with ASL to carry out various wellness programs.

 

To further its reach in the Health and Wellness Industry, on November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (“DSY Wellness”) with an independent third party which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies.

 

F-6
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for information pursuant to the rules and regulations of the Securities Exchange Commission (“SEC”), and include all normal and recurring adjustments that management of the Company considers necessary for a fair presentation of its financial position and operation results. Interim results are not necessarily indicative of results to be expected for any other interim period or for the full year. The information included in this Form 10-Q should be read in conjunction with information included in the Company’s annual report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 28, 2022.

 

The unaudited condensed consolidated financial statements include the financial statements of the Company, its subsidiaries and its variable interest entity (“VIE”) over which the Company exercises control and, where applicable, entities for which the Company has a controlling financial interest or is the primary beneficiary. All transactions and balances among the Company, its subsidiaries and its VIE have been eliminated upon consolidation.

 

Principles of consolidation

 

Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.

 

A VIE is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary and must consolidate the VIE. As of and for the three and six months ended June 30, 2022, SEA, the only VIE of the Company has no significant operations.

 

Use of estimates

 

The preparation of audited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s consolidated financial statements include allowance for doubtful accounts, allowance for inventories obsolescence, useful lives of property and equipment, useful lives of intangible assets, impairment of long-lived assets, allowance for deferred tax assets, operating right-of-use assets, operating lease liabilities and uncertain tax position and impairment of investment in non-marketable securities. Actual results could differ from these estimates.

 

Cash and cash equivalents

 

Cash and cash equivalents are carried at cost and represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less.

 

F-7
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Accounts receivable

 

Accounts receivable are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due on credit term. Accounts receivable also include money due from a third-party e-commerce platform acting as a collection agent for the Company on the sales through their platform. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of June 30, 2022 and December 31, 2021, no allowance of doubtful accounts was recorded.

 

Inventories

 

Inventories consist of finished goods and are stated at the lower of cost or net realizable value using the first-in first-out method. Management reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net realizable value. For the six months ended June 30, 2022 and 2021, the Company recognized inventory write-downs of $0 and $36,636, respectively.

 

Prepaid taxes

 

Prepaid taxes include prepaid income taxes that will either be refunded or utilized to offset future income tax.

 

Prepayments and deposits

 

Prepayments and deposits are mainly cash deposited or advanced to suppliers for future inventory purchases or service providers for future services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after management has determined that the likelihood of collection is not probable. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of June 30, 2022 and December 31, 2021, there was $120,372 and $121,095 allowance for doubtful accounts recorded, respectively.

 

F-8
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Property and equipment, net

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets with no residual value. The estimated useful lives are as follows:

 

   Useful Life
    
Computer and office equipment  5-7 years
Furniture & fixtures  6-7 years
Leasehold improvements  Lease Term
Vehicle  5 years

 

The cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements of income and comprehensive income. Expenditures for maintenance and repairs are charged to earnings as incurred, while additions, renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates the periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.

 

Intangible assets, net

 

Intangible assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the estimated useful lives of the assets as follows:

 

Classification  Useful Life
    
Computer software  5 years

 

Impairment for long-lived assets

 

Long-lived assets, including property and equipment, and intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted future cash flows the assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset. If an impairment is identified, the Company would reduce the carrying amount of the asset to its estimated fair value based on a discounted cash flows approach or, when available and appropriate, to comparable market values. As of June 30, 2022 and December 31, 2021, no impairment of long-lived assets was recognized.

 

Deferred offering costs

 

Deferred offering costs represents costs associated with the Company’s current offering which will be netted against the proceeds from the Company’s current offering.

 

Investment in marketable equity securities

 

The Company follows the provisions of ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Investments in marketable equity securities (non-current) are reported at fair value with changes in fair value recognized in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss in the caption of “unrealized holding gain loss on marketable securities” in each reporting period.

 

F-9
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Investment in non-marketable equity securities

 

The Company follows the provisions of ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Due to the Company’s non-marketable equity securities (non-current) does not qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issue.

 

At each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that raise significant concerns about the investee’s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment loss equal to the difference between the fair value of the investment and its carrying amount.

 

Customer deposits

 

Customer deposits represent amounts advanced by customers on product orders and discounted value of unapplied coupons. Customer deposits are reduced when the related sale is recognized in accordance with the Company’s revenue recognition policy.

 

Revenue recognition

 

The Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606). The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.

 

The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

 

The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.

 

F-10
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Sales of Health and Wellness products

 

- Performance obligations satisfied at a point in time

 

The Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods. The revenue is recorded net of estimated discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were insignificant sales returns.

 

The Company also sells coupons to its customers for cash at a discounted price of the value of the coupons. Customers can apply the value of the coupons for a reduction in the transaction price paid by the customer are recorded as a reduction of sales. The cash proceeds resulted from the sale of coupons are recognized as customer deposits until the coupons to be applied as a reduction of the health and wellness products transaction price upon such sales transactions occurred. The Company’s coupons have a validity period of six months. If the Company’s customers did not utilize the coupons after six months, the Company would recognize the forfeiture of the originated sales value of the coupons as net revenues. For the three months ended June 30, 2022 and 2021, the Company recognized $4,824 and $4,115, as forfeited coupon income, respectively. For the six months ended June 30, 2022 and 2021, the Company recognized $5,777 and $11,226, as forfeited coupon income, respectively.

 

The Company had contracts for the sales of health and wellness products amounting to $16,084 which it is expected to fulfill within 12 months from June 30, 2022.

 

Sales of Health and Wellness services

 

- Performance obligations satisfied at a point in time

 

The Company carries out its Wellness program, where the Company’s products are bundled with health screening test and a health camp program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test reports are completed and delivered to its customers during the consultation section in person.

 

The Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health camp program was completed in the final day of the health camp. For the three months ended June 30, 2022 and 2021, revenues from health and wellness services were $30,072 and $653 respectively. For the six months ended June 30, 2022 and 2021, revenues from health and wellness services were $31,139 and $5,746 respectively.

 

F-11
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Disaggregated information of revenues by products are as follows:

 

                     
   For the three months ended   For the six months ended 
   June 30,   June 30, 
   2022   2021   2022   2021 
                 
Survivor Select  $13,941   $24,415   $22,753   $37,641 
Energized Mineral Concentrate   -    8,291    -    52,183 
Ionized Cal-Mag   14,278    18,485    62,368    40,298 
Omega Blend   42,747    89,066    179,177    185,361 
Beta Maxx   23,564    55,943    47,637    89,800 
Iron   3,118    8,431    7,186    16,715 
Young Formula   1,075    14,458    34,269    25,901 
Organic Youth Care Cleansing Bar   -    2,990    -    2,990 
ATPR Mito+   76,605    70,148    187,926    106,843 
Lipomask   -    4,279    -    8,401 
Hyaluronic Acid Serum   1,698    1,362    3,006    3,353 
Mousse Facial Cleanser   4,355    3,042    7,394    7,660 
Trim+   2,765    2,223    6,236    22,674 
Others – Products for the provision of complementary health therapies   182,101    -    216,188    - 
Others   388    -    388    - 
Total revenues - products   366,635    303,133    774,528    599,820 
Health and Wellness services   30,072    653    31,139    5,746 
Total revenues - products and services  $396,707   $303,786   $805,667   $605,566 

 

Cost of revenue

 

Cost of revenue for the three and six months ended June 30, 2022 were $109,383, and $182,814, respectively, and comprised freight-in, purchase cost of manufactured goods for sale to customers and products for the provision of complementary health therapies. Cost of revenue for the three months and six months ended June 30, 2021, were $35,623, and $113,214, respectively, and comprised freight-in, purchase cost of manufactured goods for sale to customers. For the six months ended June 30, 2021, cost of revenue also included inventory write-downs of $36,636.

 

Shipping and handling

 

Shipping and handling charges amounted to $4,272 and $2,990 for the three months ended June 30, 2022 and 2021, respectively. Shipping and handling charges amounted to $7,179 and $5,272 for the six months ended June 30, 2022 and 2021, respectively. Shipping and handling charges are expensed as incurred and included in selling expenses.

 

Advertising costs

 

Advertising costs amounted to $4,765 and $8,721 for the three months ended June 30, 2022 and 2021, respectively. Advertising costs amounted to $4,765 and $16,658 for the six months ended June 30, 2022 and 2021, respectively. Advertising costs are expensed as incurred and included in selling expenses.

 

F-12
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Commission expenses

 

Commission expenses are the Company’s most significant expenses. As with all companies in the network marketing industry, the Company’s sales channel is external to the Company. The Company’s “external sales force” is stratified into two levels based on priority recruitment. First, there are sales distributors. Second, all members recruited by a sales distributor, directly or indirectly, are referred to as “sales network members”. The Company pays commission to every sales distributor based on purchases made by its sales network members which includes the independent direct sales members. Top performing distributors with their own physical stores may also become stockists of the Company, whereby they enjoy benefits such as maintaining a certain amount of the Company’s inventory on their store premises. The stockists shall account to the Company for all products sales from their store premises as monitored through the Company’s centralized stock tracking system. The Company pays a separate commission to stockists based on revenue generated from the stockists’ physical stores. Commission expenses amounted to $62,557 and $92,774 for the three months ended June 30, 2022 and 2021, respectively. Commission expenses amounted to $176,666 and $181,213 for the six months ended June 30, 2022 and 2021, respectively.

 

Defined contribution plan

 

The full-time employees of the Company are entitled to the government mandated defined contribution plan. The Company is required to accrue and pay for these benefits based on certain percentages of the employees’ respective salaries, subject to certain ceilings, in accordance with the relevant government regulations, and make cash contributions to the government mandated defined contribution plan. Total expenses for the plan were $35,936 and $27,067 for the three months ended June 30, 2022 and 2021, respectively. Total expenses for the plan were $63,408 and $53,034 for the six months ended June 30, 2022 and 2021, respectively.

 

The related contribution plans include:

 

  - Social Security Organization (“SOSCO”) – 1.75% based on employee’s monthly salary capped of RM 4,000;
  - Employees Provident Fund (“EPF”) – 12% based on employee’s monthly salary;
  - Employment Insurance System (“EIS”) – 0.2% based on employee’s monthly salary capped of RM 4,000;
  - Human Resource Development Fund (“HRDF”) – 1% based on employee’s monthly salary

 

Income taxes

 

The Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

 

Deferred taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled.

 

F-13
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.

 

An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. No penalties and interest related to underpayment of income taxes were incurred for the three and six months ended June 30, 2022. $395 in penalties and interest related to underpayment of income taxes were incurred for the three and six months ended June 30, 2021.

 

The Company conducts much of its business activities in Hong Kong and Malaysia and is subject to tax in each of these jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

 

Comprehensive income (loss)

 

Comprehensive income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under GAAP are recorded as an element of stockholders’ equity but are excluded from net income. Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.

 

Non-controlling interest

 

Non-controlling interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out of 9,590,598 shares) of the equity interests of ASL held by two individuals. The non-controlling interests are presented in the consolidated balance sheets, separately from equity attributable to the shareholders of the Company. Non-controlling interests in the results of the Company are presented on the face of the consolidated statements of operations as an allocation of the total income or loss for the periods between non-controlling interest holders and the shareholders of the Company.

 

Earnings (loss) per share

 

The Company computes earnings (loss) per share (“EPS”) in accordance with ASC 260, “Earnings per Share”. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is measured as net income (loss) divided by the weighted average common stocks outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential common stocks (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common stocks that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. For the three and six months ended June 30, 2022 and 2021, there were no dilutive shares.

 

F-14
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Foreign currencies translation and transaction

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the consolidated statements of operations and comprehensive income (loss).

 

The reporting currency of the Company is United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. The Company’s subsidiary in Labuan maintains its books and record in United States Dollars (“US$”) albeit its functional currency being the primary currency of the economic environment in which the entity operates, which is the Malaysian Ringgit (“MYR” or “RM”). The Company’s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars (“HK$”), similar to its functional currency. The Company’s subsidiary and VIE in Malaysia conducts its businesses and maintains its books and record in the local currency, Malaysian Ringgit (“MYR” or “RM”), as its functional currency.

 

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders’ equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.

 

Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Period-end MYR : US$1 exchange rate   4.40    4.18 
Period-end HKD : US$1 exchange rate   7.85    7.80 

 

                     
   For the three months ended
June 30,
   For the six months ended
June 30,
 
   2022   2021   2022   2021 
                 
Period-average MYR : US$1 exchange rate   4.37    4.13    4.28    4.10 
Period-average HKD : US$1 exchange rate   7.85    7.77    7.83    7.76 

 

F-15
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Related parties

 

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

 

Fair value of financial instruments

 

The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.

 

The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

 

Leases

 

The Company adopted ASU 2016-02, “Leases” (Topic 842), and elected the practical expedients that does not require the Company to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing leases and (3) initial direct costs for any expired or existing leases. For lease terms of twelve months or fewer, a lessee is permitted to make an accounting policy election not to recognize lease assets and liabilities. The Company also adopts the practical expedient that allows lessees to treat the lease and non-lease components of a lease as a single lease component. Some of the Company’s leases include one or more options to renew, which is typically at the Company’s sole discretion. The Company regularly evaluates the renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. New lease modifications result in re-measurement of the right of use (“ROU”) assets and lease liabilities. Operating ROU assets and lease liabilities are recognized at the commencement date, based on the present value of lease payments over the lease term. Since the implicit rate for the Company’s leases is not readily determinable, the Company use its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment and over a similar term.

 

F-16
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Lease terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of twelve months or less. Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease term.

 

The Company reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future pre-tax cash flows.

 

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates (“ASUs”). Management periodically reviews new accounting standards that are issued. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or revised accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.

  

In November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating the impact ASU 2019-05 may have on its unaudited condensed consolidated financial statements.

 

Except for the above-mentioned pronouncements, there are no new recent issued accounting standards that will have a material impact on the consolidated financial position, statements of operations and cash flows.

 

3. VARIABLE INTEREST ENTITY (“VIE”)

 

SEA is a trading company incorporated on March 4, 2004, under the laws of Malaysia. SEA provided majority of ASL’s purchases. Its equity at risk was insufficient to finance its activities and 100% of its business is transacted with ASL. Therefore, it was considered to be a VIE and ASL is the primary beneficiary since it has both of the following characteristics:

 

  a. The power to direct the activities of the VIE that most significantly impact the VIE’s economic performance; and
  b. The obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE.

 

Accordingly, the accounts of SEA is consolidated in the accompanying financial statements.

 

F-17
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

3. VARIABLE INTEREST ENTITY (“VIE”) (Continued)

 

The carrying amount of the VIE’s assets and liabilities were as follows:

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Current assets  $9,370   $       18,850 
Current liabilities   (43,288)   (51,272)
Net deficit  $(33,918)  $(32,422)

 

   As of 
   June 30, 2022   December 31, 2021 
         
Current assets:          
Cash  $7,626   $       17,493 
Prepaid taxes   1,744    1,357 
Total current assets  $9,370   $18,850 
           
Current liabilities:          
Accounts payable – intercompany  $42,501   $49,724 
Other payables and accrued liabilities   787    1,548 
Total current liabilities  $43,288   $51,272 
           
Net deficit  $(33,918)  $(32,422)

 

The summarized operating results of the VIE’s are as follows:

 

                     
   For the three months ended
June 30,
   For the six months ended
June 30,
 
   2022   2021   2022   2021 
                 
Operating revenues  $-   $-   $-   $- 
Gross profit  $-   $-   $-   $- 
Profit (loss) from operations  $1,723   $(5,019)  $(3,219)  $(11,967)
Net income (loss)  $1,723   $1,912   $(3,219)  $(9,949)

 

4. CASH AND CASH EQUIVALENTS

 

As of June 30, 2022 and December 31, 2021 the Company has $1,807,437 and $2,597,848, respectively, of cash and cash equivalents, which consists of $666,779 and $554,864, respectively, of cash in banks and $1,134,542 and $1,975,347, respectively, of time deposits placed with banks or other financial institutions and are all highly liquid investments with an original maturity of three months or less. The effective interest rate for the time deposits ranged between 1.10% to 1.17% per annum for the three and six months ended June 30, 2022. The effective interest rate for the time deposits ranged between 1.80% to 2.15% per annum for the three and six months ended June 30, 2021. As of June 30, 2022 and December 31, 2021, $319,994 and $295,761 of these balances are not covered by deposit insurance, respectively.

 

F-18
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

5. ACCOUNTS RECEIVABLE

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Accounts receivable  $214   $       - 
Allowance for doubtful accounts   -    - 
Total accounts receivable  $214   $- 

 

6. INVENTORIES

 

Inventories consist of the following:

 

           
   As of 
   June 30, 2022   December 31, 2021 
           
Finished goods  $346,744   $       375,535 

 

For the three months ended June 30, 2022, and 2021, the Company did not recognize any inventory write-downs. For the six months ended June 30, 2022, and 2021, the Company recognized inventory write-downs of $0 and $36,636 respectively.

 

7. PREPAYMENTS AND DEPOSITS

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Receivables from sales distributors  $58,477   $       115,379 
Deposits to suppliers   240,592    301,233 
Subtotal   299,069    416,612 
Less: Provision for doubtful accounts   (120,372)   (121,095)
Total  $178,697   $295,517 

 

Movements of allowance for doubtful accounts are as follows:

 

           
  

For the six

months ended

June 30, 2022

  

For the

year ended

December 31, 2021

 
         
Beginning balance  $121,095   $                - 
Addition   -    121,514 
Write off   -    - 
Exchange rate effect   (723)   (419)
Ending balance  $120,372   $121,095 

 

F-19
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

8. PROPERTY AND EQUIPMENT, NET

 

Property and equipment, net consist of the following:

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Computer and office equipment  $78,885   $82,298 
Furniture & fixtures   116,004    122,185 
Leasehold improvements   192,323    202,570 
Vehicle   93,709    98,702 
Subtotal   480,921    505,755 
Less: accumulated depreciation   (311,006)   (289,956)
Total  $169,915   $215,799 

 

Depreciation expense for the three months ended June 30, 2022 and 2021 amounted to $17,954 and $19,009, respectively. Depreciation expense for the six months ended June 30, 2022 and 2021 amounted to $36,661 and $38,179, respectively.

 

9. INTANGIBLE ASSETS, NET

 

Intangible assets, net, consist of the following:

 

           
    As of  
    June 30, 2022     December 31, 2021  
             
Computer software   $ 32,710     $ 34,453  
Less: accumulated amortization     (30,109 )     (30,793 )
Total   $ 2,601     $ 3,660  

 

Amortization expense for the three months ended June 30, 2022 and 2021 amounted to $439 and $496, respectively. Amortization expense for the six months ended June 30, 2022 and 2021 amounted to $897 and $1,006, respectively.

 

10. INVESTMENT IN MARKETABLE SECURITIES

 

  (i) On May 17, 2018, the Company purchased 83,333 shares of common stock in Greenpro Capital Corp. for $500,000 at a purchase price of $6 per share.
     
  (ii) On July 30, 2018, the Company disposed 20 shares of common stock in Greenpro Capital Corp. for $125 at a purchase price of $6.2613 per share.
     
  (iii) On October 16, 2018, the Company purchased 33,333 shares of common stock in Greenpro Capital Corp. for $1,000 at a purchase price of $0.03 per share.
     
  (iv) On November 3, 2020, the Company received dividend of 6,667 shares of common stock in DSwiss, Inc. for $76,671 at fair value of $11.50 per share from Greenpro Capital Corporation as result of its Spin-off of DSwiss, Inc.’s shares
     
  (v) On December 9, 2020, the Company received dividend of 16,663 shares of common stock in DSwiss, Inc. for $83,315 at fair value of $5 per share from Greenpro Capital Corporation as result of its Spin-off of DSwiss, Inc.’s shares.
     
  (vi) On September 27, 2021, the Company received dividend of 11,665 shares of common stock in SEATech Ventures Corp. for $18,874 at fair value of $1.62 per share from Greenpro Capital Corp as a dividend income since Greenpro Capital Corp previously owned these shares.

 

F-20
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

10. INVESTMENT IN MARKETABLE SECURITIES (Continued)

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Cost of investment  $89,001   $577,035 
Dividend income from Greenpro Capital Corp.   -    18,939 
Unrealized holding loss   (52,889)   (505,231)
Exchange rate effect   (405)   (1,742)
Investment in marketable securities  $35,707   $89,001 

  

11. INVESTMENT IN NON-MARKETABLE SECURITIES

 

On April 3, 2019, the Company purchased a 5% of stock or 15,000,000 shares of common stock in Phoenix Plus Corp. for $1,500 at purchase price of $0.0001 per share.

    As of  
Phoenix Plus Corporation   June 30, 2022     December 31, 2021  
             
Cost of investment   $ 1,500     $ 1,500  
                 
Investment in non-marketable securities   $ 1,500     $ 1,500  

 

12. OTHER PAYABLES AND ACCRUED LIABILITIES

           
   As of 
    June 30, 2022    December 31, 2021 
Professional fees  $142,622   $436,541 
Promotion expenses   40,360    36,024 
Payroll   54,018    22,669 
Commissions   247,645    219,721 
Tax penalty   75,000    75,000 
Others   77,388    68,400 
Total  $637,033   $858,355 

 

Certain amounts have been reclassified to conform to current period presentation.

 

F-21
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

13. RELATED PARTY BALANCES AND TRANSACTIONS

 

Related party balances

 

Accounts payable – related parties

 

Name of Related
Party
  Relationship  Nature 

As of

June 30, 2022

   As of
December 31, 2021
 
               
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)  The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd  Purchases of products for the provision of complementary health therapies  $14,322   $         - 
DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC  Purchases of products for the provision of complementary health therapies   85    - 
Total        $14,407   $- 

 

Amount due from related parties

 

Name of Related

Party

  Relationship  Nature 

As of

June 30, 2022

   As of
December 31, 2021
 
               
Agape ATP (Asia) Limited (“AATP Asia”)  Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia  Expenses paid for AATP Asia  $-   $2,214 
Hostastay Sdn. Bhd. (“Hostastay”)  Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021  Sublease rent due from Hostastay   4,548    4,790 
Total        $4,548   $7,004 

 

F-22
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

 

Related party balances

 

Amount due to related parties

 

Name of Related

Party

  Relationship  Nature 

As of

June 30, 2022

   As of
December 31, 2021
 
               
DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC  Rental due and expenses paid by DSYWLC  $2,015   $         - 
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchase of beauty products   67    - 
Total        $2,082   $- 

 

Related party transactions

 

Purchases

 

Name of Related        For the three months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)  The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd  Purchases of products for the provision of complementary health therapies  $63,142   $    - 
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchases of beauty products   395    - 
DSY Wellness & Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.  Purchases of products for the provision of complementary health therapies   127    - 
Total        $63,664   $- 

 

F-23
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

 

Related party transactions

 

Purchases

 

 

Name of Related        For the six months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)  The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd  Purchases of products for the provision of complementary health therapies  $74,909   $    - 
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchases of beauty products   395    - 
DSY Wellness & Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.  Purchases of products for the provision of complementary health therapies   127    - 
Total        $75,431   $- 

 

F-24
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

 

Related party transactions

 

Other purchases

 

Name of Related        For the three months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchases of beauty products  $69   $- 
Total        $69   $- 

 

Name of Related        For the six months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchases of beauty products  $69   $- 
Total        $69   $- 

 

Commission

 

Name of Related        For the three months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
Mr. How Kok Choong  Mr. How Kok Choong, the CEO and director of the Company  Commission expense  $2,443   $    - 
Total        $2,443   $- 

 

 

Name of Related        For the six months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
Mr. How Kok Choong  Mr. How Kok Choong, the CEO and director of the Company  Commission expense  $5,148   $   - 
Total        $5,148   $- 

 

F-25
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

 

Related party transactions

 

Office rental expense

 

Name of Related        For the three months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC  Office rental expense
  $5,602   $   - 
Total        $5,602   $- 

 

Name of Related        For the six months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC  Office rental expense
  $11,203   $   - 
Total        $11,203   $- 

 

Related party transactions

 

Other income

 

Name of Related        For the three months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
Hostastay Sdn. Bhd. (“Hostastay”)  Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021  Sublease rental income due from Hostastay  $-   $1,458 
Total        $-   $1,458 

 

Name of Related        For the six months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
Hostastay Sdn. Bhd. (“Hostastay”)  Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021  Sublease rental income due from Hostastay  $-   $2,929 
Total        $-   $2,929 

 

14. STOCKHOLDERS’ EQUITY

 

Preferred stock

 

As of June 30, 2022, and December 31, 2021, there were 200,000,000 preferred stocks authorized but none were issued and outstanding.

 

Common stock

 

As of June 30, 2022, and December 31, 2021, there were 1,000,000,000 common stocks authorized, 75,452,012 and 290,460,047 shares issued and outstanding, respectively.

 

A share forfeiture agreement (the “Share Forfeiture Agreement”) dated January 20, 2022, between the Company and Mr. How Kok Choong, the CEO and director of the Company, pursuant to which Mr. How Kok Choong agreed to forfeit 215,008,035 shares of common stock of the Company. As a result, the outstanding shares was reduced by 215,008,035 shares of common stock.

 

There were no stock options, warrants or other potentially dilutive securities outstanding as of June 30, 2022 and December 31, 2021. 

 

F-26
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

15. NON-CONTROLLING INTEREST

 

The Company’s non-controlling interest consists of the following:

 

           
   As of 
   June 30, 2022   December 31, 2021 
DSY Wellness:          
Paid-in capital  $97   $97 
Retained earnings (Accumulated deficit)   10,773    (436)
Accumulated other comprehensive (loss) income   (269)   3 
Non Controlling interest Gross   10,601    (336)
ASL   -    - 
Total  $10,601   $(336)

 

16. INCOME TAXES

 

The United States and foreign components of loss before income taxes were comprised of the following: 

 

                     
   For the three months ended
June 30,
   For the six months ended
June 30,
 
   2022   2021   2022   2021 
                 
Tax jurisdictions from:                    
Local – United States  $(187,379)  $(96,370)  $(293,804)  $(204,295)
Foreign – Malaysia   (189,395)   (177,983)   (354,459)   (469,675)
Foreign – Hong Kong   (27,178)   (363,901)   (45,847)   (291,814)
Loss before income tax  $(403,952)  $(638,254)  $(694,110)  $(965,784)

 

The provision for income taxes consisted of the following:

 

                     
   For the three months ended
June 30,
   For the six months ended
June 30,
 
   2022   2021   2022   2021 
                 
Current:                    
- Local  $-   $(22,205)  $-   $(22,205)
- Foreign   (392)   (14,461)   (8,680)   (41,185)
                     
Deferred:                    
- Local   -    -    -    - 
- Foreign   -    32,695    -    53,299 
Provision for income tax  $(392)  $(3,971)  $(8,680)  $(10,091)

 

The effective tax rate in the periods presented is the result of the mix of income earned in various tax jurisdictions that apply a broad range of income tax rates. The Company and its subsidiary that operate in various countries: United States, Malaysia (including Labuan) and Hong Kong that are subject to taxes in the jurisdictions in which they operate, as follows:

 

F-27
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

16. INCOME TAXES (Continued)

 

United States of America

 

Agape ATP Corporation was incorporated in the State of Nevada and is subject to the tax laws of the United States of America with a corporate tax rate of 21% on its taxable income. Agape ATP Corporation also subject to controlled foreign corporations Subpart F income (“Subpart F”) tax, which is a tax primarily on passive income from controlled foreign corporations with a tax rate of 35%. In addition, the Tax Cuts and Jobs Act imposed a global intangible low-taxed income (“GILTI”) tax, which is a tax on certain off-shore earnings at an effective rate of 10.5% for tax years (50% deduction of the current enacted tax rate of 21%) with a partial offset for 80% foreign tax credits. If the foreign tax rate is 13.125% or higher, there will be no U.S. corporate tax after the 80% foreign tax credits are applied.

 

For the three and six months ended June 30, 2022 and 2021, the Company’s foreign subsidiaries did not generate any income that are subject to Subpart F tax and GILTI tax.

 

As of June 30, 2022 and December 31, 2021, the operations in the United States of America incurred approximately $914,000 and $620,000, respectively, of cumulative net operating losses (“NOL”) which can be carried forward to offset future taxable income or Subpart F and GILTI taxes. These balances can be carried forward indefinitely. The deferred tax valuation allowance as of June 30, 2022 and December 31, 2021 were approximately $192,000 and $130,000, respectively.

 

Malaysia

 

Changes to the Labuan Business Activity Tax Act (LBATA) 1990 which was gazetted and came into operation on January 1, 2019 mandates companies incorporated in Labuan to satisfy the “substantial activity requirements” to qualify for the preferential tax rate of 3% on net audited profit. Subsequently, on April 29, 2020, a circular setting out revisions to the “substantial activity requirements” was issued. As Agape ATP Corporation did not maintain a permanent establishment in Labuan, and therefore did not satisfy the said requirements, the company was subjected to tax at 24% on its net audited profit. On June 11, 2021, Agape ATP Corporation made an irrevocable election to be taxed under the Malaysian Income Tax Act 1967 as the elected tax regime is more tax efficient to the entity compare to LBATA.

 

Agape Superior Living Sdn Bhd, Agape S.E.A Sdn Bhd., Wellness ATP International Holdings Sdn Bhd. and DSY Wellness International Sdn. Bhd. are governed by the income taxes laws of Malaysia and the income taxes provision in respect of operations in Malaysia is calculated at the applicable tax rates on the taxable income for the periods based on existing legislation, interpretations and practices in respect thereof. Under the Income Tax Act of Malaysia, enterprises that incorporated in Malaysia are usually subject to a unified 24% enterprise income taxes rate while preferential tax rates, tax holidays and even tax exemption may be granted on case-by-case basis. The tax rate for small and medium sized companies (generally companies incorporated in Malaysia with paid-in capital of RM 2,500,000 or less) is 17% for the first RM 600,000 (or approximately $150,000) for the three months ended June 30, 2022 and 2021, with the remaining balance being taxed at the 24% rate.

 

As of June 30, 2022 and December 31, 2021, the operations in Malaysia incurred approximately $1,311,000 and $946,000, respectively, of cumulative net operating losses (“NOL”) which can be carried forward to offset future taxable income. Approximately $944,000 of the net operating loss carry forwards will expire in 2028, if unutilized. The deferred tax valuation allowance as of June 30, 2022 and December 31, 2021 were approximately $309,000 and $227,000, respectively.

 

Hong Kong

 

Agape ATP International Holding (HK) Limited is subject to Hong Kong Profits Tax, which is charged at the statutory income rate of 16.5% on its assessable income derived from Hong Kong. Business income derived or business expenses incurred outside the Special Administrative Region is not subject to Hong Kong Profits Tax or deduction. As Agape ATP International Holding (HK) Limited is an investment holding company without operating activities, the net operating loss for Hong Kong is considered immaterial.

 

F-28
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

16. INCOME TAXES (Continued)

 

The following table sets forth the significant components of the aggregate deferred tax assets of the Company:

 

           
   As of 
   June 30, 2022   December 31, 2021 
Deferred tax assets:          
Net operating loss carry forwards in U.S.  $191,976   $130,277 
Net operating loss carry forwards in Malaysia   309,415    227,106 
Less: valuation allowance   (501,391)   (357,383)
Deferred tax liabilities:          
Depreciation   (17,975)   (15,574)
Deferred tax liabilities, net  $(17,975)  $(15,574)

 

Uncertain tax positions

 

The Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of June 30, 2022 and December 31, 2021, the Company did not have any significant unrecognized uncertain tax positions. The Company did not incur interest and penalties tax for the three and six months ended June 30, 2022 and 2021.

 

17. CONCENTRATIONS OF RISKS

 

(a) Major customers

 

For the three months ended June 30, 2022, and 2021, no customer accounted for 10% or more of the Company’s total revenues. For the six months ended June 30, 2022, and 2021, no customer accounted for 10% or more of the Company’s total revenues.

 

As of June 30, 2022, one individual customer accounted for 100.0% of the Company’s balance of accounts receivable. There was no accounts receivable balance as of December 31, 2021.

 

(b) Major vendors

 

For the three months ended June 30, 2022, three vendors accounted for approximately 70%, 11% and 17% of the Company’s total purchases, respectively. For the six months ended June 30, 2022, two vendors accounted for approximately 46% and 43% of the Company’s total purchases, respectively. For the three and six months ended June 30, 2021, one vendor accounted for 100% of the Company’s total purchases.

  

As of June 30, 2022, three vendors accounted for approximately 36%, 40% and 20% of the Company’s total balance of accounts payable, respectively. The vendor which accounted for 40% of the Company’s total balance of accounts payable is a related company, i.e. CTA Nutriceuticals (Asia) Sdn Bhd. As of December 31, 2021, one vendor accounted for 100% of the total balance of accounts payable. 

 

F-29
 

  

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

17. CONCENTRATIONS OF RISKS (Continued)

 

(c) Commission Expenses to Sales Distributors and Stockists

 

For the three months ended June 30, 2022, one sales distributor accounted for 10% of the Company’s commission expense. For the three months ended June 30, 2021, one sales distributor accounted for approximately 21.9% of the Company’s commission expense.

 

For the six months ended June 30, 2022, no sales distributor accounted for 10% or more of the Company’s commission expense. For the six months ended June 30, 2021, one distributor accounted for approximately 16.2% of the Company’s total purchases.

 

(d) Credit risk

 

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. As of June 30, 2022, and December 31, 2021, $666,779 and $554,864 were deposited with financial institutions, respectively, $319,994 and $295,761 of these balances are not covered by deposit insurance, respectively. While management believes that these financial institutions are of high credit quality, it also continually monitors their credit worthiness.

 

Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its account receivable is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. Historically, the Company did not have any bad debt on its account receivable.

 

(e) Exchange rate risk

 

The Company cannot guarantee that the current exchange rate will remain steady; therefore, there is a possibility that the Company could post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually post higher or lower profit depending on exchange rate of RM and HK$ converted to US$ on that date. The exchange rate could fluctuate depending on changes in political and economic environments without notice.

 

18. COMMITMENTS AND CONTINGENCIES

 

Lease commitments

 

On April 1, 2020, the Company adopted ASC 842 for ASL’s office space lease and sales and training center as the lease commencement date upon the acquisition of ASL. The Company recognized lease liabilities of approximately $490,000, with a corresponding right-of-use (“ROU”) asset in the same amount based on the present value of the future minimum rental payments of the lease, using an effective interest rate of 5.5%, which was determined using the Company’s estimated incremental borrowing rate.

 

On May 31, 2021, the Company entered into two separate two-year leases extension with the modified lease expiring May 31, 2023 for its office space and expiring August 31, 2023 for its training center. The lease modification required the Company to re-measure the ROU assets and lease liabilities based on the modified leases. The Company recognized a reduction of $3,250 in ROU assets and lease liabilities upon lease modifications based on the present value of the future minimum rental payments of the lease, using an effective interest rate of 5.5%, which was determined using the Company’s estimated incremental borrowing rate.

 

The weighted remaining term of the lease is approximately 1.17 years.

 

F-30
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

18. COMMITMENTS AND CONTINGENCIES (Continued)

 

The five-year maturity of the Company’s operating lease liabilities is as follow:

 

      
Twelve Months Ending June 30,  Operating lease
liabilities
 
     
2023  $155,474 
2024   10,898 
Thereafter   - 
Total lease payments   166,372 
Less: interest   (4,987)
Present value of lease liabilities  $161,385 

 

The Company also leases one office and operation center, and one shophouse with an expiring term of twelve months or less, which were classified as operation leases. Since the lease terms for these leases were twelve months or less, a lessee is permitted to elect not to recognize lease assets and liabilities. The Company has elected not to recognize lease assets and liabilities on these leases. As of June 30, 2022, the Company’s commitment for minimum lease payment under these operating leases within the next twelve months were $11,416.

 

Rent expense for the three months ended June 30, 2022 and 2021 was $54,237 and $45,560, respectively. Rent expense for the six months ended June 30, 2022, and 2021 was $98,312 and $91,521, respectively.

 

Contingencies

 

Legal

 

From time to time, the Company is party to certain legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued, as well as the total amount of reasonably possible losses with respect to such matters, individually and in the aggregate, are not deemed to be material to the consolidated financial statements.

 

COVID-19

 

Since the declaration of the COVID-19 pandemic on March 11, 2020 by the World Health Organization or WHO, Malaysia has been put through various stages of lockdowns such as (1) full movement control orders (“MCO”), under which, quarantines, travel restrictions, and the temporary closure of stores and facilities in Malaysia were made mandatory, (2) MCO were eased to a Conditional Movement Control Order (“CMCO”) where most business sectors were allowed to operate under strict rules and Standard Operating Procedures mandated by the government of Malaysia and (3) CMCO were further relaxed to Recovery Movement Control Order (“RMCO”). On January 12, 2021, due to a resurgence of COVID-19 cases, the Malaysian government declared a state of emergency nationwide to combat COVID-19. Intermittent lockdowns were imposed in various states and districts in the country. February 2021 marked a significant month for Malaysia as all frontline staff of the country, which comprised those in healthcare, police, the Volunteers Department of Malaysia, the Fire and Rescue Department of Malaysia and civil defense sectors were vaccinated. On February 16, 2021, Prime Minister Tan Sri Muhyiddin Yassin announced that a National COVID-19 Immunization Plan will be implemented for one year after February 2021, which 80% of the Malaysia population will be vaccinated to achieve herd immunization. 

 

F-31
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

18. COMMITMENTS AND CONTINGENCIES (Continued)

 

On March 5, 2021, lockdowns in most part of the country was eased to a CMCO, nevertheless, COVID-19 cases in the country continue to rise. On May 12, 2021, Malaysia was again put under a full lockdown nationwide, until the earlier of (i) daily COVID-19 cases infection of the country fall below 4,000; (ii) intensive Unit Care, or ICU, wards start operating at a moderate level; or (iii) 10% of the Malaysian population is fully vaccinated. The country was administering over 400,000 doses of COVID-19 vaccines daily. On July 17, 2021, the full lockdown was slightly eased as 13.9% of the Malaysian population was fully vaccinated, with another 30% having received at least one dose of the vaccine. The COVID-19 situation in the country showed no sign of abating. Kuala Lumpur and Selangor remained the epicenter of the latest wave of infections. Total COVID-19 cases in the country surpassed the one million mark on July 25, 2021, and daily cases hit a record high of 24,599 on August 26, 2021. Despite the deteriorating COVID-19 state, the government lifted Kuala Lumpur from Enhanced Movement Control Order (“EMCO”) ahead of schedule and ended the nationwide state of emergency on August 1, 2021. Parliament met for the first time this year on July 26, 2021. Malaysia pressed on with its National COVID-19 Immunization Plan, fast inoculating of its residents. COVID-19 infections started to drop below the 10,000 mark daily, beginning October 3, 2021. Effective October 11, 2021, interstate and international travel restrictions were lifted for residents who had been fully vaccinated against COVID-19 as the country achieved its target of inoculating 90% of its adult population.

 

Malaysia officially transitioned to the endemic phase of COVID-19 effective April 1, 2022. Restrictions on businesses and people are minimal. Meanwhile, the government continues to encourage inoculation for those between the ages of 5 to 11 years and its adolescent group which comprised those between the ages 12 to 17. Adults who have been fully vaccinated, i.e. received two doses of the COVID-19 vaccine are encouraged to take booster shots.

 

Substantially all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially, affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact, almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:

 

  temporary closure of offices, travel restrictions, financial impact of the Company’s customers or suspension supplies may be negatively affected, and could continue to negatively affect the demand for the Company’s product;
  the Company may have to provide significant sales incentives to its customers during the outbreak, which may in turn materially adversely affect its financial condition and operating results; and
  any disruption of the Company’s supply chain, logistics providers or customers could adversely impact its business and results of operations, including causing the Company or its suppliers to cease manufacturing for a period of time or materially delay delivery to its customers, which may also lead to loss of its customers.

 

Because of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the COVID-19 cannot be reasonably estimated at this time. There is no guarantee that the Company’s total revenues will grow or remain at similar levels year over year in 2022 and beyond.

 

19. SUBSEQUENT EVENT

 

On July 19, 2022, Greenpro Capital Corp. filed a certificate of change with the Secretary of State of Nevada to effect a reverse split of the company’s common stock at the ratio of 10-for-1 effective July 28, 2022. Under the reverse stock split, each 10 pre-split share of common stock outstanding will automatically combine into 1 new share of common stock of the company. As at June 30, 2022, the Company has an investment of 116,646 common stock of Greenpro Capital Corp. valued at $24,853.45. The Company’s investment of 116,646 common stock of Greenpro Capital Corp. shall be reduced to 11,665 as a result of the reverse stock split. However, the value of the Company’s investment in Greenpro Capital Corp. as at June 30,2022 remained unchanged despite the reduction in the number of common stock.

 

F-32
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The information contained in this quarter report on Form 10-Q is intended to update the information contained in our Form 10-K, dated March 28, 2022, for the year ended December 31, 2021 and presumes that readers have access to, and will have read, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other information contained in such Form 10-K. The following discussion and analysis also should be read together with our unaudited condensed consolidated financial statements and the notes to the unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q.

 

The following discussion contains certain statements that may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements appear in a number of places in this Report, including, without limitation, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements are not guarantees of future performance and involve risks, uncertainties and requirements that are difficult to predict or are beyond our control. Forward-looking statements speak only as of the date of this quarterly report. You should not put undue reliance on any forward-looking statements. We assume no responsibility to update the forward-looking statements contained in this transition report on Form 10-Q. The following should also be read in conjunction with the unaudited condensed Consolidated Financial Statements and notes thereto that appear elsewhere in this report.

 

Company Overview

 

Agape ATP Corporation, a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016.

 

Agape ATP Corporation operates through its subsidiaries, namely, Agape ATP Corporation, a company incorporated in Labuan, Malaysia, and Agape Superior Living Sdn. Bhd. (“ASL”), a company incorporated in Malaysia. .

 

Agape ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with 100% equity interest in Agape ATP International Holding Limited, a company incorporated in Hong Kong.

 

On May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in Agape Superior Living Sdn. Bhd., a network marketing entity incorporated in Malaysia.

 

Agape Superior Living Sdn. Bhd. is a limited company incorporated on August 8, 2003, under the laws of Malaysia.

 

On September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn, Bhd. (“WATP”), a wholly owned subsidiary under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle.

 

On November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (“DSY Wellness”) with an independent third party which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies.

 

The Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs.

 

Agape ATP Corporation is a company that provides health and wellness products and health solution advisory services to our clients. The Company primarily focus its efforts on attracting customers in Malaysia. Its advisory services center on the “ATP Zeta Health Program”, which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.

 

3
 

 

In order to strengthen the Company’s supply chain, on May 8, 2020, the Company has successfully acquired approximately 99.99% of ASL, with the goal of securing an established network marketing sales channel that has been established in Malaysia for the past 15 years. ASL has been offering the Company’s ATP Zeta Health Program as part of its product lineup. As such, the acquisition creates synergy in the Company’s operation by boosting the Company’s retail and marketing capabilities. The newly acquired subsidiary allows the Company to fulfill its mission of “helping people to create health and wealth” by providing a financially rewarding business opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle.

 

Via ASL, the Company offers three series of programs which consist of different services and products: ATP Zeta Health Program, ÉNERGÉTIQUE and BEAUNIQUE.

 

The ATP Zeta Health Program is a health program designed to promote health and general wellbeing designed to prevent health diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity through a combination of modern health supplements, proper nutrition and advice from skilled dieticians as well as trained members and distributors.

 

The ÉNERGÉTIQUE series aims to provide a total dermal solution for a healthy skin beginning from the cellular level. The series is comprised of the Energy Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.

 

The BEAUNIQUE product series focuses on the research of our diet’s impact on modifying gene expressions in order to address genetic variations and deliver a nutrigenomic solution for every individual.

 

The Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution advisory services; and therefore, incorporated WATP. Upon its establishment, WATP started collaborating with ASL to carry out various wellness programs.

 

To further its reach in the Health and Wellness Industry, on November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (“DSY Wellness”) with an independent third party which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies.

 

Results of Operation

 

For the three months ended June 30, 2022 and 2021

 

Revenue

 

We generated revenue of $396,707 for the three months ended June 30, 2022 as compared to $303,786 for the three months ended June 30, 2021, representing an increase of $92,921 or approximately 30.6%. The increase was predominately due to the Company’s operations in the provision of complementary health therapies which have taken off during the quarter and the business segment contributed approximately 54% of the Company’s total revenue for the three months ended June 30, 2022.

 

Cost of Revenue

 

Cost of revenue for the three months ended June 30, 2022 amounted to $109,383 as compared to $35,623 for the three months ended June 30, 2021, representing a significant increase of $73,760 or approximately 207.1%. The significant increase in cost of revenue is due to higher cost of revenue associated with the provision of complementary health therapies.

 

The Company’s cost of revenue typically comprised of freight-in, cost of goods purchased, and packing materials for the three months ended June 30, 2022 and 2021, respectively. 

 

Gross Profit

 

Gross profit for the three months ended June 30, 2022 amounted to $287,324, representing a gross margin of approximately 72.4% as compared to $268,163 for the three months ended June 30, 2021, equivalent to a gross margin of approximately 88.3%. The decrease in gross margin was predominately due to lower gross margin associated with the provision of complementary health therapies as compared to the Company’s network marketing business.

 

4
 

 

Operating Expenses

 

Our operating expenses consist of selling expenses, commission expenses and general and administrative expenses.

 

Selling expenses

 

Selling expenses for the three months ended June 30, 2022 amounted to $79,587 as compared to $100,838 for the three months ended June 30, 2021, a reduction of $21,251 or approximately 21.1%, predominantly due to a reduction in head count. The Company’s selling expenses typically comprise salaries and benefits expenses which makes up as much as approximately 70% to 80% of total selling expenses, credit card processing fees and promotional expenses.

 

Commission expenses

 

Commission expenses were $62,557 and $92,774 for the three months ended June 30, 2022 and 2021, respectively. The decrease in commission expenses was in line with the decrease in revenue contribution from the Company’s network marketing business.

 

General and administrative expenses

 

General and administrative (“G&A”) expenses for the three months ended June 30, 2022 amounted to $451,363, as compared to $361,862 for the three months ended June 30, 2021, an increase of $89,501 or approximately 24.7%. The increase in G&A expenses for the three months ended June 30, 2022 was mainly due to G&A expenses associated with the provision of complementary health therapies. The Company’s G&A expenses typically comprise salaries and benefits expenses, rental expenses, professional expenses and depreciation expenses.

 

Provision for doubtful accounts

 

Provision for doubtful accounts were $0 and $121,686 for the three months ended June 30, 2022 and 2021, respectively, a significant decrease of $121,686 or 100.0%. The provision for doubtful accounts was in respect of prepayments to a supplier. As the prepayments remain outstanding for over a year, the likelihood of recovering the prepayments is remote.

 

Other Expenses, Net

 

For the three months ended June 30, 2022, we recorded an amount of $97,769 as other expenses, net as compared to $229,257 as other expenses, net for the three months ended June 30, 2021, a decrease of $131,488 or approximately 57.4%.

 

The net other expenses of $97,769 incurred during the three months ended June 30, 2022 comprised foreign currency exchange loss of $67,417, unrealized holding loss on marketable securities of $35,219, other income of $1,341 and interest income of $3,526. The net other expense of $229,257 incurred during the three months ended June 30, 2021 comprised other income of $11,770 and unrealized holding loss on marketable securities of $241,027.

 

Provision for Income Taxes

 

The Company recorded provision for income taxes of $392 and $3,971 for the three months ended June 30, 2022 and 2021, respectively. The Company’s provision for income taxes for the three months ended June 30,2022, was in respect of its operations in Malaysia. During the three months ended June 30, 2021, we recorded income taxes from our U.S. Subpart F and GILTI taxes on the stock dividend from Greenpro Capital Corp as a result of its Spin-off of DSwiss Inc.’s shares in 2020 and income taxes on Labuan’s interest income, offset by ASL’s taxable losses that can be carried forward for 7 years, which resulted in recognition of deferred tax assets on net operating loss and income tax benefits.

 

5
 

 

Net Loss

 

Net loss reduced by $237,881 from net loss of $642,225 for the three months ended June 30, 2021 to net loss of $404,344 for the three months ended June 30, 2022, mainly due to reasons as discussed above.

 

For the six months ended June 30, 2022 and 2021  

 

Revenue

 

We generated revenue of $805,667 for the six months ended June 30, 2022 as compared to $605,566 for the six months ended June 30, 2021, representing an increase of $200,101 or approximately 33.0%. The increase in revenue was predominantly contributed by the Company’s business sector in the sales of complementary health therapies.

 

Cost of Revenue

 

Cost of revenue for the six months ended June 30, 2022 amounted to $182,814 as compared to $113,214 for the six months ended June 30, 2021, representing a significant increase of $69,600 or approximately 61.5%. As explained in the above, the significant increase in cost of revenue is due to higher cost of revenue associated with the purchases of complementary health therapies.

 

The Company’s cost of revenue typically comprised of freight-in, cost of goods purchased, and packing materials for the six months ended June 30, 2022 and 2021 respectively. However, there was an inventory write-down of $36,809 in addition to those mentioned above for the six months ended June 30, 2021.

 

Gross Profit

 

Gross profit for the six months ended June 30, 2022 amounted to $622,853 as compared to $492,352 for the six months ended June 30, 2021. Gross margin for the six months ended June 30, 2022 was approximately 77.3% as compared to approximately 81.3% for the six months ended June 30, 2021. As explained in the above, the decrease in gross margin was due to lower gross margin associated with the provision of complementary health therapies as compared to the Company’s network marketing business.

 

Operating Expenses

 

Our operating expenses consist of selling expenses, commission expenses, G&A expenses and provision for doubtful accounts.

 

Selling expenses

 

Selling expenses for six months ended June 30, 2022 amounted to $194,198 as compared to $216,952 for the six months ended June 30, 2021, representing a decrease of $22,754 or approximately 10.5%. As explained in the above, the lower selling expenses was mainly due to reduction in headcount.

 

 Commission expenses

 

Commission expenses were $176,666 and $181,213 for the six months ended June 30, 2022 and 2021, respectively, a minor decrease of $4,547 or 2.5%. Commission expenses of the Company’s network marketing business follow a fixed sales plan, as is in line with the revenue generated from the Company’s network marketing activities.

 

General and administrative expenses

 

G&A expenses for six months ended June 30, 2022, amounted to $830,404 as compared to $724,008 for the six months ended June 30, 2021, an increase of $106,396 or approximately 14.7%. The increase in G&A expenses for the six months ended June 30, 2022 was mainly due to G & A expenses associated with the provision of complementary health therapies.

 

6
 

 

Other Income (Expenses)

 

For the six months ended June 30, 2022, we recorded an amount of $115,695 as other expenses, net as compared to $214,277 other expenses, net for the six months ended June 30, 2021, representing a decrease of $98,582 or approximately 46.0%. The net other expenses of $115,695 incurred during the six months ended June 30, 2022 comprised of other income of $12,826, interest income of $8,251, unrealized holding loss on marketable securities of $52,889 and foreign currency exchange loss of $83,883. The net other expenses of $214,277 incurred during the six months ended June 30, 2021 comprised of other expenses of $48,546 and unrealized holding loss on marketable securities of $165,731.

 

Provision for Income Taxes

 

The Company recorded provision for income taxes $8,680 and $10,091 for the six months ended June 30, 2022 and 2021, respectively. The Company’s provision for income taxes for the six months ended June 30,2022, was in respect of its operations in Malaysia. During the six months ended June 30, 2021, we recorded income taxes from our U.S. Subpart F and GILTI taxes on the stock dividend from Greenpro Capital Corp as a result of its Spin-off of DSwiss Inc.’s shares in 2020 and income taxes on Labuan’s interest income, offset by ASL’s taxable losses that can be carried forward for 7 years, which resulted in recognition of deferred tax assets on net operating loss and income tax benefits.

 

Net Loss

 

Net loss decreased by $273,085 from net loss of $975,875 for the six months ended June 30, 2021 to $702,790 for the six months ended June 30, 2022, mainly due to reasons as discussed above.

 

Liquidity and Capital Resources

 

On March 11, 2020, the World Health Organization or WHO declared the corona virus or COVID-19 a pandemic. To help counter the transmission of COVID-19, the government of Malaysia initiated movement control orders (“MCO”), the first effective March 18, 2020. The MCO had resulted in quarantines, travel restrictions, and the temporary closure of stores and facilities in Malaysia. The first MCO was extended three times, each for a two-weeks period, until May 12, 2020. On May 13, 2020, the MCO was eased to a Conditional Movement Control Order (“CMCO”) where most business sectors were allowed to operate under strict rules and Standard Operating Procedures mandated by the government of Malaysia. The CMCO was further relaxed, and on June 8, 2020, Malaysia moved into the Recovery Movement Control Order (“RMCO”). Due to a resurgence of COVID-19, CMCO was reimposed in the state of Sabah, Selangor, Kuala Lumpur and Putrajaya effective October 14, 2020. On November 7, 2020, the CMCO was extended to a wider geographical area to include another six states in the country. Effectively, ten of thirteen states in Malaysia were placed under CMCO with the exceptions of Perlis, Pahang and Kelantan. On January 1, 2021, the Government of Malaysia extended the Recovery Movement Control Order (“RMCO”) through March 31, 2021. On January 12, 2021, the Malaysian government declared a state of emergency nationwide to combat COVID-19. Intermittent lockdowns were imposed in various states and districts in the country.

 

On March 5, 2021, lockdowns in most part of the country was eased to a CMCO, nevertheless, COVID-19 cases in the country continue to rise. On May 12, 2021, Malaysia was again put under a full lockdown nationwide, until the earlier of (i) daily COVID-19 cases infection of the country fall below 4,000; (ii) intensive Unit Care, or ICU, wards start operating at a moderate level; or (iii) 10% of the Malaysian population is fully vaccinated. The country is administering over 400,000 doses of COVID-19 vaccines daily. On July 17, 2021, the full lockdown was slightly eased as 13.9% of the Malaysian population was fully vaccinated, with another 30% having received at least one dose of the vaccine. The COVID-19 situation in the country showed no sign of abating. Kuala Lumpur and Selangor remained the epicenter of the latest wave of infections. Total COVID-19 cases in the country surpassed the one million mark on July 25, 2021, and daily cases hit a record high of 24,599 on August 26, 2021. Despite the deteriorating COVID-19 state, the government lifted Kuala Lumpur from Enhanced Movement Control Order (“EMCO”) ahead of schedule and ended the nationwide state of emergency on August 1, 2021. Parliament met for the first time this year on July 26, 2021. Malaysia pressed on with its National COVID-19 Immunization Plan, fast inoculating its residents. COVID-19 infection started to drop below the 10,000 mark daily since beginning October 3, 2021. Effective October 11, 2021, interstate and international travel restrictions were lifted for residents who had been fully vaccinated against COVID-19 as the country achieved its target of inoculating 90% of its adult population.

 

7
 

 

Malaysia officially transitioned to the endemic phase of COVID-19 effective April 1, 2022. Restrictions on businesses and people are minimal. Meanwhile the government continues to encourage inoculation for those between the ages of 5 to 11 years and its adolescent group which comprised those between the ages 12 to 17. Adults who have been fully vaccinated, i.e. received two doses of the COVID-19 vaccine are encouraged to take booster shots.

 

Substantially all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially, affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact, almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:

 

  temporary closure of offices, travel restrictions, disruption or suspension of supplies, our customers may be negatively impacted financially resulting in which the demand for our products may be adversely affected;
  we may have to provide significant sales incentives to our customers during the outbreak, which may in turn materially adversely affect our financial condition and operating results; and
  any disruption of our supply chain, logistics providers or customers could adversely impact our business and results of operations, including causing us or our suppliers to cease manufacturing for a period of time or materially delay delivery to our customers, which may also lead to loss of our customers.

 

Although some of the countries from which our products are sourced are experiencing lockdowns, industries involve in the provision of food especially health products and pharmaceuticals are normally exempted. We may experience slight delay in products delivery lead time but barring unforeseen circumstances, the setback should be temporary.

 

We are currently operating primarily in Malaysia and anticipate expanding into the Asian markets in the future, with a particular focus, at least initially, on expanding into Thailand, Indonesia and Taiwan. We will explore expansion via e-commerce. When the pandemic has subsided or is over and restrictions on travelling between nations are uplifted, we will set up offices in the countries in which we operate to better service our customers.

 

Because of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the COVID-19 cannot be reasonably estimated at this time. There is no guarantee that our total revenues will grow or remain at the similar level year over year in 2022 and beyond.

 

The Company entered into a share forfeiture agreement with Mr. How Kok Choong, the CEO and director of the Company on January 20, 2022 in which Mr. How agreed to forfeit 215,008,035 shares of common stock of the Company. The forfeiture of shares has no effect on the Company’s liquidity and capital resources.

 

As of June 30, 2022, we had working capital of $1,753,170, consisting of cash in bank of $666,779 and time deposits of $1,134,542 as compared to working capital of $2,599,281 consisting of cash in bank of $554,864 and time deposits of $1,975,347 as of December 31, 2021.

 

Accumulated deficit of the company was $3,972,684 and $3,258,687, as of June 30, 2022 and December 31, 2021, respectively. In assessing our liquidity and going concern, management is projecting that the company’s revenue will revert to pre-pandemic level and growth generated from the Company’s foray in other sectors of the health and wellness industry such as the provision of complementary health therapies business, etc., generating sufficient cash therefrom to cover our operating expenses.

 

If we are unable to generate sufficient cash flow within the normal operating cycle of a twelve-month period to pay for the Company’s future payment obligations, we may have to consider supplementing our available sources of funds through the following avenues:

 

8
 

 

  other available sources of financing from Malaysia banks and other financial institutions; and
     
  financial support from our related parties and shareholders.

 

Based on the above initiatives, management is of the opinion that the company should have sufficient funds to meet its working capital requirements and debt obligations as they become due in the foreseeable future from the date of issuance of this Form 10-Q. However, there is no assurance that management will be successful in its plans.

 

The following summarizes the key components of our cash flows for the six months ended June 30, 2022 and 2021:

 

   For the six months ended June 30, 
   2022   2021 
         
Net cash used in operating activities  $(493,326)  $(134,748)
Net cash used in investing activities   (750)   (1,220)
Net cash used in financing activities   (178,926)   (16,588)
Effect of exchange rate on cash and cash equivalents   (117,409)   (64,244)
Net change in cash and cash equivalents  $(790,411)  $(216,800)

 

Operating activities

 

Net cash used in operating activities for the six months ended June 30, 2022 was $493,326 and were mainly comprised of the net loss of $702,790, increase in accounts receivables of $214, decrease in customer deposits of $175,936, payment of operating lease liabilities of $75,200 and decrease in other payables and accrued liabilities (including related party) of $164,056. The net cash used in operating activities was mainly offset by the non-cash depreciation and amortization expense of $37,558, amortization of operating right-of-use assets of $75,241, unrealized holding loss on marketable securities of $52,889, deferred tax provision of $2,401, decrease in amount due from related parties of $2,201, the decrease in inventories of $28,790, refund in prepaid taxes of $296,219, decrease in prepayments and deposits of $102,099, increase in accounts payable (including related party) of $22,211 and increase in income tax payables of $5,261.

 

Net cash used in operating activities for the six months ended June 30, 2021 was $134,748 and were mainly comprised of the net loss of $975,875, deferred tax benefit of $53,299 increase in prepayments and deposits of $15,120, the decrease in customer deposits of $60,618, the payment of operating lease liabilities of $74,399 and the decrease in other payables and accrued liabilities of $129,355. The net cash used in operating activities was mainly offset by the non-cash depreciation and amortization expense of $39,185, amortization of operating right-of-use assets of $75,387, unrealized holding loss on marketable securities of $165,731, inventories write-down of $36,636, provision for doubtful accounts of $121,686, the decrease of accounts receivables of $169,393, the decrease in inventories of $80,969, the refund in prepaid taxes of $448,054 and the increase in income tax payables of $36,877.

 

Investing activities

 

Net cash used in investing activities for the six months ended June 30, 2022 was $750, which was in respect of purchase of equipment.

 

Net cash used in investing activities for the six months ended June 30, 2021 was $1,220, which was in respect of purchase of equipment.

 

Financing activities

 

Deferred offering cost made up the entire net cash used in financing activities for the six months ended June 30, 2022 of $178,926.

 

Net cash used in financing activities for the six months ended June 30, 2021 was $16,588 which were mainly comprised of payment of deferred offering cost of $14,160 and advances to related parties of $2,428.

 

9
 

 

Credit Facilities

 

We do not have any credit facilities or other access to bank credit.

 

Off-Balance Sheet Arrangements

 

As of June 30, 2022, we have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

 

Critical Accounting Polices

 

Use of estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s consolidated financial statements include allowance for doubtful accounts, allowance for inventories obsolescence, useful lives of property and equipment, useful lives of intangible assets, impairment of long-lived assets, allowance for deferred tax assets, operating right-of-use assets, operating lease liabilities and uncertain tax position and impairment of investment in non-marketable securities. Actual results could differ from these estimates.

 

Revenue recognition

 

The Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606) using the modified retrospective method for contracts that were not completed as of June 30, 2019. This did not result in an adjustment to retained earnings upon adoption of this new guidance as the Company’s revenue was recognized based on the amount of consideration expected to receive in exchange for satisfying the performance obligations.

 

The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.

 

The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.

 

Sales of Health and Wellness products

 

- Performance obligations satisfied at a point in time

 

The Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods. The revenue is recorded net of estimated discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were insignificant sales returns.

 

The Company also sells coupons to its customers for cash at a discounted price of the value of the coupons. Customers can apply the value of the coupons for a reduction in the transaction price paid by the customer are recorded as a reduction of sales. The cash proceeds resulted from the sale of coupons are recognized as customer deposits until the coupons to be applied as a reduction of the health and wellness products transaction price upon such sales transactions occurred. The Company’s coupons have a validity period of six months. If the Company’s customers did not utilize the coupons after six months, the Company would recognize the forfeiture of the originated sales value of the coupons as net revenues.

 

10
 

 

Sales of Health and Wellness services

 

- Performance obligations satisfied at a point in time

 

The Company carries out its Wellness program, where the Company’s products are bundled with health screening test and a health camp program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test reports are completed and delivered to its customers during the consultation section in person. The Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health camp program was completed in the final day of the health camp.

 

Fair value of financial instruments

 

The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.

 

The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

 

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates (“ASUs”). Management periodically reviews new accounting standards that are issued. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or revised accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.

  

In November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating the impact ASU 2019-05 may have on its unaudited condensed consolidated financial statements.

 

Except for the above-mentioned pronouncements, there are no new recent issued accounting standards that will have a material impact on the consolidated financial position, statements of operations and cash flows.

 

11
 

 

ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Foreign exchange risk. Substantially most of our revenues are denominated in the Malaysian Ringgit while most of our expenses are denominated in U.S. dollar, Malaysian Ringgit and Hong Kong Dollar. We do not believe that we currently have any significant direct foreign exchange risk and have not hedged exposures denominated in foreign currencies or any other derivative financial instruments. Although in general, our exposure to foreign exchange risks should be limited, the value of an investment in our Common Stock may be affected by the foreign exchange rate between U.S. dollar and Malaysian Ringgit; and U.S. dollar and Hong Kong Dollar because the value of our business is effectively denominated in Malaysian Ringgit and Hong Kong Dollar, while the Common Stock is traded in U.S. dollars.

 

Credit risk. Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its trade receivables is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information.

 

ITEM 4 CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

As of the end of the period covered by this Report, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures(as defined in the Exchange Act Rules 13a-15(e) and 15d-15(e)). Based on the foregoing evaluation, our chief executive officer and chief financial officer concluded that, as of June 30, 2022, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses described below. 

 

Internal Control Over Financial Reporting

 

Our management, including our chief executive officer and chief financial officer, is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the company’s principal executive and principal financial officers and effected by the company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policies and procedures that:

 

  Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;
     
  Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
     
  Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

 

12
 

 

As of June 30, 2022, our management, including our chief executive officer and chief financial officer, assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and SEC guidance on conducting such assessments. Based on such evaluation, the Company’s management, including our chief executive and chief financial officer, concluded that, during the period covered by this Report, internal controls and procedures over financial reporting were not effective. This was due to deficiencies that existed in the design or operation of our internal controls over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses.

 

Identified Material Weakness

 

A material weakness in internal control over financial reporting is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the financial statements will not be prevented or detected.

 

Management, including our chief executive officer and chief financial officer identified the following material weakness during its assessment of internal controls over financial reporting as of June 30, 2022:

 

(i) insufficient full-time personnel with appropriate levels of accounting knowledge and experience to monitor the daily recording of transactions, address complex U.S. GAAP accounting issues and to prepare and review financial statements and related disclosures under U.S. GAAP; (ii) lack of a functional internal audit department or personnel that monitors the consistencies of the preventive internal control procedures and lack of adequate policies and procedures in internal audit function to ensure that the Company’s policies and procedures have been carried out as planned; (iii) lack of adequate segregation of duties and effective risk assessment, which in turn may cause the Company to face the likelihood of fraud or theft, due to poor oversight, governance and review to detect errors; (iv) we lack of proper procedures developed for system change management policies. Change management policies and procedures have not been developed. Critical change management control processes and procedures, such as change request and approval, periodic status reporting, user testing and acceptance, post-implementation review, etc., were either not performed or formally documented; (v) we lack of the following internal control procedures in relation of Third-Party (Service Organization) Vendor Management – (a) service evaluation and qualification assessment of third-party vendors were not performed for the period ended June 30, 2022 and (b) Management was not able to provide evidence of their review of their service providers’ SOC 1 and SOC 2, or ISO 27001 certificate reports and therefore unable to provide evidence of their review of the physical security and environmental controls in place at IP Serverone cloud server (which the Company’s financial system is hosted on; (vi) we lack of the following internal control procedures in relation of User Account Management – (a) Evidence relating to the authorization of database administrator user accounts and access was not preserved for the MLM System during the period ended June 30, 2022 and (b) Evidence relating to periodic recertification of MLM and SQL Finance System end user are privileged accounts and related access rights were preserved during the period ended June 30, 2022; (vii) we lack of the following internal control procedures in relation of Audit Logs and Segregation of Duty (“SOD”) Management – (a) MLM-DB level system/audit logs were not preserved. Procedures for periodic review and analysis of application (“AP”), operating system (“OS”), and database (“DB”) level audit logs were not established and performed and (b) An SOD conflict was identified, where administrative rights to AP, OS and DB levels of the MLM system were assigned to the CTO and (viii) we lack of qualified person to be able to provide the tax provision for the U.S. income taxes in connection with the Subpart F and GILTI taxable income.

 

Accordingly, the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls.

 

13
 

 

Management’s Remediation Initiatives

 

In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we will prepare written policies and procedures for accounting and financial reporting with respect to the requirements and application of both U.S. GAAP and SEC guidelines, to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including equity and debt transactions.

 

To further strengthen the Company’s internal controls, we plan to initiate the following measures going forward:

 

1. We intend to establish an internal audit function with assessment of Sarbanes-Oxley compliance requirements and improvement of overall internal control.
   
2. Once we hire additional employees, we intend to initiate a comprehensive training program and development plan to provide ongoing company-wide trainings regarding internal control and requirements of U.S. GAAP financial statements and related disclosures, with particular emphasis on our accounting staff.
   
3. We are seeking a U.S. tax professional to assist in the preparation of the Subpart F and GILTI tax provisions.

 

We anticipate that these initiatives will be at least partially, if not fully, implemented by the end of fiscal year 2022.

 

Changes in Internal Control over Financial Reporting:

 

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

14
 

 

PART II — OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We know of no materials, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any beneficial shareholder are an adverse party or has a material interest averse to us.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

15
 

 

ITEM 6. Exhibits

 

Exhibit No.   Description
     
31.1   Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer*
     
32.1   Section 1350 Certification of principal executive officer *
     
101.INS   Inline XBRL Instance Document*
     
101.SCH   Inline XBRL Schema Document*
     
101.CAL   Inline XBRL Calculation Linkbase Document*
     
101.DEF   Inline XBRL Definition Linkbase Document*
     
101.LAB   Inline XBRL Label Linkbase Document*
     
101.PRE   Inline XBRL Presentation Linkbase Document*
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

 

16
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  AGAPE ATP CORPORATION
  (Name of Registrant)
     
Date: August 11, 2022    
  By: /s/ How Kok Choong
  Title: 

Chief Executive Officer,

President, Director, Secretary and Treasurer

    (Principal Executive Officer and Principal Financial Officer)

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  AGAPE ATP CORPORATION
  (Name of Registrant)
     
Date: August 11, 2022    
  By: /s/ Andrew Lee Kam Fan
  Title:  Chief Financial Officer,

 

17

 

 

EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION

 

I, HOW KOK CHOONG, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Agape ATP Corporation (the “Company”) for the quarter ended June 30, 2022;

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 11, 2022 By:  /s/ How Kok Choong
    HOW KOK CHOONG
   

Chief Executive Officer,

President, Director, Secretary, Treasurer

    (Principal Executive Officer and Principal Financial Officer)

 

 

 

EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATION

 

I, ANDREW LEE KAM FAN, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Agape ATP Corporation (the “Company”) for the quarter ended June 30, 2022;

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 11, 2022 By:  /s/ Andrew Lee Kam Fan
    LEE KAM FAN
    Chief Financial Officer,

 

 

 

EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Agape ATP Corporation (the “Company”) on Form 10-Q for the quarter ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), The undersigned hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: August 11, 2022 By:  /s/ How Kok Choong
    HOW KOK CHOONG
    Chief Executive Officer, President, Director, Secretary, Treasurer
    (Principal Executive Officer and Principal Financial Officer)

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

EX-32.2 5 ex32-2.htm

 

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Agape ATP Corporation (the “Company”) on Form 10-Q for the quarter ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), The undersigned hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: August 11, 2022 By:  /s/ Andrew Lee Kam Fan
    LEE KAM FAN
    Chief Financial Officer

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

EX-101.SCH 6 aatp-20220630.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - VARIABLE INTEREST ENTITY (“VIE”) link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - CASH AND CASH EQUIVALENTS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - ACCOUNTS RECEIVABLE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - PREPAYMENTS AND DEPOSITS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - PROPERTY AND EQUIPMENT, NET link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - INTANGIBLE ASSETS, NET link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - NON-CONTROLLING INTEREST link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - CONCENTRATIONS OF RISKS link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SUBSEQUENT EVENT link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - VARIABLE INTEREST ENTITY (“VIE”) (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - ACCOUNTS RECEIVABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - PREPAYMENTS AND DEPOSITS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - INTANGIBLE ASSETS, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - NON-CONTROLLING INTEREST (Tables) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - SCHEDULE OF SUBSIDIARIES AND ASSOCIATES (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - SCHEDULE OF VARIABLE INTEREST ENTITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - VARIABLE INTEREST ENTITY (“VIE”) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - CASH AND CASH EQUIVALENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - SCHEDULE OF INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - INVENTORIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND DEPOSITS (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, NET (Details) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - SCHEDULE OF RELATED PARTIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000067 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000068 - Disclosure - SCHEDULE OF NON CONTROLLING INTEREST (Details) link:presentationLink link:calculationLink link:definitionLink 00000069 - Disclosure - SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX (Details) link:presentationLink link:calculationLink link:definitionLink 00000070 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAX (Details) link:presentationLink link:calculationLink link:definitionLink 00000071 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000072 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000073 - Disclosure - CONCENTRATIONS OF RISKS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000074 - Disclosure - SCHEDULE OF LEASE COMMITMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000075 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000076 - Disclosure - SUBSEQUENT EVENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 aatp-20220630_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 aatp-20220630_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 aatp-20220630_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Noncontrolling Interest [Member] Investment, Name [Axis] Agape ATP International Holding Limited [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Share Exchange Agreement [Member] Title of Individual [Axis] Mr.How Kok Choong [Member] Subsidiary Company Two [Member] Subsidiary Company Five [Member] Subsidiary Company [Member] Subsidiary Company One [Member] Subsidiary Company Three [Member] Subsidiary Company Four [Member] Product and Service [Axis] Health and Wellness Services [Member] Shipping and Handling [Member] Legal Entity [Axis] Social Security Organization [Member] Award Type [Axis] MYR Currency [Member] Employees Provident Fund [Member] Employment Insurance System [Member] Human Resource Development Fund [Member] Long-Lived Tangible Asset [Axis] Computer Equipment [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Furniture and Fixtures [Member] Leasehold Improvements [Member] Vehicles [Member] Finite-Lived Intangible Assets by Major Class [Axis] Computer Software, Intangible Asset [Member] Survivor Select [Member] Energized Mineral Concentrate [Member] Ionized Cal-Mag [Member] Omega Blend [Member] Beta Maxx [Member] Iron [Member] Young Formula [Member] Organic Youth Care Cleansing Bar [Member] ATPR Mito+ [Member] Lipomask [Member] Hyaluronic Acid Serum [Member] Mousse Facial Cleanser [Member] Trim+ [Member] Others - Products for the Provision of Complementary Health Therapies [Member] Others [Member] Product [Member] Variable Rate [Axis] Period-end MYR [Member] Period-end HKD [Member] Period-average MYR [Member] Period-average HKD [Member] Trading Activity [Axis] Variable Income Interest Rate [Member] Computer and Office Equipment [Member] Vehicle [Member] Greenpro Capital Corp. [Member] DSwiss Inc. [Member] SEATech Ventures Corp. [Member] Phoenix Plus Corporation [Member] Related Party [Axis] CTA Nutriceuticals Sdn Bhd [Member] DSY Wellness & Longevity Center Sdn Bhd [Member] Agape ATP Asia Limited [Member] Hostastay Sdn. Bhd. (“Hostastay”) [Member] DSY Wellness & Longevity Center Sdn Bhd [Member] DSY Beauty Sdn Bhd [Member] DSY Wellness and Longevity Center Sdn Bhd [Member] DSY Beauty Sdn Bhd [Member] How Kok Choong [Member] DSY Wellness and Longevity Center Sdn Bhd [Member] Hostastay Sdn. Bhd. (“Hostastay”) [Member] Share Forfeiture Agreements [Member] How Kok Choong Talent Limited [Member] Geographical [Axis] MALAYSIA HONG KONG Income Tax Authority [Axis] State and Local Jurisdiction [Member] Foreign Tax Authority [Member] UNITED STATES Labuan [Member] Scenario [Axis] Unutilized [Member] Customer [Axis] No Customer [Member] Concentration Risk Benchmark [Axis] Revenue from Contract with Customer Benchmark [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Accounts Receivable [Member] E-commerce [Member] One Individual Customers [Member] Vendor One [Member] Cost of Goods and Service Benchmark [Member] Supplier Concentration Risk [Member] Vendor Two [Member] Vendor Three [Member] Accounts Payable [Member] Vendor [Member] One Vendor [Member] One Sales Distributor [Member] No Sales Distributor [Member] Business Acquisition [Axis] ASL [Member] Training Center [Member] Unusual Risk or Uncertainty, Nature [Axis] COVID-19 Impact [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash and cash equivalents (Included $7,626 and $17,493 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of June 30, 2022 and December 31, 2021, respectively) Accounts receivable Amount due from related parties Inventories Prepaid taxes (Included $1,744 and $1,357 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of June 30, 2022 and December 31, 2021, respectively) Prepayments and deposits Total Current Assets OTHER ASSETS Property and equipment, net Intangible assets, net Operating right-of-use assets Investment in marketable securities Investment in non-marketable securities Deferred offering costs Total Other Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable Accounts payable – a related party Customer deposits Operating lease liabilities Other payables and accrued liabilities ($787 and $1,548 are included in the consolidated VIE that are without recourse to the credit of Agape ATP Corporation as of June 30, 2022 and December 31, 2021, respectively) Other payable – a related party Income tax payable Total Current Liabilities NON-CURRENT LIABILITIES Operating lease liabilities Deferred tax liabilities Total Non-current Liabilities TOTAL LIABILITIES STOCKHOLDERS’ EQUITY Preferred stock, $0.0001 par value; 200,000,000 shares authorized; None issued and outstanding Common Stock, par value $0.0001; 1,000,000,000 shares authorized, 75,452,012 and 290,460,047 shares issued and outstanding as of June 30, 2022 and December 31, 2021 respectively Additional paid in capital Accumulated deficit Accumulated other comprehensive income TOTAL AGAPE CORPORATION STOCKHOLDERS’ EQUITY NON-CONTROLLING INTERESTS TOTAL EQUITY TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY VIE consolidated amount of cash and cash equivalents VIE consolidated amount of prepaid taxes VIE consolidated amount of other payables and accrued liabilities Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] REVENUE COST OF REVENUE GROSS PROFIT SELLING COMMISSION GENERAL AND ADMINISTRATIVE PROVISION FOR DOUBTFUL ACCOUNTS TOTAL OPERATING EXPENSES LOSS FROM OPERATIONS OTHER (EXPENSES) INCOME Other income (expenses), net Interest income Unrealized holding loss on marketable securities Exchange loss, net TOTAL OTHER EXPENSES, NET LOSS BEFORE INCOME TAXES PROVISION FOR INCOME TAXES NET LOSS LESS: NET INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS NET LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION NET LOSS OTHER COMPREHENSIVE LOSS Foreign currency translation adjustment TOTAL COMPREHENSIVE LOSS Less: Comprehensive loss attributable to non-controlling interests COMPREHENSIVE LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION LOSS PER SHARE Basic and diluted WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Basic and diluted Statement [Table] Statement [Line Items] Beginning balance, value Shares, Outstanding, Beginning Balance Net loss Foreign currency translation adjustment Forfeiture of common stock Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited Ending balance, value Shares, Outstanding, Ending Balance Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Amortization Amortization of operating right-of-use assets Unrealized holding loss on marketable securities Deferred tax provision (benefit) Inventory write-downs Provision for doubtful accounts Changes in operating assets and liabilities: Accounts receivables Amount due from related parties Inventories Prepaid taxes Prepayments and deposits Accounts payable Accounts payable – a related party Customer deposits Operating lease liabilities Other payables and accrued liabilities Amount due to a related party Income tax payable Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Deferred offering costs Advances to related parties Net cash used in financing activities EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS DECREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, beginning of period CASH AND CASH EQUIVALENTS, end of period SUPPLEMENTAL CASH FLOWS INFORMATION Income taxes paid SUPPLEMENTAL NON-CASH FLOWS INFORMATION Changes in right-of-use assets and lease liabilities due to lease modifications Accounting Policies [Abstract] ORGANIZATION AND BUSINESS BACKGROUND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation and Presentation of Financial Statements [Abstract] VARIABLE INTEREST ENTITY (“VIE”) Cash and Cash Equivalents [Abstract] CASH AND CASH EQUIVALENTS Receivables [Abstract] ACCOUNTS RECEIVABLE Inventory Disclosure [Abstract] INVENTORIES Prepayments And Deposits PREPAYMENTS AND DEPOSITS Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT, NET Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS, NET Investment In Marketable Securities INVESTMENT IN MARKETABLE SECURITIES Investment In Non-marketable Securities INVESTMENT IN NON-MARKETABLE SECURITIES Other Liabilities Disclosure [Abstract] OTHER PAYABLES AND ACCRUED LIABILITIES Related Party Transactions [Abstract] RELATED PARTY BALANCES AND TRANSACTIONS Equity [Abstract] STOCKHOLDERS’ EQUITY Noncontrolling Interest [Abstract] NON-CONTROLLING INTEREST Income Tax Disclosure [Abstract] INCOME TAXES Risks and Uncertainties [Abstract] CONCENTRATIONS OF RISKS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Subsequent Events [Abstract] SUBSEQUENT EVENT Basis of presentation Principles of consolidation Use of estimates Cash and cash equivalents Accounts receivable Inventories Prepaid taxes Prepayments and deposits Property and equipment, net Intangible assets, net Impairment for long-lived assets Deferred offering costs Investment in marketable equity securities Investment in non-marketable equity securities Customer deposits Revenue recognition Cost of revenue Shipping and handling Advertising costs Commission expenses Defined contribution plan Income taxes Comprehensive income (loss) Non-controlling interest Earnings (loss) per share Foreign currencies translation and transaction Related parties Fair value of financial instruments Leases Recent accounting pronouncements SCHEDULE OF SUBSIDIARIES AND ASSOCIATES SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES SCHEDULE OF VARIABLE INTEREST ENTITY SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY SCHEDULE OF INVENTORIES SCHEDULE OF PREPAID EXPENSES AND DEPOSITS SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS SCHEDULE OF PROPERTY AND EQUIPMENT, NET SCHEDULE OF INTANGIBLE ASSETS, NET SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES SCHEDULE OF RELATED PARTIES SCHEDULE OF NON CONTROLLING INTEREST SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX SCHEDULE OF PROVISION FOR INCOME TAX SCHEDULE OF DEFERRED TAX ASSETS SCHEDULE OF LEASE COMMITMENTS Subsidiary company name Place and date of incorporation Particulars of issued capital Principal activities Proportional of ownership interest and voting power held Ownership interest percentage Stock issued during period acquisitions, shares Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Estimated Useful Life of Property and Equipment Estimated Useful Lives of Property and Equipment Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Estimated useful lives of intangible assets Schedule of Product Information [Table] Product Information [Line Items] Total revenues - products and services Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Foreign currency exchange rate, translation Foreign currency exchange rate period average Accounts receivable, allowance for credit loss Inventories write-down Allowance for doubtful accounts Impairment of long-lived assets Value of coupons Cost of revenue Revenue from contract with customer excluding assessed tax Selling expenses Advertising costs Commission expenses Defined contribution plan expense Salary percentage Monthly salary Income tax examination, likelihood of unfavorable settlement Income tax examination, penalties and interest expense Noncontrolling interest, description Potentially dilutive securities outstanding Trading Activities, Gain and Losses, by Type, by Income Statement Location [Table] Trading Activity, Gains and Losses, Net [Line Items] Total current assets Current liabilities Net deficit Cash Prepaid taxes Accounts payable – intercompany Other payables and accrued liabilities Total current liabilities Operating revenues Gross profit Profit (loss) from operations Net income (loss) Cash and Cash Equivalents, at Carrying Value Cash Time Deposits Percentage of Interest-Bearing Domestic Deposits to Deposits, Time Deposits Time deposit uninsured Accounts receivable Allowance for doubtful accounts Total accounts receivable Finished goods Schedule Of Prepaid Expenses And Deposits Receivables from sales distributors Deposits to suppliers Subtotal Less: Provision for doubtful accounts Total Schedule Of Changes In Allowance For Doubtful Accounts Beginning balance Addition Write off Exchange rate effect Ending balance Subtotal Less: accumulated depreciation Total Computer software Less: accumulated amortization Total Amortization expense Schedule Of Investment In Marketable Securities Cost of investment Dividend income from Greenpro Capital Corp. Unrealized holding loss Exchange rate effect Investment in marketable securities Investment in securities, shares Investment amount Purchased price per shares Cost of investment Equity interest percentage Shares purchased during period Shares Issued, Price Per Share Professional fees Promotion expenses Payroll Commissions Tax penalty Others Total Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Relationship Nature Accounts payable Due from related parties Amount due to a Related Party Purchases Other purchases Commission Office rental expense Other income Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Number of shares forfeited Reduction in outstanding shares Paid-in capital Retained earnings (Accumulated deficit) Accumulated other comprehensive (loss) income Non Controlling interest Gross ASL Total Local – United States Foreign – Hong Kong Loss before income tax Current: - Local - Foreign Deferred: - Local - Foreign Provision for income tax Net operating loss carry forwards in Malaysia Less: valuation allowance Depreciation Deferred tax liabilities, net Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Tax percentage Tax rate description Net operating loss carryforward Deferred tax valuation allowance Effective income tax rate reconciliation, percent Income tax examination, description Paid in capital Additional paid in capital Net operating loss carry forwards expiration, description Concentration Risk [Table] Concentration Risk [Line Items] Concentrations of risk percentage Deposits Deposit for insurance 2023 2024 Thereafter Total lease payments Less: interest Present value of lease liabilities Schedule of Restructuring and Related Costs [Table] Restructuring Cost and Reserve [Line Items] Operating lease liability Operating lease effective interest rate Lease expiration term Reduction in ROU assets and liabilities Operating lease, weighted average remaining lease term Operating lease payments Operating lease, expense COVID-19 impact description Subsequent Event [Table] Subsequent Event [Line Items] Stockholders equity reverse stock split Investment owned, balance shares Investment owned, fair value Phoenix Plus Corporation [Member] Investment in non marketable securities noncurrent. Accrued promotion expenses, current. Accrued tax penalty, current. Related parties, relationships, description. CTA Nutriceuticals Sdn Bhd [Member] Related parties nature, description. Agape ATP Asia Limited [Member] DSY Wellness & Longevity Center Sdn Bhd [Member] VIE consolidated amount of cash and cash equivalents. VIE consolidated amount of Prepaid taxes . VIE consolidated amount of other payables and accrued liabilities. How Kok Choong [Member] Commission expense. DSY Wellness & Longevity Center Sdn Bhd [Member] Related party office rental expenses. Share Forfeiture Agreements [Member] How Kok Choong Talent Limited [Member] Reduction in common stock outstanding during period. Non controlling interest paid in capital. Non controlling interest accumulated deficit. Non controlling interest accumulated other comprehensive income. Non controlling interest ASL. Agape ATP International Holding Limited [Member] Subsidiary Company Two [Member] Share Exchange Agreement [Member] Mr.How Kok Choong [Member] Subsidiary Company Five [Member] Name of the company name. Subsidiary Company [Member] Subsidiary Company One [Member] Subsidiary Company Three [Member] Subsidiary Company Four [Member] Place and date of incorporation. Particulars of issued capital. Principal activities. Tax rate description. Labuan [Member] Unutilized [Member] Deferred tax liabilities, depreciation. Allowance for doubtful accounts, No Customer [Member] E-commerce [Member] Vendor One [Member] Forfeited coupon income. Health and Wellness Services [Member] Vendor [Member] One Vendor [Member] No Sales Distributor [Member] One Sales Distributor [Member] Deposit for insurance. ASL [Member] Lease expiration term. Training Center [Member] Reduction in ROU assets and liabilities. Amount of lessee's undiscounted obligation for lease payment for operating lease due after second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller). Salary percentage. Social Security Organization [Member] Monthly salary. MYR Currency [Member] Employees Provident Fund [Member] Employment Insurance System [Member] Human Resource Development Fund [Member] COVID-19 Impact [Member] Period-end MYR [Member] Period-end HKD [Member] Other payables - related party, current. Investment in Marketable Securities [Text Block] Greenpro Capital Corp. [Member] DSwiss Inc. [Member] SEATech Ventures Corp. [Member] Dividend income . Unrealized holding (loss) gain. Exchange rate effect. Investment in Non Marketable Securities [Text Block] Non Marketable Securities [Table Text Block] Schedule of Other Payables and Accrued Liabilities [Table Text Block] Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer. DSY Beauty Sdn Bhd [Member] Changes in right of use assets and lease liabilities due to lease modifications. Schedule of Non Controlling Interest [Table Text Block] Non-Controlling interest non controlling interest gross Prepaid Taxes [Policy Text Block] Prepayments and Deposits [Policy Text Block] Non Marketable Securities [Policy Text Block] Shipping and Handling [Policy Text Block] Defined Contribution Plan [Policy Text Block] Non-controlling Interest [Policy Text Block] Related Parties [Policy Text Block] Schedule of Estimated Useful Lives of Property and Equipment [Table Text Block] Schedule of Estimated Useful Lives of Intangible Assets Net [Table Text Block] One Individual Customers [Member] Vendor Two [Member] Vendor Three [Member] Schedule of Disaggregated Information of Revenues [Table Text Block] Others [Member] Period-average MYR [Member] Foreign currency exchange rate period average. Period-average HKD [Member] DSY Beauty Sdn Bhd [Member] DSY Wellness and Longevity Center Sdn Bhd [Member] DSY Wellness and Longevity Center Sdn Bhd [Member] Prepayments and Deposits [Text Block] Receivables from sales distributors. Deposits to supplier. Prepaid expenses gross. Schedule of Changes in Allowance for Doubtful Accounts [Table Text Block] Allowance for doubtful accounts receivable exchange rate effect. ATPR Mito+ [Member] Net operating loss carry forwards expiration, description. Survivor Select [Member] Energized Mineral Concentrate [Member] Ionized Cal-Mag [Member] Omega Blend [Member] Beta Maxx [Member] Iron [Member] Young Formula [Member] Organic Youth Care Cleansing Bar [Member] Lipomask [Member] Hyaluronic Acid Serum [Member] Mousse Facial Cleanser [Member] Trim+ [Member] Others - Products for the Provision of Complementary Health Therapies [Member] Computer and Office Equipment [Member] Vehicle [Member] Hostastay Sdn. Bhd. (“Hostastay”) [Member] Hostastay Sdn. Bhd. (“Hostastay”) [Member] DSY Wellness & Longevity Center Sdn Bhd [Member] [Default Label] DSY Beauty Sdn Bhd [Member] [Default Label] DSY Wellness and Longevity Center Sdn Bhd [Member] [Default Label] Hostastay Sdn. Bhd. (“Hostastay”) [Member] Assets, Noncurrent Assets Operating Lease, Liability, Noncurrent Liabilities, Noncurrent Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Cost of Goods and Services Sold Sales Commissions and Fees General and Administrative Expense Operating Expenses Nonoperating Income (Expense) Income Tax Expense (Benefit) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Parent Weighted Average Number of Shares Outstanding, Basic Shares, Outstanding Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Increase (Decrease) in Accounts Receivable Increase (Decrease) in Due from Other Related Parties, Current Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Taxes Increase (Decrease) in Prepaid Expenses, Other Increase (Decrease) in Other Accounts Payable Increase (Decrease) in Accounts Payable, Related Parties Increase (Decrease) in Contract with Customer, Liability Increase (Decrease) in Operating Lease Liability Increase (Decrease) in Income Taxes Payable Net Cash Provided by (Used in) Operating Activities Payments to Acquire Machinery and Equipment Net Cash Provided by (Used in) Investing Activities Payments of Debt Issuance Costs Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Stockholders' Equity Note Disclosure [Text Block] Accounts Receivable [Policy Text Block] Inventory, Policy [Policy Text Block] PrepaymentsAndDepositsPolicyTextBlock Property, Plant and Equipment, Policy [Policy Text Block] Intangible Assets, Finite-Lived, Policy [Policy Text Block] Deferred Charges, Policy [Policy Text Block] Revenue from Contract with Customer [Policy Text Block] Advertising Expense Commission expenses [Default Label] OtherPayablesRelatedPartyCurrent Accounts Receivable, before Allowance for Credit Loss, Current Prepaid expenses gross Allowance for Doubtful Accounts, Premiums and Other Receivables Accounts Receivable, Allowance for Credit Loss Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Net Dividend income Unrealized holding (loss) gain Exchange rate effect [Default Label] OtherAccountPayableAndAccruedLiabilities NonControllingInterestNonControllingInterestGross Current State and Local Tax Expense (Benefit) Current Foreign Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Foreign Income Tax Expense (Benefit) DeferredTaxLiabilitiesDepreciation Deferred Tax Assets, Net Adjustments to Additional Paid in Capital, Stock Split Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount EX-101.PRE 10 aatp-20220630_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover - shares
6 Months Ended
Jun. 30, 2022
Aug. 09, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2022  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --12-31  
Entity File Number 333-220144  
Entity Registrant Name AGAPE ATP CORPORATION  
Entity Central Index Key 0001713210  
Entity Tax Identification Number 36-4838886  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One Tower 2  
Entity Address, Address Line Two Faber Tower  
Entity Address, Address Line Three Jalan Desa Bahagia  
Entity Address, City or Town Kuala Lumpur  
Entity Address, Country MY  
Entity Address, Postal Zip Code 58100  
City Area Code (60)  
Local Phone Number 192230099  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   75,452,012
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
CURRENT ASSETS    
Cash and cash equivalents (Included $7,626 and $17,493 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of June 30, 2022 and December 31, 2021, respectively) $ 1,807,437 $ 2,597,848
Accounts receivable 214
Amount due from related parties 4,548 7,004
Inventories 346,744 375,535
Prepaid taxes (Included $1,744 and $1,357 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of June 30, 2022 and December 31, 2021, respectively) 339,999 636,218
Prepayments and deposits 178,697 295,517
Total Current Assets 2,677,639 3,912,122
OTHER ASSETS    
Property and equipment, net 169,915 215,799
Intangible assets, net 2,601 3,660
Operating right-of-use assets 158,630 237,718
Investment in marketable securities 35,707 89,001
Investment in non-marketable securities 1,500 1,500
Deferred offering costs 443,661 264,735
Total Other Assets 812,014 812,413
TOTAL ASSETS 3,489,653 4,724,535
CURRENT LIABILITIES    
Accounts payable 21,519 13,715
Accounts payable – a related party 14,407
Customer deposits 89,606 279,689
Operating lease liabilities 150,573 157,094
Other payables and accrued liabilities ($787 and $1,548 are included in the consolidated VIE that are without recourse to the credit of Agape ATP Corporation as of June 30, 2022 and December 31, 2021, respectively) 637,033 858,355
Other payable – a related party 2,082
Income tax payable 9,249 3,988
Total Current Liabilities 924,469 1,312,841
NON-CURRENT LIABILITIES    
Operating lease liabilities 10,812 83,484
Deferred tax liabilities 17,975 15,574
Total Non-current Liabilities 28,787 99,058
TOTAL LIABILITIES 953,256 1,411,899
STOCKHOLDERS’ EQUITY    
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; None issued and outstanding
Common Stock, par value $0.0001; 1,000,000,000 shares authorized, 75,452,012 and 290,460,047 shares issued and outstanding as of June 30, 2022 and December 31, 2021 respectively 7,545 29,046
Additional paid in capital 6,470,716 6,449,215
Accumulated deficit (3,972,684) (3,258,687)
Accumulated other comprehensive income 20,219 93,398
TOTAL AGAPE CORPORATION STOCKHOLDERS’ EQUITY 2,525,796 3,312,972
NON-CONTROLLING INTERESTS 10,601 (336)
TOTAL EQUITY 2,536,397 3,312,636
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 3,489,653 $ 4,724,535
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
VIE consolidated amount of cash and cash equivalents $ 7,626 $ 17,493
VIE consolidated amount of prepaid taxes 1,744 1,357
VIE consolidated amount of other payables and accrued liabilities $ 787 $ 1,548
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 200,000,000 200,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 1,000,000,000 1,000,000,000
Common stock, shares issued 75,452,012 290,460,047
Common stock, shares outstanding 75,452,012 290,460,047
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Income Statement [Abstract]        
REVENUE $ 396,707 $ 303,786 $ 805,667 $ 605,566
COST OF REVENUE (109,383) (35,623) (182,814) (113,214)
GROSS PROFIT 287,324 268,163 622,853 492,352
SELLING (79,587) (100,838) (194,198) (216,952)
COMMISSION (62,557) (92,774) (176,666) (181,213)
GENERAL AND ADMINISTRATIVE (451,363) (361,862) (830,404) (724,008)
PROVISION FOR DOUBTFUL ACCOUNTS (121,686) (121,686)
TOTAL OPERATING EXPENSES (593,507) (677,160) (1,201,268) (1,243,859)
LOSS FROM OPERATIONS (306,183) (408,997) (578,415) (751,507)
OTHER (EXPENSES) INCOME        
Other income (expenses), net 1,341 11,770 12,826 (48,546)
Interest income 3,526 8,251
Unrealized holding loss on marketable securities (35,219) (241,027) (52,889) (165,731)
Exchange loss, net (67,417) (83,883)
TOTAL OTHER EXPENSES, NET (97,769) (229,257) (115,695) (214,277)
LOSS BEFORE INCOME TAXES (403,952) (638,254) (694,110) (965,784)
PROVISION FOR INCOME TAXES (392) (3,971) (8,680) (10,091)
NET LOSS (404,344) (642,225) (702,790) (975,875)
LESS: NET INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS 10,556 11,207
NET LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION (414,900) (642,225) (713,997) (975,875)
NET LOSS (404,344) (642,225) (702,790) (975,875)
OTHER COMPREHENSIVE LOSS        
Foreign currency translation adjustment (61,156) (36,347) (73,179) (74,631)
TOTAL COMPREHENSIVE LOSS (465,500) (678,572) (775,969) (1,050,506)
Less: Comprehensive loss attributable to non-controlling interests (271) (270)
COMPREHENSIVE LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION $ (465,229) $ (678,572) $ (775,699) $ (1,050,506)
LOSS PER SHARE        
Basic and diluted $ (0.01) $ 0.00 $ (0.01) $ 0.00
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING        
Basic and diluted 75,452,012 376,452,047 100,397,696 376,452,047
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 37,645 $ 6,440,616 $ (734,443) $ 181,016 $ 5,924,834
Shares, Outstanding, Beginning Balance at Dec. 31, 2020 376,452,047          
Net loss (333,650)   (333,650)
Foreign currency translation adjustment (38,284) (38,284)
Ending balance, value at Mar. 31, 2021 $ 37,645 6,440,616 (1,068,093) 142,732 5,552,900
Shares, Outstanding, Ending Balance at Mar. 31, 2021 376,452,047          
Beginning balance, value at Dec. 31, 2020 $ 37,645 6,440,616 (734,443) 181,016 5,924,834
Shares, Outstanding, Beginning Balance at Dec. 31, 2020 376,452,047          
Net loss           (975,875)
Ending balance, value at Jun. 30, 2021 $ 37,645 6,440,616 (1,710,318) 106,385 4,874,328
Shares, Outstanding, Ending Balance at Jun. 30, 2021 376,452,047          
Beginning balance, value at Mar. 31, 2021 $ 37,645 6,440,616 (1,068,093) 142,732 5,552,900
Shares, Outstanding, Beginning Balance at Mar. 31, 2021 376,452,047          
Net loss (642,225)   (642,225)
Foreign currency translation adjustment (36,347) (36,347)
Ending balance, value at Jun. 30, 2021 $ 37,645 6,440,616 (1,710,318) 106,385 4,874,328
Shares, Outstanding, Ending Balance at Jun. 30, 2021 376,452,047          
Beginning balance, value at Dec. 31, 2021 $ 29,046 6,449,215 (3,258,687) 93,398 (336) 3,312,636
Shares, Outstanding, Beginning Balance at Dec. 31, 2021 290,460,047          
Net loss (299,097) 651 (298,446)
Foreign currency translation adjustment (12,023) 1 (12,022)
Forfeiture of common stock $ (21,501) 21,501
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited (215,008,035)          
Ending balance, value at Mar. 31, 2022 $ 7,545 6,470,716 (3,557,784) 81,375 316 3,002,168
Shares, Outstanding, Ending Balance at Mar. 31, 2022 75,452,012          
Beginning balance, value at Dec. 31, 2021 $ 29,046 6,449,215 (3,258,687) 93,398 (336) 3,312,636
Shares, Outstanding, Beginning Balance at Dec. 31, 2021 290,460,047          
Net loss           (702,790)
Ending balance, value at Jun. 30, 2022 $ 7,545 6,470,716 (3,972,684) 20,219 10,601 2,536,397
Shares, Outstanding, Ending Balance at Jun. 30, 2022 75,452,012          
Beginning balance, value at Mar. 31, 2022 $ 7,545 6,470,716 (3,557,784) 81,375 316 3,002,168
Shares, Outstanding, Beginning Balance at Mar. 31, 2022 75,452,012          
Net loss (414,900) 10,556 (404,344)
Foreign currency translation adjustment (61,156) (271) (61,427)
Ending balance, value at Jun. 30, 2022 $ 7,545 $ 6,470,716 $ (3,972,684) $ 20,219 $ 10,601 $ 2,536,397
Shares, Outstanding, Ending Balance at Jun. 30, 2022 75,452,012          
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (702,790) $ (975,875)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 36,661 38,179
Amortization 897 1,006
Amortization of operating right-of-use assets 75,241 75,387
Unrealized holding loss on marketable securities 52,889 165,731
Deferred tax provision (benefit) 2,401 (53,299)
Inventory write-downs 36,636
Provision for doubtful accounts 121,686
Changes in operating assets and liabilities:    
Accounts receivables (214) 169,393
Amount due from related parties 2,201
Inventories 28,790 80,969
Prepaid taxes 296,219 448,054
Prepayments and deposits 102,099 (15,120)
Accounts payable 7,804
Accounts payable – a related party 14,407
Customer deposits (175,936) (60,618)
Operating lease liabilities (75,200) (74,399)
Other payables and accrued liabilities (166,137) (129,355)
Amount due to a related party 2,081
Income tax payable 5,261 36,877
Net cash used in operating activities (493,326) (134,748)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of equipment (750) (1,220)
Net cash used in investing activities (750) (1,220)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Deferred offering costs (178,926) (14,160)
Advances to related parties (2,428)
Net cash used in financing activities (178,926) (16,588)
EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS (117,409) (64,244)
DECREASE IN CASH AND CASH EQUIVALENTS (790,411) (216,800)
CASH AND CASH EQUIVALENTS, beginning of period 2,597,848 3,517,600
CASH AND CASH EQUIVALENTS, end of period 1,807,437 3,300,800
SUPPLEMENTAL CASH FLOWS INFORMATION    
Income taxes paid 77,117 249,583
SUPPLEMENTAL NON-CASH FLOWS INFORMATION    
Changes in right-of-use assets and lease liabilities due to lease modifications $ 3,286
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2
ORGANIZATION AND BUSINESS BACKGROUND
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
ORGANIZATION AND BUSINESS BACKGROUND

1. ORGANIZATION AND BUSINESS BACKGROUND

 

Agape ATP Corporation, a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016.

 

Agape ATP Corporation operates through its subsidiaries, namely, Agape ATP Corporation, a company incorporated in Labuan, Malaysia, and Agape Superior Living Sdn. Bhd. (“ASL”), a company incorporated in Malaysia. .

 

Agape ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with 100% equity interest in Agape ATP International Holding Limited, a company incorporated in Hong Kong.

 

On May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in Agape Superior Living Sdn. Bhd., a network marketing entity incorporated in Malaysia.

 

Agape Superior Living Sdn. Bhd. is a limited company incorporated on August 8, 2003, under the laws of Malaysia.

 

On September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn, Bhd. (“WATP”), a wholly owned subsidiary under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle.

 

On November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (“DSY Wellness”) with an independent third party which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies.

 

The Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs.

 

The accompanying consolidated financial statements reflect the activities of the Company, AATP LB, AATP HK, WATP, ASL and its variable interest entity (“VIE”), Agape S.E.A. Sdn. Bhd. (“SEA”) (See Note 3), and DSY Wellness.

 

Details of the Company’s subsidiaries:

 

  

Subsidiary

company name

 

Place and date of

incorporation

 

Particulars of

issued capital

  Principal activities 

Proportional of

ownership interest

and voting power

held

 
                 
1.  Agape ATP Corporation  Labuan,
March 6, 2017
  100 shares of ordinary share of US$1 each  Investment holding   100%
                  
2.  Agape ATP International Holding Limited  Hong Kong,
June 1, 2017
  1,000,000 shares of ordinary share of HK$1 each  Wholesaling of health and wellness products; and health solution advisory services   100%
                  
3.  Agape Superior Living Sdn. Bhd.  Malaysia,
August 8, 2003
  9,590,598 shares of ordinary share of RM1 each  Health and wellness products and health solution advisory services via network marketing   99.99%
                  
4.  Agape S.E.A. Sdn. Bhd.  Malaysia,
March 4, 2004
  2 shares of ordinary share of RM1 each  VIE of Agape Superior Living Sdn. Bhd.   VIE 
                  
5.  Wellness ATP International Holdings Sdn, Bhd  Malaysia,
September 11, 2020
  100 shares of ordinary share of RM1 each  The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns   100%
                  
6.  DSY Wellness International Sdn Bhd.  Malaysia,
November 11, 2021
  1,000 shares of ordinary share of RM1 each  Provision of complementary health therapies   60%

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

1. ORGANIZATION AND BUSINESS BACKGROUND (Continued)

 

Business Overview

 

Agape ATP Corporation is a company that provides health and wellness products and health solution advisory services to our clients. The Company primarily focus its efforts on attracting customers in Malaysia. Its advisory services center on the “ATP Zeta Health Program”, which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.

 

In order to strengthen the Company’s supply chain, on May 8, 2020, the Company has successfully acquired approximately 99.99% of ASL, with the goal of securing an established network marketing sales channel that has been established in Malaysia for the past 15 years. ASL has been offering the Company’s ATP Zeta Health Program as part of its product lineup. As such, the acquisition creates synergy in the Company’s operation by boosting the Company’s retail and marketing capabilities. The newly acquired subsidiary allows the Company to fulfill its mission of “helping people to create health and wealth” by providing a financially rewarding business opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle.

 

Via ASL, the Company offers three series of programs which consist of different services and products: ATP Zeta Health Program, ÉNERGÉTIQUE and BEAUNIQUE.

 

The ATP Zeta Health Program is a health program designed to promote health and general wellbeing designed to prevent health diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity through a combination of modern health supplements, proper nutrition and advice from skilled dieticians as well as trained members and distributors.

 

The ÉNERGÉTIQUE series aims to provide a total dermal solution for a healthy skin beginning from the cellular level. The series is comprised of the Energy Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.

 

The BEAUNIQUE product series focuses on the research of our diet’s impact on modifying gene expressions in order to address genetic variations and deliver a nutrigenomic solution for every individual.

 

The Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution advisory services; and therefore, incorporated WATP. Upon its establishment, WATP started collaborating with ASL to carry out various wellness programs.

 

To further its reach in the Health and Wellness Industry, on November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (“DSY Wellness”) with an independent third party which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for information pursuant to the rules and regulations of the Securities Exchange Commission (“SEC”), and include all normal and recurring adjustments that management of the Company considers necessary for a fair presentation of its financial position and operation results. Interim results are not necessarily indicative of results to be expected for any other interim period or for the full year. The information included in this Form 10-Q should be read in conjunction with information included in the Company’s annual report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 28, 2022.

 

The unaudited condensed consolidated financial statements include the financial statements of the Company, its subsidiaries and its variable interest entity (“VIE”) over which the Company exercises control and, where applicable, entities for which the Company has a controlling financial interest or is the primary beneficiary. All transactions and balances among the Company, its subsidiaries and its VIE have been eliminated upon consolidation.

 

Principles of consolidation

 

Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.

 

A VIE is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary and must consolidate the VIE. As of and for the three and six months ended June 30, 2022, SEA, the only VIE of the Company has no significant operations.

 

Use of estimates

 

The preparation of audited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s consolidated financial statements include allowance for doubtful accounts, allowance for inventories obsolescence, useful lives of property and equipment, useful lives of intangible assets, impairment of long-lived assets, allowance for deferred tax assets, operating right-of-use assets, operating lease liabilities and uncertain tax position and impairment of investment in non-marketable securities. Actual results could differ from these estimates.

 

Cash and cash equivalents

 

Cash and cash equivalents are carried at cost and represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Accounts receivable

 

Accounts receivable are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due on credit term. Accounts receivable also include money due from a third-party e-commerce platform acting as a collection agent for the Company on the sales through their platform. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of June 30, 2022 and December 31, 2021, no allowance of doubtful accounts was recorded.

 

Inventories

 

Inventories consist of finished goods and are stated at the lower of cost or net realizable value using the first-in first-out method. Management reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net realizable value. For the six months ended June 30, 2022 and 2021, the Company recognized inventory write-downs of $0 and $36,636, respectively.

 

Prepaid taxes

 

Prepaid taxes include prepaid income taxes that will either be refunded or utilized to offset future income tax.

 

Prepayments and deposits

 

Prepayments and deposits are mainly cash deposited or advanced to suppliers for future inventory purchases or service providers for future services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after management has determined that the likelihood of collection is not probable. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of June 30, 2022 and December 31, 2021, there was $120,372 and $121,095 allowance for doubtful accounts recorded, respectively.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Property and equipment, net

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets with no residual value. The estimated useful lives are as follows:

 

   Useful Life
    
Computer and office equipment  5-7 years
Furniture & fixtures  6-7 years
Leasehold improvements  Lease Term
Vehicle  5 years

 

The cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements of income and comprehensive income. Expenditures for maintenance and repairs are charged to earnings as incurred, while additions, renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates the periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.

 

Intangible assets, net

 

Intangible assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the estimated useful lives of the assets as follows:

 

Classification  Useful Life
    
Computer software  5 years

 

Impairment for long-lived assets

 

Long-lived assets, including property and equipment, and intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted future cash flows the assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset. If an impairment is identified, the Company would reduce the carrying amount of the asset to its estimated fair value based on a discounted cash flows approach or, when available and appropriate, to comparable market values. As of June 30, 2022 and December 31, 2021, no impairment of long-lived assets was recognized.

 

Deferred offering costs

 

Deferred offering costs represents costs associated with the Company’s current offering which will be netted against the proceeds from the Company’s current offering.

 

Investment in marketable equity securities

 

The Company follows the provisions of ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Investments in marketable equity securities (non-current) are reported at fair value with changes in fair value recognized in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss in the caption of “unrealized holding gain loss on marketable securities” in each reporting period.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Investment in non-marketable equity securities

 

The Company follows the provisions of ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Due to the Company’s non-marketable equity securities (non-current) does not qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issue.

 

At each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that raise significant concerns about the investee’s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment loss equal to the difference between the fair value of the investment and its carrying amount.

 

Customer deposits

 

Customer deposits represent amounts advanced by customers on product orders and discounted value of unapplied coupons. Customer deposits are reduced when the related sale is recognized in accordance with the Company’s revenue recognition policy.

 

Revenue recognition

 

The Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606). The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.

 

The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

 

The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Sales of Health and Wellness products

 

- Performance obligations satisfied at a point in time

 

The Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods. The revenue is recorded net of estimated discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were insignificant sales returns.

 

The Company also sells coupons to its customers for cash at a discounted price of the value of the coupons. Customers can apply the value of the coupons for a reduction in the transaction price paid by the customer are recorded as a reduction of sales. The cash proceeds resulted from the sale of coupons are recognized as customer deposits until the coupons to be applied as a reduction of the health and wellness products transaction price upon such sales transactions occurred. The Company’s coupons have a validity period of six months. If the Company’s customers did not utilize the coupons after six months, the Company would recognize the forfeiture of the originated sales value of the coupons as net revenues. For the three months ended June 30, 2022 and 2021, the Company recognized $4,824 and $4,115, as forfeited coupon income, respectively. For the six months ended June 30, 2022 and 2021, the Company recognized $5,777 and $11,226, as forfeited coupon income, respectively.

 

The Company had contracts for the sales of health and wellness products amounting to $16,084 which it is expected to fulfill within 12 months from June 30, 2022.

 

Sales of Health and Wellness services

 

- Performance obligations satisfied at a point in time

 

The Company carries out its Wellness program, where the Company’s products are bundled with health screening test and a health camp program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test reports are completed and delivered to its customers during the consultation section in person.

 

The Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health camp program was completed in the final day of the health camp. For the three months ended June 30, 2022 and 2021, revenues from health and wellness services were $30,072 and $653 respectively. For the six months ended June 30, 2022 and 2021, revenues from health and wellness services were $31,139 and $5,746 respectively.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Disaggregated information of revenues by products are as follows:

 

                     
   For the three months ended   For the six months ended 
   June 30,   June 30, 
   2022   2021   2022   2021 
                 
Survivor Select  $13,941   $24,415   $22,753   $37,641 
Energized Mineral Concentrate   -    8,291    -    52,183 
Ionized Cal-Mag   14,278    18,485    62,368    40,298 
Omega Blend   42,747    89,066    179,177    185,361 
Beta Maxx   23,564    55,943    47,637    89,800 
Iron   3,118    8,431    7,186    16,715 
Young Formula   1,075    14,458    34,269    25,901 
Organic Youth Care Cleansing Bar   -    2,990    -    2,990 
ATPR Mito+   76,605    70,148    187,926    106,843 
Lipomask   -    4,279    -    8,401 
Hyaluronic Acid Serum   1,698    1,362    3,006    3,353 
Mousse Facial Cleanser   4,355    3,042    7,394    7,660 
Trim+   2,765    2,223    6,236    22,674 
Others – Products for the provision of complementary health therapies   182,101    -    216,188    - 
Others   388    -    388    - 
Total revenues - products   366,635    303,133    774,528    599,820 
Health and Wellness services   30,072    653    31,139    5,746 
Total revenues - products and services  $396,707   $303,786   $805,667   $605,566 

 

Cost of revenue

 

Cost of revenue for the three and six months ended June 30, 2022 were $109,383, and $182,814, respectively, and comprised freight-in, purchase cost of manufactured goods for sale to customers and products for the provision of complementary health therapies. Cost of revenue for the three months and six months ended June 30, 2021, were $35,623, and $113,214, respectively, and comprised freight-in, purchase cost of manufactured goods for sale to customers. For the six months ended June 30, 2021, cost of revenue also included inventory write-downs of $36,636.

 

Shipping and handling

 

Shipping and handling charges amounted to $4,272 and $2,990 for the three months ended June 30, 2022 and 2021, respectively. Shipping and handling charges amounted to $7,179 and $5,272 for the six months ended June 30, 2022 and 2021, respectively. Shipping and handling charges are expensed as incurred and included in selling expenses.

 

Advertising costs

 

Advertising costs amounted to $4,765 and $8,721 for the three months ended June 30, 2022 and 2021, respectively. Advertising costs amounted to $4,765 and $16,658 for the six months ended June 30, 2022 and 2021, respectively. Advertising costs are expensed as incurred and included in selling expenses.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Commission expenses

 

Commission expenses are the Company’s most significant expenses. As with all companies in the network marketing industry, the Company’s sales channel is external to the Company. The Company’s “external sales force” is stratified into two levels based on priority recruitment. First, there are sales distributors. Second, all members recruited by a sales distributor, directly or indirectly, are referred to as “sales network members”. The Company pays commission to every sales distributor based on purchases made by its sales network members which includes the independent direct sales members. Top performing distributors with their own physical stores may also become stockists of the Company, whereby they enjoy benefits such as maintaining a certain amount of the Company’s inventory on their store premises. The stockists shall account to the Company for all products sales from their store premises as monitored through the Company’s centralized stock tracking system. The Company pays a separate commission to stockists based on revenue generated from the stockists’ physical stores. Commission expenses amounted to $62,557 and $92,774 for the three months ended June 30, 2022 and 2021, respectively. Commission expenses amounted to $176,666 and $181,213 for the six months ended June 30, 2022 and 2021, respectively.

 

Defined contribution plan

 

The full-time employees of the Company are entitled to the government mandated defined contribution plan. The Company is required to accrue and pay for these benefits based on certain percentages of the employees’ respective salaries, subject to certain ceilings, in accordance with the relevant government regulations, and make cash contributions to the government mandated defined contribution plan. Total expenses for the plan were $35,936 and $27,067 for the three months ended June 30, 2022 and 2021, respectively. Total expenses for the plan were $63,408 and $53,034 for the six months ended June 30, 2022 and 2021, respectively.

 

The related contribution plans include:

 

  - Social Security Organization (“SOSCO”) – 1.75% based on employee’s monthly salary capped of RM 4,000;
  - Employees Provident Fund (“EPF”) – 12% based on employee’s monthly salary;
  - Employment Insurance System (“EIS”) – 0.2% based on employee’s monthly salary capped of RM 4,000;
  - Human Resource Development Fund (“HRDF”) – 1% based on employee’s monthly salary

 

Income taxes

 

The Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

 

Deferred taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.

 

An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. No penalties and interest related to underpayment of income taxes were incurred for the three and six months ended June 30, 2022. $395 in penalties and interest related to underpayment of income taxes were incurred for the three and six months ended June 30, 2021.

 

The Company conducts much of its business activities in Hong Kong and Malaysia and is subject to tax in each of these jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

 

Comprehensive income (loss)

 

Comprehensive income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under GAAP are recorded as an element of stockholders’ equity but are excluded from net income. Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.

 

Non-controlling interest

 

Non-controlling interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out of 9,590,598 shares) of the equity interests of ASL held by two individuals. The non-controlling interests are presented in the consolidated balance sheets, separately from equity attributable to the shareholders of the Company. Non-controlling interests in the results of the Company are presented on the face of the consolidated statements of operations as an allocation of the total income or loss for the periods between non-controlling interest holders and the shareholders of the Company.

 

Earnings (loss) per share

 

The Company computes earnings (loss) per share (“EPS”) in accordance with ASC 260, “Earnings per Share”. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is measured as net income (loss) divided by the weighted average common stocks outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential common stocks (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common stocks that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. For the three and six months ended June 30, 2022 and 2021, there were no dilutive shares.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Foreign currencies translation and transaction

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the consolidated statements of operations and comprehensive income (loss).

 

The reporting currency of the Company is United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. The Company’s subsidiary in Labuan maintains its books and record in United States Dollars (“US$”) albeit its functional currency being the primary currency of the economic environment in which the entity operates, which is the Malaysian Ringgit (“MYR” or “RM”). The Company’s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars (“HK$”), similar to its functional currency. The Company’s subsidiary and VIE in Malaysia conducts its businesses and maintains its books and record in the local currency, Malaysian Ringgit (“MYR” or “RM”), as its functional currency.

 

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders’ equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.

 

Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Period-end MYR : US$1 exchange rate   4.40    4.18 
Period-end HKD : US$1 exchange rate   7.85    7.80 

 

                     
   For the three months ended
June 30,
   For the six months ended
June 30,
 
   2022   2021   2022   2021 
                 
Period-average MYR : US$1 exchange rate   4.37    4.13    4.28    4.10 
Period-average HKD : US$1 exchange rate   7.85    7.77    7.83    7.76 

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Related parties

 

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

 

Fair value of financial instruments

 

The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.

 

The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

 

Leases

 

The Company adopted ASU 2016-02, “Leases” (Topic 842), and elected the practical expedients that does not require the Company to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing leases and (3) initial direct costs for any expired or existing leases. For lease terms of twelve months or fewer, a lessee is permitted to make an accounting policy election not to recognize lease assets and liabilities. The Company also adopts the practical expedient that allows lessees to treat the lease and non-lease components of a lease as a single lease component. Some of the Company’s leases include one or more options to renew, which is typically at the Company’s sole discretion. The Company regularly evaluates the renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. New lease modifications result in re-measurement of the right of use (“ROU”) assets and lease liabilities. Operating ROU assets and lease liabilities are recognized at the commencement date, based on the present value of lease payments over the lease term. Since the implicit rate for the Company’s leases is not readily determinable, the Company use its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment and over a similar term.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Lease terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of twelve months or less. Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease term.

 

The Company reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future pre-tax cash flows.

 

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates (“ASUs”). Management periodically reviews new accounting standards that are issued. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or revised accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.

  

In November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating the impact ASU 2019-05 may have on its unaudited condensed consolidated financial statements.

 

Except for the above-mentioned pronouncements, there are no new recent issued accounting standards that will have a material impact on the consolidated financial position, statements of operations and cash flows.

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2
VARIABLE INTEREST ENTITY (“VIE”)
6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
VARIABLE INTEREST ENTITY (“VIE”)

3. VARIABLE INTEREST ENTITY (“VIE”)

 

SEA is a trading company incorporated on March 4, 2004, under the laws of Malaysia. SEA provided majority of ASL’s purchases. Its equity at risk was insufficient to finance its activities and 100% of its business is transacted with ASL. Therefore, it was considered to be a VIE and ASL is the primary beneficiary since it has both of the following characteristics:

 

  a. The power to direct the activities of the VIE that most significantly impact the VIE’s economic performance; and
  b. The obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE.

 

Accordingly, the accounts of SEA is consolidated in the accompanying financial statements.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

3. VARIABLE INTEREST ENTITY (“VIE”) (Continued)

 

The carrying amount of the VIE’s assets and liabilities were as follows:

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Current assets  $9,370   $       18,850 
Current liabilities   (43,288)   (51,272)
Net deficit  $(33,918)  $(32,422)

 

   As of 
   June 30, 2022   December 31, 2021 
         
Current assets:          
Cash  $7,626   $       17,493 
Prepaid taxes   1,744    1,357 
Total current assets  $9,370   $18,850 
           
Current liabilities:          
Accounts payable – intercompany  $42,501   $49,724 
Other payables and accrued liabilities   787    1,548 
Total current liabilities  $43,288   $51,272 
           
Net deficit  $(33,918)  $(32,422)

 

The summarized operating results of the VIE’s are as follows:

 

                     
   For the three months ended
June 30,
   For the six months ended
June 30,
 
   2022   2021   2022   2021 
                 
Operating revenues  $-   $-   $-   $- 
Gross profit  $-   $-   $-   $- 
Profit (loss) from operations  $1,723   $(5,019)  $(3,219)  $(11,967)
Net income (loss)  $1,723   $1,912   $(3,219)  $(9,949)

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2
CASH AND CASH EQUIVALENTS
6 Months Ended
Jun. 30, 2022
Cash and Cash Equivalents [Abstract]  
CASH AND CASH EQUIVALENTS

4. CASH AND CASH EQUIVALENTS

 

As of June 30, 2022 and December 31, 2021 the Company has $1,807,437 and $2,597,848, respectively, of cash and cash equivalents, which consists of $666,779 and $554,864, respectively, of cash in banks and $1,134,542 and $1,975,347, respectively, of time deposits placed with banks or other financial institutions and are all highly liquid investments with an original maturity of three months or less. The effective interest rate for the time deposits ranged between 1.10% to 1.17% per annum for the three and six months ended June 30, 2022. The effective interest rate for the time deposits ranged between 1.80% to 2.15% per annum for the three and six months ended June 30, 2021. As of June 30, 2022 and December 31, 2021, $319,994 and $295,761 of these balances are not covered by deposit insurance, respectively.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2
ACCOUNTS RECEIVABLE
6 Months Ended
Jun. 30, 2022
Receivables [Abstract]  
ACCOUNTS RECEIVABLE

5. ACCOUNTS RECEIVABLE

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Accounts receivable  $214   $       - 
Allowance for doubtful accounts   -    - 
Total accounts receivable  $214   $- 

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2
INVENTORIES
6 Months Ended
Jun. 30, 2022
Inventory Disclosure [Abstract]  
INVENTORIES

6. INVENTORIES

 

Inventories consist of the following:

 

           
   As of 
   June 30, 2022   December 31, 2021 
           
Finished goods  $346,744   $       375,535 

 

For the three months ended June 30, 2022, and 2021, the Company did not recognize any inventory write-downs. For the six months ended June 30, 2022, and 2021, the Company recognized inventory write-downs of $0 and $36,636 respectively.

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2
PREPAYMENTS AND DEPOSITS
6 Months Ended
Jun. 30, 2022
Prepayments And Deposits  
PREPAYMENTS AND DEPOSITS

7. PREPAYMENTS AND DEPOSITS

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Receivables from sales distributors  $58,477   $       115,379 
Deposits to suppliers   240,592    301,233 
Subtotal   299,069    416,612 
Less: Provision for doubtful accounts   (120,372)   (121,095)
Total  $178,697   $295,517 

 

Movements of allowance for doubtful accounts are as follows:

 

           
  

For the six

months ended

June 30, 2022

  

For the

year ended

December 31, 2021

 
         
Beginning balance  $121,095   $                - 
Addition   -    121,514 
Write off   -    - 
Exchange rate effect   (723)   (419)
Ending balance  $120,372   $121,095 

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2
PROPERTY AND EQUIPMENT, NET
6 Months Ended
Jun. 30, 2022
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT, NET

8. PROPERTY AND EQUIPMENT, NET

 

Property and equipment, net consist of the following:

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Computer and office equipment  $78,885   $82,298 
Furniture & fixtures   116,004    122,185 
Leasehold improvements   192,323    202,570 
Vehicle   93,709    98,702 
Subtotal   480,921    505,755 
Less: accumulated depreciation   (311,006)   (289,956)
Total  $169,915   $215,799 

 

Depreciation expense for the three months ended June 30, 2022 and 2021 amounted to $17,954 and $19,009, respectively. Depreciation expense for the six months ended June 30, 2022 and 2021 amounted to $36,661 and $38,179, respectively.

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2
INTANGIBLE ASSETS, NET
6 Months Ended
Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS, NET

9. INTANGIBLE ASSETS, NET

 

Intangible assets, net, consist of the following:

 

           
    As of  
    June 30, 2022     December 31, 2021  
             
Computer software   $ 32,710     $ 34,453  
Less: accumulated amortization     (30,109 )     (30,793 )
Total   $ 2,601     $ 3,660  

 

Amortization expense for the three months ended June 30, 2022 and 2021 amounted to $439 and $496, respectively. Amortization expense for the six months ended June 30, 2022 and 2021 amounted to $897 and $1,006, respectively.

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2
INVESTMENT IN MARKETABLE SECURITIES
6 Months Ended
Jun. 30, 2022
Investment In Marketable Securities  
INVESTMENT IN MARKETABLE SECURITIES

10. INVESTMENT IN MARKETABLE SECURITIES

 

  (i) On May 17, 2018, the Company purchased 83,333 shares of common stock in Greenpro Capital Corp. for $500,000 at a purchase price of $6 per share.
     
  (ii) On July 30, 2018, the Company disposed 20 shares of common stock in Greenpro Capital Corp. for $125 at a purchase price of $6.2613 per share.
     
  (iii) On October 16, 2018, the Company purchased 33,333 shares of common stock in Greenpro Capital Corp. for $1,000 at a purchase price of $0.03 per share.
     
  (iv) On November 3, 2020, the Company received dividend of 6,667 shares of common stock in DSwiss, Inc. for $76,671 at fair value of $11.50 per share from Greenpro Capital Corporation as result of its Spin-off of DSwiss, Inc.’s shares
     
  (v) On December 9, 2020, the Company received dividend of 16,663 shares of common stock in DSwiss, Inc. for $83,315 at fair value of $5 per share from Greenpro Capital Corporation as result of its Spin-off of DSwiss, Inc.’s shares.
     
  (vi) On September 27, 2021, the Company received dividend of 11,665 shares of common stock in SEATech Ventures Corp. for $18,874 at fair value of $1.62 per share from Greenpro Capital Corp as a dividend income since Greenpro Capital Corp previously owned these shares.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

10. INVESTMENT IN MARKETABLE SECURITIES (Continued)

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Cost of investment  $89,001   $577,035 
Dividend income from Greenpro Capital Corp.   -    18,939 
Unrealized holding loss   (52,889)   (505,231)
Exchange rate effect   (405)   (1,742)
Investment in marketable securities  $35,707   $89,001 

  

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2
INVESTMENT IN NON-MARKETABLE SECURITIES
6 Months Ended
Jun. 30, 2022
Investment In Non-marketable Securities  
INVESTMENT IN NON-MARKETABLE SECURITIES

11. INVESTMENT IN NON-MARKETABLE SECURITIES

 

On April 3, 2019, the Company purchased a 5% of stock or 15,000,000 shares of common stock in Phoenix Plus Corp. for $1,500 at purchase price of $0.0001 per share.

    As of  
Phoenix Plus Corporation   June 30, 2022     December 31, 2021  
             
Cost of investment   $ 1,500     $ 1,500  
                 
Investment in non-marketable securities   $ 1,500     $ 1,500  

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2
OTHER PAYABLES AND ACCRUED LIABILITIES
6 Months Ended
Jun. 30, 2022
Other Liabilities Disclosure [Abstract]  
OTHER PAYABLES AND ACCRUED LIABILITIES

12. OTHER PAYABLES AND ACCRUED LIABILITIES

           
   As of 
    June 30, 2022    December 31, 2021 
Professional fees  $142,622   $436,541 
Promotion expenses   40,360    36,024 
Payroll   54,018    22,669 
Commissions   247,645    219,721 
Tax penalty   75,000    75,000 
Others   77,388    68,400 
Total  $637,033   $858,355 

 

Certain amounts have been reclassified to conform to current period presentation.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2
RELATED PARTY BALANCES AND TRANSACTIONS
6 Months Ended
Jun. 30, 2022
Related Party Transactions [Abstract]  
RELATED PARTY BALANCES AND TRANSACTIONS

13. RELATED PARTY BALANCES AND TRANSACTIONS

 

Related party balances

 

Accounts payable – related parties

 

Name of Related
Party
  Relationship  Nature 

As of

June 30, 2022

   As of
December 31, 2021
 
               
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)  The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd  Purchases of products for the provision of complementary health therapies  $14,322   $         - 
DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC  Purchases of products for the provision of complementary health therapies   85    - 
Total        $14,407   $- 

 

Amount due from related parties

 

Name of Related

Party

  Relationship  Nature 

As of

June 30, 2022

   As of
December 31, 2021
 
               
Agape ATP (Asia) Limited (“AATP Asia”)  Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia  Expenses paid for AATP Asia  $-   $2,214 
Hostastay Sdn. Bhd. (“Hostastay”)  Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021  Sublease rent due from Hostastay   4,548    4,790 
Total        $4,548   $7,004 

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

 

Related party balances

 

Amount due to related parties

 

Name of Related

Party

  Relationship  Nature 

As of

June 30, 2022

   As of
December 31, 2021
 
               
DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC  Rental due and expenses paid by DSYWLC  $2,015   $         - 
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchase of beauty products   67    - 
Total        $2,082   $- 

 

Related party transactions

 

Purchases

 

Name of Related        For the three months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)  The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd  Purchases of products for the provision of complementary health therapies  $63,142   $    - 
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchases of beauty products   395    - 
DSY Wellness & Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.  Purchases of products for the provision of complementary health therapies   127    - 
Total        $63,664   $- 

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

 

Related party transactions

 

Purchases

 

 

Name of Related        For the six months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)  The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd  Purchases of products for the provision of complementary health therapies  $74,909   $    - 
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchases of beauty products   395    - 
DSY Wellness & Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.  Purchases of products for the provision of complementary health therapies   127    - 
Total        $75,431   $- 

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

 

Related party transactions

 

Other purchases

 

Name of Related        For the three months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchases of beauty products  $69   $- 
Total        $69   $- 

 

Name of Related        For the six months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchases of beauty products  $69   $- 
Total        $69   $- 

 

Commission

 

Name of Related        For the three months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
Mr. How Kok Choong  Mr. How Kok Choong, the CEO and director of the Company  Commission expense  $2,443   $    - 
Total        $2,443   $- 

 

 

Name of Related        For the six months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
Mr. How Kok Choong  Mr. How Kok Choong, the CEO and director of the Company  Commission expense  $5,148   $   - 
Total        $5,148   $- 

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

 

Related party transactions

 

Office rental expense

 

Name of Related        For the three months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC  Office rental expense
  $5,602   $   - 
Total        $5,602   $- 

 

Name of Related        For the six months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC  Office rental expense
  $11,203   $   - 
Total        $11,203   $- 

 

Related party transactions

 

Other income

 

Name of Related        For the three months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
Hostastay Sdn. Bhd. (“Hostastay”)  Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021  Sublease rental income due from Hostastay  $-   $1,458 
Total        $-   $1,458 

 

Name of Related        For the six months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
Hostastay Sdn. Bhd. (“Hostastay”)  Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021  Sublease rental income due from Hostastay  $-   $2,929 
Total        $-   $2,929 

 

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2
STOCKHOLDERS’ EQUITY
6 Months Ended
Jun. 30, 2022
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

14. STOCKHOLDERS’ EQUITY

 

Preferred stock

 

As of June 30, 2022, and December 31, 2021, there were 200,000,000 preferred stocks authorized but none were issued and outstanding.

 

Common stock

 

As of June 30, 2022, and December 31, 2021, there were 1,000,000,000 common stocks authorized, 75,452,012 and 290,460,047 shares issued and outstanding, respectively.

 

A share forfeiture agreement (the “Share Forfeiture Agreement”) dated January 20, 2022, between the Company and Mr. How Kok Choong, the CEO and director of the Company, pursuant to which Mr. How Kok Choong agreed to forfeit 215,008,035 shares of common stock of the Company. As a result, the outstanding shares was reduced by 215,008,035 shares of common stock.

 

There were no stock options, warrants or other potentially dilutive securities outstanding as of June 30, 2022 and December 31, 2021. 

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2
NON-CONTROLLING INTEREST
6 Months Ended
Jun. 30, 2022
Noncontrolling Interest [Abstract]  
NON-CONTROLLING INTEREST

15. NON-CONTROLLING INTEREST

 

The Company’s non-controlling interest consists of the following:

 

           
   As of 
   June 30, 2022   December 31, 2021 
DSY Wellness:          
Paid-in capital  $97   $97 
Retained earnings (Accumulated deficit)   10,773    (436)
Accumulated other comprehensive (loss) income   (269)   3 
Non Controlling interest Gross   10,601    (336)
ASL   -    - 
Total  $10,601   $(336)

 

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2
INCOME TAXES
6 Months Ended
Jun. 30, 2022
Income Tax Disclosure [Abstract]  
INCOME TAXES

16. INCOME TAXES

 

The United States and foreign components of loss before income taxes were comprised of the following: 

 

                     
   For the three months ended
June 30,
   For the six months ended
June 30,
 
   2022   2021   2022   2021 
                 
Tax jurisdictions from:                    
Local – United States  $(187,379)  $(96,370)  $(293,804)  $(204,295)
Foreign – Malaysia   (189,395)   (177,983)   (354,459)   (469,675)
Foreign – Hong Kong   (27,178)   (363,901)   (45,847)   (291,814)
Loss before income tax  $(403,952)  $(638,254)  $(694,110)  $(965,784)

 

The provision for income taxes consisted of the following:

 

                     
   For the three months ended
June 30,
   For the six months ended
June 30,
 
   2022   2021   2022   2021 
                 
Current:                    
- Local  $-   $(22,205)  $-   $(22,205)
- Foreign   (392)   (14,461)   (8,680)   (41,185)
                     
Deferred:                    
- Local   -    -    -    - 
- Foreign   -    32,695    -    53,299 
Provision for income tax  $(392)  $(3,971)  $(8,680)  $(10,091)

 

The effective tax rate in the periods presented is the result of the mix of income earned in various tax jurisdictions that apply a broad range of income tax rates. The Company and its subsidiary that operate in various countries: United States, Malaysia (including Labuan) and Hong Kong that are subject to taxes in the jurisdictions in which they operate, as follows:

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

16. INCOME TAXES (Continued)

 

United States of America

 

Agape ATP Corporation was incorporated in the State of Nevada and is subject to the tax laws of the United States of America with a corporate tax rate of 21% on its taxable income. Agape ATP Corporation also subject to controlled foreign corporations Subpart F income (“Subpart F”) tax, which is a tax primarily on passive income from controlled foreign corporations with a tax rate of 35%. In addition, the Tax Cuts and Jobs Act imposed a global intangible low-taxed income (“GILTI”) tax, which is a tax on certain off-shore earnings at an effective rate of 10.5% for tax years (50% deduction of the current enacted tax rate of 21%) with a partial offset for 80% foreign tax credits. If the foreign tax rate is 13.125% or higher, there will be no U.S. corporate tax after the 80% foreign tax credits are applied.

 

For the three and six months ended June 30, 2022 and 2021, the Company’s foreign subsidiaries did not generate any income that are subject to Subpart F tax and GILTI tax.

 

As of June 30, 2022 and December 31, 2021, the operations in the United States of America incurred approximately $914,000 and $620,000, respectively, of cumulative net operating losses (“NOL”) which can be carried forward to offset future taxable income or Subpart F and GILTI taxes. These balances can be carried forward indefinitely. The deferred tax valuation allowance as of June 30, 2022 and December 31, 2021 were approximately $192,000 and $130,000, respectively.

 

Malaysia

 

Changes to the Labuan Business Activity Tax Act (LBATA) 1990 which was gazetted and came into operation on January 1, 2019 mandates companies incorporated in Labuan to satisfy the “substantial activity requirements” to qualify for the preferential tax rate of 3% on net audited profit. Subsequently, on April 29, 2020, a circular setting out revisions to the “substantial activity requirements” was issued. As Agape ATP Corporation did not maintain a permanent establishment in Labuan, and therefore did not satisfy the said requirements, the company was subjected to tax at 24% on its net audited profit. On June 11, 2021, Agape ATP Corporation made an irrevocable election to be taxed under the Malaysian Income Tax Act 1967 as the elected tax regime is more tax efficient to the entity compare to LBATA.

 

Agape Superior Living Sdn Bhd, Agape S.E.A Sdn Bhd., Wellness ATP International Holdings Sdn Bhd. and DSY Wellness International Sdn. Bhd. are governed by the income taxes laws of Malaysia and the income taxes provision in respect of operations in Malaysia is calculated at the applicable tax rates on the taxable income for the periods based on existing legislation, interpretations and practices in respect thereof. Under the Income Tax Act of Malaysia, enterprises that incorporated in Malaysia are usually subject to a unified 24% enterprise income taxes rate while preferential tax rates, tax holidays and even tax exemption may be granted on case-by-case basis. The tax rate for small and medium sized companies (generally companies incorporated in Malaysia with paid-in capital of RM 2,500,000 or less) is 17% for the first RM 600,000 (or approximately $150,000) for the three months ended June 30, 2022 and 2021, with the remaining balance being taxed at the 24% rate.

 

As of June 30, 2022 and December 31, 2021, the operations in Malaysia incurred approximately $1,311,000 and $946,000, respectively, of cumulative net operating losses (“NOL”) which can be carried forward to offset future taxable income. Approximately $944,000 of the net operating loss carry forwards will expire in 2028, if unutilized. The deferred tax valuation allowance as of June 30, 2022 and December 31, 2021 were approximately $309,000 and $227,000, respectively.

 

Hong Kong

 

Agape ATP International Holding (HK) Limited is subject to Hong Kong Profits Tax, which is charged at the statutory income rate of 16.5% on its assessable income derived from Hong Kong. Business income derived or business expenses incurred outside the Special Administrative Region is not subject to Hong Kong Profits Tax or deduction. As Agape ATP International Holding (HK) Limited is an investment holding company without operating activities, the net operating loss for Hong Kong is considered immaterial.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

16. INCOME TAXES (Continued)

 

The following table sets forth the significant components of the aggregate deferred tax assets of the Company:

 

           
   As of 
   June 30, 2022   December 31, 2021 
Deferred tax assets:          
Net operating loss carry forwards in U.S.  $191,976   $130,277 
Net operating loss carry forwards in Malaysia   309,415    227,106 
Less: valuation allowance   (501,391)   (357,383)
Deferred tax liabilities:          
Depreciation   (17,975)   (15,574)
Deferred tax liabilities, net  $(17,975)  $(15,574)

 

Uncertain tax positions

 

The Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of June 30, 2022 and December 31, 2021, the Company did not have any significant unrecognized uncertain tax positions. The Company did not incur interest and penalties tax for the three and six months ended June 30, 2022 and 2021.

 

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2
CONCENTRATIONS OF RISKS
6 Months Ended
Jun. 30, 2022
Risks and Uncertainties [Abstract]  
CONCENTRATIONS OF RISKS

17. CONCENTRATIONS OF RISKS

 

(a) Major customers

 

For the three months ended June 30, 2022, and 2021, no customer accounted for 10% or more of the Company’s total revenues. For the six months ended June 30, 2022, and 2021, no customer accounted for 10% or more of the Company’s total revenues.

 

As of June 30, 2022, one individual customer accounted for 100.0% of the Company’s balance of accounts receivable. There was no accounts receivable balance as of December 31, 2021.

 

(b) Major vendors

 

For the three months ended June 30, 2022, three vendors accounted for approximately 70%, 11% and 17% of the Company’s total purchases, respectively. For the six months ended June 30, 2022, two vendors accounted for approximately 46% and 43% of the Company’s total purchases, respectively. For the three and six months ended June 30, 2021, one vendor accounted for 100% of the Company’s total purchases.

  

As of June 30, 2022, three vendors accounted for approximately 36%, 40% and 20% of the Company’s total balance of accounts payable, respectively. The vendor which accounted for 40% of the Company’s total balance of accounts payable is a related company, i.e. CTA Nutriceuticals (Asia) Sdn Bhd. As of December 31, 2021, one vendor accounted for 100% of the total balance of accounts payable. 

 

  

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

17. CONCENTRATIONS OF RISKS (Continued)

 

(c) Commission Expenses to Sales Distributors and Stockists

 

For the three months ended June 30, 2022, one sales distributor accounted for 10% of the Company’s commission expense. For the three months ended June 30, 2021, one sales distributor accounted for approximately 21.9% of the Company’s commission expense.

 

For the six months ended June 30, 2022, no sales distributor accounted for 10% or more of the Company’s commission expense. For the six months ended June 30, 2021, one distributor accounted for approximately 16.2% of the Company’s total purchases.

 

(d) Credit risk

 

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. As of June 30, 2022, and December 31, 2021, $666,779 and $554,864 were deposited with financial institutions, respectively, $319,994 and $295,761 of these balances are not covered by deposit insurance, respectively. While management believes that these financial institutions are of high credit quality, it also continually monitors their credit worthiness.

 

Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its account receivable is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. Historically, the Company did not have any bad debt on its account receivable.

 

(e) Exchange rate risk

 

The Company cannot guarantee that the current exchange rate will remain steady; therefore, there is a possibility that the Company could post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually post higher or lower profit depending on exchange rate of RM and HK$ converted to US$ on that date. The exchange rate could fluctuate depending on changes in political and economic environments without notice.

 

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2
COMMITMENTS AND CONTINGENCIES
6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

18. COMMITMENTS AND CONTINGENCIES

 

Lease commitments

 

On April 1, 2020, the Company adopted ASC 842 for ASL’s office space lease and sales and training center as the lease commencement date upon the acquisition of ASL. The Company recognized lease liabilities of approximately $490,000, with a corresponding right-of-use (“ROU”) asset in the same amount based on the present value of the future minimum rental payments of the lease, using an effective interest rate of 5.5%, which was determined using the Company’s estimated incremental borrowing rate.

 

On May 31, 2021, the Company entered into two separate two-year leases extension with the modified lease expiring May 31, 2023 for its office space and expiring August 31, 2023 for its training center. The lease modification required the Company to re-measure the ROU assets and lease liabilities based on the modified leases. The Company recognized a reduction of $3,250 in ROU assets and lease liabilities upon lease modifications based on the present value of the future minimum rental payments of the lease, using an effective interest rate of 5.5%, which was determined using the Company’s estimated incremental borrowing rate.

 

The weighted remaining term of the lease is approximately 1.17 years.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

18. COMMITMENTS AND CONTINGENCIES (Continued)

 

The five-year maturity of the Company’s operating lease liabilities is as follow:

 

      
Twelve Months Ending June 30,  Operating lease
liabilities
 
     
2023  $155,474 
2024   10,898 
Thereafter   - 
Total lease payments   166,372 
Less: interest   (4,987)
Present value of lease liabilities  $161,385 

 

The Company also leases one office and operation center, and one shophouse with an expiring term of twelve months or less, which were classified as operation leases. Since the lease terms for these leases were twelve months or less, a lessee is permitted to elect not to recognize lease assets and liabilities. The Company has elected not to recognize lease assets and liabilities on these leases. As of June 30, 2022, the Company’s commitment for minimum lease payment under these operating leases within the next twelve months were $11,416.

 

Rent expense for the three months ended June 30, 2022 and 2021 was $54,237 and $45,560, respectively. Rent expense for the six months ended June 30, 2022, and 2021 was $98,312 and $91,521, respectively.

 

Contingencies

 

Legal

 

From time to time, the Company is party to certain legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued, as well as the total amount of reasonably possible losses with respect to such matters, individually and in the aggregate, are not deemed to be material to the consolidated financial statements.

 

COVID-19

 

Since the declaration of the COVID-19 pandemic on March 11, 2020 by the World Health Organization or WHO, Malaysia has been put through various stages of lockdowns such as (1) full movement control orders (“MCO”), under which, quarantines, travel restrictions, and the temporary closure of stores and facilities in Malaysia were made mandatory, (2) MCO were eased to a Conditional Movement Control Order (“CMCO”) where most business sectors were allowed to operate under strict rules and Standard Operating Procedures mandated by the government of Malaysia and (3) CMCO were further relaxed to Recovery Movement Control Order (“RMCO”). On January 12, 2021, due to a resurgence of COVID-19 cases, the Malaysian government declared a state of emergency nationwide to combat COVID-19. Intermittent lockdowns were imposed in various states and districts in the country. February 2021 marked a significant month for Malaysia as all frontline staff of the country, which comprised those in healthcare, police, the Volunteers Department of Malaysia, the Fire and Rescue Department of Malaysia and civil defense sectors were vaccinated. On February 16, 2021, Prime Minister Tan Sri Muhyiddin Yassin announced that a National COVID-19 Immunization Plan will be implemented for one year after February 2021, which 80% of the Malaysia population will be vaccinated to achieve herd immunization. 

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

18. COMMITMENTS AND CONTINGENCIES (Continued)

 

On March 5, 2021, lockdowns in most part of the country was eased to a CMCO, nevertheless, COVID-19 cases in the country continue to rise. On May 12, 2021, Malaysia was again put under a full lockdown nationwide, until the earlier of (i) daily COVID-19 cases infection of the country fall below 4,000; (ii) intensive Unit Care, or ICU, wards start operating at a moderate level; or (iii) 10% of the Malaysian population is fully vaccinated. The country was administering over 400,000 doses of COVID-19 vaccines daily. On July 17, 2021, the full lockdown was slightly eased as 13.9% of the Malaysian population was fully vaccinated, with another 30% having received at least one dose of the vaccine. The COVID-19 situation in the country showed no sign of abating. Kuala Lumpur and Selangor remained the epicenter of the latest wave of infections. Total COVID-19 cases in the country surpassed the one million mark on July 25, 2021, and daily cases hit a record high of 24,599 on August 26, 2021. Despite the deteriorating COVID-19 state, the government lifted Kuala Lumpur from Enhanced Movement Control Order (“EMCO”) ahead of schedule and ended the nationwide state of emergency on August 1, 2021. Parliament met for the first time this year on July 26, 2021. Malaysia pressed on with its National COVID-19 Immunization Plan, fast inoculating of its residents. COVID-19 infections started to drop below the 10,000 mark daily, beginning October 3, 2021. Effective October 11, 2021, interstate and international travel restrictions were lifted for residents who had been fully vaccinated against COVID-19 as the country achieved its target of inoculating 90% of its adult population.

 

Malaysia officially transitioned to the endemic phase of COVID-19 effective April 1, 2022. Restrictions on businesses and people are minimal. Meanwhile, the government continues to encourage inoculation for those between the ages of 5 to 11 years and its adolescent group which comprised those between the ages 12 to 17. Adults who have been fully vaccinated, i.e. received two doses of the COVID-19 vaccine are encouraged to take booster shots.

 

Substantially all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially, affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact, almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:

 

  temporary closure of offices, travel restrictions, financial impact of the Company’s customers or suspension supplies may be negatively affected, and could continue to negatively affect the demand for the Company’s product;
  the Company may have to provide significant sales incentives to its customers during the outbreak, which may in turn materially adversely affect its financial condition and operating results; and
  any disruption of the Company’s supply chain, logistics providers or customers could adversely impact its business and results of operations, including causing the Company or its suppliers to cease manufacturing for a period of time or materially delay delivery to its customers, which may also lead to loss of its customers.

 

Because of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the COVID-19 cannot be reasonably estimated at this time. There is no guarantee that the Company’s total revenues will grow or remain at similar levels year over year in 2022 and beyond.

 

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2
SUBSEQUENT EVENT
6 Months Ended
Jun. 30, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENT

19. SUBSEQUENT EVENT

 

On July 19, 2022, Greenpro Capital Corp. filed a certificate of change with the Secretary of State of Nevada to effect a reverse split of the company’s common stock at the ratio of 10-for-1 effective July 28, 2022. Under the reverse stock split, each 10 pre-split share of common stock outstanding will automatically combine into 1 new share of common stock of the company. As at June 30, 2022, the Company has an investment of 116,646 common stock of Greenpro Capital Corp. valued at $24,853.45. The Company’s investment of 116,646 common stock of Greenpro Capital Corp. shall be reduced to 11,665 as a result of the reverse stock split. However, the value of the Company’s investment in Greenpro Capital Corp. as at June 30,2022 remained unchanged despite the reduction in the number of common stock.

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Basis of presentation

Basis of presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for information pursuant to the rules and regulations of the Securities Exchange Commission (“SEC”), and include all normal and recurring adjustments that management of the Company considers necessary for a fair presentation of its financial position and operation results. Interim results are not necessarily indicative of results to be expected for any other interim period or for the full year. The information included in this Form 10-Q should be read in conjunction with information included in the Company’s annual report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 28, 2022.

 

The unaudited condensed consolidated financial statements include the financial statements of the Company, its subsidiaries and its variable interest entity (“VIE”) over which the Company exercises control and, where applicable, entities for which the Company has a controlling financial interest or is the primary beneficiary. All transactions and balances among the Company, its subsidiaries and its VIE have been eliminated upon consolidation.

 

Principles of consolidation

Principles of consolidation

 

Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.

 

A VIE is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary and must consolidate the VIE. As of and for the three and six months ended June 30, 2022, SEA, the only VIE of the Company has no significant operations.

 

Use of estimates

Use of estimates

 

The preparation of audited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s consolidated financial statements include allowance for doubtful accounts, allowance for inventories obsolescence, useful lives of property and equipment, useful lives of intangible assets, impairment of long-lived assets, allowance for deferred tax assets, operating right-of-use assets, operating lease liabilities and uncertain tax position and impairment of investment in non-marketable securities. Actual results could differ from these estimates.

 

Cash and cash equivalents

Cash and cash equivalents

 

Cash and cash equivalents are carried at cost and represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Accounts receivable

Accounts receivable

 

Accounts receivable are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due on credit term. Accounts receivable also include money due from a third-party e-commerce platform acting as a collection agent for the Company on the sales through their platform. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of June 30, 2022 and December 31, 2021, no allowance of doubtful accounts was recorded.

 

Inventories

Inventories

 

Inventories consist of finished goods and are stated at the lower of cost or net realizable value using the first-in first-out method. Management reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net realizable value. For the six months ended June 30, 2022 and 2021, the Company recognized inventory write-downs of $0 and $36,636, respectively.

 

Prepaid taxes

Prepaid taxes

 

Prepaid taxes include prepaid income taxes that will either be refunded or utilized to offset future income tax.

 

Prepayments and deposits

Prepayments and deposits

 

Prepayments and deposits are mainly cash deposited or advanced to suppliers for future inventory purchases or service providers for future services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after management has determined that the likelihood of collection is not probable. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of June 30, 2022 and December 31, 2021, there was $120,372 and $121,095 allowance for doubtful accounts recorded, respectively.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Property and equipment, net

Property and equipment, net

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets with no residual value. The estimated useful lives are as follows:

 

   Useful Life
    
Computer and office equipment  5-7 years
Furniture & fixtures  6-7 years
Leasehold improvements  Lease Term
Vehicle  5 years

 

The cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements of income and comprehensive income. Expenditures for maintenance and repairs are charged to earnings as incurred, while additions, renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates the periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.

 

Intangible assets, net

Intangible assets, net

 

Intangible assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the estimated useful lives of the assets as follows:

 

Classification  Useful Life
    
Computer software  5 years

 

Impairment for long-lived assets

Impairment for long-lived assets

 

Long-lived assets, including property and equipment, and intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted future cash flows the assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset. If an impairment is identified, the Company would reduce the carrying amount of the asset to its estimated fair value based on a discounted cash flows approach or, when available and appropriate, to comparable market values. As of June 30, 2022 and December 31, 2021, no impairment of long-lived assets was recognized.

 

Deferred offering costs

Deferred offering costs

 

Deferred offering costs represents costs associated with the Company’s current offering which will be netted against the proceeds from the Company’s current offering.

 

Investment in marketable equity securities

Investment in marketable equity securities

 

The Company follows the provisions of ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Investments in marketable equity securities (non-current) are reported at fair value with changes in fair value recognized in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss in the caption of “unrealized holding gain loss on marketable securities” in each reporting period.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Investment in non-marketable equity securities

Investment in non-marketable equity securities

 

The Company follows the provisions of ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Due to the Company’s non-marketable equity securities (non-current) does not qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issue.

 

At each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that raise significant concerns about the investee’s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment loss equal to the difference between the fair value of the investment and its carrying amount.

 

Customer deposits

Customer deposits

 

Customer deposits represent amounts advanced by customers on product orders and discounted value of unapplied coupons. Customer deposits are reduced when the related sale is recognized in accordance with the Company’s revenue recognition policy.

 

Revenue recognition

Revenue recognition

 

The Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606). The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.

 

The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

 

The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Sales of Health and Wellness products

 

- Performance obligations satisfied at a point in time

 

The Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods. The revenue is recorded net of estimated discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were insignificant sales returns.

 

The Company also sells coupons to its customers for cash at a discounted price of the value of the coupons. Customers can apply the value of the coupons for a reduction in the transaction price paid by the customer are recorded as a reduction of sales. The cash proceeds resulted from the sale of coupons are recognized as customer deposits until the coupons to be applied as a reduction of the health and wellness products transaction price upon such sales transactions occurred. The Company’s coupons have a validity period of six months. If the Company’s customers did not utilize the coupons after six months, the Company would recognize the forfeiture of the originated sales value of the coupons as net revenues. For the three months ended June 30, 2022 and 2021, the Company recognized $4,824 and $4,115, as forfeited coupon income, respectively. For the six months ended June 30, 2022 and 2021, the Company recognized $5,777 and $11,226, as forfeited coupon income, respectively.

 

The Company had contracts for the sales of health and wellness products amounting to $16,084 which it is expected to fulfill within 12 months from June 30, 2022.

 

Sales of Health and Wellness services

 

- Performance obligations satisfied at a point in time

 

The Company carries out its Wellness program, where the Company’s products are bundled with health screening test and a health camp program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test reports are completed and delivered to its customers during the consultation section in person.

 

The Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health camp program was completed in the final day of the health camp. For the three months ended June 30, 2022 and 2021, revenues from health and wellness services were $30,072 and $653 respectively. For the six months ended June 30, 2022 and 2021, revenues from health and wellness services were $31,139 and $5,746 respectively.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Disaggregated information of revenues by products are as follows:

 

                     
   For the three months ended   For the six months ended 
   June 30,   June 30, 
   2022   2021   2022   2021 
                 
Survivor Select  $13,941   $24,415   $22,753   $37,641 
Energized Mineral Concentrate   -    8,291    -    52,183 
Ionized Cal-Mag   14,278    18,485    62,368    40,298 
Omega Blend   42,747    89,066    179,177    185,361 
Beta Maxx   23,564    55,943    47,637    89,800 
Iron   3,118    8,431    7,186    16,715 
Young Formula   1,075    14,458    34,269    25,901 
Organic Youth Care Cleansing Bar   -    2,990    -    2,990 
ATPR Mito+   76,605    70,148    187,926    106,843 
Lipomask   -    4,279    -    8,401 
Hyaluronic Acid Serum   1,698    1,362    3,006    3,353 
Mousse Facial Cleanser   4,355    3,042    7,394    7,660 
Trim+   2,765    2,223    6,236    22,674 
Others – Products for the provision of complementary health therapies   182,101    -    216,188    - 
Others   388    -    388    - 
Total revenues - products   366,635    303,133    774,528    599,820 
Health and Wellness services   30,072    653    31,139    5,746 
Total revenues - products and services  $396,707   $303,786   $805,667   $605,566 

 

Cost of revenue

Cost of revenue

 

Cost of revenue for the three and six months ended June 30, 2022 were $109,383, and $182,814, respectively, and comprised freight-in, purchase cost of manufactured goods for sale to customers and products for the provision of complementary health therapies. Cost of revenue for the three months and six months ended June 30, 2021, were $35,623, and $113,214, respectively, and comprised freight-in, purchase cost of manufactured goods for sale to customers. For the six months ended June 30, 2021, cost of revenue also included inventory write-downs of $36,636.

 

Shipping and handling

Shipping and handling

 

Shipping and handling charges amounted to $4,272 and $2,990 for the three months ended June 30, 2022 and 2021, respectively. Shipping and handling charges amounted to $7,179 and $5,272 for the six months ended June 30, 2022 and 2021, respectively. Shipping and handling charges are expensed as incurred and included in selling expenses.

 

Advertising costs

Advertising costs

 

Advertising costs amounted to $4,765 and $8,721 for the three months ended June 30, 2022 and 2021, respectively. Advertising costs amounted to $4,765 and $16,658 for the six months ended June 30, 2022 and 2021, respectively. Advertising costs are expensed as incurred and included in selling expenses.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Commission expenses

Commission expenses

 

Commission expenses are the Company’s most significant expenses. As with all companies in the network marketing industry, the Company’s sales channel is external to the Company. The Company’s “external sales force” is stratified into two levels based on priority recruitment. First, there are sales distributors. Second, all members recruited by a sales distributor, directly or indirectly, are referred to as “sales network members”. The Company pays commission to every sales distributor based on purchases made by its sales network members which includes the independent direct sales members. Top performing distributors with their own physical stores may also become stockists of the Company, whereby they enjoy benefits such as maintaining a certain amount of the Company’s inventory on their store premises. The stockists shall account to the Company for all products sales from their store premises as monitored through the Company’s centralized stock tracking system. The Company pays a separate commission to stockists based on revenue generated from the stockists’ physical stores. Commission expenses amounted to $62,557 and $92,774 for the three months ended June 30, 2022 and 2021, respectively. Commission expenses amounted to $176,666 and $181,213 for the six months ended June 30, 2022 and 2021, respectively.

 

Defined contribution plan

Defined contribution plan

 

The full-time employees of the Company are entitled to the government mandated defined contribution plan. The Company is required to accrue and pay for these benefits based on certain percentages of the employees’ respective salaries, subject to certain ceilings, in accordance with the relevant government regulations, and make cash contributions to the government mandated defined contribution plan. Total expenses for the plan were $35,936 and $27,067 for the three months ended June 30, 2022 and 2021, respectively. Total expenses for the plan were $63,408 and $53,034 for the six months ended June 30, 2022 and 2021, respectively.

 

The related contribution plans include:

 

  - Social Security Organization (“SOSCO”) – 1.75% based on employee’s monthly salary capped of RM 4,000;
  - Employees Provident Fund (“EPF”) – 12% based on employee’s monthly salary;
  - Employment Insurance System (“EIS”) – 0.2% based on employee’s monthly salary capped of RM 4,000;
  - Human Resource Development Fund (“HRDF”) – 1% based on employee’s monthly salary

 

Income taxes

Income taxes

 

The Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

 

Deferred taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.

 

An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. No penalties and interest related to underpayment of income taxes were incurred for the three and six months ended June 30, 2022. $395 in penalties and interest related to underpayment of income taxes were incurred for the three and six months ended June 30, 2021.

 

The Company conducts much of its business activities in Hong Kong and Malaysia and is subject to tax in each of these jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

 

Comprehensive income (loss)

Comprehensive income (loss)

 

Comprehensive income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under GAAP are recorded as an element of stockholders’ equity but are excluded from net income. Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.

 

Non-controlling interest

Non-controlling interest

 

Non-controlling interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out of 9,590,598 shares) of the equity interests of ASL held by two individuals. The non-controlling interests are presented in the consolidated balance sheets, separately from equity attributable to the shareholders of the Company. Non-controlling interests in the results of the Company are presented on the face of the consolidated statements of operations as an allocation of the total income or loss for the periods between non-controlling interest holders and the shareholders of the Company.

 

Earnings (loss) per share

Earnings (loss) per share

 

The Company computes earnings (loss) per share (“EPS”) in accordance with ASC 260, “Earnings per Share”. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is measured as net income (loss) divided by the weighted average common stocks outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential common stocks (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common stocks that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. For the three and six months ended June 30, 2022 and 2021, there were no dilutive shares.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Foreign currencies translation and transaction

Foreign currencies translation and transaction

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the consolidated statements of operations and comprehensive income (loss).

 

The reporting currency of the Company is United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. The Company’s subsidiary in Labuan maintains its books and record in United States Dollars (“US$”) albeit its functional currency being the primary currency of the economic environment in which the entity operates, which is the Malaysian Ringgit (“MYR” or “RM”). The Company’s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars (“HK$”), similar to its functional currency. The Company’s subsidiary and VIE in Malaysia conducts its businesses and maintains its books and record in the local currency, Malaysian Ringgit (“MYR” or “RM”), as its functional currency.

 

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders’ equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.

 

Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Period-end MYR : US$1 exchange rate   4.40    4.18 
Period-end HKD : US$1 exchange rate   7.85    7.80 

 

                     
   For the three months ended
June 30,
   For the six months ended
June 30,
 
   2022   2021   2022   2021 
                 
Period-average MYR : US$1 exchange rate   4.37    4.13    4.28    4.10 
Period-average HKD : US$1 exchange rate   7.85    7.77    7.83    7.76 

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Related parties

Related parties

 

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

 

Fair value of financial instruments

Fair value of financial instruments

 

The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.

 

The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

 

Leases

Leases

 

The Company adopted ASU 2016-02, “Leases” (Topic 842), and elected the practical expedients that does not require the Company to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing leases and (3) initial direct costs for any expired or existing leases. For lease terms of twelve months or fewer, a lessee is permitted to make an accounting policy election not to recognize lease assets and liabilities. The Company also adopts the practical expedient that allows lessees to treat the lease and non-lease components of a lease as a single lease component. Some of the Company’s leases include one or more options to renew, which is typically at the Company’s sole discretion. The Company regularly evaluates the renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. New lease modifications result in re-measurement of the right of use (“ROU”) assets and lease liabilities. Operating ROU assets and lease liabilities are recognized at the commencement date, based on the present value of lease payments over the lease term. Since the implicit rate for the Company’s leases is not readily determinable, the Company use its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment and over a similar term.

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Lease terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of twelve months or less. Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease term.

 

The Company reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future pre-tax cash flows.

 

Recent accounting pronouncements

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates (“ASUs”). Management periodically reviews new accounting standards that are issued. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or revised accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.

  

In November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating the impact ASU 2019-05 may have on its unaudited condensed consolidated financial statements.

 

Except for the above-mentioned pronouncements, there are no new recent issued accounting standards that will have a material impact on the consolidated financial position, statements of operations and cash flows.

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2
ORGANIZATION AND BUSINESS BACKGROUND (Tables)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
SCHEDULE OF SUBSIDIARIES AND ASSOCIATES

Details of the Company’s subsidiaries:

 

  

Subsidiary

company name

 

Place and date of

incorporation

 

Particulars of

issued capital

  Principal activities 

Proportional of

ownership interest

and voting power

held

 
                 
1.  Agape ATP Corporation  Labuan,
March 6, 2017
  100 shares of ordinary share of US$1 each  Investment holding   100%
                  
2.  Agape ATP International Holding Limited  Hong Kong,
June 1, 2017
  1,000,000 shares of ordinary share of HK$1 each  Wholesaling of health and wellness products; and health solution advisory services   100%
                  
3.  Agape Superior Living Sdn. Bhd.  Malaysia,
August 8, 2003
  9,590,598 shares of ordinary share of RM1 each  Health and wellness products and health solution advisory services via network marketing   99.99%
                  
4.  Agape S.E.A. Sdn. Bhd.  Malaysia,
March 4, 2004
  2 shares of ordinary share of RM1 each  VIE of Agape Superior Living Sdn. Bhd.   VIE 
                  
5.  Wellness ATP International Holdings Sdn, Bhd  Malaysia,
September 11, 2020
  100 shares of ordinary share of RM1 each  The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns   100%
                  
6.  DSY Wellness International Sdn Bhd.  Malaysia,
November 11, 2021
  1,000 shares of ordinary share of RM1 each  Provision of complementary health therapies   60%
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT

Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets with no residual value. The estimated useful lives are as follows:

 

   Useful Life
    
Computer and office equipment  5-7 years
Furniture & fixtures  6-7 years
Leasehold improvements  Lease Term
Vehicle  5 years
SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET

Intangible assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the estimated useful lives of the assets as follows:

 

Classification  Useful Life
    
Computer software  5 years
SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES

Disaggregated information of revenues by products are as follows:

 

                     
   For the three months ended   For the six months ended 
   June 30,   June 30, 
   2022   2021   2022   2021 
                 
Survivor Select  $13,941   $24,415   $22,753   $37,641 
Energized Mineral Concentrate   -    8,291    -    52,183 
Ionized Cal-Mag   14,278    18,485    62,368    40,298 
Omega Blend   42,747    89,066    179,177    185,361 
Beta Maxx   23,564    55,943    47,637    89,800 
Iron   3,118    8,431    7,186    16,715 
Young Formula   1,075    14,458    34,269    25,901 
Organic Youth Care Cleansing Bar   -    2,990    -    2,990 
ATPR Mito+   76,605    70,148    187,926    106,843 
Lipomask   -    4,279    -    8,401 
Hyaluronic Acid Serum   1,698    1,362    3,006    3,353 
Mousse Facial Cleanser   4,355    3,042    7,394    7,660 
Trim+   2,765    2,223    6,236    22,674 
Others – Products for the provision of complementary health therapies   182,101    -    216,188    - 
Others   388    -    388    - 
Total revenues - products   366,635    303,133    774,528    599,820 
Health and Wellness services   30,072    653    31,139    5,746 
Total revenues - products and services  $396,707   $303,786   $805,667   $605,566 
SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES

Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Period-end MYR : US$1 exchange rate   4.40    4.18 
Period-end HKD : US$1 exchange rate   7.85    7.80 

 

                     
   For the three months ended
June 30,
   For the six months ended
June 30,
 
   2022   2021   2022   2021 
                 
Period-average MYR : US$1 exchange rate   4.37    4.13    4.28    4.10 
Period-average HKD : US$1 exchange rate   7.85    7.77    7.83    7.76 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2
VARIABLE INTEREST ENTITY (“VIE”) (Tables)
6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
SCHEDULE OF VARIABLE INTEREST ENTITY

The carrying amount of the VIE’s assets and liabilities were as follows:

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Current assets  $9,370   $       18,850 
Current liabilities   (43,288)   (51,272)
Net deficit  $(33,918)  $(32,422)

 

   As of 
   June 30, 2022   December 31, 2021 
         
Current assets:          
Cash  $7,626   $       17,493 
Prepaid taxes   1,744    1,357 
Total current assets  $9,370   $18,850 
           
Current liabilities:          
Accounts payable – intercompany  $42,501   $49,724 
Other payables and accrued liabilities   787    1,548 
Total current liabilities  $43,288   $51,272 
           
Net deficit  $(33,918)  $(32,422)

 

The summarized operating results of the VIE’s are as follows:

 

                     
   For the three months ended
June 30,
   For the six months ended
June 30,
 
   2022   2021   2022   2021 
                 
Operating revenues  $-   $-   $-   $- 
Gross profit  $-   $-   $-   $- 
Profit (loss) from operations  $1,723   $(5,019)  $(3,219)  $(11,967)
Net income (loss)  $1,723   $1,912   $(3,219)  $(9,949)
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2
ACCOUNTS RECEIVABLE (Tables)
6 Months Ended
Jun. 30, 2022
Receivables [Abstract]  
SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Accounts receivable  $214   $       - 
Allowance for doubtful accounts   -    - 
Total accounts receivable  $214   $- 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2
INVENTORIES (Tables)
6 Months Ended
Jun. 30, 2022
Inventory Disclosure [Abstract]  
SCHEDULE OF INVENTORIES

Inventories consist of the following:

 

           
   As of 
   June 30, 2022   December 31, 2021 
           
Finished goods  $346,744   $       375,535 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2
PREPAYMENTS AND DEPOSITS (Tables)
6 Months Ended
Jun. 30, 2022
Prepayments And Deposits  
SCHEDULE OF PREPAID EXPENSES AND DEPOSITS

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Receivables from sales distributors  $58,477   $       115,379 
Deposits to suppliers   240,592    301,233 
Subtotal   299,069    416,612 
Less: Provision for doubtful accounts   (120,372)   (121,095)
Total  $178,697   $295,517 
SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS

Movements of allowance for doubtful accounts are as follows:

 

           
  

For the six

months ended

June 30, 2022

  

For the

year ended

December 31, 2021

 
         
Beginning balance  $121,095   $                - 
Addition   -    121,514 
Write off   -    - 
Exchange rate effect   (723)   (419)
Ending balance  $120,372   $121,095 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2
PROPERTY AND EQUIPMENT, NET (Tables)
6 Months Ended
Jun. 30, 2022
Property, Plant and Equipment [Abstract]  
SCHEDULE OF PROPERTY AND EQUIPMENT, NET

Property and equipment, net consist of the following:

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Computer and office equipment  $78,885   $82,298 
Furniture & fixtures   116,004    122,185 
Leasehold improvements   192,323    202,570 
Vehicle   93,709    98,702 
Subtotal   480,921    505,755 
Less: accumulated depreciation   (311,006)   (289,956)
Total  $169,915   $215,799 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2
INTANGIBLE ASSETS, NET (Tables)
6 Months Ended
Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
SCHEDULE OF INTANGIBLE ASSETS, NET

Intangible assets, net, consist of the following:

 

           
    As of  
    June 30, 2022     December 31, 2021  
             
Computer software   $ 32,710     $ 34,453  
Less: accumulated amortization     (30,109 )     (30,793 )
Total   $ 2,601     $ 3,660  
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2
INVESTMENT IN MARKETABLE SECURITIES (Tables)
6 Months Ended
Jun. 30, 2022
Investment In Marketable Securities  
SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES

 

           
   As of 
   June 30, 2022   December 31, 2021 
         
Cost of investment  $89,001   $577,035 
Dividend income from Greenpro Capital Corp.   -    18,939 
Unrealized holding loss   (52,889)   (505,231)
Exchange rate effect   (405)   (1,742)
Investment in marketable securities  $35,707   $89,001 
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2
INVESTMENT IN NON-MARKETABLE SECURITIES (Tables)
6 Months Ended
Jun. 30, 2022
Investment In Non-marketable Securities  
SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES

    As of  
Phoenix Plus Corporation   June 30, 2022     December 31, 2021  
             
Cost of investment   $ 1,500     $ 1,500  
                 
Investment in non-marketable securities   $ 1,500     $ 1,500  
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2
OTHER PAYABLES AND ACCRUED LIABILITIES (Tables)
6 Months Ended
Jun. 30, 2022
Other Liabilities Disclosure [Abstract]  
SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES

           
   As of 
    June 30, 2022    December 31, 2021 
Professional fees  $142,622   $436,541 
Promotion expenses   40,360    36,024 
Payroll   54,018    22,669 
Commissions   247,645    219,721 
Tax penalty   75,000    75,000 
Others   77,388    68,400 
Total  $637,033   $858,355 
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2
RELATED PARTY BALANCES AND TRANSACTIONS (Tables)
6 Months Ended
Jun. 30, 2022
Related Party Transactions [Abstract]  
SCHEDULE OF RELATED PARTIES

Name of Related
Party
  Relationship  Nature 

As of

June 30, 2022

   As of
December 31, 2021
 
               
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)  The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd  Purchases of products for the provision of complementary health therapies  $14,322   $         - 
DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC  Purchases of products for the provision of complementary health therapies   85    - 
Total        $14,407   $- 

 

Amount due from related parties

 

Name of Related

Party

  Relationship  Nature 

As of

June 30, 2022

   As of
December 31, 2021
 
               
Agape ATP (Asia) Limited (“AATP Asia”)  Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia  Expenses paid for AATP Asia  $-   $2,214 
Hostastay Sdn. Bhd. (“Hostastay”)  Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021  Sublease rent due from Hostastay   4,548    4,790 
Total        $4,548   $7,004 

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

 

Related party balances

 

Amount due to related parties

 

Name of Related

Party

  Relationship  Nature 

As of

June 30, 2022

   As of
December 31, 2021
 
               
DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC  Rental due and expenses paid by DSYWLC  $2,015   $         - 
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchase of beauty products   67    - 
Total        $2,082   $- 

 

Related party transactions

 

Purchases

 

Name of Related        For the three months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)  The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd  Purchases of products for the provision of complementary health therapies  $63,142   $    - 
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchases of beauty products   395    - 
DSY Wellness & Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.  Purchases of products for the provision of complementary health therapies   127    - 
Total        $63,664   $- 

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

 

Related party transactions

 

Purchases

 

 

Name of Related        For the six months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)  The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd  Purchases of products for the provision of complementary health therapies  $74,909   $    - 
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchases of beauty products   395    - 
DSY Wellness & Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.  Purchases of products for the provision of complementary health therapies   127    - 
Total        $75,431   $- 

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

 

Related party transactions

 

Other purchases

 

Name of Related        For the three months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchases of beauty products  $69   $- 
Total        $69   $- 

 

Name of Related        For the six months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchases of beauty products  $69   $- 
Total        $69   $- 

 

Commission

 

Name of Related        For the three months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
Mr. How Kok Choong  Mr. How Kok Choong, the CEO and director of the Company  Commission expense  $2,443   $    - 
Total        $2,443   $- 

 

 

Name of Related        For the six months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
Mr. How Kok Choong  Mr. How Kok Choong, the CEO and director of the Company  Commission expense  $5,148   $   - 
Total        $5,148   $- 

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

 

Related party transactions

 

Office rental expense

 

Name of Related        For the three months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC  Office rental expense
  $5,602   $   - 
Total        $5,602   $- 

 

Name of Related        For the six months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC  Office rental expense
  $11,203   $   - 
Total        $11,203   $- 

 

Related party transactions

 

Other income

 

Name of Related        For the three months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
Hostastay Sdn. Bhd. (“Hostastay”)  Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021  Sublease rental income due from Hostastay  $-   $1,458 
Total        $-   $1,458 

 

Name of Related        For the six months ended 
Party  Relationship  Nature  June 30, 2022   June 30, 2021 
               
Hostastay Sdn. Bhd. (“Hostastay”)  Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021  Sublease rental income due from Hostastay  $-   $2,929 
Total        $-   $2,929 
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2
NON-CONTROLLING INTEREST (Tables)
6 Months Ended
Jun. 30, 2022
Noncontrolling Interest [Abstract]  
SCHEDULE OF NON CONTROLLING INTEREST

The Company’s non-controlling interest consists of the following:

 

           
   As of 
   June 30, 2022   December 31, 2021 
DSY Wellness:          
Paid-in capital  $97   $97 
Retained earnings (Accumulated deficit)   10,773    (436)
Accumulated other comprehensive (loss) income   (269)   3 
Non Controlling interest Gross   10,601    (336)
ASL   -    - 
Total  $10,601   $(336)
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.2
INCOME TAXES (Tables)
6 Months Ended
Jun. 30, 2022
Income Tax Disclosure [Abstract]  
SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX

The United States and foreign components of loss before income taxes were comprised of the following: 

 

                     
   For the three months ended
June 30,
   For the six months ended
June 30,
 
   2022   2021   2022   2021 
                 
Tax jurisdictions from:                    
Local – United States  $(187,379)  $(96,370)  $(293,804)  $(204,295)
Foreign – Malaysia   (189,395)   (177,983)   (354,459)   (469,675)
Foreign – Hong Kong   (27,178)   (363,901)   (45,847)   (291,814)
Loss before income tax  $(403,952)  $(638,254)  $(694,110)  $(965,784)
SCHEDULE OF PROVISION FOR INCOME TAX

The provision for income taxes consisted of the following:

 

                     
   For the three months ended
June 30,
   For the six months ended
June 30,
 
   2022   2021   2022   2021 
                 
Current:                    
- Local  $-   $(22,205)  $-   $(22,205)
- Foreign   (392)   (14,461)   (8,680)   (41,185)
                     
Deferred:                    
- Local   -    -    -    - 
- Foreign   -    32,695    -    53,299 
Provision for income tax  $(392)  $(3,971)  $(8,680)  $(10,091)
SCHEDULE OF DEFERRED TAX ASSETS

The following table sets forth the significant components of the aggregate deferred tax assets of the Company:

 

           
   As of 
   June 30, 2022   December 31, 2021 
Deferred tax assets:          
Net operating loss carry forwards in U.S.  $191,976   $130,277 
Net operating loss carry forwards in Malaysia   309,415    227,106 
Less: valuation allowance   (501,391)   (357,383)
Deferred tax liabilities:          
Depreciation   (17,975)   (15,574)
Deferred tax liabilities, net  $(17,975)  $(15,574)
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.2
COMMITMENTS AND CONTINGENCIES (Tables)
6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
SCHEDULE OF LEASE COMMITMENTS

The five-year maturity of the Company’s operating lease liabilities is as follow:

 

      
Twelve Months Ending June 30,  Operating lease
liabilities
 
     
2023  $155,474 
2024   10,898 
Thereafter   - 
Total lease payments   166,372 
Less: interest   (4,987)
Present value of lease liabilities  $161,385 
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF SUBSIDIARIES AND ASSOCIATES (Details)
6 Months Ended
Jun. 30, 2022
Nov. 11, 2021
May 08, 2020
Subsidiary Company [Member]      
Subsidiary company name Agape ATP Corporation    
Place and date of incorporation Labuan, March 6, 2017    
Particulars of issued capital 100 shares of ordinary share of US$1 each    
Principal activities Investment holding    
Proportional of ownership interest and voting power held 100.00%    
Subsidiary Company One [Member]      
Subsidiary company name Agape ATP International Holding Limited    
Place and date of incorporation Hong Kong, June 1, 2017    
Particulars of issued capital 1,000,000 shares of ordinary share of HK$1 each    
Principal activities Wholesaling of health and wellness products; and health solution advisory services    
Proportional of ownership interest and voting power held 100.00%    
Subsidiary Company Two [Member]      
Subsidiary company name Agape Superior Living Sdn. Bhd.    
Place and date of incorporation Malaysia, August 8, 2003    
Particulars of issued capital 9,590,598 shares of ordinary share of RM1 each    
Principal activities Health and wellness products and health solution advisory services via network marketing    
Proportional of ownership interest and voting power held 99.99%   99.99%
Subsidiary Company Three [Member]      
Subsidiary company name Agape S.E.A. Sdn. Bhd.    
Place and date of incorporation Malaysia, March 4, 2004    
Particulars of issued capital 2 shares of ordinary share of RM1 each    
Principal activities VIE of Agape Superior Living Sdn. Bhd.    
Proportional of ownership interest and voting power held 100.00%    
Subsidiary Company Four [Member]      
Subsidiary company name Wellness ATP International Holdings Sdn, Bhd    
Place and date of incorporation Malaysia, September 11, 2020    
Particulars of issued capital 100 shares of ordinary share of RM1 each    
Principal activities The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns    
Proportional of ownership interest and voting power held 100.00%    
Subsidiary Company Five [Member]      
Subsidiary company name DSY Wellness International Sdn Bhd.    
Place and date of incorporation Malaysia, November 11, 2021    
Particulars of issued capital 1,000 shares of ordinary share of RM1 each    
Principal activities Provision of complementary health therapies    
Proportional of ownership interest and voting power held 60.00% 60.00%  
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.2
ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative) - shares
May 08, 2020
Jun. 30, 2022
Nov. 11, 2021
Share Exchange Agreement [Member] | Mr.How Kok Choong [Member]      
Stock issued during period acquisitions, shares 9,590,596    
Agape ATP International Holding Limited [Member]      
Ownership interest percentage   100.00%  
Subsidiary Company Two [Member]      
Ownership interest percentage 99.99% 99.99%  
Subsidiary Company Five [Member]      
Ownership interest percentage   60.00% 60.00%
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)
6 Months Ended
Jun. 30, 2022
Computer Equipment [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Estimated Useful Life of Property and Equipment 5 years
Computer Equipment [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Estimated Useful Life of Property and Equipment 7 years
Furniture and Fixtures [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Estimated Useful Life of Property and Equipment 6 years
Furniture and Fixtures [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Estimated Useful Life of Property and Equipment 7 years
Leasehold Improvements [Member]  
Property, Plant and Equipment [Line Items]  
Estimated Useful Lives of Property and Equipment Lease Term
Vehicles [Member]  
Property, Plant and Equipment [Line Items]  
Estimated Useful Life of Property and Equipment 5 years
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET (Details)
6 Months Ended
Jun. 30, 2022
Computer Software, Intangible Asset [Member]  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful lives of intangible assets 5 years
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Product Information [Line Items]        
Total revenues - products and services $ 396,707 $ 303,786 $ 805,667 $ 605,566
Survivor Select [Member]        
Product Information [Line Items]        
Total revenues - products and services 13,941 24,415 22,753 37,641
Energized Mineral Concentrate [Member]        
Product Information [Line Items]        
Total revenues - products and services 8,291 52,183
Ionized Cal-Mag [Member]        
Product Information [Line Items]        
Total revenues - products and services 14,278 18,485 62,368 40,298
Omega Blend [Member]        
Product Information [Line Items]        
Total revenues - products and services 42,747 89,066 179,177 185,361
Beta Maxx [Member]        
Product Information [Line Items]        
Total revenues - products and services 23,564 55,943 47,637 89,800
Iron [Member]        
Product Information [Line Items]        
Total revenues - products and services 3,118 8,431 7,186 16,715
Young Formula [Member]        
Product Information [Line Items]        
Total revenues - products and services 1,075 14,458 34,269 25,901
Organic Youth Care Cleansing Bar [Member]        
Product Information [Line Items]        
Total revenues - products and services 2,990 2,990
ATPR Mito+ [Member]        
Product Information [Line Items]        
Total revenues - products and services 76,605 70,148 187,926 106,843
Lipomask [Member]        
Product Information [Line Items]        
Total revenues - products and services 4,279 8,401
Hyaluronic Acid Serum [Member]        
Product Information [Line Items]        
Total revenues - products and services 1,698 1,362 3,006 3,353
Mousse Facial Cleanser [Member]        
Product Information [Line Items]        
Total revenues - products and services 4,355 3,042 7,394 7,660
Trim+ [Member]        
Product Information [Line Items]        
Total revenues - products and services 2,765 2,223 6,236 22,674
Others - Products for the Provision of Complementary Health Therapies [Member]        
Product Information [Line Items]        
Total revenues - products and services 182,101 216,188
Others [Member]        
Product Information [Line Items]        
Total revenues - products and services 388 388
Product [Member]        
Product Information [Line Items]        
Total revenues - products and services 366,635 303,133 774,528 599,820
Health and Wellness Services [Member]        
Product Information [Line Items]        
Total revenues - products and services $ 30,072 $ 653 $ 31,139 $ 5,746
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Period-end MYR [Member]          
Debt Instrument [Line Items]          
Foreign currency exchange rate, translation 4.40   4.40   4.18
Period-end HKD [Member]          
Debt Instrument [Line Items]          
Foreign currency exchange rate, translation 7.85   7.85   7.80
Period-average MYR [Member]          
Debt Instrument [Line Items]          
Foreign currency exchange rate period average 4.37 4.13 4.28 4.10  
Period-average HKD [Member]          
Debt Instrument [Line Items]          
Foreign currency exchange rate period average 7.85 7.77 7.83 7.76  
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
USD ($)
shares
Jun. 30, 2021
USD ($)
shares
Jun. 30, 2022
USD ($)
shares
Jun. 30, 2022
MYR (RM)
shares
Jun. 30, 2021
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Product Information [Line Items]            
Accounts receivable, allowance for credit loss      
Inventories write-down       $ 36,636  
Allowance for doubtful accounts 120,372   120,372     121,095
Impairment of long-lived assets     0     $ 0
Value of coupons 4,824 $ 4,115 5,777   11,226  
Cost of revenue 109,383 35,623 182,814   113,214  
Revenue from contract with customer excluding assessed tax 396,707 303,786 805,667   605,566  
Selling expenses 79,587 100,838 194,198   216,952  
Advertising costs 4,765 8,721 4,765   16,658  
Commission expenses 62,557 92,774 176,666   181,213  
Defined contribution plan expense 35,936 27,067 $ 63,408   53,034  
Income tax examination, likelihood of unfavorable settlement     greater than 50% greater than 50%    
Income tax examination, penalties and interest expense $ 0 $ 395 $ 0   $ 395  
Noncontrolling interest, description     Non-controlling interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out of 9,590,598 shares) of the equity interests of ASL held by two individuals Non-controlling interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out of 9,590,598 shares) of the equity interests of ASL held by two individuals    
Potentially dilutive securities outstanding | shares 0 0 0 0 0 0
Social Security Organization [Member]            
Product Information [Line Items]            
Salary percentage     1.75% 1.75%    
Social Security Organization [Member] | MYR Currency [Member]            
Product Information [Line Items]            
Monthly salary | RM       RM 4,000    
Employees Provident Fund [Member]            
Product Information [Line Items]            
Salary percentage     12.00% 12.00%    
Employment Insurance System [Member]            
Product Information [Line Items]            
Salary percentage     0.20% 0.20%    
Employment Insurance System [Member] | MYR Currency [Member]            
Product Information [Line Items]            
Monthly salary | RM       RM 4,000    
Human Resource Development Fund [Member]            
Product Information [Line Items]            
Salary percentage     1.00% 1.00%    
Health and Wellness Services [Member]            
Product Information [Line Items]            
Cost of revenue     $ 16,084      
Revenue from contract with customer excluding assessed tax $ 30,072 $ 653 31,139   $ 5,746  
Shipping and Handling [Member]            
Product Information [Line Items]            
Selling expenses $ 4,272 $ 2,990 $ 7,179   $ 5,272  
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF VARIABLE INTEREST ENTITY (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Trading Activity, Gains and Losses, Net [Line Items]          
Total current assets $ 2,677,639   $ 2,677,639   $ 3,912,122
Current liabilities (924,469)   (924,469)   (1,312,841)
Net deficit 2,525,796   2,525,796   3,312,972
Cash 1,807,437   1,807,437   2,597,848
Prepaid taxes 339,999   339,999   636,218
Total current liabilities 924,469   924,469   1,312,841
Operating revenues 396,707 $ 303,786 805,667 $ 605,566  
Gross profit 287,324 268,163 622,853 492,352  
Profit (loss) from operations (306,183) (408,997) (578,415) (751,507)  
Net income (loss) (414,900) (642,225) (713,997) (975,875)  
Variable Income Interest Rate [Member]          
Trading Activity, Gains and Losses, Net [Line Items]          
Total current assets 9,370   9,370   18,850
Current liabilities (43,288)   (43,288)   (51,272)
Net deficit (33,918)   (33,918)   (32,422)
Cash 7,626   7,626   17,493
Prepaid taxes 1,744   1,744   1,357
Accounts payable – intercompany 42,501   42,501   49,724
Other payables and accrued liabilities 787   787   1,548
Total current liabilities 43,288   43,288   $ 51,272
Operating revenues  
Gross profit  
Profit (loss) from operations 1,723 (5,019) (3,219) (11,967)  
Net income (loss) $ 1,723 $ 1,912 $ (3,219) $ (9,949)  
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.2
VARIABLE INTEREST ENTITY (“VIE”) (Details Narrative)
Jun. 30, 2022
Subsidiary Company Three [Member]  
Proportional of ownership interest and voting power held 100.00%
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.2
CASH AND CASH EQUIVALENTS (Details Narrative) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Cash and Cash Equivalents, at Carrying Value $ 1,807,437 $ 2,597,848  
Cash 666,779 554,864  
Time Deposits 1,134,542 1,975,347  
Time deposit uninsured $ 319,994 $ 295,761  
Minimum [Member]      
Percentage of Interest-Bearing Domestic Deposits to Deposits, Time Deposits 1.10%   1.80%
Maximum [Member]      
Percentage of Interest-Bearing Domestic Deposits to Deposits, Time Deposits 1.17%   2.15%
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Receivables [Abstract]    
Accounts receivable $ 214
Allowance for doubtful accounts
Total accounts receivable $ 214
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF INVENTORIES (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Finished goods $ 346,744 $ 375,535
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.2
INVENTORIES (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Inventory Disclosure [Abstract]    
Inventory write-downs $ 36,636
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF PREPAID EXPENSES AND DEPOSITS (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Prepayments And Deposits    
Receivables from sales distributors $ 58,477 $ 115,379
Deposits to suppliers 240,592 301,233
Subtotal 299,069 416,612
Less: Provision for doubtful accounts (120,372) (121,095)
Total $ 178,697 $ 295,517
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Prepayments And Deposits    
Beginning balance $ 121,095
Addition 121,514
Write off
Exchange rate effect (723) (419)
Ending balance $ 120,372 $ 121,095
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Subtotal $ 480,921 $ 505,755
Less: accumulated depreciation (311,006) (289,956)
Total 169,915 215,799
Computer and Office Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Subtotal 78,885 82,298
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Subtotal 116,004 122,185
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Subtotal 192,323 202,570
Vehicle [Member]    
Property, Plant and Equipment [Line Items]    
Subtotal $ 93,709 $ 98,702
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.2
PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Property, Plant and Equipment [Abstract]        
Depreciation $ 17,954 $ 19,009 $ 36,661 $ 38,179
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF INTANGIBLE ASSETS, NET (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
Computer software $ 32,710 $ 34,453
Less: accumulated amortization (30,109) (30,793)
Total $ 2,601 $ 3,660
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.22.2
INTANGIBLE ASSETS, NET (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization expense $ 439 $ 496 $ 897 $ 1,006
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Investment In Marketable Securities    
Cost of investment $ 89,001 $ 577,035
Dividend income from Greenpro Capital Corp. 18,939
Unrealized holding loss (52,889) (505,231)
Exchange rate effect (405) (1,742)
Investment in marketable securities $ 35,707 $ 89,001
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.22.2
INVESTMENT IN MARKETABLE SECURITIES (Details Narrative) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Sep. 27, 2021
Dec. 09, 2020
Nov. 03, 2020
Oct. 16, 2018
Jul. 30, 2018
May 17, 2018
Investment amount $ 89,001 $ 577,035            
Greenpro Capital Corp. [Member]                
Investment in securities, shares 116,646         33,333 20 83,333
Investment amount           $ 1,000 $ 125 $ 500,000
Purchased price per shares           $ 0.03 $ 6.2613 $ 6
DSwiss Inc. [Member]                
Investment in securities, shares       16,663 6,667      
Investment amount       $ 83,315 $ 76,671      
Purchased price per shares       $ 5 $ 11.50      
SEATech Ventures Corp. [Member]                
Investment in securities, shares     11,665          
Investment amount     $ 18,874          
Purchased price per shares     $ 1.62          
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Cost of investment $ 89,001 $ 577,035
Cost of investment 1,500 1,500
Phoenix Plus Corporation [Member]    
Cost of investment 1,500 1,500
Cost of investment $ 1,500 $ 1,500
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.22.2
INVESTMENT IN NON-MARKETABLE SECURITIES (Details Narrative) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Apr. 03, 2019
Investment amount $ 89,001 $ 577,035  
Phoenix Plus Corporation [Member]      
Equity interest percentage     5.00%
Investment amount     $ 1,500
Shares Issued, Price Per Share     $ 0.0001
Phoenix Plus Corporation [Member] | Common Stock [Member]      
Shares purchased during period     15,000,000
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Other Liabilities Disclosure [Abstract]    
Professional fees $ 142,622 $ 436,541
Promotion expenses 40,360 36,024
Payroll 54,018 22,669
Commissions 247,645 219,721
Tax penalty 75,000 75,000
Others 77,388 68,400
Total $ 637,033 $ 858,355
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF RELATED PARTIES (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Related Party Transaction [Line Items]          
Accounts payable $ 14,407   $ 14,407  
Due from related parties 4,548   4,548   7,004
Amount due to a Related Party 2,082   2,082  
Purchases 63,664 75,431  
Other purchases 69 69  
Commission 2,443 5,148  
Office rental expense 5,602 11,203  
Other income $ 1,458 $ 2,929  
CTA Nutriceuticals Sdn Bhd [Member]          
Related Party Transaction [Line Items]          
Relationship The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd
Nature Purchases of products for the provision of complementary health therapies Purchases of products for the provision of complementary health therapies Purchases of products for the provision of complementary health therapies Purchases of products for the provision of complementary health therapies Purchases of products for the provision of complementary health therapies
Accounts payable $ 14,322   $ 14,322  
Purchases 63,142 $ 74,909  
DSY Wellness & Longevity Center Sdn Bhd [Member]          
Related Party Transaction [Line Items]          
Relationship     Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC   Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC
Nature     Purchases of products for the provision of complementary health therapies   Purchases of products for the provision of complementary health therapies
Accounts payable 85   $ 85  
Agape ATP Asia Limited [Member]          
Related Party Transaction [Line Items]          
Relationship     Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia   Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia
Nature     Expenses paid for AATP Asia   Expenses paid for AATP Asia
Due from related parties     $ 2,214
Hostastay Sdn. Bhd. (“Hostastay”) [Member]          
Related Party Transaction [Line Items]          
Relationship     Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021   Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021
Nature     Sublease rent due from Hostastay   Sublease rent due from Hostastay
Due from related parties 4,548   $ 4,548   $ 4,790
DSY Wellness & Longevity Center Sdn Bhd [Member]          
Related Party Transaction [Line Items]          
Relationship     Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC   Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC
Nature     Rental due and expenses paid by DSYWLC   Rental due and expenses paid by DSYWLC
Amount due to a Related Party $ 2,015   $ 2,015  
DSY Beauty Sdn Bhd [Member]          
Related Party Transaction [Line Items]          
Relationship The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd
Nature Purchases of beauty products Purchases of beauty products Purchases of beauty products Purchases of beauty products Purchases of beauty products
Amount due to a Related Party $ 67   $ 67  
Purchases 395      
Other purchases $ 69 $ 69  
DSY Wellness and Longevity Center Sdn Bhd [Member]          
Related Party Transaction [Line Items]          
Relationship Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC. Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC. Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC. Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.  
Nature Purchases of products for the provision of complementary health therapies Purchases of products for the provision of complementary health therapies Purchases of products for the provision of complementary health therapies Purchases of products for the provision of complementary health therapies  
Purchases $ 127 $ 127  
DSY Beauty Sdn Bhd [Member]          
Related Party Transaction [Line Items]          
Relationship     The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  
Nature     Purchases of beauty products Purchases of beauty products  
Purchases     $ 395  
How Kok Choong [Member]          
Related Party Transaction [Line Items]          
Relationship Mr. How Kok Choong, the CEO and director of the Company Mr. How Kok Choong, the CEO and director of the Company Mr. How Kok Choong, the CEO and director of the Company Mr. How Kok Choong, the CEO and director of the Company  
Nature Commission expense Commission expense Commission expense Commission expense  
Commission $ 2,443 $ 5,148  
DSY Wellness and Longevity Center Sdn Bhd [Member]          
Related Party Transaction [Line Items]          
Relationship Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC  
Nature Office rental expense Office rental expense Office rental expense Office rental expense  
Office rental expense $ 5,602 $ 11,203  
Hostastay Sdn. Bhd. (“Hostastay”) [Member]          
Related Party Transaction [Line Items]          
Relationship Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021 Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021 Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021 Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021  
Nature Sublease rental income due from Hostastay Sublease rental income due from Hostastay Sublease rental income due from Hostastay Sublease rental income due from Hostastay  
Other income $ 1,458 $ 2,929  
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.22.2
STOCKHOLDERS’ EQUITY (Details Narrative) - shares
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Preferred stock, shares authorized 200,000,000   200,000,000   200,000,000
Preferred stock, shares issued 0   0   0
Preferred stock, shares outstanding 0   0   0
Common stock, shares authorized 1,000,000,000   1,000,000,000   1,000,000,000
Common stock, shares issued 75,452,012   75,452,012   290,460,047
Common stock, shares outstanding 75,452,012   75,452,012   290,460,047
Potentially dilutive securities outstanding 0 0 0 0 0
Share Forfeiture Agreements [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Reduction in outstanding shares     215,008,035    
Share Forfeiture Agreements [Member] | How Kok Choong Talent Limited [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of shares forfeited     215,008,035    
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF NON CONTROLLING INTEREST (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Noncontrolling Interest [Abstract]    
Paid-in capital $ 97 $ 97
Retained earnings (Accumulated deficit) 10,773 (436)
Accumulated other comprehensive (loss) income (269) 3
Non Controlling interest Gross 10,601 (336)
ASL
Total $ 10,601 $ (336)
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Local – United States $ (187,379) $ (96,370) $ (293,804) $ (204,295)
Loss before income tax (403,952) (638,254) (694,110) (965,784)
MALAYSIA        
Foreign – Hong Kong (189,395) (177,983) (354,459) (469,675)
HONG KONG        
Foreign – Hong Kong $ (27,178) $ (363,901) $ (45,847) $ (291,814)
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF PROVISION FOR INCOME TAX (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Current:        
- Local $ (22,205) $ (22,205)
- Foreign (392) (14,461) (8,680) (41,185)
Deferred:        
- Local
- Foreign 32,695 53,299
Provision for income tax $ (392) $ (3,971) $ (8,680) $ (10,091)
XML 81 R71.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Less: valuation allowance $ (501,391) $ (357,383)
Depreciation (17,975) (15,574)
Deferred tax liabilities, net (17,975) (15,574)
UNITED STATES    
Net operating loss carry forwards in Malaysia 191,976 130,277
Less: valuation allowance (192,000) (130,000)
MALAYSIA    
Net operating loss carry forwards in Malaysia 309,415 227,106
Less: valuation allowance $ (309,000) $ (227,000)
XML 82 R72.htm IDEA: XBRL DOCUMENT v3.22.2
INCOME TAXES (Details Narrative)
3 Months Ended 6 Months Ended
Jan. 02, 2019
Jun. 30, 2022
MYR (RM)
Jun. 30, 2021
MYR (RM)
Jun. 30, 2022
USD ($)
Jun. 30, 2022
MYR (RM)
Dec. 31, 2021
USD ($)
Operating Loss Carryforwards [Line Items]            
Tax rate description       In addition, the Tax Cuts and Jobs Act imposed a global intangible low-taxed income (“GILTI”) tax, which is a tax on certain off-shore earnings at an effective rate of 10.5% for tax years (50% deduction of the current enacted tax rate of 21%) with a partial offset for 80% foreign tax credits. If the foreign tax rate is 13.125% or higher, there will be no U.S. corporate tax after the 80% foreign tax credits are applied    
Deferred tax valuation allowance       $ 501,391   $ 357,383
Additional paid in capital | RM   RM 600,000 RM 150,000      
Unutilized [Member]            
Operating Loss Carryforwards [Line Items]            
Net operating loss carryforward       $ 944,000   944,000
Net operating loss carry forwards expiration, description       expire in 2028    
Maximum [Member]            
Operating Loss Carryforwards [Line Items]            
Paid in capital | RM         RM 2,500,000  
UNITED STATES            
Operating Loss Carryforwards [Line Items]            
Net operating loss carryforward       $ 914,000   620,000
Deferred tax valuation allowance       $ 192,000   130,000
Labuan [Member]            
Operating Loss Carryforwards [Line Items]            
Tax percentage 24.00%          
Effective income tax rate reconciliation, percent 3.00%          
MALAYSIA            
Operating Loss Carryforwards [Line Items]            
Tax percentage       17.00%    
Net operating loss carryforward       $ 1,311,000   946,000
Deferred tax valuation allowance       $ 309,000   $ 227,000
Income tax examination, description       The tax rate for small and medium sized companies (generally companies incorporated in Malaysia with paid-in capital of RM 2,500,000 or less) is 17% for the first RM 600,000 (or approximately $150,000) for the three months ended June 30, 2022 and 2021, with the remaining balance being taxed at the 24% rate    
HONG KONG            
Operating Loss Carryforwards [Line Items]            
Tax percentage       16.50%    
State and Local Jurisdiction [Member]            
Operating Loss Carryforwards [Line Items]            
Tax percentage       21.00%    
Foreign Tax Authority [Member]            
Operating Loss Carryforwards [Line Items]            
Tax percentage       35.00%    
XML 83 R73.htm IDEA: XBRL DOCUMENT v3.22.2
CONCENTRATIONS OF RISKS (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Concentration Risk [Line Items]          
Deposits $ 666,779   $ 666,779   $ 554,864
Deposit for insurance $ 319,994   $ 319,994   $ 295,761
No Customer [Member] | Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentrations of risk percentage 10.00% 10.00% 10.00% 10.00%  
One Individual Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | E-commerce [Member]          
Concentration Risk [Line Items]          
Concentrations of risk percentage     100.00%    
Vendor One [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentrations of risk percentage 70.00% 100.00% 46.00% 100.00%  
Vendor One [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentrations of risk percentage     36.00%    
Vendor Two [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentrations of risk percentage 11.00%   43.00%    
Vendor Two [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentrations of risk percentage     40.00%    
Vendor Three [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentrations of risk percentage 17.00%        
Vendor Three [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentrations of risk percentage     20.00%    
Vendor [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentrations of risk percentage     40.00%    
One Vendor [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentrations of risk percentage         100.00%
One Sales Distributor [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentrations of risk percentage 10.00% 21.90%   16.20%  
No Sales Distributor [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentrations of risk percentage     10.00%    
XML 84 R74.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF LEASE COMMITMENTS (Details)
Jun. 30, 2022
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2023 $ 155,474
2024 10,898
Thereafter
Total lease payments 166,372
Less: interest (4,987)
Present value of lease liabilities $ 161,385
XML 85 R75.htm IDEA: XBRL DOCUMENT v3.22.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
May 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Apr. 01, 2020
Restructuring Cost and Reserve [Line Items]            
Operating lease liability   $ 161,385   $ 161,385    
Lease expiration term May 31, 2023          
Reduction in ROU assets and liabilities $ 3,250          
Operating lease payments       11,416    
Operating lease, expense   $ 54,237 $ 45,560 $ 98,312 $ 91,521  
COVID-19 Impact [Member]            
Restructuring Cost and Reserve [Line Items]            
COVID-19 impact description       On May 12, 2021, Malaysia was again put under a full lockdown nationwide, until the earlier of (i) daily COVID-19 cases infection of the country fall below 4,000; (ii) intensive Unit Care, or ICU, wards start operating at a moderate level; or (iii) 10% of the Malaysian population is fully vaccinated. The country was administering over 400,000 doses of COVID-19 vaccines daily. On July 17, 2021, the full lockdown was slightly eased as 13.9% of the Malaysian population was fully vaccinated, with another 30% having received at least one dose of the vaccine. The COVID-19 situation in the country showed no sign of abating. Kuala Lumpur and Selangor remained the epicenter of the latest wave of infections. Total COVID-19 cases in the country surpassed the one million mark on July 25, 2021, and daily cases hit a record high of 24,599 on August 26, 2021. Despite the deteriorating COVID-19 state, the government lifted Kuala Lumpur from Enhanced Movement Control Order (“EMCO”) ahead of schedule and ended the nationwide state of emergency on August 1, 2021. Parliament met for the first time this year on July 26, 2021. Malaysia pressed on with its National COVID-19 Immunization Plan, fast inoculating of its residents. COVID-19 infections started to drop below the 10,000 mark daily, beginning October 3, 2021. Effective October 11, 2021, interstate and international travel restrictions were lifted for residents who had been fully vaccinated against COVID-19 as the country achieved its target of inoculating 90% of its adult population    
Training Center [Member]            
Restructuring Cost and Reserve [Line Items]            
Lease expiration term Aug. 31, 2023          
ASL [Member]            
Restructuring Cost and Reserve [Line Items]            
Operating lease liability           $ 490,000
Operating lease effective interest rate 5.50%         5.50%
Operating lease, weighted average remaining lease term   1 year 2 months 1 day   1 year 2 months 1 day    
XML 86 R76.htm IDEA: XBRL DOCUMENT v3.22.2
SUBSEQUENT EVENT (Details Narrative) - USD ($)
Jul. 19, 2022
Jun. 30, 2022
Oct. 16, 2018
Jul. 30, 2018
May 17, 2018
Greenpro Capital Corp. [Member]          
Subsequent Event [Line Items]          
Investment owned, balance shares   116,646 33,333 20 83,333
Investment owned, fair value   $ 24,853.45      
Subsequent Event [Member]          
Subsequent Event [Line Items]          
Stockholders equity reverse stock split the company’s common stock at the ratio of 10-for-1 effective July 28, 2022. Under the reverse stock split, each 10 pre-split share of common stock outstanding will automatically combine into 1 new share of common stock of the company        
Subsequent Event [Member] | Greenpro Capital Corp. [Member]          
Subsequent Event [Line Items]          
Investment owned, balance shares 11,665        
XML 87 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001713210 2022-01-01 2022-06-30 0001713210 2022-08-09 0001713210 2022-06-30 0001713210 2021-12-31 0001713210 2022-04-01 2022-06-30 0001713210 2021-04-01 2021-06-30 0001713210 2021-01-01 2021-06-30 0001713210 us-gaap:CommonStockMember 2020-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001713210 us-gaap:RetainedEarningsMember 2020-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001713210 us-gaap:NoncontrollingInterestMember 2020-12-31 0001713210 2020-12-31 0001713210 us-gaap:CommonStockMember 2021-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001713210 us-gaap:RetainedEarningsMember 2021-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001713210 us-gaap:NoncontrollingInterestMember 2021-03-31 0001713210 2021-03-31 0001713210 us-gaap:CommonStockMember 2021-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001713210 us-gaap:RetainedEarningsMember 2021-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001713210 us-gaap:NoncontrollingInterestMember 2021-12-31 0001713210 us-gaap:CommonStockMember 2022-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001713210 us-gaap:RetainedEarningsMember 2022-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001713210 us-gaap:NoncontrollingInterestMember 2022-03-31 0001713210 2022-03-31 0001713210 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001713210 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001713210 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001713210 2021-01-01 2021-03-31 0001713210 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001713210 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001713210 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001713210 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001713210 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001713210 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001713210 2022-01-01 2022-03-31 0001713210 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001713210 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001713210 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001713210 us-gaap:CommonStockMember 2021-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001713210 us-gaap:RetainedEarningsMember 2021-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001713210 us-gaap:NoncontrollingInterestMember 2021-06-30 0001713210 2021-06-30 0001713210 us-gaap:CommonStockMember 2022-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001713210 us-gaap:RetainedEarningsMember 2022-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001713210 us-gaap:NoncontrollingInterestMember 2022-06-30 0001713210 AATP:AgapeATPInternationalHoldingLimitedMember 2022-06-30 0001713210 AATP:MrHowKokChoongMember AATP:ShareExchangeAgreementMember 2020-05-07 2020-05-08 0001713210 AATP:SubsidiaryCompanyTwoMember 2020-05-08 0001713210 AATP:SubsidiaryCompanyFiveMember 2021-11-11 0001713210 AATP:SubsidiaryCompanyMember 2022-01-01 2022-06-30 0001713210 AATP:SubsidiaryCompanyMember 2022-06-30 0001713210 AATP:SubsidiaryCompanyOneMember 2022-01-01 2022-06-30 0001713210 AATP:SubsidiaryCompanyOneMember 2022-06-30 0001713210 AATP:SubsidiaryCompanyTwoMember 2022-01-01 2022-06-30 0001713210 AATP:SubsidiaryCompanyTwoMember 2022-06-30 0001713210 AATP:SubsidiaryCompanyThreeMember 2022-01-01 2022-06-30 0001713210 AATP:SubsidiaryCompanyFourMember 2022-01-01 2022-06-30 0001713210 AATP:SubsidiaryCompanyFourMember 2022-06-30 0001713210 AATP:SubsidiaryCompanyFiveMember 2022-01-01 2022-06-30 0001713210 AATP:SubsidiaryCompanyFiveMember 2022-06-30 0001713210 2021-01-01 2021-12-31 0001713210 AATP:HealthAndWellnessServicesMember 2022-01-01 2022-06-30 0001713210 AATP:HealthAndWellnessServicesMember 2022-04-01 2022-06-30 0001713210 AATP:HealthAndWellnessServicesMember 2021-04-01 2021-06-30 0001713210 AATP:HealthAndWellnessServicesMember 2021-01-01 2021-06-30 0001713210 us-gaap:ShippingAndHandlingMember 2022-04-01 2022-06-30 0001713210 us-gaap:ShippingAndHandlingMember 2021-04-01 2021-06-30 0001713210 us-gaap:ShippingAndHandlingMember 2022-01-01 2022-06-30 0001713210 us-gaap:ShippingAndHandlingMember 2021-01-01 2021-06-30 0001713210 AATP:SocialSecurityOrganizationMember 2022-01-01 2022-06-30 0001713210 AATP:MYRCurrencyMember AATP:SocialSecurityOrganizationMember 2022-01-01 2022-06-30 0001713210 AATP:EmployeesProvidentFundMember 2022-01-01 2022-06-30 0001713210 AATP:EmploymentInsuranceSystemMember 2022-01-01 2022-06-30 0001713210 AATP:MYRCurrencyMember AATP:EmploymentInsuranceSystemMember 2022-01-01 2022-06-30 0001713210 AATP:HumanResourceDevelopmentFundMember 2022-01-01 2022-06-30 0001713210 srt:MinimumMember us-gaap:ComputerEquipmentMember 2022-01-01 2022-06-30 0001713210 srt:MaximumMember us-gaap:ComputerEquipmentMember 2022-01-01 2022-06-30 0001713210 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-06-30 0001713210 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-06-30 0001713210 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-06-30 0001713210 us-gaap:VehiclesMember 2022-01-01 2022-06-30 0001713210 us-gaap:ComputerSoftwareIntangibleAssetMember 2022-01-01 2022-06-30 0001713210 AATP:SurvivorSelectMember 2022-04-01 2022-06-30 0001713210 AATP:SurvivorSelectMember 2021-04-01 2021-06-30 0001713210 AATP:SurvivorSelectMember 2022-01-01 2022-06-30 0001713210 AATP:SurvivorSelectMember 2021-01-01 2021-06-30 0001713210 AATP:EnergizedMineralConcentrateMember 2022-04-01 2022-06-30 0001713210 AATP:EnergizedMineralConcentrateMember 2021-04-01 2021-06-30 0001713210 AATP:EnergizedMineralConcentrateMember 2022-01-01 2022-06-30 0001713210 AATP:EnergizedMineralConcentrateMember 2021-01-01 2021-06-30 0001713210 AATP:IonizedCalMagMember 2022-04-01 2022-06-30 0001713210 AATP:IonizedCalMagMember 2021-04-01 2021-06-30 0001713210 AATP:IonizedCalMagMember 2022-01-01 2022-06-30 0001713210 AATP:IonizedCalMagMember 2021-01-01 2021-06-30 0001713210 AATP:OmegaBlendMember 2022-04-01 2022-06-30 0001713210 AATP:OmegaBlendMember 2021-04-01 2021-06-30 0001713210 AATP:OmegaBlendMember 2022-01-01 2022-06-30 0001713210 AATP:OmegaBlendMember 2021-01-01 2021-06-30 0001713210 AATP:BetaMaxxMember 2022-04-01 2022-06-30 0001713210 AATP:BetaMaxxMember 2021-04-01 2021-06-30 0001713210 AATP:BetaMaxxMember 2022-01-01 2022-06-30 0001713210 AATP:BetaMaxxMember 2021-01-01 2021-06-30 0001713210 AATP:IronMember 2022-04-01 2022-06-30 0001713210 AATP:IronMember 2021-04-01 2021-06-30 0001713210 AATP:IronMember 2022-01-01 2022-06-30 0001713210 AATP:IronMember 2021-01-01 2021-06-30 0001713210 AATP:YoungFormulaMember 2022-04-01 2022-06-30 0001713210 AATP:YoungFormulaMember 2021-04-01 2021-06-30 0001713210 AATP:YoungFormulaMember 2022-01-01 2022-06-30 0001713210 AATP:YoungFormulaMember 2021-01-01 2021-06-30 0001713210 AATP:OrganicYouthCarCleansingBarMember 2022-04-01 2022-06-30 0001713210 AATP:OrganicYouthCarCleansingBarMember 2021-04-01 2021-06-30 0001713210 AATP:OrganicYouthCarCleansingBarMember 2022-01-01 2022-06-30 0001713210 AATP:OrganicYouthCarCleansingBarMember 2021-01-01 2021-06-30 0001713210 AATP:ATPRMITOPlusMember 2022-04-01 2022-06-30 0001713210 AATP:ATPRMITOPlusMember 2021-04-01 2021-06-30 0001713210 AATP:ATPRMITOPlusMember 2022-01-01 2022-06-30 0001713210 AATP:ATPRMITOPlusMember 2021-01-01 2021-06-30 0001713210 AATP:LipomaskMember 2022-04-01 2022-06-30 0001713210 AATP:LipomaskMember 2021-04-01 2021-06-30 0001713210 AATP:LipomaskMember 2022-01-01 2022-06-30 0001713210 AATP:LipomaskMember 2021-01-01 2021-06-30 0001713210 AATP:HyaluronicAcidSerumMember 2022-04-01 2022-06-30 0001713210 AATP:HyaluronicAcidSerumMember 2021-04-01 2021-06-30 0001713210 AATP:HyaluronicAcidSerumMember 2022-01-01 2022-06-30 0001713210 AATP:HyaluronicAcidSerumMember 2021-01-01 2021-06-30 0001713210 AATP:MousseFacialCleanserMember 2022-04-01 2022-06-30 0001713210 AATP:MousseFacialCleanserMember 2021-04-01 2021-06-30 0001713210 AATP:MousseFacialCleanserMember 2022-01-01 2022-06-30 0001713210 AATP:MousseFacialCleanserMember 2021-01-01 2021-06-30 0001713210 AATP:TrimPlusMember 2022-04-01 2022-06-30 0001713210 AATP:TrimPlusMember 2021-04-01 2021-06-30 0001713210 AATP:TrimPlusMember 2022-01-01 2022-06-30 0001713210 AATP:TrimPlusMember 2021-01-01 2021-06-30 0001713210 AATP:ProductHealthTherapiesMember 2022-04-01 2022-06-30 0001713210 AATP:ProductHealthTherapiesMember 2021-04-01 2021-06-30 0001713210 AATP:ProductHealthTherapiesMember 2022-01-01 2022-06-30 0001713210 AATP:ProductHealthTherapiesMember 2021-01-01 2021-06-30 0001713210 AATP:OthersMember 2022-04-01 2022-06-30 0001713210 AATP:OthersMember 2021-04-01 2021-06-30 0001713210 AATP:OthersMember 2022-01-01 2022-06-30 0001713210 AATP:OthersMember 2021-01-01 2021-06-30 0001713210 us-gaap:ProductMember 2022-04-01 2022-06-30 0001713210 us-gaap:ProductMember 2021-04-01 2021-06-30 0001713210 us-gaap:ProductMember 2022-01-01 2022-06-30 0001713210 us-gaap:ProductMember 2021-01-01 2021-06-30 0001713210 AATP:PeriodEndMYRMember 2022-06-30 0001713210 AATP:PeriodEndMYRMember 2021-12-31 0001713210 AATP:PeriodEndHKDMember 2022-06-30 0001713210 AATP:PeriodEndHKDMember 2021-12-31 0001713210 AATP:PeriodAverageMYRMember 2022-04-01 2022-06-30 0001713210 AATP:PeriodAverageMYRMember 2021-04-01 2021-06-30 0001713210 AATP:PeriodAverageMYRMember 2022-01-01 2022-06-30 0001713210 AATP:PeriodAverageMYRMember 2021-01-01 2021-06-30 0001713210 AATP:PeriodAverageHKDMember 2022-04-01 2022-06-30 0001713210 AATP:PeriodAverageHKDMember 2021-04-01 2021-06-30 0001713210 AATP:PeriodAverageHKDMember 2022-01-01 2022-06-30 0001713210 AATP:PeriodAverageHKDMember 2021-01-01 2021-06-30 0001713210 AATP:SubsidiaryCompanyThreeMember 2022-06-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2022-06-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2021-12-31 0001713210 us-gaap:VariableIncomeInterestRateMember 2022-04-01 2022-06-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2021-04-01 2021-06-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2022-01-01 2022-06-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2021-01-01 2021-06-30 0001713210 srt:MinimumMember 2022-06-30 0001713210 srt:MaximumMember 2022-06-30 0001713210 srt:MinimumMember 2021-06-30 0001713210 srt:MaximumMember 2021-06-30 0001713210 AATP:ComputerAndOfficeEquipmentMember 2022-06-30 0001713210 AATP:ComputerAndOfficeEquipmentMember 2021-12-31 0001713210 us-gaap:FurnitureAndFixturesMember 2022-06-30 0001713210 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001713210 us-gaap:LeaseholdImprovementsMember 2022-06-30 0001713210 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001713210 AATP:VehicleMember 2022-06-30 0001713210 AATP:VehicleMember 2021-12-31 0001713210 AATP:GreenproCapitalCorpMember 2018-05-17 0001713210 AATP:GreenproCapitalCorpMember 2018-07-30 0001713210 AATP:GreenproCapitalCorpMember 2018-10-16 0001713210 AATP:DSwissIncMember 2020-11-03 0001713210 AATP:DSwissIncMember 2020-12-09 0001713210 AATP:SEATechVenturesCorpMember 2021-09-27 0001713210 AATP:PhoenixPlusCorpMember 2019-04-03 0001713210 AATP:PhoenixPlusCorpMember us-gaap:CommonStockMember 2019-04-03 0001713210 AATP:PhoenixPlusCorpMember 2022-06-30 0001713210 AATP:PhoenixPlusCorpMember 2021-12-31 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2022-01-01 2022-06-30 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2021-01-01 2021-12-31 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2022-06-30 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2021-12-31 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdMember 2022-01-01 2022-06-30 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdMember 2021-01-01 2021-12-31 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdMember 2022-06-30 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdMember 2021-12-31 0001713210 AATP:AgapeATPAsiaLimitedMember 2022-01-01 2022-06-30 0001713210 AATP:AgapeATPAsiaLimitedMember 2021-01-01 2021-12-31 0001713210 AATP:AgapeATPAsiaLimitedMember 2022-06-30 0001713210 AATP:AgapeATPAsiaLimitedMember 2021-12-31 0001713210 AATP:HostastaySdnBhdMember 2022-01-01 2022-06-30 0001713210 AATP:HostastaySdnBhdMember 2021-01-01 2021-12-31 0001713210 AATP:HostastaySdnBhdMember 2022-06-30 0001713210 AATP:HostastaySdnBhdMember 2021-12-31 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdOneMember 2022-01-01 2022-06-30 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdOneMember 2021-01-01 2021-12-31 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdOneMember 2022-06-30 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdOneMember 2021-12-31 0001713210 AATP:DSYBeautySdnBhdMember 2022-01-01 2022-06-30 0001713210 AATP:DSYBeautySdnBhdMember 2021-01-01 2021-12-31 0001713210 AATP:DSYBeautySdnBhdMember 2022-06-30 0001713210 AATP:DSYBeautySdnBhdMember 2021-12-31 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2022-04-01 2022-06-30 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2021-04-01 2021-06-30 0001713210 AATP:DSYBeautySdnBhdMember 2022-04-01 2022-06-30 0001713210 AATP:DSYBeautySdnBhdMember 2021-04-01 2021-06-30 0001713210 AATP:DSYWellnessandLongevityCenterSdnBhdTwoMember 2022-04-01 2022-06-30 0001713210 AATP:DSYWellnessandLongevityCenterSdnBhdTwoMember 2021-04-01 2021-06-30 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2021-01-01 2021-06-30 0001713210 AATP:DSYBeautySdnBhdOneMember 2022-01-01 2022-06-30 0001713210 AATP:DSYBeautySdnBhdOneMember 2021-01-01 2021-06-30 0001713210 AATP:DSYWellnessandLongevityCenterSdnBhdTwoMember 2022-01-01 2022-06-30 0001713210 AATP:DSYWellnessandLongevityCenterSdnBhdTwoMember 2021-01-01 2021-06-30 0001713210 AATP:DSYBeautySdnBhdMember 2021-01-01 2021-06-30 0001713210 AATP:HowKokChoongMember 2022-04-01 2022-06-30 0001713210 AATP:HowKokChoongMember 2021-04-01 2021-06-30 0001713210 AATP:HowKokChoongMember 2022-01-01 2022-06-30 0001713210 AATP:HowKokChoongMember 2021-01-01 2021-06-30 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdThreeMember 2022-04-01 2022-06-30 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdThreeMember 2021-04-01 2021-06-30 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdThreeMember 2022-01-01 2022-06-30 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdThreeMember 2021-01-01 2021-06-30 0001713210 AATP:HostastaySdnBhdHostastayMember 2022-04-01 2022-06-30 0001713210 AATP:HostastaySdnBhdHostastayMember 2021-04-01 2021-06-30 0001713210 AATP:HostastaySdnBhdHostastayMember 2021-01-01 2021-06-30 0001713210 AATP:HostastaySdnBhdHostastayMember 2022-01-01 2022-06-30 0001713210 AATP:HowKokChoongTalentLimitedMember AATP:ShareForfeitureAgreementsMember 2022-01-01 2022-06-30 0001713210 AATP:ShareForfeitureAgreementsMember 2022-01-01 2022-06-30 0001713210 country:MY 2022-04-01 2022-06-30 0001713210 country:MY 2021-04-01 2021-06-30 0001713210 country:MY 2022-01-01 2022-06-30 0001713210 country:MY 2021-01-01 2021-06-30 0001713210 country:HK 2022-04-01 2022-06-30 0001713210 country:HK 2021-04-01 2021-06-30 0001713210 country:HK 2022-01-01 2022-06-30 0001713210 country:HK 2021-01-01 2021-06-30 0001713210 us-gaap:StateAndLocalJurisdictionMember 2022-01-01 2022-06-30 0001713210 us-gaap:ForeignCountryMember 2022-01-01 2022-06-30 0001713210 country:US 2022-06-30 0001713210 country:US 2021-12-31 0001713210 AATP:LabuanMember 2018-12-28 2019-01-02 0001713210 country:MY 2022-06-30 0001713210 country:MY 2021-12-31 0001713210 AATP:UnutilizedMember 2022-06-30 0001713210 AATP:UnutilizedMember 2021-12-31 0001713210 AATP:UnutilizedMember 2022-01-01 2022-06-30 0001713210 AATP:NoCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001713210 AATP:NoCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001713210 AATP:NoCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001713210 AATP:NoCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001713210 AATP:OneIndividualCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember AATP:ECommerceCompanyMember 2022-01-01 2022-06-30 0001713210 AATP:VendorOneMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-04-01 2022-06-30 0001713210 AATP:VendorTwoMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-04-01 2022-06-30 0001713210 AATP:VendorThreeMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-04-01 2022-06-30 0001713210 AATP:VendorOneMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001713210 AATP:VendorTwoMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001713210 AATP:VendorOneMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-04-01 2021-06-30 0001713210 AATP:VendorOneMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-06-30 0001713210 AATP:VendorOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001713210 AATP:VendorTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001713210 AATP:VendorThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001713210 AATP:VendorMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001713210 AATP:OneVendorMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-12-31 0001713210 AATP:OneSalesDistributorMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-04-01 2022-06-30 0001713210 AATP:OneSalesDistributorMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-04-01 2021-06-30 0001713210 AATP:NoSalesDistributorMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001713210 AATP:OneSalesDistributorMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-06-30 0001713210 AATP:AgapeSuperiorLivingMember 2020-04-01 0001713210 2021-05-30 2021-05-31 0001713210 AATP:TrainingCenterMember 2021-05-30 2021-05-31 0001713210 2021-05-31 0001713210 AATP:AgapeSuperiorLivingMember 2021-05-31 0001713210 AATP:AgapeSuperiorLivingMember 2022-06-30 0001713210 AATP:COVIDNineteenImpactMember 2022-01-01 2022-06-30 0001713210 us-gaap:SubsequentEventMember 2022-07-18 2022-07-19 0001713210 AATP:GreenproCapitalCorpMember 2022-06-30 0001713210 us-gaap:SubsequentEventMember AATP:GreenproCapitalCorpMember 2022-07-19 iso4217:USD shares iso4217:USD shares pure iso4217:MYR 0001713210 false --12-31 Q2 36636 Purchases of beauty products 10-Q true 2022-06-30 2022 false 333-220144 AGAPE ATP CORPORATION NV 36-4838886 Tower 2 Faber Tower Jalan Desa Bahagia 58100 Kuala Lumpur MY (60) 192230099 Yes Yes Non-accelerated Filer true true false false 75452012 7626 17493 1807437 2597848 214 4548 7004 346744 375535 1744 1357 339999 636218 178697 295517 2677639 3912122 169915 215799 2601 3660 158630 237718 35707 89001 1500 1500 443661 264735 812014 812413 3489653 4724535 21519 13715 14407 89606 279689 150573 157094 787 1548 637033 858355 2082 9249 3988 924469 1312841 10812 83484 17975 15574 28787 99058 953256 1411899 0.0001 0.0001 200000000 200000000 0 0 0 0 0.0001 0.0001 1000000000 1000000000 75452012 75452012 290460047 290460047 7545 29046 6470716 6449215 -3972684 -3258687 20219 93398 2525796 3312972 10601 -336 2536397 3312636 3489653 4724535 396707 303786 805667 605566 109383 35623 182814 113214 287324 268163 622853 492352 79587 100838 194198 216952 62557 92774 176666 181213 451363 361862 830404 724008 121686 121686 593507 677160 1201268 1243859 -306183 -408997 -578415 -751507 1341 11770 12826 -48546 3526 8251 -35219 -241027 -52889 -165731 -67417 -83883 -97769 -229257 -115695 -214277 -403952 -638254 -694110 -965784 392 3971 8680 10091 -404344 -642225 -702790 -975875 10556 11207 -414900 -642225 -713997 -975875 -404344 -642225 -702790 -975875 -61156 -36347 -73179 -74631 -465500 -678572 -775969 -1050506 -271 -270 -465229 -678572 -775699 -1050506 -0.01 0.00 -0.01 0.00 75452012 376452047 100397696 376452047 376452047 37645 6440616 -734443 181016 5924834 -333650 -333650 -38284 -38284 376452047 37645 6440616 -1068093 142732 5552900 -642225 -642225 -36347 -36347 376452047 37645 6440616 -1710318 106385 4874328 290460047 29046 6449215 -3258687 93398 -336 3312636 215008035 -21501 21501 -299097 651 -298446 -12023 1 -12022 75452012 7545 6470716 -3557784 81375 316 3002168 -414900 10556 -404344 -61156 -271 -61427 75452012 7545 6470716 -3972684 20219 10601 2536397 -702790 -975875 36661 38179 897 1006 75241 75387 -52889 -165731 2401 -53299 36636 121686 214 -169393 -2201 -28790 -80969 -296219 -448054 -102099 15120 7804 14407 -175936 -60618 -75200 -74399 -166137 -129355 2081 5261 36877 -493326 -134748 750 1220 -750 -1220 178926 14160 -2428 -178926 -16588 -117409 -64244 -790411 -216800 2597848 3517600 1807437 3300800 77117 249583 3286 <p id="xdx_80D_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zHtWtyK3PYOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_821_z8JPkVACkKR8">ORGANIZATION AND BUSINESS BACKGROUND</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape ATP Corporation, a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape ATP Corporation operates through its subsidiaries, namely, Agape ATP Corporation, a company incorporated in Labuan, Malaysia, and Agape Superior Living Sdn. Bhd. (“ASL”), a company incorporated in Malaysia. .</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AgapeATPInternationalHoldingLimitedMember_z6Lvvk2B5KA3" title="Ownership interest percentage">100</span>% equity interest in Agape ATP International Holding Limited, a company incorporated in Hong Kong.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20200507__20200508__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--TitleOfIndividualAxis__custom--MrHowKokChoongMember_zlTSqFJmuJYe" title="Stock issued during period acquisitions, shares">9,590,596</span> ordinary shares, no par value, equivalent to approximately <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20200508__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zN10yyxXHzwf" title="Ownership interest percentage">99.99</span>% of the equity interest in Agape Superior Living Sdn. Bhd., a network marketing entity incorporated in Malaysia.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape Superior Living Sdn. Bhd. is a limited company incorporated on August 8, 2003, under the laws of Malaysia.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn, Bhd. (“WATP”), a wholly owned subsidiary under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (“DSY Wellness”) with an independent third party which Agape ATP Corporation (Labuan) owns <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20211111__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zntcA7UCD9we" title="Ownership interest percentage">60</span>% of the equity interest, to pursue the business of providing complementary health therapies</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements reflect the activities of the Company, AATP LB, AATP HK, WATP, ASL and its variable interest entity (“VIE”), Agape S.E.A. Sdn. Bhd. (“SEA”) (See Note 3), and DSY Wellness.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_zDhBoltgZ9kd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details of the Company’s subsidiaries:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_z4OwQEqxUC0l" style="display: none">SCHEDULE OF SUBSIDIARIES AND ASSOCIATES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Subsidiary</p> <p style="margin-top: 0; margin-bottom: 0">company name</p></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Place and date of</p> <p style="margin-top: 0; margin-bottom: 0">incorporation</p></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Particulars of<br/></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>issued capital</b></span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Principal activities</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Proportional of</p> <p style="margin-top: 0; margin-bottom: 0">ownership interest</p> <p style="margin-top: 0; margin-bottom: 0">and voting power</p> <p style="margin-top: 0; margin-bottom: 0">held</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 5%; text-align: left">1.</td><td style="width: 2%"> </td> <td id="xdx_985_ecustom--NameOftheCompany_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zPR20wxjnDpk" style="vertical-align: top; width: 15%; text-align: center">Agape ATP Corporation</td><td style="width: 2%"> </td> <td id="xdx_981_ecustom--PlaceAndDateOfIncorporation_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zjEDWlIvwpei" style="vertical-align: top; width: 15%; text-align: center" title="Place and date of incorporation">Labuan, <br/> March 6, 2017</td><td style="width: 2%"> </td> <td id="xdx_98C_ecustom--ParticularsOfIssuedCapital_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zeUzETzg24ja" style="width: 19%; text-align: center" title="Particulars of issued capital">100 shares of ordinary share of US$1 each</td><td style="width: 2%"> </td> <td id="xdx_982_ecustom--PrincipalActivities_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zfSHZOQQUCQ2" style="vertical-align: top; width: 19%; text-align: center" title="Principal activities">Investment holding</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zOwaIlNpNcud" style="width: 15%; text-align: right" title="Proportional of ownership interest and voting power held">100</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">2.</td><td> </td> <td id="xdx_986_ecustom--NameOftheCompany_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zS8zYw2cHqG9" style="vertical-align: top; text-align: center">Agape ATP International Holding Limited</td><td> </td> <td id="xdx_985_ecustom--PlaceAndDateOfIncorporation_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zPLmOWQp2lI" style="vertical-align: top; text-align: center">Hong Kong,<br/> June 1, 2017</td><td> </td> <td id="xdx_988_ecustom--ParticularsOfIssuedCapital_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zYFnrh0wXnr6" style="vertical-align: top; text-align: center" title="Particulars of issued capital">1,000,000 shares of ordinary share of HK$1 each</td><td> </td> <td id="xdx_982_ecustom--PrincipalActivities_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zjIYrd1LDkzk" style="text-align: center">Wholesaling of health and wellness products; and health solution advisory services</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zNqmLFzoInn9" style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">3.</td><td> </td> <td id="xdx_98D_ecustom--NameOftheCompany_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_z7E0eypAJvyg" style="vertical-align: top; text-align: center">Agape Superior Living Sdn. Bhd.</td><td> </td> <td id="xdx_981_ecustom--PlaceAndDateOfIncorporation_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zmhI0DasrIck" style="vertical-align: top; text-align: center">Malaysia, <br/> August 8, 2003</td><td> </td> <td id="xdx_98C_ecustom--ParticularsOfIssuedCapital_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_z5TZrnnObEtc" style="vertical-align: top; text-align: center">9,590,598 shares of ordinary share of RM1 each</td><td> </td> <td id="xdx_98D_ecustom--PrincipalActivities_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zxB7Zy1Jeqja" style="text-align: center">Health and wellness products and health solution advisory services via network marketing</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zLMrZOytXlec" style="text-align: right">99.99</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">4.</td><td> </td> <td id="xdx_983_ecustom--NameOftheCompany_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zFYezpic7ckd" style="text-align: center" title="Subsidiary company name">Agape S.E.A. Sdn. Bhd.</td><td> </td> <td id="xdx_98D_ecustom--PlaceAndDateOfIncorporation_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_z3MBYqXVj6xl" style="text-align: center">Malaysia, <br/> March 4, 2004</td><td> </td> <td id="xdx_981_ecustom--ParticularsOfIssuedCapital_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zRqgvqvNuJC9" style="text-align: center">2 shares of ordinary share of RM1 each</td><td> </td> <td id="xdx_98E_ecustom--PrincipalActivities_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zEZnjBITPZ91" style="text-align: center">VIE of Agape Superior Living Sdn. Bhd.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">5.</td><td> </td> <td id="xdx_98B_ecustom--NameOftheCompany_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zw886gNl6G03" style="vertical-align: top; text-align: center" title="Subsidiary company name">Wellness ATP International Holdings Sdn, Bhd</td><td> </td> <td id="xdx_986_ecustom--PlaceAndDateOfIncorporation_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zvMOSvgoCmWk" style="vertical-align: top; text-align: center">Malaysia, <br/> September 11, 2020</td><td> </td> <td id="xdx_98B_ecustom--ParticularsOfIssuedCapital_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zdsthAmzx5Dk" style="vertical-align: top; text-align: center">100 shares of ordinary share of RM1 each</td><td> </td> <td id="xdx_986_ecustom--PrincipalActivities_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zZOeXkfYSDt" style="text-align: center">The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_z1aJ51oBdYs9" style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">6.</td><td> </td> <td id="xdx_988_ecustom--NameOftheCompany_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zIRJdVr0hqm2" style="vertical-align: top; text-align: center" title="Subsidiary company name">DSY Wellness International Sdn Bhd.</td><td> </td> <td id="xdx_98A_ecustom--PlaceAndDateOfIncorporation_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zMf2h8aFGN3i" style="vertical-align: top; text-align: center" title="Place and date of incorporation">Malaysia, <br/> November 11, 2021</td><td> </td> <td id="xdx_980_ecustom--ParticularsOfIssuedCapital_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zIMAIJJw3VSf" style="vertical-align: top; text-align: center" title="Particulars of issued capital">1,000 shares of ordinary share of RM1 each</td><td> </td> <td id="xdx_98B_ecustom--PrincipalActivities_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zY9HdRcCcVa3" style="vertical-align: top; text-align: center" title="Principal activities">Provision of complementary health therapies</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_za1lGWbPv6th" style="text-align: right" title="Proportional of ownership interest and voting power held">60</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AC_zSPw4u3kp9d8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. ORGANIZATION AND BUSINESS BACKGROUND (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Overview</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape ATP Corporation is a company that provides health and wellness products and health solution advisory services to our clients. The Company primarily focus its efforts on attracting customers in Malaysia. Its advisory services center on the “ATP Zeta Health Program”, which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In order to strengthen the Company’s supply chain, on May 8, 2020, the Company has successfully acquired approximately <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20200508__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zHALxOOfbIg9" title="Ownership interest percentage">99.99</span>% of ASL, with the goal of securing an established network marketing sales channel that has been established in Malaysia for the past 15 years. ASL has been offering the Company’s ATP Zeta Health Program as part of its product lineup. As such, the acquisition creates synergy in the Company’s operation by boosting the Company’s retail and marketing capabilities. The newly acquired subsidiary allows the Company to fulfill its mission of “helping people to create health and wealth” by providing a financially rewarding business opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Via ASL, the Company offers three series of programs which consist of different services and products: ATP Zeta Health Program, ÉNERGÉTIQUE and BEAUNIQUE.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ATP Zeta Health Program is a health program designed to promote health and general wellbeing designed to prevent health diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity through a combination of modern health supplements, proper nutrition and advice from skilled dieticians as well as trained members and distributors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ÉNERGÉTIQUE series aims to provide a total dermal solution for a healthy skin beginning from the cellular level. The series is comprised of the Energy Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The BEAUNIQUE product series focuses on the research of our diet’s impact on modifying gene expressions in order to address genetic variations and deliver a nutrigenomic solution for every individual.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution advisory services; and therefore, incorporated WATP. Upon its establishment, WATP started collaborating with ASL to carry out various wellness programs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">To further its reach in the Health and Wellness Industry, on November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (“DSY Wellness”) with an independent third party which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1 9590596 0.9999 0.60 <p id="xdx_89A_eus-gaap--ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_zDhBoltgZ9kd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details of the Company’s subsidiaries:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_z4OwQEqxUC0l" style="display: none">SCHEDULE OF SUBSIDIARIES AND ASSOCIATES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Subsidiary</p> <p style="margin-top: 0; margin-bottom: 0">company name</p></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Place and date of</p> <p style="margin-top: 0; margin-bottom: 0">incorporation</p></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Particulars of<br/></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>issued capital</b></span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Principal activities</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Proportional of</p> <p style="margin-top: 0; margin-bottom: 0">ownership interest</p> <p style="margin-top: 0; margin-bottom: 0">and voting power</p> <p style="margin-top: 0; margin-bottom: 0">held</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 5%; text-align: left">1.</td><td style="width: 2%"> </td> <td id="xdx_985_ecustom--NameOftheCompany_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zPR20wxjnDpk" style="vertical-align: top; width: 15%; text-align: center">Agape ATP Corporation</td><td style="width: 2%"> </td> <td id="xdx_981_ecustom--PlaceAndDateOfIncorporation_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zjEDWlIvwpei" style="vertical-align: top; width: 15%; text-align: center" title="Place and date of incorporation">Labuan, <br/> March 6, 2017</td><td style="width: 2%"> </td> <td id="xdx_98C_ecustom--ParticularsOfIssuedCapital_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zeUzETzg24ja" style="width: 19%; text-align: center" title="Particulars of issued capital">100 shares of ordinary share of US$1 each</td><td style="width: 2%"> </td> <td id="xdx_982_ecustom--PrincipalActivities_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zfSHZOQQUCQ2" style="vertical-align: top; width: 19%; text-align: center" title="Principal activities">Investment holding</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zOwaIlNpNcud" style="width: 15%; text-align: right" title="Proportional of ownership interest and voting power held">100</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">2.</td><td> </td> <td id="xdx_986_ecustom--NameOftheCompany_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zS8zYw2cHqG9" style="vertical-align: top; text-align: center">Agape ATP International Holding Limited</td><td> </td> <td id="xdx_985_ecustom--PlaceAndDateOfIncorporation_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zPLmOWQp2lI" style="vertical-align: top; text-align: center">Hong Kong,<br/> June 1, 2017</td><td> </td> <td id="xdx_988_ecustom--ParticularsOfIssuedCapital_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zYFnrh0wXnr6" style="vertical-align: top; text-align: center" title="Particulars of issued capital">1,000,000 shares of ordinary share of HK$1 each</td><td> </td> <td id="xdx_982_ecustom--PrincipalActivities_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zjIYrd1LDkzk" style="text-align: center">Wholesaling of health and wellness products; and health solution advisory services</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zNqmLFzoInn9" style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">3.</td><td> </td> <td id="xdx_98D_ecustom--NameOftheCompany_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_z7E0eypAJvyg" style="vertical-align: top; text-align: center">Agape Superior Living Sdn. Bhd.</td><td> </td> <td id="xdx_981_ecustom--PlaceAndDateOfIncorporation_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zmhI0DasrIck" style="vertical-align: top; text-align: center">Malaysia, <br/> August 8, 2003</td><td> </td> <td id="xdx_98C_ecustom--ParticularsOfIssuedCapital_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_z5TZrnnObEtc" style="vertical-align: top; text-align: center">9,590,598 shares of ordinary share of RM1 each</td><td> </td> <td id="xdx_98D_ecustom--PrincipalActivities_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zxB7Zy1Jeqja" style="text-align: center">Health and wellness products and health solution advisory services via network marketing</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zLMrZOytXlec" style="text-align: right">99.99</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">4.</td><td> </td> <td id="xdx_983_ecustom--NameOftheCompany_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zFYezpic7ckd" style="text-align: center" title="Subsidiary company name">Agape S.E.A. Sdn. Bhd.</td><td> </td> <td id="xdx_98D_ecustom--PlaceAndDateOfIncorporation_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_z3MBYqXVj6xl" style="text-align: center">Malaysia, <br/> March 4, 2004</td><td> </td> <td id="xdx_981_ecustom--ParticularsOfIssuedCapital_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zRqgvqvNuJC9" style="text-align: center">2 shares of ordinary share of RM1 each</td><td> </td> <td id="xdx_98E_ecustom--PrincipalActivities_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zEZnjBITPZ91" style="text-align: center">VIE of Agape Superior Living Sdn. Bhd.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">5.</td><td> </td> <td id="xdx_98B_ecustom--NameOftheCompany_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zw886gNl6G03" style="vertical-align: top; text-align: center" title="Subsidiary company name">Wellness ATP International Holdings Sdn, Bhd</td><td> </td> <td id="xdx_986_ecustom--PlaceAndDateOfIncorporation_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zvMOSvgoCmWk" style="vertical-align: top; text-align: center">Malaysia, <br/> September 11, 2020</td><td> </td> <td id="xdx_98B_ecustom--ParticularsOfIssuedCapital_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zdsthAmzx5Dk" style="vertical-align: top; text-align: center">100 shares of ordinary share of RM1 each</td><td> </td> <td id="xdx_986_ecustom--PrincipalActivities_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zZOeXkfYSDt" style="text-align: center">The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_z1aJ51oBdYs9" style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">6.</td><td> </td> <td id="xdx_988_ecustom--NameOftheCompany_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zIRJdVr0hqm2" style="vertical-align: top; text-align: center" title="Subsidiary company name">DSY Wellness International Sdn Bhd.</td><td> </td> <td id="xdx_98A_ecustom--PlaceAndDateOfIncorporation_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zMf2h8aFGN3i" style="vertical-align: top; text-align: center" title="Place and date of incorporation">Malaysia, <br/> November 11, 2021</td><td> </td> <td id="xdx_980_ecustom--ParticularsOfIssuedCapital_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zIMAIJJw3VSf" style="vertical-align: top; text-align: center" title="Particulars of issued capital">1,000 shares of ordinary share of RM1 each</td><td> </td> <td id="xdx_98B_ecustom--PrincipalActivities_c20220101__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zY9HdRcCcVa3" style="vertical-align: top; text-align: center" title="Principal activities">Provision of complementary health therapies</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_za1lGWbPv6th" style="text-align: right" title="Proportional of ownership interest and voting power held">60</td><td style="text-align: left">%</td></tr> </table> Agape ATP Corporation Labuan, March 6, 2017 100 shares of ordinary share of US$1 each Investment holding 1 Agape ATP International Holding Limited Hong Kong, June 1, 2017 1,000,000 shares of ordinary share of HK$1 each Wholesaling of health and wellness products; and health solution advisory services 1 Agape Superior Living Sdn. Bhd. Malaysia, August 8, 2003 9,590,598 shares of ordinary share of RM1 each Health and wellness products and health solution advisory services via network marketing 0.9999 Agape S.E.A. Sdn. Bhd. Malaysia, March 4, 2004 2 shares of ordinary share of RM1 each VIE of Agape Superior Living Sdn. Bhd. Wellness ATP International Holdings Sdn, Bhd Malaysia, September 11, 2020 100 shares of ordinary share of RM1 each The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns 1 DSY Wellness International Sdn Bhd. Malaysia, November 11, 2021 1,000 shares of ordinary share of RM1 each Provision of complementary health therapies 0.60 0.9999 <p id="xdx_80B_eus-gaap--SignificantAccountingPoliciesTextBlock_zvCBBtzaY6ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. <span id="xdx_822_zfAaVtbzlVzk">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zQkYKhvdURj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Basis of presentation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for information pursuant to the rules and regulations of the Securities Exchange Commission (“SEC”), and include all normal and recurring adjustments that management of the Company considers necessary for a fair presentation of its financial position and operation results. Interim results are not necessarily indicative of results to be expected for any other interim period or for the full year. The information included in this Form 10-Q should be read in conjunction with information included in the Company’s annual report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 28, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed consolidated financial statements include the financial statements of the Company, its subsidiaries and its variable interest entity (“VIE”) over which the Company exercises control and, where applicable, entities for which the Company has a controlling financial interest or is the primary beneficiary. All transactions and balances among the Company, its subsidiaries and its VIE have been eliminated upon consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zolCIZXJ6axl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Principles of consolidation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A VIE is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary and must consolidate the VIE. As of and for the three and six months ended June 30, 2022, SEA, the only VIE of the Company has no significant operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--UseOfEstimates_zSQNzrwYC0rd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Use of estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of audited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s consolidated financial statements include allowance for doubtful accounts, allowance for inventories obsolescence, useful lives of property and equipment, useful lives of intangible assets, impairment of long-lived assets, allowance for deferred tax assets, operating right-of-use assets, operating lease liabilities and uncertain tax position and impairment of investment in non-marketable securities. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqZsWvGRr9jb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cash and cash equivalents</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents are carried at cost and represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z5ff173i7RD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Accounts receivable</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due on credit term. Accounts receivable also include money due from a third-party e-commerce platform acting as a collection agent for the Company on the sales through their platform. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of June 30, 2022 and December 31, 2021, <span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_dxL_c20220630_z4PyWZ0bdZS3" title="Accounts receivable, allowance for credit loss::XDX::-"><span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_dxL_c20211231_zuZveRaUGhpk" title="Accounts receivable, allowance for credit loss::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0658"><span style="-sec-ix-hidden: xdx2ixbrl0660">no</span></span></span></span> allowance of doubtful accounts was recorded.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--InventoryPolicyTextBlock_zX7SGzrsKqRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Inventories</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories consist of finished goods and are stated at the lower of cost or net realizable value using the first-in first-out method. Management reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net realizable value. For the six months ended June 30, 2022 and 2021, the Company recognized inventory write-downs of $<span id="xdx_90B_eus-gaap--InventoryWriteDown_pp0p0_dxL_c20220101__20220630_zYx99txgiJp6" title="Inventories write-down::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0664">0</span></span> and $<span id="xdx_90F_eus-gaap--InventoryWriteDown_pp0p0_c20210101__20210630_zUqh13lGZEQ4" title="Inventories write-down">36,636</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_ecustom--PrepaidTaxesPolicyTextBlock_zmi13NHSdo2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Prepaid taxes</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Prepaid taxes include prepaid income taxes that will either be refunded or utilized to offset future income tax</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_ecustom--PrepaymentsAndDepositsPolicyTextBlock_zY3MU8S2FYtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Prepayments and deposits</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayments and deposits are mainly cash deposited or advanced to suppliers for future inventory purchases or service providers for future services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after management has determined that the likelihood of collection is not probable. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of June 30, 2022 and December 31, 2021, there was $<span id="xdx_90F_ecustom--AllowanceForDoubtfulAccountsReceivablesCurrent_iI_pp0p0_do_c20220630_zWfSBaiWflhi">120,372</span> and $<span id="xdx_902_ecustom--AllowanceForDoubtfulAccountsReceivablesCurrent_iI_pp0p0_do_c20211231_zGc4b59QSHUd" title="Allowance for doubtful accounts">121,095</span> allowance for doubtful accounts recorded, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zY5ZoZDfJF45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Property and equipment, net</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_z40jpTvik994" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets with no residual value. The estimated useful lives are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zVUK4LxMKo1f" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: justify">Computer and office equipment</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_ztMsvgmPT6N8" title="Estimated Useful Life of Property and Equipment">5</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zVPdTOdnsvse" title="Estimated Useful Life of Property and Equipment">7</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Furniture &amp; fixtures</td><td> </td> <td style="text-align: center"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zjuq3FJ2QWCj" title="Estimated Useful Life of Property and Equipment">6</span>-<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_ztWsAWTdyAga" title="Estimated Useful Life of Property and Equipment">7</span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVMGFsPyV6wb" title="Estimated Useful Lives of Property and Equipment">Lease Term</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vehicle</td><td> </td> <td style="text-align: center"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zlud9B9kIbTd" title="Estimated Useful Life of Property and Equipment">5</span> years</td></tr> </table> <p id="xdx_8A9_zzaMS5OLmp7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements of income and comprehensive income. Expenditures for maintenance and repairs are charged to earnings as incurred, while additions, renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates the periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zdsrgMN69Lv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Intangible assets, net</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock_zuXWInM9pYzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the estimated useful lives of the assets as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zZ2OL1KnY5Md" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 78%; font-weight: bold">Classification</td><td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; width: 20%; font-weight: bold; text-align: center">Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Computer software</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_z7WZoJUw0c0b" title="Estimated useful lives of intangible assets">5</span> years</td></tr> </table> <p id="xdx_8AF_z9N02g7Rtfhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zc1mXpIX8sdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Impairment for long-lived assets</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets, including property and equipment, and intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted future cash flows the assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset. If an impairment is identified, the Company would reduce the carrying amount of the asset to its estimated fair value based on a discounted cash flows approach or, when available and appropriate, to comparable market values. As of June 30, 2022 and December 31, 2021, <span id="xdx_901_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20220101__20220630_zxJyCfU2cRuk" title="Impairment of long-lived assets"><span id="xdx_902_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20210101__20211231_z2cUJXqeEKpl" title="Impairment of long-lived assets">no</span></span> impairment of long-lived assets was recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--DeferredChargesPolicyTextBlock_z2BRoJWNbCD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Deferred offering costs</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred offering costs represents costs associated with the Company’s current offering which will be netted against the proceeds from the Company’s current offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--MarketableSecuritiesPolicy_zBeTXF0ojqFi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Investment in marketable equity securities</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company follows the provisions of ASU 2016-01, <i>Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>. Investments in marketable equity securities (non-current) are reported at fair value with changes in fair value recognized in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss in the caption of “unrealized holding gain loss on marketable securities” in each reporting period</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84C_ecustom--NonMarketableSecuritiesPolicyTextBlock_zcRjgEOnPnEd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Investment in non-marketable equity securities</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the provisions of ASU 2016-01, <i>Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>. Due to the Company’s non-marketable equity securities (non-current) does not qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that raise significant concerns about the investee’s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment loss equal to the difference between the fair value of the investment and its carrying amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zOxiqBF1Zkk2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Customer deposits</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer deposits represent amounts advanced by customers on product orders and discounted value of unapplied coupons. Customer deposits are reduced when the related sale is recognized in accordance with the Company’s revenue recognition policy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--RevenueRecognitionPolicyTextBlock_z32xCRNcWAp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenue recognition</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606). The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales of Health and Wellness products</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <i>Performance obligations satisfied at a point in time</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods. The revenue is recorded net of estimated discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were insignificant sales returns.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also sells coupons to its customers for cash at a discounted price of the value of the coupons. Customers can apply the value of the coupons for a reduction in the transaction price paid by the customer are recorded as a reduction of sales. The cash proceeds resulted from the sale of coupons are recognized as customer deposits until the coupons to be applied as a reduction of the health and wellness products transaction price upon such sales transactions occurred. The Company’s coupons have a validity period of six months. If the Company’s customers did not utilize the coupons after six months, the Company would recognize the forfeiture of the originated sales value of the coupons as net revenues. For the three months ended June 30, 2022 and 2021, the Company recognized $<span id="xdx_903_ecustom--ForfeitedCouponIncome_pp0p0_c20220401__20220630_zOQVSyJB43og" title="Value of coupons">4,824</span> and $<span id="xdx_909_ecustom--ForfeitedCouponIncome_pp0p0_c20210401__20210630_z4Qf8Mj8DpCh" title="Value of coupons">4,115</span>, as forfeited coupon income, respectively. For the six months ended June 30, 2022 and 2021, the Company recognized $<span id="xdx_909_ecustom--ForfeitedCouponIncome_pp0p0_c20220101__20220630_zK1iKrEuD6H2">5,777</span> and $<span id="xdx_90A_ecustom--ForfeitedCouponIncome_pp0p0_c20210101__20210630_zYRTOdQbB2Ed" title="Value of coupons">11,226</span>, as forfeited coupon income, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had contracts for the sales of health and wellness products amounting to $<span id="xdx_904_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20220630__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_pp0p0" title="Cost of revenue">16,084</span> which it is expected to fulfill within 12 months from June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales of Health and Wellness services</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <i>Performance obligations satisfied at a point in time</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company carries out its Wellness program, where the Company’s products are bundled with health screening test and a health camp program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test reports are completed and delivered to its customers during the consultation section in person.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health camp program was completed in the final day of the health camp. For the three months ended June 30, 2022 and 2021, revenues from health and wellness services were $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20220630__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_z0FMKuBe16Ii" title="Revenue from contract with customer excluding assessed tax">30,072</span> and $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20210630__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zFzY4eL5DJt7" title="Revenue from contract with customer excluding assessed tax">653</span> respectively. For the six months ended June 30, 2022 and 2021, revenues from health and wellness services were $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220101__20220630__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zLJpCFx6dlx5">31,139</span> and $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20210630__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zJS5oK8rCMrb" title="Revenue from contract with customer excluding assessed tax">5,746</span> respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--ScheduleOfDisaggregatedInformationOfRevenuesTableTextBlock_zSxIzwzIGKVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaggregated information of revenues by products are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zd0t8TKcdJ02" style="display: none">SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20220401__20220630_zs5w0YJWFHyd" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20210401__20210630_zTnoHofg3ofh" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20220101__20220630_z1vNQ4lCKixe" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20210101__20210630_zqwwW1glHf24" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SurvivorSelectMember_zFqJu3X0vBJl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Survivor Select</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">13,941</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">24,415</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">22,753</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">37,641</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergizedMineralConcentrateMember_zAtiVqveONEk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Energized Mineral Concentrate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0736">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,183</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IonizedCalMagMember_zWhSCIX2rvqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Ionized Cal-Mag</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,278</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,485</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,298</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OmegaBlendMember_zbgEErQP9wPc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Omega Blend</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42,747</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89,066</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">179,177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185,361</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--BetaMaxxMember_zC2acUiwJ9S1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Beta Maxx</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,564</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">55,943</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89,800</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IronMember_z4bZPwrrXFae" style="vertical-align: bottom; background-color: White"> <td>Iron</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,118</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,431</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,186</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,715</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--YoungFormulaMember_zxAr3r1BUdK5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Young Formula</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,075</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,458</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,269</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,901</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--OrganicYouthCarCleansingBarMember_z1ktuaYDRv1g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Organic Youth Care Cleansing Bar</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0766">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,990</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,990</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ATPRMITOPlusMember_zbhGjP2Uue69" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">ATPR Mito+</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76,605</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70,148</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">187,926</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,843</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--LipomaskMember_zNBfA7QGDZJ3" style="vertical-align: bottom; background-color: White"> <td>Lipomask</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0776">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,279</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0778">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,401</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--HyaluronicAcidSerumMember_znhgSMMtlvl5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Hyaluronic Acid Serum</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,698</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,362</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,006</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,353</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--MousseFacialCleanserMember_zw8u1N127wcl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Mousse Facial Cleanser</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,355</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,042</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,394</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,660</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--TrimPlusMember_zqsd5VIafjy6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Trim+</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,765</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,223</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,236</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,674</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ProductHealthTherapiesMember_zoQP4CRxKBt4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Others – Products for the provision of complementary health therapies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182,101</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0797">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">216,188</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0799">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OthersMember_z36E1weWceRj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">388</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0802">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">388</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zkBZp8Jrzcl6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total revenues - products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">366,635</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">303,133</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">774,528</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">599,820</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_z1fxRKFgGQu5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Health and Wellness services</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,072</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">653</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,139</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,746</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--Revenues_zZAtWs8fAMW4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total revenues - products and services</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">396,707</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">303,786</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">805,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">605,566</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zCJxQUND43a6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--CostOfSalesPolicyTextBlock_z4Tpg8wiUXJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cost of revenue</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of revenue for the three and six months ended June 30, 2022 were $<span id="xdx_908_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20220401__20220630_z3FY5upMon1l">109,383</span>, and $<span id="xdx_90C_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20220101__20220630_zcuoB3gnGO67" title="Cost of revenue">182,814</span>, respectively, and comprised freight-in, purchase cost of manufactured goods for sale to customers and products for the provision of complementary health therapies. Cost of revenue for the three months and six months ended June 30, 2021, were $<span id="xdx_90C_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20210401__20210630_zKyLMS4477Zg">35,623</span>, and $<span id="xdx_902_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20210101__20210630_ziSocrRWPaN9" title="Cost of revenue">113,214</span>, respectively, and comprised freight-in, purchase cost of manufactured goods for sale to customers. For the six months ended June 30, 2021, cost of revenue also included inventory write-downs of $<span id="xdx_906_eus-gaap--InventoryWriteDown_pp0p0_c20210101__20210630_zvntIyx04Or2" title="Inventories write-down">36,636</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_ecustom--ShippingAndHandlingPolicyTextBlock_zsFwRDO7gSsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Shipping and handling</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping and handling charges amounted to $<span id="xdx_90C_eus-gaap--SellingExpense_pp0p0_c20220401__20220630__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zDmJMunQVR87" title="Selling expenses">4,272</span> and $<span id="xdx_905_eus-gaap--SellingExpense_pp0p0_c20210401__20210630__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zjwQtKAlRbL" title="Selling expenses">2,990</span> for the three months ended June 30, 2022 and 2021, respectively. Shipping and handling charges amounted to $<span id="xdx_90D_eus-gaap--SellingExpense_pp0p0_c20220101__20220630__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zT33w1OJ6OH4">7,179</span> and $<span id="xdx_906_eus-gaap--SellingExpense_pp0p0_c20210101__20210630__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_z77tUil1mDh9" title="Selling expenses">5,272</span> for the six months ended June 30, 2022 and 2021, respectively. Shipping and handling charges are expensed as incurred and included in selling expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--AdvertisingCostsPolicyTextBlock_zxiA1qyLIeCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Advertising costs</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising costs amounted to $<span id="xdx_903_eus-gaap--AdvertisingExpense_pp0p0_c20220401__20220630_z7qd7sr33qeg" title="Advertising costs">4,765</span> and $<span id="xdx_90B_eus-gaap--AdvertisingExpense_pp0p0_c20210401__20210630_zUrRhshXRQOc" title="Advertising costs">8,721</span> for the three months ended June 30, 2022 and 2021, respectively. Advertising costs amounted to $<span id="xdx_90F_eus-gaap--AdvertisingExpense_pp0p0_c20220101__20220630_zZ2Rh4W9ywKf" title="Advertising costs">4,765</span> and $<span id="xdx_902_eus-gaap--AdvertisingExpense_pp0p0_c20210101__20210630_zrbgEAdarJu6" title="Advertising costs">16,658</span> for the six months ended June 30, 2022 and 2021, respectively. Advertising costs are expensed as incurred and included in selling expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--CommissionsExpensePolicyPolicyTextBlock_zhWLlmd5CYT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Commission expenses</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission expenses are the Company’s most significant expenses. As with all companies in the network marketing industry, the Company’s sales channel is external to the Company. The Company’s “external sales force” is stratified into two levels based on priority recruitment. First, there are sales distributors. Second, all members recruited by a sales distributor, directly or indirectly, are referred to as “sales network members”. The Company pays commission to every sales distributor based on purchases made by its sales network members which includes the independent direct sales members. Top performing distributors with their own physical stores may also become stockists of the Company, whereby they enjoy benefits such as maintaining a certain amount of the Company’s inventory on their store premises. The stockists shall account to the Company for all products sales from their store premises as monitored through the Company’s centralized stock tracking system. The Company pays a separate commission to stockists based on revenue generated from the stockists’ physical stores. Commission expenses amounted to $<span id="xdx_905_ecustom--SalesCommissionsAndFees1_pp0p0_c20220401__20220630_ziswmavsSS9g">62,557</span> and $<span id="xdx_907_ecustom--SalesCommissionsAndFees1_pp0p0_c20210401__20210630_z7q0lA7m4ev7" title="Commission expenses">92,774</span> for the three months ended June 30, 2022 and 2021, respectively. Commission expenses amounted to $<span id="xdx_906_ecustom--SalesCommissionsAndFees1_pp0p0_c20220101__20220630_zXChCKSo52kl" title="Commission expenses">176,666</span> and $<span id="xdx_905_ecustom--SalesCommissionsAndFees1_pp0p0_c20210101__20210630_zWhqcKhTiTo5" title="Commission expenses">181,213</span> for the six months ended June 30, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_ecustom--DefinedContributionPlanPolicyTextBlock_zcyJuKB4lqdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline">Defined contribution plan</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The full-time employees of the Company are entitled to the government mandated defined contribution plan. The Company is required to accrue and pay for these benefits based on certain percentages of the employees’ respective salaries, subject to certain ceilings, in accordance with the relevant government regulations, and make cash contributions to the government mandated defined contribution plan</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Total expenses for the plan were $<span id="xdx_90D_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20220401__20220630_zkIdASUdFe2f">35,936</span> and $<span id="xdx_905_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20210401__20210630_z4I6SzH9b1t1">27,067</span> for the three months ended June 30, 2022 and 2021, respectively. Total expenses for the plan were $<span id="xdx_90F_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20220101__20220630_zDoSik42nYyd" title="Defined contribution plan expense">63,408</span> and $<span id="xdx_90B_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20210101__20210630_zM9msZgsHbNa" title="Defined contribution plan expense">53,034</span> for the six months ended June 30, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The related contribution plans include:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social Security Organization (“SOSCO”) – <span id="xdx_902_ecustom--SalaryPercentage_pid_dp_c20220101__20220630__dei--LegalEntityAxis__custom--SocialSecurityOrganizationMember_zYJCzNlA7dta" title="Salary percentage">1.75</span>% based on employee’s monthly salary capped of RM <span id="xdx_903_ecustom--MonthlySalary_pp0p0_uRM_c20220101__20220630__dei--LegalEntityAxis__custom--SocialSecurityOrganizationMember__us-gaap--AwardTypeAxis__custom--MYRCurrencyMember_zb6P517f0QR7" title="Monthly salary">4,000</span>;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees Provident Fund (“EPF”) – <span id="xdx_902_ecustom--SalaryPercentage_pid_dp_c20220101__20220630__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember_zVF6HTS0Yh32" title="Salary percentage">12</span>% based on employee’s monthly salary;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Insurance System (“EIS”) – <span id="xdx_90D_ecustom--SalaryPercentage_pid_dp_c20220101__20220630__dei--LegalEntityAxis__custom--EmploymentInsuranceSystemMember_zzTuJ8sGm6jk" title="Salary percentage">0.2</span>% based on employee’s monthly salary capped of RM <span id="xdx_903_ecustom--MonthlySalary_pp0p0_uRM_c20220101__20220630__dei--LegalEntityAxis__custom--EmploymentInsuranceSystemMember__us-gaap--AwardTypeAxis__custom--MYRCurrencyMember_zmS7Run4L8Mh" title="Monthly salary">4,000</span>;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human Resource Development Fund (“HRDF”) – <span id="xdx_904_ecustom--SalaryPercentage_pid_dp_c20220101__20220630__dei--LegalEntityAxis__custom--HumanResourceDevelopmentFundMember_z7TPdnlvcnPf" title="Salary percentage">1</span>% based on employee’s monthly salary</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_zKVrHcVwMR9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Income taxes</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is <span id="xdx_909_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20220101__20220630_zoh49HKX1mPi" title="Income tax examination, likelihood of unfavorable settlement">greater than 50%</span> likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. <span id="xdx_908_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_do_c20220401__20220630_zSwlWh3Zsqfe" title="Income tax examination, penalties and interest expense"><span id="xdx_906_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_do_c20220101__20220630_zfRoB7TAM8Pc" title="Income tax examination, penalties and interest expense">No</span></span> penalties and interest related to underpayment of income taxes were incurred for the three and six months ended June 30, 2022. $<span id="xdx_90B_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_do_c20210401__20210630_z2eHqSAdc252" title="Income tax examination, penalties and interest expense"><span id="xdx_900_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_do_c20210101__20210630_zGWleud7YwQl" title="Income tax examination, penalties and interest expense">395</span></span> in penalties and interest related to underpayment of income taxes were incurred for the three and six months ended June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company conducts much of its business activities in Hong Kong and Malaysia and is subject to tax in each of these jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zfKKJ4MCM8K8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Comprehensive income (loss)</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under GAAP are recorded as an element of stockholders’ equity but are excluded from net income. Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_ecustom--NoncontrollingInterestPolicyTextBlock_zJLdOS38GUr2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Non-controlling interest</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--MinorityInterestDescription_c20220101__20220630_znmc8nCqwyi" title="Noncontrolling interest, description">Non-controlling interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out of 9,590,598 shares) of the equity interests of ASL held by two individuals</span>. The non-controlling interests are presented in the consolidated balance sheets, separately from equity attributable to the shareholders of the Company. Non-controlling interests in the results of the Company are presented on the face of the consolidated statements of operations as an allocation of the total income or loss for the periods between non-controlling interest holders and the shareholders of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zmLMaVMPco49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Earnings (loss) per share</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company computes earnings (loss) per share (“EPS”) in accordance with ASC 260, “Earnings per Share”. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is measured as net income (loss) divided by the weighted average <span style="background-color: white">common stocks</span> outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential <span style="background-color: white">common stocks</span> (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential <span style="background-color: white">common stocks</span> that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. For the three and six months ended June 30, 2022 and 2021, there were <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20220401__20220630_zathA04kfiWa" title="Potentially dilutive securities outstanding"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20210401__20210630_z86YpQpjBgMj"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20220101__20220630_zjO9Y8EVLTT7"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20210101__20210630_z765FWzNixT9" title="Potentially dilutive securities outstanding">no</span></span></span></span> dilutive shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zMm2ND7Iuj3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Foreign currencies translation and transaction</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the consolidated statements of operations and comprehensive income (loss).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reporting currency of the Company is United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. The Company’s subsidiary in Labuan maintains its books and record in United States Dollars (“US$”) albeit its functional currency being the primary currency of the economic environment in which the entity operates, which is the Malaysian Ringgit (“MYR” or “RM”). The Company’s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars (“HK$”), similar to its functional currency. The Company’s subsidiary and VIE in Malaysia conducts its businesses and maintains its books and record in the local currency, Malaysian Ringgit (“MYR” or “RM”), as its functional currency.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “<i>Translation of Financial Statement”</i>, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders’ equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_z7coOOHAXqb7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zxWyPA8vEeYa" style="display: none">SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20220630_zZEmJyuh1Uf6" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20211231_zpqCueevhSF2" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndMYRMember_z1lyB1RJxcRg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Period-end MYR : US$1 exchange rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4.40</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4.18</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_zU9ZTOzm8cb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Period-end HKD : US$1 exchange rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.80</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_zhZh1kkBh1d" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign currency exchange rate, translation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.80</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20220401__20220630_z3JfYpfLAS45" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20210401__20210630_z8yDw3Jr3mwa" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20220101__20220630_zwPge16CIYAi" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20210101__20210630_zCfZJVpap3v6" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_400_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageMYRMember_zJGW0fULsuT2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Period-average MYR : US$1 exchange rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4.37</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4.28</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4.10</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_z6wz10MhZDMf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Period-average HKD : US$1 exchange rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.77</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.76</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_ztiBGZSQNy1d" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign currency exchange rate period average</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.77</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.76</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A3_zakmFkDhBPOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_ecustom--RelatedPartiesPolicyTextBlock_zNNHBuwRtIfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related parties</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zStfc2k1nr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair value of financial instruments</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_z7Xelv60wNP9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Leases</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted ASU 2016-02, “Leases” (Topic 842), and elected the practical expedients that does not require the Company to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing leases and (3) initial direct costs for any expired or existing leases. For lease terms of twelve months or fewer, a lessee is permitted to make an accounting policy election not to recognize lease assets and liabilities. The Company also adopts the practical expedient that allows lessees to treat the lease and non-lease components of a lease as a single lease component. Some of the Company’s leases include one or more options to renew, which is typically at the Company’s sole discretion. The Company regularly evaluates the renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. New lease modifications result in re-measurement of the right of use (“ROU”) assets and lease liabilities. Operating ROU assets and lease liabilities are recognized at the commencement date, based on the present value of lease payments over the lease term. Since the implicit rate for the Company’s leases is not readily determinable, the Company use its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment and over a similar term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of twelve months or less. Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future pre-tax cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zlwTo63cpG9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Recent accounting pronouncements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates (“ASUs”). Management periodically reviews new accounting standards that are issued. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or revised accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating the impact ASU 2019-05 may have on its unaudited condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except for the above-mentioned pronouncements, there are no new recent issued accounting standards that will have a material impact on the consolidated financial position, statements of operations and cash flows.</span></p> <p id="xdx_853_zGO43WVkA687" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zQkYKhvdURj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Basis of presentation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for information pursuant to the rules and regulations of the Securities Exchange Commission (“SEC”), and include all normal and recurring adjustments that management of the Company considers necessary for a fair presentation of its financial position and operation results. Interim results are not necessarily indicative of results to be expected for any other interim period or for the full year. The information included in this Form 10-Q should be read in conjunction with information included in the Company’s annual report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 28, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed consolidated financial statements include the financial statements of the Company, its subsidiaries and its variable interest entity (“VIE”) over which the Company exercises control and, where applicable, entities for which the Company has a controlling financial interest or is the primary beneficiary. All transactions and balances among the Company, its subsidiaries and its VIE have been eliminated upon consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zolCIZXJ6axl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Principles of consolidation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A VIE is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary and must consolidate the VIE. As of and for the three and six months ended June 30, 2022, SEA, the only VIE of the Company has no significant operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--UseOfEstimates_zSQNzrwYC0rd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Use of estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of audited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s consolidated financial statements include allowance for doubtful accounts, allowance for inventories obsolescence, useful lives of property and equipment, useful lives of intangible assets, impairment of long-lived assets, allowance for deferred tax assets, operating right-of-use assets, operating lease liabilities and uncertain tax position and impairment of investment in non-marketable securities. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqZsWvGRr9jb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cash and cash equivalents</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents are carried at cost and represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z5ff173i7RD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Accounts receivable</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due on credit term. Accounts receivable also include money due from a third-party e-commerce platform acting as a collection agent for the Company on the sales through their platform. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of June 30, 2022 and December 31, 2021, <span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_dxL_c20220630_z4PyWZ0bdZS3" title="Accounts receivable, allowance for credit loss::XDX::-"><span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_dxL_c20211231_zuZveRaUGhpk" title="Accounts receivable, allowance for credit loss::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0658"><span style="-sec-ix-hidden: xdx2ixbrl0660">no</span></span></span></span> allowance of doubtful accounts was recorded.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--InventoryPolicyTextBlock_zX7SGzrsKqRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Inventories</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories consist of finished goods and are stated at the lower of cost or net realizable value using the first-in first-out method. Management reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net realizable value. For the six months ended June 30, 2022 and 2021, the Company recognized inventory write-downs of $<span id="xdx_90B_eus-gaap--InventoryWriteDown_pp0p0_dxL_c20220101__20220630_zYx99txgiJp6" title="Inventories write-down::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0664">0</span></span> and $<span id="xdx_90F_eus-gaap--InventoryWriteDown_pp0p0_c20210101__20210630_zUqh13lGZEQ4" title="Inventories write-down">36,636</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 36636 <p id="xdx_840_ecustom--PrepaidTaxesPolicyTextBlock_zmi13NHSdo2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Prepaid taxes</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Prepaid taxes include prepaid income taxes that will either be refunded or utilized to offset future income tax</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_ecustom--PrepaymentsAndDepositsPolicyTextBlock_zY3MU8S2FYtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Prepayments and deposits</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayments and deposits are mainly cash deposited or advanced to suppliers for future inventory purchases or service providers for future services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after management has determined that the likelihood of collection is not probable. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of June 30, 2022 and December 31, 2021, there was $<span id="xdx_90F_ecustom--AllowanceForDoubtfulAccountsReceivablesCurrent_iI_pp0p0_do_c20220630_zWfSBaiWflhi">120,372</span> and $<span id="xdx_902_ecustom--AllowanceForDoubtfulAccountsReceivablesCurrent_iI_pp0p0_do_c20211231_zGc4b59QSHUd" title="Allowance for doubtful accounts">121,095</span> allowance for doubtful accounts recorded, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 120372 121095 <p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zY5ZoZDfJF45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Property and equipment, net</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_z40jpTvik994" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets with no residual value. The estimated useful lives are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zVUK4LxMKo1f" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: justify">Computer and office equipment</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_ztMsvgmPT6N8" title="Estimated Useful Life of Property and Equipment">5</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zVPdTOdnsvse" title="Estimated Useful Life of Property and Equipment">7</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Furniture &amp; fixtures</td><td> </td> <td style="text-align: center"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zjuq3FJ2QWCj" title="Estimated Useful Life of Property and Equipment">6</span>-<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_ztWsAWTdyAga" title="Estimated Useful Life of Property and Equipment">7</span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVMGFsPyV6wb" title="Estimated Useful Lives of Property and Equipment">Lease Term</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vehicle</td><td> </td> <td style="text-align: center"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zlud9B9kIbTd" title="Estimated Useful Life of Property and Equipment">5</span> years</td></tr> </table> <p id="xdx_8A9_zzaMS5OLmp7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements of income and comprehensive income. Expenditures for maintenance and repairs are charged to earnings as incurred, while additions, renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates the periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_z40jpTvik994" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets with no residual value. The estimated useful lives are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zVUK4LxMKo1f" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: justify">Computer and office equipment</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_ztMsvgmPT6N8" title="Estimated Useful Life of Property and Equipment">5</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zVPdTOdnsvse" title="Estimated Useful Life of Property and Equipment">7</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Furniture &amp; fixtures</td><td> </td> <td style="text-align: center"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zjuq3FJ2QWCj" title="Estimated Useful Life of Property and Equipment">6</span>-<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_ztWsAWTdyAga" title="Estimated Useful Life of Property and Equipment">7</span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVMGFsPyV6wb" title="Estimated Useful Lives of Property and Equipment">Lease Term</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vehicle</td><td> </td> <td style="text-align: center"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zlud9B9kIbTd" title="Estimated Useful Life of Property and Equipment">5</span> years</td></tr> </table> P5Y P7Y P6Y P7Y Lease Term P5Y <p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zdsrgMN69Lv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Intangible assets, net</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock_zuXWInM9pYzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the estimated useful lives of the assets as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zZ2OL1KnY5Md" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 78%; font-weight: bold">Classification</td><td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; width: 20%; font-weight: bold; text-align: center">Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Computer software</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_z7WZoJUw0c0b" title="Estimated useful lives of intangible assets">5</span> years</td></tr> </table> <p id="xdx_8AF_z9N02g7Rtfhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock_zuXWInM9pYzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the estimated useful lives of the assets as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zZ2OL1KnY5Md" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 78%; font-weight: bold">Classification</td><td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; width: 20%; font-weight: bold; text-align: center">Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Computer software</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_z7WZoJUw0c0b" title="Estimated useful lives of intangible assets">5</span> years</td></tr> </table> P5Y <p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zc1mXpIX8sdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Impairment for long-lived assets</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets, including property and equipment, and intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted future cash flows the assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset. If an impairment is identified, the Company would reduce the carrying amount of the asset to its estimated fair value based on a discounted cash flows approach or, when available and appropriate, to comparable market values. As of June 30, 2022 and December 31, 2021, <span id="xdx_901_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20220101__20220630_zxJyCfU2cRuk" title="Impairment of long-lived assets"><span id="xdx_902_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20210101__20211231_z2cUJXqeEKpl" title="Impairment of long-lived assets">no</span></span> impairment of long-lived assets was recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_844_eus-gaap--DeferredChargesPolicyTextBlock_z2BRoJWNbCD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Deferred offering costs</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred offering costs represents costs associated with the Company’s current offering which will be netted against the proceeds from the Company’s current offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--MarketableSecuritiesPolicy_zBeTXF0ojqFi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Investment in marketable equity securities</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company follows the provisions of ASU 2016-01, <i>Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>. Investments in marketable equity securities (non-current) are reported at fair value with changes in fair value recognized in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss in the caption of “unrealized holding gain loss on marketable securities” in each reporting period</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84C_ecustom--NonMarketableSecuritiesPolicyTextBlock_zcRjgEOnPnEd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Investment in non-marketable equity securities</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the provisions of ASU 2016-01, <i>Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>. Due to the Company’s non-marketable equity securities (non-current) does not qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that raise significant concerns about the investee’s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment loss equal to the difference between the fair value of the investment and its carrying amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zOxiqBF1Zkk2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Customer deposits</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer deposits represent amounts advanced by customers on product orders and discounted value of unapplied coupons. Customer deposits are reduced when the related sale is recognized in accordance with the Company’s revenue recognition policy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--RevenueRecognitionPolicyTextBlock_z32xCRNcWAp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenue recognition</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606). The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales of Health and Wellness products</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <i>Performance obligations satisfied at a point in time</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods. The revenue is recorded net of estimated discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were insignificant sales returns.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also sells coupons to its customers for cash at a discounted price of the value of the coupons. Customers can apply the value of the coupons for a reduction in the transaction price paid by the customer are recorded as a reduction of sales. The cash proceeds resulted from the sale of coupons are recognized as customer deposits until the coupons to be applied as a reduction of the health and wellness products transaction price upon such sales transactions occurred. The Company’s coupons have a validity period of six months. If the Company’s customers did not utilize the coupons after six months, the Company would recognize the forfeiture of the originated sales value of the coupons as net revenues. For the three months ended June 30, 2022 and 2021, the Company recognized $<span id="xdx_903_ecustom--ForfeitedCouponIncome_pp0p0_c20220401__20220630_zOQVSyJB43og" title="Value of coupons">4,824</span> and $<span id="xdx_909_ecustom--ForfeitedCouponIncome_pp0p0_c20210401__20210630_z4Qf8Mj8DpCh" title="Value of coupons">4,115</span>, as forfeited coupon income, respectively. For the six months ended June 30, 2022 and 2021, the Company recognized $<span id="xdx_909_ecustom--ForfeitedCouponIncome_pp0p0_c20220101__20220630_zK1iKrEuD6H2">5,777</span> and $<span id="xdx_90A_ecustom--ForfeitedCouponIncome_pp0p0_c20210101__20210630_zYRTOdQbB2Ed" title="Value of coupons">11,226</span>, as forfeited coupon income, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had contracts for the sales of health and wellness products amounting to $<span id="xdx_904_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20220630__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_pp0p0" title="Cost of revenue">16,084</span> which it is expected to fulfill within 12 months from June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales of Health and Wellness services</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <i>Performance obligations satisfied at a point in time</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company carries out its Wellness program, where the Company’s products are bundled with health screening test and a health camp program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test reports are completed and delivered to its customers during the consultation section in person.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health camp program was completed in the final day of the health camp. For the three months ended June 30, 2022 and 2021, revenues from health and wellness services were $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20220630__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_z0FMKuBe16Ii" title="Revenue from contract with customer excluding assessed tax">30,072</span> and $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20210630__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zFzY4eL5DJt7" title="Revenue from contract with customer excluding assessed tax">653</span> respectively. For the six months ended June 30, 2022 and 2021, revenues from health and wellness services were $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220101__20220630__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zLJpCFx6dlx5">31,139</span> and $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20210630__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zJS5oK8rCMrb" title="Revenue from contract with customer excluding assessed tax">5,746</span> respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--ScheduleOfDisaggregatedInformationOfRevenuesTableTextBlock_zSxIzwzIGKVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaggregated information of revenues by products are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zd0t8TKcdJ02" style="display: none">SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20220401__20220630_zs5w0YJWFHyd" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20210401__20210630_zTnoHofg3ofh" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20220101__20220630_z1vNQ4lCKixe" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20210101__20210630_zqwwW1glHf24" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SurvivorSelectMember_zFqJu3X0vBJl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Survivor Select</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">13,941</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">24,415</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">22,753</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">37,641</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergizedMineralConcentrateMember_zAtiVqveONEk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Energized Mineral Concentrate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0736">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,183</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IonizedCalMagMember_zWhSCIX2rvqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Ionized Cal-Mag</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,278</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,485</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,298</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OmegaBlendMember_zbgEErQP9wPc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Omega Blend</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42,747</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89,066</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">179,177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185,361</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--BetaMaxxMember_zC2acUiwJ9S1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Beta Maxx</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,564</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">55,943</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89,800</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IronMember_z4bZPwrrXFae" style="vertical-align: bottom; background-color: White"> <td>Iron</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,118</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,431</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,186</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,715</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--YoungFormulaMember_zxAr3r1BUdK5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Young Formula</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,075</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,458</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,269</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,901</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--OrganicYouthCarCleansingBarMember_z1ktuaYDRv1g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Organic Youth Care Cleansing Bar</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0766">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,990</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,990</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ATPRMITOPlusMember_zbhGjP2Uue69" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">ATPR Mito+</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76,605</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70,148</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">187,926</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,843</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--LipomaskMember_zNBfA7QGDZJ3" style="vertical-align: bottom; background-color: White"> <td>Lipomask</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0776">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,279</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0778">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,401</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--HyaluronicAcidSerumMember_znhgSMMtlvl5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Hyaluronic Acid Serum</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,698</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,362</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,006</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,353</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--MousseFacialCleanserMember_zw8u1N127wcl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Mousse Facial Cleanser</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,355</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,042</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,394</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,660</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--TrimPlusMember_zqsd5VIafjy6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Trim+</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,765</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,223</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,236</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,674</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ProductHealthTherapiesMember_zoQP4CRxKBt4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Others – Products for the provision of complementary health therapies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182,101</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0797">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">216,188</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0799">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OthersMember_z36E1weWceRj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">388</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0802">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">388</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zkBZp8Jrzcl6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total revenues - products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">366,635</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">303,133</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">774,528</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">599,820</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_z1fxRKFgGQu5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Health and Wellness services</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,072</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">653</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,139</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,746</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--Revenues_zZAtWs8fAMW4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total revenues - products and services</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">396,707</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">303,786</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">805,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">605,566</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zCJxQUND43a6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 4824 4115 5777 11226 16084 30072 653 31139 5746 <p id="xdx_89E_ecustom--ScheduleOfDisaggregatedInformationOfRevenuesTableTextBlock_zSxIzwzIGKVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaggregated information of revenues by products are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zd0t8TKcdJ02" style="display: none">SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20220401__20220630_zs5w0YJWFHyd" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20210401__20210630_zTnoHofg3ofh" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20220101__20220630_z1vNQ4lCKixe" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20210101__20210630_zqwwW1glHf24" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SurvivorSelectMember_zFqJu3X0vBJl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Survivor Select</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">13,941</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">24,415</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">22,753</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">37,641</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergizedMineralConcentrateMember_zAtiVqveONEk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Energized Mineral Concentrate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0736">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,183</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IonizedCalMagMember_zWhSCIX2rvqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Ionized Cal-Mag</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,278</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,485</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,298</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OmegaBlendMember_zbgEErQP9wPc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Omega Blend</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42,747</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89,066</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">179,177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185,361</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--BetaMaxxMember_zC2acUiwJ9S1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Beta Maxx</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,564</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">55,943</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89,800</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IronMember_z4bZPwrrXFae" style="vertical-align: bottom; background-color: White"> <td>Iron</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,118</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,431</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,186</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,715</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--YoungFormulaMember_zxAr3r1BUdK5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Young Formula</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,075</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,458</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,269</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,901</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--OrganicYouthCarCleansingBarMember_z1ktuaYDRv1g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Organic Youth Care Cleansing Bar</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0766">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,990</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,990</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ATPRMITOPlusMember_zbhGjP2Uue69" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">ATPR Mito+</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76,605</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70,148</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">187,926</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,843</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--LipomaskMember_zNBfA7QGDZJ3" style="vertical-align: bottom; background-color: White"> <td>Lipomask</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0776">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,279</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0778">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,401</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--HyaluronicAcidSerumMember_znhgSMMtlvl5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Hyaluronic Acid Serum</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,698</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,362</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,006</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,353</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--MousseFacialCleanserMember_zw8u1N127wcl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Mousse Facial Cleanser</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,355</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,042</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,394</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,660</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--TrimPlusMember_zqsd5VIafjy6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Trim+</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,765</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,223</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,236</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,674</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ProductHealthTherapiesMember_zoQP4CRxKBt4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Others – Products for the provision of complementary health therapies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182,101</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0797">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">216,188</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0799">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OthersMember_z36E1weWceRj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">388</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0802">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">388</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zkBZp8Jrzcl6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total revenues - products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">366,635</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">303,133</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">774,528</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">599,820</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_z1fxRKFgGQu5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Health and Wellness services</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,072</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">653</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,139</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,746</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--Revenues_zZAtWs8fAMW4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total revenues - products and services</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">396,707</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">303,786</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">805,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">605,566</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 13941 24415 22753 37641 8291 52183 14278 18485 62368 40298 42747 89066 179177 185361 23564 55943 47637 89800 3118 8431 7186 16715 1075 14458 34269 25901 2990 2990 76605 70148 187926 106843 4279 8401 1698 1362 3006 3353 4355 3042 7394 7660 2765 2223 6236 22674 182101 216188 388 388 366635 303133 774528 599820 30072 653 31139 5746 396707 303786 805667 605566 <p id="xdx_84C_eus-gaap--CostOfSalesPolicyTextBlock_z4Tpg8wiUXJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cost of revenue</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of revenue for the three and six months ended June 30, 2022 were $<span id="xdx_908_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20220401__20220630_z3FY5upMon1l">109,383</span>, and $<span id="xdx_90C_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20220101__20220630_zcuoB3gnGO67" title="Cost of revenue">182,814</span>, respectively, and comprised freight-in, purchase cost of manufactured goods for sale to customers and products for the provision of complementary health therapies. Cost of revenue for the three months and six months ended June 30, 2021, were $<span id="xdx_90C_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20210401__20210630_zKyLMS4477Zg">35,623</span>, and $<span id="xdx_902_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20210101__20210630_ziSocrRWPaN9" title="Cost of revenue">113,214</span>, respectively, and comprised freight-in, purchase cost of manufactured goods for sale to customers. For the six months ended June 30, 2021, cost of revenue also included inventory write-downs of $<span id="xdx_906_eus-gaap--InventoryWriteDown_pp0p0_c20210101__20210630_zvntIyx04Or2" title="Inventories write-down">36,636</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 109383 182814 35623 113214 36636 <p id="xdx_84F_ecustom--ShippingAndHandlingPolicyTextBlock_zsFwRDO7gSsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Shipping and handling</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping and handling charges amounted to $<span id="xdx_90C_eus-gaap--SellingExpense_pp0p0_c20220401__20220630__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zDmJMunQVR87" title="Selling expenses">4,272</span> and $<span id="xdx_905_eus-gaap--SellingExpense_pp0p0_c20210401__20210630__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zjwQtKAlRbL" title="Selling expenses">2,990</span> for the three months ended June 30, 2022 and 2021, respectively. Shipping and handling charges amounted to $<span id="xdx_90D_eus-gaap--SellingExpense_pp0p0_c20220101__20220630__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zT33w1OJ6OH4">7,179</span> and $<span id="xdx_906_eus-gaap--SellingExpense_pp0p0_c20210101__20210630__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_z77tUil1mDh9" title="Selling expenses">5,272</span> for the six months ended June 30, 2022 and 2021, respectively. Shipping and handling charges are expensed as incurred and included in selling expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 4272 2990 7179 5272 <p id="xdx_84F_eus-gaap--AdvertisingCostsPolicyTextBlock_zxiA1qyLIeCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Advertising costs</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising costs amounted to $<span id="xdx_903_eus-gaap--AdvertisingExpense_pp0p0_c20220401__20220630_z7qd7sr33qeg" title="Advertising costs">4,765</span> and $<span id="xdx_90B_eus-gaap--AdvertisingExpense_pp0p0_c20210401__20210630_zUrRhshXRQOc" title="Advertising costs">8,721</span> for the three months ended June 30, 2022 and 2021, respectively. Advertising costs amounted to $<span id="xdx_90F_eus-gaap--AdvertisingExpense_pp0p0_c20220101__20220630_zZ2Rh4W9ywKf" title="Advertising costs">4,765</span> and $<span id="xdx_902_eus-gaap--AdvertisingExpense_pp0p0_c20210101__20210630_zrbgEAdarJu6" title="Advertising costs">16,658</span> for the six months ended June 30, 2022 and 2021, respectively. Advertising costs are expensed as incurred and included in selling expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 4765 8721 4765 16658 <p id="xdx_844_eus-gaap--CommissionsExpensePolicyPolicyTextBlock_zhWLlmd5CYT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Commission expenses</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission expenses are the Company’s most significant expenses. As with all companies in the network marketing industry, the Company’s sales channel is external to the Company. The Company’s “external sales force” is stratified into two levels based on priority recruitment. First, there are sales distributors. Second, all members recruited by a sales distributor, directly or indirectly, are referred to as “sales network members”. The Company pays commission to every sales distributor based on purchases made by its sales network members which includes the independent direct sales members. Top performing distributors with their own physical stores may also become stockists of the Company, whereby they enjoy benefits such as maintaining a certain amount of the Company’s inventory on their store premises. The stockists shall account to the Company for all products sales from their store premises as monitored through the Company’s centralized stock tracking system. The Company pays a separate commission to stockists based on revenue generated from the stockists’ physical stores. Commission expenses amounted to $<span id="xdx_905_ecustom--SalesCommissionsAndFees1_pp0p0_c20220401__20220630_ziswmavsSS9g">62,557</span> and $<span id="xdx_907_ecustom--SalesCommissionsAndFees1_pp0p0_c20210401__20210630_z7q0lA7m4ev7" title="Commission expenses">92,774</span> for the three months ended June 30, 2022 and 2021, respectively. Commission expenses amounted to $<span id="xdx_906_ecustom--SalesCommissionsAndFees1_pp0p0_c20220101__20220630_zXChCKSo52kl" title="Commission expenses">176,666</span> and $<span id="xdx_905_ecustom--SalesCommissionsAndFees1_pp0p0_c20210101__20210630_zWhqcKhTiTo5" title="Commission expenses">181,213</span> for the six months ended June 30, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 62557 92774 176666 181213 <p id="xdx_840_ecustom--DefinedContributionPlanPolicyTextBlock_zcyJuKB4lqdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline">Defined contribution plan</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The full-time employees of the Company are entitled to the government mandated defined contribution plan. The Company is required to accrue and pay for these benefits based on certain percentages of the employees’ respective salaries, subject to certain ceilings, in accordance with the relevant government regulations, and make cash contributions to the government mandated defined contribution plan</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Total expenses for the plan were $<span id="xdx_90D_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20220401__20220630_zkIdASUdFe2f">35,936</span> and $<span id="xdx_905_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20210401__20210630_z4I6SzH9b1t1">27,067</span> for the three months ended June 30, 2022 and 2021, respectively. Total expenses for the plan were $<span id="xdx_90F_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20220101__20220630_zDoSik42nYyd" title="Defined contribution plan expense">63,408</span> and $<span id="xdx_90B_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20210101__20210630_zM9msZgsHbNa" title="Defined contribution plan expense">53,034</span> for the six months ended June 30, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The related contribution plans include:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social Security Organization (“SOSCO”) – <span id="xdx_902_ecustom--SalaryPercentage_pid_dp_c20220101__20220630__dei--LegalEntityAxis__custom--SocialSecurityOrganizationMember_zYJCzNlA7dta" title="Salary percentage">1.75</span>% based on employee’s monthly salary capped of RM <span id="xdx_903_ecustom--MonthlySalary_pp0p0_uRM_c20220101__20220630__dei--LegalEntityAxis__custom--SocialSecurityOrganizationMember__us-gaap--AwardTypeAxis__custom--MYRCurrencyMember_zb6P517f0QR7" title="Monthly salary">4,000</span>;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees Provident Fund (“EPF”) – <span id="xdx_902_ecustom--SalaryPercentage_pid_dp_c20220101__20220630__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember_zVF6HTS0Yh32" title="Salary percentage">12</span>% based on employee’s monthly salary;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Insurance System (“EIS”) – <span id="xdx_90D_ecustom--SalaryPercentage_pid_dp_c20220101__20220630__dei--LegalEntityAxis__custom--EmploymentInsuranceSystemMember_zzTuJ8sGm6jk" title="Salary percentage">0.2</span>% based on employee’s monthly salary capped of RM <span id="xdx_903_ecustom--MonthlySalary_pp0p0_uRM_c20220101__20220630__dei--LegalEntityAxis__custom--EmploymentInsuranceSystemMember__us-gaap--AwardTypeAxis__custom--MYRCurrencyMember_zmS7Run4L8Mh" title="Monthly salary">4,000</span>;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human Resource Development Fund (“HRDF”) – <span id="xdx_904_ecustom--SalaryPercentage_pid_dp_c20220101__20220630__dei--LegalEntityAxis__custom--HumanResourceDevelopmentFundMember_z7TPdnlvcnPf" title="Salary percentage">1</span>% based on employee’s monthly salary</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 35936 27067 63408 53034 0.0175 4000 0.12 0.002 4000 0.01 <p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_zKVrHcVwMR9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Income taxes</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is <span id="xdx_909_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20220101__20220630_zoh49HKX1mPi" title="Income tax examination, likelihood of unfavorable settlement">greater than 50%</span> likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. <span id="xdx_908_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_do_c20220401__20220630_zSwlWh3Zsqfe" title="Income tax examination, penalties and interest expense"><span id="xdx_906_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_do_c20220101__20220630_zfRoB7TAM8Pc" title="Income tax examination, penalties and interest expense">No</span></span> penalties and interest related to underpayment of income taxes were incurred for the three and six months ended June 30, 2022. $<span id="xdx_90B_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_do_c20210401__20210630_z2eHqSAdc252" title="Income tax examination, penalties and interest expense"><span id="xdx_900_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_do_c20210101__20210630_zGWleud7YwQl" title="Income tax examination, penalties and interest expense">395</span></span> in penalties and interest related to underpayment of income taxes were incurred for the three and six months ended June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company conducts much of its business activities in Hong Kong and Malaysia and is subject to tax in each of these jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> greater than 50% 0 0 395 395 <p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zfKKJ4MCM8K8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Comprehensive income (loss)</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under GAAP are recorded as an element of stockholders’ equity but are excluded from net income. Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_ecustom--NoncontrollingInterestPolicyTextBlock_zJLdOS38GUr2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Non-controlling interest</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--MinorityInterestDescription_c20220101__20220630_znmc8nCqwyi" title="Noncontrolling interest, description">Non-controlling interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out of 9,590,598 shares) of the equity interests of ASL held by two individuals</span>. The non-controlling interests are presented in the consolidated balance sheets, separately from equity attributable to the shareholders of the Company. Non-controlling interests in the results of the Company are presented on the face of the consolidated statements of operations as an allocation of the total income or loss for the periods between non-controlling interest holders and the shareholders of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> Non-controlling interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out of 9,590,598 shares) of the equity interests of ASL held by two individuals <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zmLMaVMPco49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Earnings (loss) per share</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company computes earnings (loss) per share (“EPS”) in accordance with ASC 260, “Earnings per Share”. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is measured as net income (loss) divided by the weighted average <span style="background-color: white">common stocks</span> outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential <span style="background-color: white">common stocks</span> (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential <span style="background-color: white">common stocks</span> that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. For the three and six months ended June 30, 2022 and 2021, there were <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20220401__20220630_zathA04kfiWa" title="Potentially dilutive securities outstanding"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20210401__20210630_z86YpQpjBgMj"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20220101__20220630_zjO9Y8EVLTT7"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20210101__20210630_z765FWzNixT9" title="Potentially dilutive securities outstanding">no</span></span></span></span> dilutive shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0 0 0 0 <p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zMm2ND7Iuj3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Foreign currencies translation and transaction</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the consolidated statements of operations and comprehensive income (loss).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reporting currency of the Company is United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. The Company’s subsidiary in Labuan maintains its books and record in United States Dollars (“US$”) albeit its functional currency being the primary currency of the economic environment in which the entity operates, which is the Malaysian Ringgit (“MYR” or “RM”). The Company’s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars (“HK$”), similar to its functional currency. The Company’s subsidiary and VIE in Malaysia conducts its businesses and maintains its books and record in the local currency, Malaysian Ringgit (“MYR” or “RM”), as its functional currency.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “<i>Translation of Financial Statement”</i>, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders’ equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_z7coOOHAXqb7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zxWyPA8vEeYa" style="display: none">SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20220630_zZEmJyuh1Uf6" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20211231_zpqCueevhSF2" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndMYRMember_z1lyB1RJxcRg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Period-end MYR : US$1 exchange rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4.40</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4.18</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_zU9ZTOzm8cb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Period-end HKD : US$1 exchange rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.80</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_zhZh1kkBh1d" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign currency exchange rate, translation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.80</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20220401__20220630_z3JfYpfLAS45" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20210401__20210630_z8yDw3Jr3mwa" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20220101__20220630_zwPge16CIYAi" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20210101__20210630_zCfZJVpap3v6" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_400_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageMYRMember_zJGW0fULsuT2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Period-average MYR : US$1 exchange rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4.37</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4.28</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4.10</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_z6wz10MhZDMf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Period-average HKD : US$1 exchange rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.77</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.76</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_ztiBGZSQNy1d" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign currency exchange rate period average</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.77</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.76</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A3_zakmFkDhBPOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_z7coOOHAXqb7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zxWyPA8vEeYa" style="display: none">SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20220630_zZEmJyuh1Uf6" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20211231_zpqCueevhSF2" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndMYRMember_z1lyB1RJxcRg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Period-end MYR : US$1 exchange rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4.40</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4.18</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_zU9ZTOzm8cb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Period-end HKD : US$1 exchange rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.80</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_zhZh1kkBh1d" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign currency exchange rate, translation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.80</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20220401__20220630_z3JfYpfLAS45" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20210401__20210630_z8yDw3Jr3mwa" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20220101__20220630_zwPge16CIYAi" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20210101__20210630_zCfZJVpap3v6" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_400_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageMYRMember_zJGW0fULsuT2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Period-average MYR : US$1 exchange rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4.37</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4.28</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4.10</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_z6wz10MhZDMf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Period-average HKD : US$1 exchange rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.77</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.76</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_ztiBGZSQNy1d" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign currency exchange rate period average</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.77</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.76</td><td style="text-align: left"> </td></tr> </table> 4.40 4.18 7.85 7.80 7.85 7.80 4.37 4.13 4.28 4.10 7.85 7.77 7.83 7.76 7.85 7.77 7.83 7.76 <p id="xdx_84F_ecustom--RelatedPartiesPolicyTextBlock_zNNHBuwRtIfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related parties</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zStfc2k1nr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair value of financial instruments</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_z7Xelv60wNP9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Leases</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted ASU 2016-02, “Leases” (Topic 842), and elected the practical expedients that does not require the Company to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing leases and (3) initial direct costs for any expired or existing leases. For lease terms of twelve months or fewer, a lessee is permitted to make an accounting policy election not to recognize lease assets and liabilities. The Company also adopts the practical expedient that allows lessees to treat the lease and non-lease components of a lease as a single lease component. Some of the Company’s leases include one or more options to renew, which is typically at the Company’s sole discretion. The Company regularly evaluates the renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. New lease modifications result in re-measurement of the right of use (“ROU”) assets and lease liabilities. Operating ROU assets and lease liabilities are recognized at the commencement date, based on the present value of lease payments over the lease term. Since the implicit rate for the Company’s leases is not readily determinable, the Company use its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment and over a similar term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of twelve months or less. Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future pre-tax cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zlwTo63cpG9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Recent accounting pronouncements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates (“ASUs”). Management periodically reviews new accounting standards that are issued. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or revised accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating the impact ASU 2019-05 may have on its unaudited condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except for the above-mentioned pronouncements, there are no new recent issued accounting standards that will have a material impact on the consolidated financial position, statements of operations and cash flows.</span></p> <p id="xdx_80B_eus-gaap--VariableInterestEntityDisclosureTextBlock_zu5iorhlf0bj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. <span id="xdx_826_zm3u9K9exBQ8">VARIABLE INTEREST ENTITY (“VIE”)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEA is a trading company incorporated on March 4, 2004, under the laws of Malaysia. SEA provided majority of ASL’s purchases. Its equity at risk was insufficient to finance its activities and <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_z88s1HQEpsSj" title="Proportional of ownership interest and voting power held">100</span>% of its business is transacted with ASL. Therefore, it was considered to be a VIE and ASL is the primary beneficiary since it has both of the following characteristics:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The power to direct the activities of the VIE that most significantly impact the VIE’s economic performance; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly, the accounts of SEA is consolidated in the accompanying financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. VARIABLE INTEREST ENTITY (“VIE”) (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_891_eus-gaap--ScheduleOfVariableInterestEntitiesTextBlock_zQKt0tIM5xl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amount of the VIE’s assets and liabilities were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_znoRRANMUSEf" style="display: none">SCHEDULE OF VARIABLE INTEREST ENTITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20220630__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zQF3SylQt6Ij" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zVxz7FdVtSu8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_406_eus-gaap--AssetsCurrent_iI_zaUDP7lruuH" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,370</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">       18,850</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LiabilitiesCurrent_iNI_di_zcVnEcdlONn6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,288</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,272</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--StockholdersEquity_iI_zjdHyDXtRjo4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deficit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(33,918</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(32,422</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_zZbPutwVye86" style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,626</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">       17,493</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PrepaidTaxes_iI_zI6JCDPBhQx9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Prepaid taxes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,744</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,357</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AssetsCurrent_iI_ztotCtrfyiG6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,370</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,850</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iI_zqyRUQq2zONa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accounts payable – intercompany</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">42,501</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">49,724</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--OtherPayablesRelatedPartyCurrent_iI_zf6C1xlFX7j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other payables and accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">787</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,548</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LiabilitiesCurrent_iI_zfW8hejYWdL8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,288</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,272</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--StockholdersEquity_iI_z5scMRVjseac" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deficit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(33,918</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(32,422</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The summarized operating results of the VIE’s are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_495_20220401__20220630__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zeXqcdC56PDk" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_498_20210401__20210630__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zAJojardDqU7" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_491_20220101__20220630__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zkj3zXBUpLcb" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_49B_20210101__20210630__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zr3UupvGnSLj" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zCCXcuAaQ3Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0978">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0979">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0980">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--GrossProfit_ztQYXbpkfKj3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Gross profit</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0982">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0985">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_z7QEFmdmYRMe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left; padding-bottom: 2.5pt">Profit (loss) from operations</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">1,723</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(5,019</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(3,219</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(11,967</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_zKc2krUxt6m6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,723</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,912</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,219</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,949</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A7_zZu5zwrwipOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 1 <p id="xdx_891_eus-gaap--ScheduleOfVariableInterestEntitiesTextBlock_zQKt0tIM5xl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amount of the VIE’s assets and liabilities were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_znoRRANMUSEf" style="display: none">SCHEDULE OF VARIABLE INTEREST ENTITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20220630__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zQF3SylQt6Ij" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zVxz7FdVtSu8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_406_eus-gaap--AssetsCurrent_iI_zaUDP7lruuH" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,370</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">       18,850</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LiabilitiesCurrent_iNI_di_zcVnEcdlONn6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,288</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,272</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--StockholdersEquity_iI_zjdHyDXtRjo4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deficit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(33,918</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(32,422</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_zZbPutwVye86" style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,626</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">       17,493</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PrepaidTaxes_iI_zI6JCDPBhQx9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Prepaid taxes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,744</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,357</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AssetsCurrent_iI_ztotCtrfyiG6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,370</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,850</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iI_zqyRUQq2zONa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accounts payable – intercompany</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">42,501</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">49,724</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--OtherPayablesRelatedPartyCurrent_iI_zf6C1xlFX7j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other payables and accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">787</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,548</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LiabilitiesCurrent_iI_zfW8hejYWdL8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,288</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,272</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--StockholdersEquity_iI_z5scMRVjseac" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deficit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(33,918</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(32,422</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The summarized operating results of the VIE’s are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_495_20220401__20220630__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zeXqcdC56PDk" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_498_20210401__20210630__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zAJojardDqU7" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_491_20220101__20220630__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zkj3zXBUpLcb" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_49B_20210101__20210630__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zr3UupvGnSLj" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zCCXcuAaQ3Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0978">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0979">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0980">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--GrossProfit_ztQYXbpkfKj3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Gross profit</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0982">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0985">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_z7QEFmdmYRMe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left; padding-bottom: 2.5pt">Profit (loss) from operations</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">1,723</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(5,019</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(3,219</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(11,967</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_zKc2krUxt6m6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,723</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,912</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,219</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,949</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 9370 18850 43288 51272 -33918 -32422 7626 17493 1744 1357 9370 18850 42501 49724 787 1548 43288 51272 -33918 -32422 1723 -5019 -3219 -11967 1723 1912 -3219 -9949 <p id="xdx_80F_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zQ10yvA1aDSc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. <span id="xdx_82F_zkBC7ZfdQnz2">CASH AND CASH EQUIVALENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As of June 30, 2022 and December 31, 2021 the Company has $<span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20220630_zluPVCNnk9vc">1,807,437 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">and $<span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20211231_zgZXYiUHMuV6">2,597,848</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">, respectively, of cash and cash equivalents, which consists of $<span id="xdx_909_eus-gaap--Cash_iI_pp0p0_c20220630_zcRffnGmo967">666,779 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">and $<span id="xdx_90E_eus-gaap--Cash_iI_pp0p0_c20211231_zAqSBxmgdnFg">554,864</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">, respectively, of cash in banks and </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_900_eus-gaap--TimeDeposits_iI_pp0p0_c20220630_znEgLStSVYyk">1,134,542 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">and $<span id="xdx_90A_eus-gaap--TimeDeposits_iI_pp0p0_c20211231_zAiB3WQzBfZb">1,975,347</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">, respectively, of time deposits placed with banks or other financial institutions and are all highly liquid investments with an original maturity of three months or less. The effective interest rate for the time deposits ranged between <span id="xdx_902_eus-gaap--PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_iI_dp_c20220630__srt--RangeAxis__srt--MinimumMember_zI2r1tetsEP2">1.10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">% to <span id="xdx_904_eus-gaap--PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_iI_dp_c20220630__srt--RangeAxis__srt--MaximumMember_zLsRngOKVe6c">1.17</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">% per annum for the three and six months ended June 30, 2022. The effective interest rate for the time deposits ranged between <span id="xdx_904_eus-gaap--PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_iI_dp_c20210630__srt--RangeAxis__srt--MinimumMember_zJSwbFiru1Rj">1.80</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">% to <span id="xdx_90A_eus-gaap--PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_iI_dp_c20210630__srt--RangeAxis__srt--MaximumMember_zbOJF6pQNTl7">2.15</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">% per annum for the three and six months ended June 30, 2021. As of June 30, 2022 and December 31, 2021, $<span id="xdx_90E_eus-gaap--TimeDepositLiabilityUninsured_iI_c20220630_zpyHdsID8Rj6" title="Time deposit uninsured"><span style="background-color: white">319,994</span></span> and $<span id="xdx_90A_eus-gaap--TimeDepositLiabilityUninsured_iI_c20211231_zOk22ssPEWgg" title="Time deposit uninsured">295,761</span> of these balances are not covered by deposit insurance, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1807437 2597848 666779 554864 1134542 1975347 0.0110 0.0117 0.0180 0.0215 319994 295761 <p id="xdx_80C_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zBSxJfFxys28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>5. <span id="xdx_823_zA98pouYXwI">ACCOUNTS RECEIVABLE</span></b></span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zYJCc6Ymtb9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zRatB8R4Q6Y4" style="display: none">SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20220630_zVjTeG6A5S6g" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20211231_zIscKDGGVZ1i" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--AccountsReceivableGrossCurrent_iI_maCzL9Q_zAKQTYEsxTU4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">214</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">       <span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_di_msCzL9Q_zN6zbYKYW9Ok" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1020">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccountsReceivableNetCurrent_iTI_mtCzL9Q_zRTfsSL9SxN1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total accounts receivable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">214</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zHNwzuHyAhVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zYJCc6Ymtb9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zRatB8R4Q6Y4" style="display: none">SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20220630_zVjTeG6A5S6g" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20211231_zIscKDGGVZ1i" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--AccountsReceivableGrossCurrent_iI_maCzL9Q_zAKQTYEsxTU4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">214</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">       <span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_di_msCzL9Q_zN6zbYKYW9Ok" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1020">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccountsReceivableNetCurrent_iTI_mtCzL9Q_zRTfsSL9SxN1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total accounts receivable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">214</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 214 214 <p id="xdx_80C_eus-gaap--InventoryDisclosureTextBlock_zqzBvO0Voaxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. <span id="xdx_823_zxpNOpvvjdr3">INVENTORIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zDLmUP0RdJW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zNeFOI5kM8Yl" style="display: none">SCHEDULE OF INVENTORIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20220630_zQt8WZGCfa9d" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20211231_zgTCbepZTS8c" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 60%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InventoryFinishedGoods_iI_zqWdf9xMeiie" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Finished goods</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">346,744</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">       375,535</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zBvR0MgnUOff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended June 30, 2022, and 2021, the Company did not recognize any inventory write-downs. For the six months ended June 30, 2022, and 2021, the Company recognized inventory write-downs of $<span id="xdx_907_eus-gaap--InventoryWriteDown_pp0p0_dxL_c20220101__20220630_zLobwApEYEQj" title="Inventory write-downs::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1033">0</span></span> and $<span id="xdx_90A_eus-gaap--InventoryWriteDown_pp0p0_dxL_c20210101__20210630_zOXlwxut14O1" title="Inventory write-downs"><span style="-sec-ix-hidden: xdx2ixbrl1035">36,636</span></span> respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zDLmUP0RdJW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zNeFOI5kM8Yl" style="display: none">SCHEDULE OF INVENTORIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20220630_zQt8WZGCfa9d" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20211231_zgTCbepZTS8c" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 60%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InventoryFinishedGoods_iI_zqWdf9xMeiie" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Finished goods</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">346,744</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">       375,535</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 346744 375535 <p id="xdx_806_ecustom--PrepaymentsAndDepositsTextBlock_z1hpNPs9wqH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>7. <span id="xdx_82A_zUZExMuGobb">PREPAYMENTS AND DEPOSITS</span></b></span></p> <p id="xdx_89C_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zSA2o3KiaBfb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zT1GuYDXV0x" style="display: none">SCHEDULE OF PREPAID EXPENSES AND DEPOSITS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20220630_zYlA2blFX4f" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20211231_zO0hBFOKyOk5" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_ecustom--ReceivablesFromSalesDistributors_iI_maCzFPV_zrMeVPIweqz1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Receivables from sales distributors</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">58,477</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">       115,379</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DepositsToSupplier_iI_maCzFPV_zYf5PiV4W422" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Deposits to suppliers</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">240,592</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">301,233</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--PrepaidExpensesGross_iTI_maCzxAt_mtCzFPV_z9SumycqQAv9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Subtotal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">299,069</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">416,612</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iNI_di_msCzxAt_z3VuqUSJNp5g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Provision for doubtful accounts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(120,372</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(121,095</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtCzxAt_zqlIMs9KbVK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">178,697</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">295,517</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zbQmGTtRhO1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_898_ecustom--ScheduleOfChangesInAllowanceForDoubtfulAccountsTableTextBlock_zXkSkZXaJAFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movements of allowance for doubtful accounts are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zdAGJZn8o2j7" style="display: none">SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20220101__20220630_zgP9pCkB6HA9" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20210101__20211231_zGYhKrUxihI3" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the six</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>months ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, 2022</b></p></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>year </b></span><b>ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, 2021</b></p></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_z8aqIgt8dEbk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Beginning balance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">121,095</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">                <span style="-sec-ix-hidden: xdx2ixbrl1059">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_zJHFRDVhEJ5g" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt">Addition</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1061">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">121,514</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_z0afPdXzZ7Q8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Write off</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_ziE1YatAqF0e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Exchange rate effect</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(723</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(419</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_zUE1eJMZPCCe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">120,372</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">121,095</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zvaWea77Wi58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zSA2o3KiaBfb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zT1GuYDXV0x" style="display: none">SCHEDULE OF PREPAID EXPENSES AND DEPOSITS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20220630_zYlA2blFX4f" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20211231_zO0hBFOKyOk5" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_ecustom--ReceivablesFromSalesDistributors_iI_maCzFPV_zrMeVPIweqz1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Receivables from sales distributors</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">58,477</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">       115,379</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DepositsToSupplier_iI_maCzFPV_zYf5PiV4W422" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Deposits to suppliers</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">240,592</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">301,233</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--PrepaidExpensesGross_iTI_maCzxAt_mtCzFPV_z9SumycqQAv9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Subtotal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">299,069</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">416,612</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iNI_di_msCzxAt_z3VuqUSJNp5g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Provision for doubtful accounts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(120,372</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(121,095</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtCzxAt_zqlIMs9KbVK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">178,697</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">295,517</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 58477 115379 240592 301233 299069 416612 120372 121095 178697 295517 <p id="xdx_898_ecustom--ScheduleOfChangesInAllowanceForDoubtfulAccountsTableTextBlock_zXkSkZXaJAFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movements of allowance for doubtful accounts are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zdAGJZn8o2j7" style="display: none">SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20220101__20220630_zgP9pCkB6HA9" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20210101__20211231_zGYhKrUxihI3" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the six</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>months ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, 2022</b></p></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>year </b></span><b>ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, 2021</b></p></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_z8aqIgt8dEbk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Beginning balance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">121,095</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">                <span style="-sec-ix-hidden: xdx2ixbrl1059">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_zJHFRDVhEJ5g" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt">Addition</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1061">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">121,514</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_z0afPdXzZ7Q8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Write off</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_ziE1YatAqF0e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Exchange rate effect</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(723</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(419</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_zUE1eJMZPCCe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">120,372</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">121,095</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 121095 121514 -723 -419 120372 121095 <p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zfPfA9qnLWzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. <span id="xdx_827_zMsTnTs50uE">PROPERTY AND EQUIPMENT, NET</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zkgasbYeOXy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zfgOP3P4mvZk" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT, NET</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20220630_z5poJEbCaGf" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20211231_zkNYkoUSVgY6" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndOfficeEquipmentMember_zeZJA3Gcrfnf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Computer and office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">78,885</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">82,298</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zuoXnvYDcMQb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Furniture &amp; fixtures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">116,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">122,185</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z5mTzdNXMSAl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">192,323</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">202,570</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--VehicleMember_zMJZ6HX62aG3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Vehicle</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,709</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">98,702</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz5ZB_zcxDZRlzyWY1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Subtotal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">480,921</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">505,755</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz5ZB_zIzN0qh0bGYl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(311,006</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(289,956</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz5ZB_zgt1nEUZ1hSe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">169,915</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">215,799</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zCAYQ58kqkqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense for the three months ended June 30, 2022 and 2021 amounted to $<span id="xdx_903_eus-gaap--Depreciation_pp0p0_c20220401__20220630_zDEme8UoVRkc">17,954</span> and $<span id="xdx_905_eus-gaap--Depreciation_pp0p0_c20210401__20210630_z8hSeYctg2Rk">19,009</span>, respectively. Depreciation expense for the six months ended June 30, 2022 and 2021 amounted to $<span id="xdx_900_eus-gaap--Depreciation_pp0p0_c20220101__20220630_zcE51d8VgbDk" title="Depreciation">36,661</span> and $<span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20210101__20210630_zeA1bMcrlOr4" title="Depreciation">38,179</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zkgasbYeOXy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zfgOP3P4mvZk" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT, NET</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20220630_z5poJEbCaGf" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20211231_zkNYkoUSVgY6" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndOfficeEquipmentMember_zeZJA3Gcrfnf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Computer and office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">78,885</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">82,298</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zuoXnvYDcMQb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Furniture &amp; fixtures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">116,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">122,185</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z5mTzdNXMSAl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">192,323</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">202,570</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--VehicleMember_zMJZ6HX62aG3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Vehicle</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,709</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">98,702</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz5ZB_zcxDZRlzyWY1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Subtotal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">480,921</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">505,755</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz5ZB_zIzN0qh0bGYl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(311,006</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(289,956</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz5ZB_zgt1nEUZ1hSe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">169,915</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">215,799</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 78885 82298 116004 122185 192323 202570 93709 98702 480921 505755 311006 289956 169915 215799 17954 19009 36661 38179 <p id="xdx_807_eus-gaap--IntangibleAssetsDisclosureTextBlock_zfugZSwHTD77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9. <span id="xdx_82B_z3np8SGtLq64">INTANGIBLE ASSETS, NET</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zPJIBD25zv2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net, consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zT2j33p9Qv43" style="display: none">SCHEDULE OF INTANGIBLE ASSETS, NET</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20220630_zpPhtnyflMAd" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20211231_zROlppmm2Gph" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCzFod_zwSiLGkoB123" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer software</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,710</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,453</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msCzFod_zEfRfDjgwSPf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: accumulated amortization</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30,109</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30,793</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCzFod_zVCsOWvLSfch" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,601</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,660</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A6_zM2Y9FOJDBH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization expense for the three months ended June 30, 2022 and 2021 amounted to $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220401__20220630_z0TtnjANfnS2">439</span> and $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210401__20210630_zHQyojVJyed3">496</span>, respectively. Amortization expense for the six months ended June 30, 2022 and 2021 amounted to $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220101__20220630_zH1kpMAXNAy6">897</span> and $<span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210101__20210630_zSOaQEHkH7a1" title="Amortization expense">1,006</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zPJIBD25zv2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net, consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zT2j33p9Qv43" style="display: none">SCHEDULE OF INTANGIBLE ASSETS, NET</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20220630_zpPhtnyflMAd" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20211231_zROlppmm2Gph" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCzFod_zwSiLGkoB123" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer software</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,710</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,453</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msCzFod_zEfRfDjgwSPf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: accumulated amortization</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30,109</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30,793</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCzFod_zVCsOWvLSfch" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,601</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,660</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 32710 34453 30109 30793 2601 3660 439 496 897 1006 <p id="xdx_808_ecustom--InvestmentInMarketableSecuritiesTextBlock_zF6nt3DujYKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10. <span id="xdx_82A_zWY74keUEVq">INVESTMENT IN MARKETABLE SECURITIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 17, 2018, the Company purchased <span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_c20180517__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_z9nZ31pRBIh4">83,333</span> shares of common stock in Greenpro Capital Corp. for $<span id="xdx_904_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20180517__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zqG72mmF81ch">500,000</span> at a purchase price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20180517__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zTXtIu5vR5Ta">6</span> per share.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 30, 2018, the Company disposed <span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_c20180730__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zm5uuYy7NPXf">20</span> shares of common stock in Greenpro Capital Corp. for $<span id="xdx_904_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20180730__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zNd4FF4VXJy6">125</span> at a purchase price of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20180730__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zlptmIvbWLrf">6.2613</span> per share.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 16, 2018, the Company purchased <span id="xdx_907_eus-gaap--InvestmentOwnedBalanceShares_c20181016__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_pdd">33,333</span> shares of common stock in Greenpro Capital Corp. for $<span id="xdx_906_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20181016__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zNkLK47fwLA9">1,000</span> at a purchase price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20181016__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zGktzDmxv4Fl">0.03</span> per share.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 3, 2020, the Company received dividend of <span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_c20201103__dei--LegalEntityAxis__custom--DSwissIncMember_zmQcU8rAtXt5">6,667</span> shares of common stock in DSwiss, Inc. for $<span id="xdx_900_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20201103__dei--LegalEntityAxis__custom--DSwissIncMember_z9Qor4pqI1H6">76,671</span> at fair value of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20201103__dei--LegalEntityAxis__custom--DSwissIncMember_zHVC4OCkoZQ8">11.50</span> per share from Greenpro Capital Corporation as result of its Spin-off of DSwiss, Inc.’s shares</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 9, 2020, the Company received dividend of <span id="xdx_901_eus-gaap--InvestmentOwnedBalanceShares_iI_c20201209__dei--LegalEntityAxis__custom--DSwissIncMember_zBZLPQp8rZEg">16,663</span> shares of common stock in DSwiss, Inc. for $<span id="xdx_904_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20201209__dei--LegalEntityAxis__custom--DSwissIncMember_zCNguPwWNeJ">83,315</span> at fair value of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20201209__dei--LegalEntityAxis__custom--DSwissIncMember_zjldwNFbYyeh">5</span> per share from Greenpro Capital Corporation as result of its Spin-off of DSwiss, Inc.’s shares.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 27, 2021, the Company received dividend of <span id="xdx_90C_eus-gaap--InvestmentOwnedBalanceShares_iI_c20210927__dei--LegalEntityAxis__custom--SEATechVenturesCorpMember_zMVmwzwwyJN3" title="Investment in securities, shares">11,665</span> shares of common stock in SEATech Ventures Corp. for $<span id="xdx_90C_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20210927__dei--LegalEntityAxis__custom--SEATechVenturesCorpMember_zGRzXbE4NmJc" title="Investment amount">18,874</span> at fair value of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20210927__dei--LegalEntityAxis__custom--SEATechVenturesCorpMember_zX2r3UPY3ANh" title="Purchased price per shares">1.62</span> per share from Greenpro Capital Corp as a dividend income since Greenpro Capital Corp previously owned these shares.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10. INVESTMENT IN MARKETABLE SECURITIES (Continued)</b></span></p> <p id="xdx_894_eus-gaap--MarketableSecuritiesTextBlock_zKRxu3VcMLtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> <span id="xdx_8BD_zHq6WSoNSy13" style="display: none">SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20220630_zocWGXrbdPz6" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20211231_zxxIHqQxudp9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_maMSNzd9C_zRsTtc8EyET1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Cost of investment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">89,001</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">577,035</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--InvestmentsIncomeDividend_iNI_pp0p0_di_msMSNzd9C_zGCMkzVKn9i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend income from Greenpro Capital Corp.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,939</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--MarketableSecuritiesUnrealizedHoldingGainLoss_iNI_pp0p0_di_msMSNzd9C_zzAhmLL6XDtg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unrealized holding loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(52,889</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(505,231</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_ecustom--ExchangeRateEffectOnInvestmentInMarketableSecurites_iI_pp0p0_maMSNzd9C_zcxg1BxJQCHk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate effect</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(405</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,742</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--MarketableSecuritiesNoncurrent_iTI_pp0p0_mtMSNzd9C_zmqxTXyiFAGi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Investment in marketable securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,707</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">89,001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zWRsBeitNAxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> 83333 500000 6 20 125 6.2613 33333 1000 0.03 6667 76671 11.50 16663 83315 5 11665 18874 1.62 <p id="xdx_894_eus-gaap--MarketableSecuritiesTextBlock_zKRxu3VcMLtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> <span id="xdx_8BD_zHq6WSoNSy13" style="display: none">SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20220630_zocWGXrbdPz6" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20211231_zxxIHqQxudp9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_maMSNzd9C_zRsTtc8EyET1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Cost of investment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">89,001</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">577,035</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--InvestmentsIncomeDividend_iNI_pp0p0_di_msMSNzd9C_zGCMkzVKn9i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend income from Greenpro Capital Corp.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,939</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--MarketableSecuritiesUnrealizedHoldingGainLoss_iNI_pp0p0_di_msMSNzd9C_zzAhmLL6XDtg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unrealized holding loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(52,889</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(505,231</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_ecustom--ExchangeRateEffectOnInvestmentInMarketableSecurites_iI_pp0p0_maMSNzd9C_zcxg1BxJQCHk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate effect</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(405</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,742</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--MarketableSecuritiesNoncurrent_iTI_pp0p0_mtMSNzd9C_zmqxTXyiFAGi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Investment in marketable securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,707</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">89,001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 89001 577035 -18939 52889 505231 -405 -1742 35707 89001 <p id="xdx_806_ecustom--InvestmentInNonMarketableSecuritiesTextBlock_za1zaeqz6Xql" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11. <span id="xdx_824_zIc2a1HeyKRk">INVESTMENT IN NON-MARKETABLE SECURITIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 3, 2019, the Company purchased a <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zMR0FypUK6wg" title="Equity interest percentage">5</span>% of stock or <span id="xdx_90C_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20190403__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zaQ2PZNNmRq7" title="Shares purchased during period">15,000,000</span> shares of common stock in Phoenix Plus Corp. for $<span id="xdx_903_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zeJb3YvIBDid" title="Investment amount">1,500</span> at purchase price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zpMELmahy6Af" title="Shares Issued, Price Per Share">0.0001</span> per share.</span></p> <p id="xdx_896_ecustom--NonMarketableSecuritiesTableTextBlock_zjy5BGcO1sgh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zbcjaL4MZKvh" style="display: none">SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phoenix Plus Corporation</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of investment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20220630__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_z1R2Rz8gKXHg" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Cost of investment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20211231__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_z33HlPGD4Bil" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Cost of investment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost of investment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost of investment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in non-marketable securities</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_ecustom--InvestmentInNonMarketableSecuritiesNoncurrent_iI_pp0p0_c20220630__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_z6MYwB3LFWhd" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost of investment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_ecustom--InvestmentInNonMarketableSecuritiesNoncurrent_iI_pp0p0_c20211231__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_z78kpzwvC1J1" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost of investment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AB_zVGkxWxaA5Fj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.05 15000000 1500 0.0001 <p id="xdx_896_ecustom--NonMarketableSecuritiesTableTextBlock_zjy5BGcO1sgh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zbcjaL4MZKvh" style="display: none">SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phoenix Plus Corporation</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of investment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20220630__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_z1R2Rz8gKXHg" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Cost of investment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20211231__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_z33HlPGD4Bil" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Cost of investment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost of investment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost of investment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in non-marketable securities</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_ecustom--InvestmentInNonMarketableSecuritiesNoncurrent_iI_pp0p0_c20220630__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_z6MYwB3LFWhd" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost of investment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_ecustom--InvestmentInNonMarketableSecuritiesNoncurrent_iI_pp0p0_c20211231__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_z78kpzwvC1J1" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost of investment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 1500 1500 1500 1500 <p id="xdx_80B_eus-gaap--OtherLiabilitiesDisclosureTextBlock_zKwUbMK9ZT09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12. <span id="xdx_829_zz6NQkFJCwwl">OTHER PAYABLES AND ACCRUED LIABILITIES</span></b></span></p> <p id="xdx_89D_ecustom--ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock_zUI88Otoct6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zeSeQ6kYkPtl" style="display: none">SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20220630_zNrPdCFgdiw" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20211231_zygS0zqiY48l" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><b> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b>June 30, 2022</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2021</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td></tr> <tr id="xdx_405_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOAPAAzvdo_zKPZV5FB3iOh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Professional fees</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">142,622</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">436,541</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AccruedPromotionExpensesCurrent_iI_pp0p0_maOAPAAzvdo_z1JFZNHs9VM3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Promotion expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,360</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36,024</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maOAPAAzvdo_ziO22VyDRcr9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Payroll</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,018</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,669</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedSalesCommissionCurrent_iI_pp0p0_maOAPAAzvdo_z7b6NzRhYDKb" style="vertical-align: bottom; background-color: White"> <td>Commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">247,645</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">219,721</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AccruedTaxPenaltyCurrent_iI_pp0p0_maOAPAAzvdo_z7xUiKNj28S8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tax penalty</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_pp0p0_maOAPAAzvdo_zpZByQyclht7" style="vertical-align: bottom; background-color: White"> <td>Others</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,388</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--OtherAccountPayableAndAccruedLiabilities_iTI_pp0p0_mtOAPAAzvdo_z4zjEfPFDsR3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">637,033</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">858,355</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A9_z2z73Gm6GANj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts have been reclassified to conform to current period presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_ecustom--ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock_zUI88Otoct6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zeSeQ6kYkPtl" style="display: none">SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20220630_zNrPdCFgdiw" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20211231_zygS0zqiY48l" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><b> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b>June 30, 2022</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2021</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td></tr> <tr id="xdx_405_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOAPAAzvdo_zKPZV5FB3iOh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Professional fees</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">142,622</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">436,541</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AccruedPromotionExpensesCurrent_iI_pp0p0_maOAPAAzvdo_z1JFZNHs9VM3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Promotion expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,360</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36,024</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maOAPAAzvdo_ziO22VyDRcr9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Payroll</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,018</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,669</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedSalesCommissionCurrent_iI_pp0p0_maOAPAAzvdo_z7b6NzRhYDKb" style="vertical-align: bottom; background-color: White"> <td>Commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">247,645</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">219,721</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AccruedTaxPenaltyCurrent_iI_pp0p0_maOAPAAzvdo_z7xUiKNj28S8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tax penalty</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_pp0p0_maOAPAAzvdo_zpZByQyclht7" style="vertical-align: bottom; background-color: White"> <td>Others</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,388</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--OtherAccountPayableAndAccruedLiabilities_iTI_pp0p0_mtOAPAAzvdo_z4zjEfPFDsR3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">637,033</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">858,355</td><td style="text-align: left"> </td></tr> </table> 142622 436541 40360 36024 54018 22669 247645 219721 75000 75000 77388 68400 637033 858355 <p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zN4wUlwFaLR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. <span id="xdx_828_zAHjYUO9M6gj">RELATED PARTY BALANCES AND TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related party balances</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounts payable – related parties</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_899_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zrJMZ5VVnTG3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zl1BjMbSkt2f" style="display: none">SCHEDULE OF RELATED PARTIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Name of Related<br/> Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center"><span id="xdx_902_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zhrsPrwuOTre" title="Relationship"><span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zyqVWSh77tr3" title="Relationship">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</span></span></td><td style="width: 2%"> </td> <td style="vertical-align: top; width: 20%; text-align: center"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_z347MdDyzaX8" title="Nature"><span id="xdx_90E_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zXosDkvSqls8" title="Nature">Purchases of products for the provision of complementary health therapies</span></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zByO0BCj0tCk" style="width: 15%; text-align: right" title="Accounts payable">14,322</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zBVvm5HZyA3b" style="width: 15%; text-align: right">         <span style="-sec-ix-hidden: xdx2ixbrl1220">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdMember_zCM08SukNEf6"><span id="xdx_90F_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdMember_zjXzgTU3YH15">Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdMember_zYyzNsUqHNv6"><span id="xdx_906_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdMember_zweDq5YbXape">Purchases of products for the provision of complementary health therapies</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdMember_zfKNAdv87Dfj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accounts payable">85</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdMember_zrxvvotGQPo1" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1227">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20220630_z0osPnVyBfE4" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable">14,407</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231_zI2772tO3mWc" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1230">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount due from related parties</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Related</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Party</b></span></p></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relationship</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nature</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2022</b></span></p></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of <br/> December 31, 2021</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape ATP (Asia) Limited (“AATP Asia”)</span></td><td style="width: 2%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top; width: 20%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zCftLCweCdX5"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zyFwjuBFbzni">Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia</span></span></span></td><td style="width: 2%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top; width: 20%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zC1pLuuwzG93"><span id="xdx_90D_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zE5jb96TB6uk">Expenses paid for AATP Asia</span></span></span></td><td style="width: 2%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zJAyrpfYqxnl" style="width: 15%; font-size: 10pt; text-align: right" title="Due from related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1236">-</span></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 2%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zu9pNw6gG3J4" style="width: 15%; font-size: 10pt; text-align: right" title="Due from related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,214</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hostastay Sdn. Bhd. (“Hostastay”)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zPDYb6f7i78e"><span id="xdx_907_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zPtlncmsn4Cc">Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021</span></span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zZ7kZPg1ZgH7"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zOkxaonnnpn5">Sublease rent due from Hostastay</span></span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zLo640MDIlU4" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,548</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zwGmcHjYG1Qh" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,790</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20220630_zuOzVTTrLgc4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,548</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231_zeL2k0s8morf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,004</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related party balances</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount due to related parties</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Related</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Party</b></span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left">DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center"><span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdOneMember_zAYud4EUGvLd" title="Relationship"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdOneMember_zmF94Tp7oVJ8" title="Relationship">Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC</span></span></td><td style="width: 2%"> </td> <td style="vertical-align: top; width: 20%; text-align: center"><span id="xdx_909_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdOneMember_z7AzfPCSMKkl" title="Nature"><span id="xdx_90D_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdOneMember_zLR6ubXuEiD2" title="Nature">Rental due and expenses paid by DSYWLC</span></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AccountsPayableOtherCurrent_iI_pp0p0_c20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdOneMember_zi492XGxms2h" style="width: 15%; text-align: right" title="Amount due to a Related Party">2,015</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AccountsPayableOtherCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdOneMember_zyikwiNGXE6a" style="width: 15%; text-align: right" title="Amount due to a Related Party">         <span style="-sec-ix-hidden: xdx2ixbrl1258">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Beauty Sdn Bhd (“DSY Beauty”)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90B_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zRS96jDpqaPa" title="Relationship"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zW6Qb87b0CUj">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_909_ecustom--RelatedPartiesNatureDescription_dxL_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zjWFDKBLkYf5" title="::XDX::Purchases%20of%20beauty%20products"><span style="-sec-ix-hidden: xdx2ixbrl1262">Purchase</span><span style="font-family: Times New Roman, Times, Serif"> </span>of beauty products</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccountsPayableOtherCurrent_iI_pp0p0_c20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zYwJ7iubB1k7" style="border-bottom: Black 1.5pt solid; text-align: right">67</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AccountsPayableOtherCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z1otoabIhode" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1264">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AccountsPayableOtherCurrent_iI_pp0p0_c20220630_zwrVWP4vd4Oc" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount due to a Related Party">2,082</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccountsPayableOtherCurrent_iI_pp0p0_c20211231_zZj7oGnv8Mm5" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount due to a Related Party"><span style="-sec-ix-hidden: xdx2ixbrl1268">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related party transactions</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchases</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center"><span id="xdx_90A_ecustom--RelatedPartiesRelationshipsDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zATie1UK2PA7" title="Relationship"><span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_z4lgN89YwBQ1" title="Relationship">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</span></span></td><td style="width: 2%"> </td> <td style="vertical-align: top; width: 20%; text-align: center"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zU1WCL2BTWWk" title="Nature"><span id="xdx_90D_ecustom--RelatedPartiesNatureDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zEYMgRcdB8r9">Purchases of products for the provision of complementary health therapies</span></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zRejumKhhat8" style="width: 15%; text-align: right" title="Purchases">63,142</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zU8uWg9GDQki" style="width: 15%; text-align: right" title="Purchases">    <span style="-sec-ix-hidden: xdx2ixbrl1279">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (“DSY Beauty”)</td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--RelatedPartiesRelationshipsDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z8gEYBAE0Fs"><span id="xdx_90F_ecustom--RelatedPartiesRelationshipsDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z6x2LEciVhYd">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td> </td> <td style="vertical-align: top; text-align: center"><span id="xdx_903_ecustom--RelatedPartiesNatureDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zBFPpIxpEcLb"><span id="xdx_909_ecustom--RelatedPartiesNatureDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zW5tAOdl5Gz5">Purchases of beauty products</span></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zqeazXuuSwO6" style="text-align: right">395</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zHSZmXofHp1l" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1285">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness &amp; Longevity Center Sdn Bhd (“DSYWLC”)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90F_ecustom--RelatedPartiesRelationshipsDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_z364vAcCCzih"><span id="xdx_90A_ecustom--RelatedPartiesRelationshipsDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zpnsfB8eLjPj">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90D_ecustom--RelatedPartiesNatureDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zie9wGXr9U2d"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_ztIX6WXdZ8fg">Purchases of products for the provision of complementary health therapies</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zUo6xxUMS9h4" style="border-bottom: Black 1.5pt solid; text-align: right">127</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_z84BhmrlMfk2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1291">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220401__20220630_zbucRa95d489" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchases">63,664</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210401__20210630_z9VFSDwHd2Ei" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchases"><span style="-sec-ix-hidden: xdx2ixbrl1295">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related party transactions</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchases</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center"><span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zQ877Zd1pe37" title="Relationship"><span id="xdx_907_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zFO6rUa2hKM4" title="Relationship">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</span></span></td><td style="width: 2%"> </td> <td style="vertical-align: top; width: 20%; text-align: center"><span id="xdx_90D_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_ziLbuvUicIQg" title="Nature"><span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zL9WGi9bH23k" title="Nature">Purchases of products for the provision of complementary health therapies</span></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zc90hAxSFjUh" style="width: 15%; text-align: right" title="Purchases">74,909</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zYP5EJG1uY46" style="width: 15%; text-align: right" title="Purchases">    <span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (“DSY Beauty”)</td><td> </td> <td style="text-align: center"><span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zWb6iLceyMA9"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zpSIzKoMcaJ1">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td> </td> <td style="vertical-align: top; text-align: center"><span id="xdx_906_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zP78PEkiQnhe"><span id="xdx_902_ecustom--RelatedPartiesNatureDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_z7j5bOoSrRUa">Purchases of beauty products</span></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zTJIUTrw9Rlh" style="text-align: right">395</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zC3y3e5LxMj6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1313">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness &amp; Longevity Center Sdn Bhd (“DSYWLC”)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90B_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zIEgkfeYQif6"><span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zmXJpJ2xOUN5">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zZ02FUT1YN1k"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zerg3G5LA2Kc">Purchases of products for the provision of complementary health therapies</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zjWUsdmLMrzl" style="border-bottom: Black 1.5pt solid; text-align: right">127</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zVaB0KzjCuu8" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1319">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20220630_zS3eaq3JLOri" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchases">75,431</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20210630_zDeDiqDv60sg" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchases"><span style="-sec-ix-hidden: xdx2ixbrl1323">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AGAPE ATP CORPORATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Related party transactions</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other purchases</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left; padding-bottom: 1.5pt">DSY Beauty Sdn Bhd (“DSY Beauty”)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zkEWSDLwvHt9"><span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zajkrx5x7nxf">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90F_ecustom--RelatedPartiesNatureDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z4pT9bcRhGGk"><span id="xdx_903_ecustom--RelatedPartiesNatureDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z6Y7ktF1C3X">Purchases of beauty products</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zDKIQA8bOfE2" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Other purchases">69</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zJGaVE2Ayphg" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1330">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220401__20220630_zaqqkTW5b2vf" style="border-bottom: Black 2.5pt double; text-align: right">69</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210401__20210630_z2odB3oqNoJh" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1332">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left; padding-bottom: 1.5pt">DSY Beauty Sdn Bhd (“DSY Beauty”)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zifGCrG5d5Wb"><span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zCWCm0N2K6Je">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zWeTTJ79Fgv2"><span id="xdx_908_ecustom--RelatedPartiesNatureDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zvu097LjVqc3">Purchases of beauty products</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zxqpJI47M0f2" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right">69</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zh7Wo4NOTfMk" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1338">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20220630_zZPHQhrhv0A7" style="border-bottom: Black 2.5pt double; text-align: right">69</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20210630_zWrGzkTo0oA7" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left; padding-bottom: 1.5pt">Mr. How Kok Choong</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zaBtwJlIagz7" title="Relationship"><span id="xdx_90F_ecustom--RelatedPartiesRelationshipsDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zmCD1WHSdVlg" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_ecustom--RelatedPartiesNatureDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_ztvfmjjrK5Ti" title="Nature"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zcZZIsBWUH29" title="Nature">Commission expense</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--SalesCommissionsAndFee_pp0p0_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zqL5DH5dfHMg" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Commission">2,443</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--SalesCommissionsAndFee_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zAjxoXN7Dcv4" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Commission">    <span style="-sec-ix-hidden: xdx2ixbrl1352">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--SalesCommissionsAndFee_c20220401__20220630_zptU0VzdxhMi" style="border-bottom: Black 2.5pt double; text-align: right" title="Commission">2,443</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--SalesCommissionsAndFee_pdp0_c20210401__20210630_zaxnDvWjY1D5" style="border-bottom: Black 2.5pt double; text-align: right" title="Commission"><span style="-sec-ix-hidden: xdx2ixbrl1356">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left; padding-bottom: 1.5pt">Mr. How Kok Choong</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_907_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zA9X7SRbrHH2" title="Relationship"><span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zfoW8rTuHtEe" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_902_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zKQZcyX7qxG5" title="Nature"><span id="xdx_908_ecustom--RelatedPartiesNatureDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_z7fZLEBvrnDj" title="Nature">Commission expense</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--SalesCommissionsAndFee_pp0p0_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zIm0wMyfmpSb" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Commission">5,148</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--SalesCommissionsAndFee_pp0p0_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zW0zEPmdULF8" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Commission">   <span style="-sec-ix-hidden: xdx2ixbrl1368">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--SalesCommissionsAndFee_c20220101__20220630_z42HboRTgxKh" style="border-bottom: Black 2.5pt double; text-align: right" title="Commission">5,148</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--SalesCommissionsAndFee_pdp0_c20210101__20210630_zsA3WWy6Hi67" style="border-bottom: Black 2.5pt double; text-align: right" title="Commission"><span style="-sec-ix-hidden: xdx2ixbrl1372">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related party transactions</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Office rental expense</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left; padding-bottom: 1.5pt">DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zqFDIVGx3wy8" title="Relationship"><span id="xdx_907_ecustom--RelatedPartiesRelationshipsDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zUYtwVnVtDya" title="Relationship">Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_907_ecustom--RelatedPartiesNatureDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zxci2vuIup2l" title="Nature"><span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zhCxjpgygur" title="Nature">Office rental expense</span></span> <br/></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--RelatedPartyOfficeRentalExpenses_pp0p0_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zJPTpZvKI4xd" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Office rental expense">5,602</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--RelatedPartyOfficeRentalExpenses_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zCbdAoIBmdA7" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Office rental expense">   <span style="-sec-ix-hidden: xdx2ixbrl1384">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--RelatedPartyOfficeRentalExpenses_pp0p0_c20220401__20220630_zMSdIAqrQPp2" style="border-bottom: Black 2.5pt double; text-align: right" title="Office rental expense">5,602</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--RelatedPartyOfficeRentalExpenses_pp0p0_c20210401__20210630_zn7UC0Mgr6F6" style="border-bottom: Black 2.5pt double; text-align: right" title="Office rental expense"><span style="-sec-ix-hidden: xdx2ixbrl1388">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left; padding-bottom: 1.5pt">DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zfAILsGpZ5Mi" title="Relationship"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zagFZQRbVqAb" title="Relationship">Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_907_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_z9CKF8pjLLd6" title="Nature"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zk06uJiPUjnc" title="Nature">Office rental expense</span></span> <br/></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--RelatedPartyOfficeRentalExpenses_pp0p0_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zMS5qO2Tha9g" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Office rental expense">11,203</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--RelatedPartyOfficeRentalExpenses_pp0p0_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_z2thT02Lzfxf" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Office rental expense">   <span style="-sec-ix-hidden: xdx2ixbrl1400">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--RelatedPartyOfficeRentalExpenses_pp0p0_c20220101__20220630_zXBmbrLksnt8" style="border-bottom: Black 2.5pt double; text-align: right" title="Office rental expense">11,203</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--RelatedPartyOfficeRentalExpenses_pp0p0_c20210101__20210630_zXKSFVTE5a27" style="border-bottom: Black 2.5pt double; text-align: right" title="Office rental expense"><span style="-sec-ix-hidden: xdx2ixbrl1404">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related party transactions</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other income</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left; padding-bottom: 1.5pt">Hostastay Sdn. Bhd. (“Hostastay”)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z01fMQcgMKIf"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zPCUcsXE0Poi">Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zzasBohWQYVl"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zVBAEFwrzJ67">Sublease rental income due from Hostastay</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--RelatedPartyOtherIncome_pp0p0_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zcaF8vfY58U6" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Other income"><span style="-sec-ix-hidden: xdx2ixbrl1410">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--RelatedPartyOtherIncome_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zBSGRqUQV9zd" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right">1,458</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--RelatedPartyOtherIncome_pp0p0_c20220401__20220630_zJHAoLPxhc5f" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1412">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--RelatedPartyOtherIncome_pp0p0_c20210401__20210630_zRj8l6Z3mhZ" style="border-bottom: Black 2.5pt double; text-align: right">1,458</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left; padding-bottom: 1.5pt">Hostastay Sdn. Bhd. (“Hostastay”)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zC1RISIKePSj"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zLouV4UJEHca">Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zuLrv2zTUrL3"><span id="xdx_90F_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zGdx2U5Q72e1">Sublease rental income due from Hostastay</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--RelatedPartyOtherIncome_pp0p0_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zzvHXJ8yrCFb" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1418">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--RelatedPartyOtherIncome_pp0p0_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zoMNbGicshy3" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right">2,929</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--RelatedPartyOtherIncome_pp0p0_c20220101__20220630_zccv7GaGDDY6" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1420">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--RelatedPartyOtherIncome_pp0p0_c20210101__20210630_zaIpMfkclXub" style="border-bottom: Black 2.5pt double; text-align: right">2,929</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zqbn5RbXXB37" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_899_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zrJMZ5VVnTG3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zl1BjMbSkt2f" style="display: none">SCHEDULE OF RELATED PARTIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Name of Related<br/> Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center"><span id="xdx_902_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zhrsPrwuOTre" title="Relationship"><span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zyqVWSh77tr3" title="Relationship">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</span></span></td><td style="width: 2%"> </td> <td style="vertical-align: top; width: 20%; text-align: center"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_z347MdDyzaX8" title="Nature"><span id="xdx_90E_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zXosDkvSqls8" title="Nature">Purchases of products for the provision of complementary health therapies</span></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zByO0BCj0tCk" style="width: 15%; text-align: right" title="Accounts payable">14,322</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zBVvm5HZyA3b" style="width: 15%; text-align: right">         <span style="-sec-ix-hidden: xdx2ixbrl1220">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdMember_zCM08SukNEf6"><span id="xdx_90F_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdMember_zjXzgTU3YH15">Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdMember_zYyzNsUqHNv6"><span id="xdx_906_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdMember_zweDq5YbXape">Purchases of products for the provision of complementary health therapies</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdMember_zfKNAdv87Dfj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accounts payable">85</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdMember_zrxvvotGQPo1" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1227">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20220630_z0osPnVyBfE4" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable">14,407</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231_zI2772tO3mWc" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1230">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount due from related parties</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Related</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Party</b></span></p></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relationship</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nature</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2022</b></span></p></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of <br/> December 31, 2021</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape ATP (Asia) Limited (“AATP Asia”)</span></td><td style="width: 2%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top; width: 20%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zCftLCweCdX5"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zyFwjuBFbzni">Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia</span></span></span></td><td style="width: 2%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top; width: 20%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zC1pLuuwzG93"><span id="xdx_90D_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zE5jb96TB6uk">Expenses paid for AATP Asia</span></span></span></td><td style="width: 2%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zJAyrpfYqxnl" style="width: 15%; font-size: 10pt; text-align: right" title="Due from related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1236">-</span></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 2%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zu9pNw6gG3J4" style="width: 15%; font-size: 10pt; text-align: right" title="Due from related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,214</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hostastay Sdn. Bhd. (“Hostastay”)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zPDYb6f7i78e"><span id="xdx_907_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zPtlncmsn4Cc">Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021</span></span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zZ7kZPg1ZgH7"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zOkxaonnnpn5">Sublease rent due from Hostastay</span></span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zLo640MDIlU4" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,548</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zwGmcHjYG1Qh" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,790</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20220630_zuOzVTTrLgc4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,548</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231_zeL2k0s8morf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,004</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related party balances</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount due to related parties</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Related</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Party</b></span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left">DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center"><span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdOneMember_zAYud4EUGvLd" title="Relationship"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdOneMember_zmF94Tp7oVJ8" title="Relationship">Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC</span></span></td><td style="width: 2%"> </td> <td style="vertical-align: top; width: 20%; text-align: center"><span id="xdx_909_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdOneMember_z7AzfPCSMKkl" title="Nature"><span id="xdx_90D_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdOneMember_zLR6ubXuEiD2" title="Nature">Rental due and expenses paid by DSYWLC</span></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AccountsPayableOtherCurrent_iI_pp0p0_c20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdOneMember_zi492XGxms2h" style="width: 15%; text-align: right" title="Amount due to a Related Party">2,015</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AccountsPayableOtherCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdOneMember_zyikwiNGXE6a" style="width: 15%; text-align: right" title="Amount due to a Related Party">         <span style="-sec-ix-hidden: xdx2ixbrl1258">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Beauty Sdn Bhd (“DSY Beauty”)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90B_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zRS96jDpqaPa" title="Relationship"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zW6Qb87b0CUj">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_909_ecustom--RelatedPartiesNatureDescription_dxL_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zjWFDKBLkYf5" title="::XDX::Purchases%20of%20beauty%20products"><span style="-sec-ix-hidden: xdx2ixbrl1262">Purchase</span><span style="font-family: Times New Roman, Times, Serif"> </span>of beauty products</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccountsPayableOtherCurrent_iI_pp0p0_c20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zYwJ7iubB1k7" style="border-bottom: Black 1.5pt solid; text-align: right">67</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AccountsPayableOtherCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z1otoabIhode" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1264">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AccountsPayableOtherCurrent_iI_pp0p0_c20220630_zwrVWP4vd4Oc" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount due to a Related Party">2,082</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccountsPayableOtherCurrent_iI_pp0p0_c20211231_zZj7oGnv8Mm5" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount due to a Related Party"><span style="-sec-ix-hidden: xdx2ixbrl1268">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related party transactions</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchases</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center"><span id="xdx_90A_ecustom--RelatedPartiesRelationshipsDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zATie1UK2PA7" title="Relationship"><span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_z4lgN89YwBQ1" title="Relationship">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</span></span></td><td style="width: 2%"> </td> <td style="vertical-align: top; width: 20%; text-align: center"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zU1WCL2BTWWk" title="Nature"><span id="xdx_90D_ecustom--RelatedPartiesNatureDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zEYMgRcdB8r9">Purchases of products for the provision of complementary health therapies</span></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zRejumKhhat8" style="width: 15%; text-align: right" title="Purchases">63,142</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zU8uWg9GDQki" style="width: 15%; text-align: right" title="Purchases">    <span style="-sec-ix-hidden: xdx2ixbrl1279">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (“DSY Beauty”)</td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--RelatedPartiesRelationshipsDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z8gEYBAE0Fs"><span id="xdx_90F_ecustom--RelatedPartiesRelationshipsDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z6x2LEciVhYd">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td> </td> <td style="vertical-align: top; text-align: center"><span id="xdx_903_ecustom--RelatedPartiesNatureDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zBFPpIxpEcLb"><span id="xdx_909_ecustom--RelatedPartiesNatureDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zW5tAOdl5Gz5">Purchases of beauty products</span></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zqeazXuuSwO6" style="text-align: right">395</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zHSZmXofHp1l" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1285">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness &amp; Longevity Center Sdn Bhd (“DSYWLC”)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90F_ecustom--RelatedPartiesRelationshipsDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_z364vAcCCzih"><span id="xdx_90A_ecustom--RelatedPartiesRelationshipsDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zpnsfB8eLjPj">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90D_ecustom--RelatedPartiesNatureDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zie9wGXr9U2d"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_ztIX6WXdZ8fg">Purchases of products for the provision of complementary health therapies</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zUo6xxUMS9h4" style="border-bottom: Black 1.5pt solid; text-align: right">127</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_z84BhmrlMfk2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1291">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220401__20220630_zbucRa95d489" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchases">63,664</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210401__20210630_z9VFSDwHd2Ei" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchases"><span style="-sec-ix-hidden: xdx2ixbrl1295">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related party transactions</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchases</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center"><span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zQ877Zd1pe37" title="Relationship"><span id="xdx_907_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zFO6rUa2hKM4" title="Relationship">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</span></span></td><td style="width: 2%"> </td> <td style="vertical-align: top; width: 20%; text-align: center"><span id="xdx_90D_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_ziLbuvUicIQg" title="Nature"><span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zL9WGi9bH23k" title="Nature">Purchases of products for the provision of complementary health therapies</span></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zc90hAxSFjUh" style="width: 15%; text-align: right" title="Purchases">74,909</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zYP5EJG1uY46" style="width: 15%; text-align: right" title="Purchases">    <span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (“DSY Beauty”)</td><td> </td> <td style="text-align: center"><span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zWb6iLceyMA9"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zpSIzKoMcaJ1">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td> </td> <td style="vertical-align: top; text-align: center"><span id="xdx_906_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zP78PEkiQnhe"><span id="xdx_902_ecustom--RelatedPartiesNatureDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_z7j5bOoSrRUa">Purchases of beauty products</span></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zTJIUTrw9Rlh" style="text-align: right">395</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zC3y3e5LxMj6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1313">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness &amp; Longevity Center Sdn Bhd (“DSYWLC”)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90B_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zIEgkfeYQif6"><span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zmXJpJ2xOUN5">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zZ02FUT1YN1k"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zerg3G5LA2Kc">Purchases of products for the provision of complementary health therapies</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zjWUsdmLMrzl" style="border-bottom: Black 1.5pt solid; text-align: right">127</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zVaB0KzjCuu8" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1319">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20220630_zS3eaq3JLOri" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchases">75,431</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20210630_zDeDiqDv60sg" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchases"><span style="-sec-ix-hidden: xdx2ixbrl1323">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AGAPE ATP CORPORATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Related party transactions</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other purchases</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left; padding-bottom: 1.5pt">DSY Beauty Sdn Bhd (“DSY Beauty”)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zkEWSDLwvHt9"><span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zajkrx5x7nxf">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90F_ecustom--RelatedPartiesNatureDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z4pT9bcRhGGk"><span id="xdx_903_ecustom--RelatedPartiesNatureDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z6Y7ktF1C3X">Purchases of beauty products</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zDKIQA8bOfE2" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Other purchases">69</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zJGaVE2Ayphg" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1330">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220401__20220630_zaqqkTW5b2vf" style="border-bottom: Black 2.5pt double; text-align: right">69</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210401__20210630_z2odB3oqNoJh" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1332">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left; padding-bottom: 1.5pt">DSY Beauty Sdn Bhd (“DSY Beauty”)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zifGCrG5d5Wb"><span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zCWCm0N2K6Je">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zWeTTJ79Fgv2"><span id="xdx_908_ecustom--RelatedPartiesNatureDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zvu097LjVqc3">Purchases of beauty products</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zxqpJI47M0f2" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right">69</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zh7Wo4NOTfMk" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1338">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20220630_zZPHQhrhv0A7" style="border-bottom: Black 2.5pt double; text-align: right">69</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20210630_zWrGzkTo0oA7" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left; padding-bottom: 1.5pt">Mr. How Kok Choong</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zaBtwJlIagz7" title="Relationship"><span id="xdx_90F_ecustom--RelatedPartiesRelationshipsDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zmCD1WHSdVlg" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_ecustom--RelatedPartiesNatureDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_ztvfmjjrK5Ti" title="Nature"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zcZZIsBWUH29" title="Nature">Commission expense</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--SalesCommissionsAndFee_pp0p0_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zqL5DH5dfHMg" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Commission">2,443</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--SalesCommissionsAndFee_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zAjxoXN7Dcv4" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Commission">    <span style="-sec-ix-hidden: xdx2ixbrl1352">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--SalesCommissionsAndFee_c20220401__20220630_zptU0VzdxhMi" style="border-bottom: Black 2.5pt double; text-align: right" title="Commission">2,443</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--SalesCommissionsAndFee_pdp0_c20210401__20210630_zaxnDvWjY1D5" style="border-bottom: Black 2.5pt double; text-align: right" title="Commission"><span style="-sec-ix-hidden: xdx2ixbrl1356">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left; padding-bottom: 1.5pt">Mr. How Kok Choong</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_907_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zA9X7SRbrHH2" title="Relationship"><span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zfoW8rTuHtEe" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_902_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zKQZcyX7qxG5" title="Nature"><span id="xdx_908_ecustom--RelatedPartiesNatureDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_z7fZLEBvrnDj" title="Nature">Commission expense</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--SalesCommissionsAndFee_pp0p0_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zIm0wMyfmpSb" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Commission">5,148</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--SalesCommissionsAndFee_pp0p0_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zW0zEPmdULF8" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Commission">   <span style="-sec-ix-hidden: xdx2ixbrl1368">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--SalesCommissionsAndFee_c20220101__20220630_z42HboRTgxKh" style="border-bottom: Black 2.5pt double; text-align: right" title="Commission">5,148</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--SalesCommissionsAndFee_pdp0_c20210101__20210630_zsA3WWy6Hi67" style="border-bottom: Black 2.5pt double; text-align: right" title="Commission"><span style="-sec-ix-hidden: xdx2ixbrl1372">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related party transactions</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Office rental expense</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left; padding-bottom: 1.5pt">DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zqFDIVGx3wy8" title="Relationship"><span id="xdx_907_ecustom--RelatedPartiesRelationshipsDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zUYtwVnVtDya" title="Relationship">Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_907_ecustom--RelatedPartiesNatureDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zxci2vuIup2l" title="Nature"><span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zhCxjpgygur" title="Nature">Office rental expense</span></span> <br/></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--RelatedPartyOfficeRentalExpenses_pp0p0_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zJPTpZvKI4xd" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Office rental expense">5,602</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--RelatedPartyOfficeRentalExpenses_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zCbdAoIBmdA7" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Office rental expense">   <span style="-sec-ix-hidden: xdx2ixbrl1384">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--RelatedPartyOfficeRentalExpenses_pp0p0_c20220401__20220630_zMSdIAqrQPp2" style="border-bottom: Black 2.5pt double; text-align: right" title="Office rental expense">5,602</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--RelatedPartyOfficeRentalExpenses_pp0p0_c20210401__20210630_zn7UC0Mgr6F6" style="border-bottom: Black 2.5pt double; text-align: right" title="Office rental expense"><span style="-sec-ix-hidden: xdx2ixbrl1388">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left; padding-bottom: 1.5pt">DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zfAILsGpZ5Mi" title="Relationship"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zagFZQRbVqAb" title="Relationship">Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_907_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_z9CKF8pjLLd6" title="Nature"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zk06uJiPUjnc" title="Nature">Office rental expense</span></span> <br/></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--RelatedPartyOfficeRentalExpenses_pp0p0_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zMS5qO2Tha9g" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Office rental expense">11,203</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--RelatedPartyOfficeRentalExpenses_pp0p0_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_z2thT02Lzfxf" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Office rental expense">   <span style="-sec-ix-hidden: xdx2ixbrl1400">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--RelatedPartyOfficeRentalExpenses_pp0p0_c20220101__20220630_zXBmbrLksnt8" style="border-bottom: Black 2.5pt double; text-align: right" title="Office rental expense">11,203</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--RelatedPartyOfficeRentalExpenses_pp0p0_c20210101__20210630_zXKSFVTE5a27" style="border-bottom: Black 2.5pt double; text-align: right" title="Office rental expense"><span style="-sec-ix-hidden: xdx2ixbrl1404">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related party transactions</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other income</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left; padding-bottom: 1.5pt">Hostastay Sdn. Bhd. (“Hostastay”)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z01fMQcgMKIf"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zPCUcsXE0Poi">Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zzasBohWQYVl"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zVBAEFwrzJ67">Sublease rental income due from Hostastay</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--RelatedPartyOtherIncome_pp0p0_c20220401__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zcaF8vfY58U6" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right" title="Other income"><span style="-sec-ix-hidden: xdx2ixbrl1410">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--RelatedPartyOtherIncome_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zBSGRqUQV9zd" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right">1,458</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--RelatedPartyOtherIncome_pp0p0_c20220401__20220630_zJHAoLPxhc5f" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1412">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--RelatedPartyOtherIncome_pp0p0_c20210401__20210630_zRj8l6Z3mhZ" style="border-bottom: Black 2.5pt double; text-align: right">1,458</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 18%; text-align: left; padding-bottom: 1.5pt">Hostastay Sdn. Bhd. (“Hostastay”)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zC1RISIKePSj"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zLouV4UJEHca">Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zuLrv2zTUrL3"><span id="xdx_90F_ecustom--RelatedPartiesNatureDescription_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zGdx2U5Q72e1">Sublease rental income due from Hostastay</span></span></td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--RelatedPartyOtherIncome_pp0p0_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zzvHXJ8yrCFb" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1418">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--RelatedPartyOtherIncome_pp0p0_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zoMNbGicshy3" style="border-bottom: Black 1.5pt solid; width: 15%; text-align: right">2,929</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--RelatedPartyOtherIncome_pp0p0_c20220101__20220630_zccv7GaGDDY6" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1420">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--RelatedPartyOtherIncome_pp0p0_c20210101__20210630_zaIpMfkclXub" style="border-bottom: Black 2.5pt double; text-align: right">2,929</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd Purchases of products for the provision of complementary health therapies Purchases of products for the provision of complementary health therapies 14322 Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC Purchases of products for the provision of complementary health therapies Purchases of products for the provision of complementary health therapies 85 14407 Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia Expenses paid for AATP Asia Expenses paid for AATP Asia 2214 Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021 Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021 Sublease rent due from Hostastay Sublease rent due from Hostastay 4548 4790 4548 7004 Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC Rental due and expenses paid by DSYWLC Rental due and expenses paid by DSYWLC 2015 The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd 67 2082 The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd Purchases of products for the provision of complementary health therapies Purchases of products for the provision of complementary health therapies 63142 The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd Purchases of beauty products Purchases of beauty products 395 Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC. Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC. Purchases of products for the provision of complementary health therapies Purchases of products for the provision of complementary health therapies 127 63664 The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd Purchases of products for the provision of complementary health therapies Purchases of products for the provision of complementary health therapies 74909 The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd Purchases of beauty products Purchases of beauty products 395 Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC. Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC. Purchases of products for the provision of complementary health therapies Purchases of products for the provision of complementary health therapies 127 75431 The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd Purchases of beauty products Purchases of beauty products 69 69 The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd Purchases of beauty products Purchases of beauty products 69 69 Mr. How Kok Choong, the CEO and director of the Company Mr. How Kok Choong, the CEO and director of the Company Commission expense Commission expense 2443 2443 Mr. How Kok Choong, the CEO and director of the Company Mr. How Kok Choong, the CEO and director of the Company Commission expense Commission expense 5148 5148 Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC Office rental expense Office rental expense 5602 5602 Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd is also a director of DSYWLC Office rental expense Office rental expense 11203 11203 Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021 Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021 Sublease rental income due from Hostastay Sublease rental income due from Hostastay 1458 1458 Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021 Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021 Sublease rental income due from Hostastay Sublease rental income due from Hostastay 2929 2929 <p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zHhXfgCkRkJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14. <span id="xdx_82D_z64K7lChQxyb">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Preferred stock</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2022, and December 31, 2021, there were <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20220630_z0UKcfbvgYH8" title="Preferred stock, shares authorized"><span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211231_zZRiPZpev4Ec" title="Preferred stock, shares authorized">200,000,000</span></span> preferred stocks authorized but <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_dn_c20220630_zbYOY6fusJHi" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_dn_c20211231_zP7UEjagEyB1" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20220630_zArCkjhQFCGl" title="Preferred stock, shares outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20211231_zpNdzDioY6Zb" title="Preferred stock, shares outstanding">none</span></span></span></span> were issued and outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Common stock</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2022, and December 31, 2021, there were <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20220630_zT797Jb2Nzk6" title="Common stock, shares authorized"><span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20211231_z26YcuChpSF6" title="Common stock, shares authorized">1,000,000,000</span></span> common stocks authorized, <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20220630_z5LhKLiCpRCf" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20220630_zd2h3eus2rLh" title="Common stock, shares outstanding">75,452,012</span></span> and <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_c20211231_zKuYTxvRhlef" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231_zRxhGnv5apr" title="Common stock, shares outstanding">290,460,047</span></span> shares issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A share forfeiture agreement (the “Share Forfeiture Agreement”) dated January 20, 2022, between the Company and Mr. How Kok Choong, the CEO and director of the Company, pursuant to which Mr. How Kok Choong agreed to forfeit <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_pid_c20220101__20220630__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongTalentLimitedMember_z30Nt5K1ZNEd" title="Number of shares forfeited">215,008,035</span> shares of common stock of the Company. As a result, the outstanding shares was reduced by <span id="xdx_90A_ecustom--ReductionInCommonStockOutstanding_pid_c20220101__20220630__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember_zyxsWzwajvCa" title="Reduction in outstanding shares">215,008,035</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20210101__20211231_z1TAXauibjle" title="Potentially dilutive securities outstanding"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20220101__20220630_zCdbDftbWcj5" title="Potentially dilutive securities outstanding">no</span></span> stock options, warrants or other potentially dilutive securities outstanding as of June 30, 2022 and December 31, 2021. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 200000000 200000000 0 0 0 0 1000000000 1000000000 75452012 75452012 290460047 290460047 215008035 215008035 0 0 <p id="xdx_80C_eus-gaap--MinorityInterestDisclosureTextBlock_zpH3Ly5KyuV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15. <span id="xdx_82C_zX6r6K4xexZ3">NON-CONTROLLING INTEREST</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_896_ecustom--ScheduleOfNonControllingInterestTableTextBlock_z2O65kWnU3E5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s non-controlling interest consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zu1CsP5KRSB3" style="display: none">SCHEDULE OF NON CONTROLLING INTEREST</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20220630_zNE8QljBNby7" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20211231_zzu4NKSgwcw3" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">DSY Wellness:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--NonControllingInterestPaidinCapital_iI_maNCINCzwzX_maNCINCzgCA_zP6sPgj2QbC2" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Paid-in capital</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">97</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">97</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--NonControllingInterestAccumulatedDeficit_iI_maNCINCzwzX_maNCINCzgCA_zb1BDRtySdT4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Retained earnings (Accumulated deficit)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,773</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(436</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--NonControllingInterestAccumulatedOtherComprehensiveIncome_iI_maNCINCzwzX_maNCINCzgCA_zuWOyjFbOBva" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated other comprehensive (loss) income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(269</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--NonControllingInterestNonControllingInterestGross_iTI_mtNCINCzgCA_zvloSPzHJpv3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Non Controlling interest Gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,601</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(336</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_ecustom--NonControllingInterestAsl_iI_maMIzbTf_zbOHrAITYVt9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">ASL</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1473">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1474">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--MinorityInterest_iI_z44kz4dNX1Yc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,601</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(336</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A4_zrLzWSPumF55" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_896_ecustom--ScheduleOfNonControllingInterestTableTextBlock_z2O65kWnU3E5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s non-controlling interest consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zu1CsP5KRSB3" style="display: none">SCHEDULE OF NON CONTROLLING INTEREST</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20220630_zNE8QljBNby7" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20211231_zzu4NKSgwcw3" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">DSY Wellness:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--NonControllingInterestPaidinCapital_iI_maNCINCzwzX_maNCINCzgCA_zP6sPgj2QbC2" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Paid-in capital</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">97</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">97</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--NonControllingInterestAccumulatedDeficit_iI_maNCINCzwzX_maNCINCzgCA_zb1BDRtySdT4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Retained earnings (Accumulated deficit)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,773</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(436</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--NonControllingInterestAccumulatedOtherComprehensiveIncome_iI_maNCINCzwzX_maNCINCzgCA_zuWOyjFbOBva" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated other comprehensive (loss) income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(269</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--NonControllingInterestNonControllingInterestGross_iTI_mtNCINCzgCA_zvloSPzHJpv3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Non Controlling interest Gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,601</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(336</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_ecustom--NonControllingInterestAsl_iI_maMIzbTf_zbOHrAITYVt9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">ASL</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1473">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1474">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--MinorityInterest_iI_z44kz4dNX1Yc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,601</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(336</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 97 97 10773 -436 -269 3 10601 -336 10601 -336 <p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_z2Ylzwu7DZak" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16. <span id="xdx_823_z8a7u4HYvYa">INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_z9jboVTISCM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The United States and foreign components of loss before income taxes were comprised of the following:<b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> <span id="xdx_8B4_zQ8gSp4puwJc" style="display: none">SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20220401__20220630_zfAl5oKMFxy5" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20210401__20210630_z06O6xF8vv13" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20220101__20220630_zC1fW8rZZDKk" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20210101__20210630_z9YPrB5GCjmh" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tax jurisdictions from:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zOB8g85tMnPd" style="vertical-align: bottom; background-color: White"> <td style="width: 44%; text-align: left">Local – United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(187,379</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(96,370</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(293,804</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(204,295</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--MY_zn01OaYrdaI" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Foreign – Malaysia</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(189,395</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(177,983</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(354,459</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(469,675</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--HK_zi0rZzPQRRs9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Foreign – Hong Kong</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,178</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(363,901</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(45,847</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(291,814</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_z9aYOP7lf7nh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Loss before income tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(403,952</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(638,254</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(694,110</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(965,784</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A0_zeCipCGF0L0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zAS3cfoZd9Cg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provision for income taxes consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zBKI9bqrcVQh" style="display: none">SCHEDULE OF PROVISION FOR INCOME TAX</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20220401__20220630_zTgbuQl4t875" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20210401__20210630_zMrEB1wZ2dEc" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20220101__20220630_z1zZZJi0BbH" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20210101__20210630_zBfZM0VgGr64" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zQQepApzpBe6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maITEBzhRF_zn8dSGRL88K6" style="vertical-align: bottom; background-color: White"> <td style="width: 44%">- Local</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1510">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(22,205</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1512">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(22,205</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maITEBzhRF_zfpz4T8OaCCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>- Foreign</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(392</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(14,461</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,680</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(41,185</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zbZxxKpBOgt" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maITEBzhRF_z8G0Cii9egp3" style="vertical-align: bottom; background-color: White"> <td>- Local</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1525">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1526">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1527">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1528">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maITEBzhRF_zGzBzFT5AMyh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">- Foreign</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1530">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,695</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1532">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,299</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iNT_pp0p0_di_mtITEBzhRF_zxPvOEVjs853" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Provision for income tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(392</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,971</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,680</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(10,091</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A2_zc49vqAH7gvj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The effective tax rate in the periods presented is the result of the mix of income earned in various tax jurisdictions that apply a broad range of income tax rates. The Company and its subsidiary that operate in various countries: United States, Malaysia (including Labuan) and Hong Kong that are subject to taxes in the jurisdictions in which they operate, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16. INCOME TAXES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>United States of America</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape ATP Corporation was incorporated in the State of Nevada and is subject to the tax laws of the United States of America with a corporate tax rate of <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20220630__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zf5zRtkA0ZAh" title="Tax percentage">21</span>% on its taxable income. Agape ATP Corporation also subject to controlled foreign corporations Subpart F income (“Subpart F”) tax, which is a tax primarily on passive income from controlled foreign corporations with a tax rate of <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20220630__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z0kkwLf1onBb" title="Tax percentage">35</span>%. <span id="xdx_90D_ecustom--TaxRateDescription_c20220101__20220630_zUGduiPnI73b" title="Tax rate description">In addition, the Tax Cuts and Jobs Act imposed a global intangible low-taxed income (“GILTI”) tax, which is a tax on certain off-shore earnings at an effective rate of 10.5% for tax years (50% deduction of the current enacted tax rate of 21%) with a partial offset for 80% foreign tax credits. If the foreign tax rate is 13.125% or higher, there will be no U.S. corporate tax after the 80% foreign tax credits are applied</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three and six months ended June 30, 2022 and 2021, the Company’s foreign subsidiaries did not generate any income that are subject to Subpart F tax and GILTI tax.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2022 and December 31, 2021, the operations in the United States of America incurred approximately $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20220630__srt--StatementGeographicalAxis__country--US_zIG1w5bAGbSh" title="Operating loss">914,000</span> and $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--US_zjuE2GV43NV4" title="Operating loss">620,000</span>, respectively, of cumulative net operating losses (“NOL”) which can be carried forward to offset future taxable income or Subpart F and GILTI taxes. These balances can be carried forward indefinitely. The deferred tax valuation allowance as of June 30, 2022 and December 31, 2021 were approximately $<span id="xdx_909_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20220630__srt--StatementGeographicalAxis__country--US_zc78pmA8Y4qh" title="Deferred tax valuation allowance">192,000</span> and $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--US_zIdd3Vp690Dk" title="Deferred tax valuation allowance">130,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Malaysia</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes to the Labuan Business Activity Tax Act (LBATA) 1990 which was gazetted and came into operation on January 1, 2019 mandates companies incorporated in Labuan to satisfy the “substantial activity requirements” to qualify for the preferential tax rate of <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20181228__20190102__srt--StatementGeographicalAxis__custom--LabuanMember_z3I3O6gVN2ae" title="Effective income tax rate reconciliation, percent">3</span>% on net audited profit. Subsequently, on April 29, 2020, a circular setting out revisions to the “substantial activity requirements” was issued. As Agape ATP Corporation did not maintain a permanent establishment in Labuan, and therefore did not satisfy the said requirements, the company was subjected to tax at <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20181228__20190102__srt--StatementGeographicalAxis__custom--LabuanMember_zynZ4o9Kl3u3" title="Tax percentage">24</span>% on its net audited profit. On June 11, 2021, Agape ATP Corporation made an irrevocable election to be taxed under the Malaysian Income Tax Act 1967 as the elected tax regime is more tax efficient to the entity compare to LBATA.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape Superior Living Sdn Bhd, Agape S.E.A Sdn Bhd., Wellness ATP International Holdings Sdn Bhd. and DSY Wellness International Sdn. Bhd. are governed by the income taxes laws of Malaysia and the income taxes provision in respect of operations in Malaysia is calculated at the applicable tax rates on the taxable income for the periods based on existing legislation, interpretations and practices in respect thereof. Under the Income Tax Act of Malaysia, enterprises that incorporated in Malaysia are usually subject to a unified 24% enterprise income taxes rate while preferential tax rates, tax holidays and even tax exemption may be granted on case-by-case basis. <span id="xdx_90C_eus-gaap--IncomeTaxExaminationDescription_c20220101__20220630__srt--StatementGeographicalAxis__country--MY_zexkZioqrSj4" title="Income tax examination, description">The tax rate for small and medium sized companies (generally companies incorporated in Malaysia with paid-in capital of RM <span id="xdx_90B_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_uRM_c20220630__srt--RangeAxis__srt--MaximumMember_zK0vMQ5PQtr9" title="Paid in capital">2,500,000</span> or less) is <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20220630__srt--StatementGeographicalAxis__country--MY_zPxnPhGbgHQf" title="Tax percentage">17</span>% for the first RM <span id="xdx_90A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_uRM_c20220401__20220630_zOdSZC1tgdE4" title="Additional paid in capital">600,000</span> (or approximately $<span id="xdx_903_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_uRM_c20210401__20210630_zba8CUFvqLF3">150,000</span>) for the three months ended June 30, 2022 and 2021, with the remaining balance being taxed at the 24% rate</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2022 and December 31, 2021, the operations in Malaysia incurred approximately $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20220630__srt--StatementGeographicalAxis__country--MY_zJJdAgYbpDj" title="Net operating loss carryforward">1,311,000</span> and $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--MY_zFTph9M134Nd">946,000</span>, respectively, of cumulative net operating losses (“NOL”) which can be carried forward to offset future taxable income. Approximately $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_c20220630__srt--StatementScenarioAxis__custom--UnutilizedMember_zzv2sVdtTxbk" title="Net operating loss carryforward"><span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_c20211231__srt--StatementScenarioAxis__custom--UnutilizedMember_zhXRHmsuGsO5">944,000</span></span> of the net operating loss carry forwards will <span id="xdx_902_ecustom--NetOperatingLossCarryForwardsExpirationDescription_c20220101__20220630__srt--StatementScenarioAxis__custom--UnutilizedMember" title="Net operating loss carry forwards expiration, description">expire in 2028</span>, if unutilized. The deferred tax valuation allowance as of June 30, 2022 and December 31, 2021 were approximately $<span id="xdx_909_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20220630__srt--StatementGeographicalAxis__country--MY_z6rJzrncgl77">309,000</span> and $<span id="xdx_903_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--MY_zq5siCmNH5dh" title="Deferred tax valuation allowance">227,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Hong Kong</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape ATP International Holding (HK) Limited is subject to Hong Kong Profits Tax, which is charged at the statutory income rate of <span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20220630__srt--StatementGeographicalAxis__country--HK_zwOocvSwmNZa" title="Tax percentage">16.5</span>% on its assessable income derived from Hong Kong. Business income derived or business expenses incurred outside the Special Administrative Region is not subject to Hong Kong Profits Tax or deduction. As Agape ATP International Holding (HK) Limited is an investment holding company without operating activities, the net operating loss for Hong Kong is considered immaterial.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16. INCOME TAXES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ziNwS5pL3mok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the significant components of the aggregate deferred tax assets of the Company:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zuR1zMPmevo8" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20220630_zPwyF75bcDq4" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20211231_zKUcsDqCriek" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--US_zO95jjGIBvs5" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net operating loss carry forwards in U.S.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">191,976</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">130,277</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--MY_zLe31iUgi11h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net operating loss carry forwards in Malaysia</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">309,415</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">227,106</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zjWIIXZEhEVc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(501,391</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(357,383</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DeferredTaxLiabilitiesDepreciation_iI_zDcbZhgF7vme" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,975</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,574</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNI_di_z3G7Uw9v0XSj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Deferred tax liabilities, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,975</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,574</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AD_zGbp1g8ZD3Ub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Uncertain tax positions</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of June 30, 2022 and December 31, 2021, the Company did not have any significant unrecognized uncertain tax positions. The Company did not incur interest and penalties tax for the three and six months ended June 30, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89F_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_z9jboVTISCM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The United States and foreign components of loss before income taxes were comprised of the following:<b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> <span id="xdx_8B4_zQ8gSp4puwJc" style="display: none">SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20220401__20220630_zfAl5oKMFxy5" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20210401__20210630_z06O6xF8vv13" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20220101__20220630_zC1fW8rZZDKk" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20210101__20210630_z9YPrB5GCjmh" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tax jurisdictions from:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zOB8g85tMnPd" style="vertical-align: bottom; background-color: White"> <td style="width: 44%; text-align: left">Local – United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(187,379</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(96,370</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(293,804</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(204,295</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--MY_zn01OaYrdaI" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Foreign – Malaysia</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(189,395</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(177,983</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(354,459</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(469,675</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--HK_zi0rZzPQRRs9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Foreign – Hong Kong</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,178</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(363,901</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(45,847</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(291,814</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_z9aYOP7lf7nh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Loss before income tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(403,952</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(638,254</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(694,110</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(965,784</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> -187379 -96370 -293804 -204295 -189395 -177983 -354459 -469675 -27178 -363901 -45847 -291814 -403952 -638254 -694110 -965784 <p id="xdx_89A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zAS3cfoZd9Cg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provision for income taxes consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zBKI9bqrcVQh" style="display: none">SCHEDULE OF PROVISION FOR INCOME TAX</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20220401__20220630_zTgbuQl4t875" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20210401__20210630_zMrEB1wZ2dEc" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20220101__20220630_z1zZZJi0BbH" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20210101__20210630_zBfZM0VgGr64" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zQQepApzpBe6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maITEBzhRF_zn8dSGRL88K6" style="vertical-align: bottom; background-color: White"> <td style="width: 44%">- Local</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1510">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(22,205</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1512">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(22,205</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maITEBzhRF_zfpz4T8OaCCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>- Foreign</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(392</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(14,461</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,680</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(41,185</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zbZxxKpBOgt" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maITEBzhRF_z8G0Cii9egp3" style="vertical-align: bottom; background-color: White"> <td>- Local</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1525">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1526">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1527">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1528">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maITEBzhRF_zGzBzFT5AMyh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">- Foreign</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1530">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,695</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1532">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,299</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iNT_pp0p0_di_mtITEBzhRF_zxPvOEVjs853" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Provision for income tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(392</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,971</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,680</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(10,091</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 22205 22205 392 14461 8680 41185 -32695 -53299 392 3971 8680 10091 0.21 0.35 In addition, the Tax Cuts and Jobs Act imposed a global intangible low-taxed income (“GILTI”) tax, which is a tax on certain off-shore earnings at an effective rate of 10.5% for tax years (50% deduction of the current enacted tax rate of 21%) with a partial offset for 80% foreign tax credits. If the foreign tax rate is 13.125% or higher, there will be no U.S. corporate tax after the 80% foreign tax credits are applied 914000 620000 192000 130000 0.03 0.24 The tax rate for small and medium sized companies (generally companies incorporated in Malaysia with paid-in capital of RM 2,500,000 or less) is 17% for the first RM 600,000 (or approximately $150,000) for the three months ended June 30, 2022 and 2021, with the remaining balance being taxed at the 24% rate 2500000 0.17 600000 150000 1311000 946000 944000 944000 expire in 2028 309000 227000 0.165 <p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ziNwS5pL3mok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the significant components of the aggregate deferred tax assets of the Company:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zuR1zMPmevo8" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20220630_zPwyF75bcDq4" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20211231_zKUcsDqCriek" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--US_zO95jjGIBvs5" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net operating loss carry forwards in U.S.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">191,976</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">130,277</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--MY_zLe31iUgi11h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net operating loss carry forwards in Malaysia</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">309,415</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">227,106</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zjWIIXZEhEVc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(501,391</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(357,383</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DeferredTaxLiabilitiesDepreciation_iI_zDcbZhgF7vme" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,975</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,574</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNI_di_z3G7Uw9v0XSj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Deferred tax liabilities, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,975</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,574</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 191976 130277 309415 227106 501391 357383 -17975 -15574 17975 15574 <p id="xdx_806_eus-gaap--ConcentrationRiskDisclosureTextBlock_zjALduVCbpRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17. <span id="xdx_822_zGiuVIMePPh5">CONCENTRATIONS OF RISKS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Major customers</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended June 30, 2022, and 2021, no customer accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zV0IQeY1J58a" title="Concentrations of risk percentage"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zYT2xAdeVBU5" title="Concentrations of risk percentage">10</span></span>% or more of the Company’s total revenues. For the six months ended June 30, 2022, and 2021, no customer accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zsnPHjdR16Bd" title="Concentrations of risk percentage"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z4nN6IgWQdaj" title="Concentrations of risk percentage">10</span></span>% or more of the Company’s total revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2022, one individual customer accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__dei--LegalEntityAxis__custom--ECommerceCompanyMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneIndividualCustomersMember_zOeowW4uVeZ6" title="Concentrations of risk percentage">100.0</span>% of the Company’s balance of accounts receivable. There was no accounts receivable balance as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Major vendors</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended June 30, 2022, three vendors accounted for approximately <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zmlzq9MchVv7" title="Concentrations of risk percentage">70</span>%, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zruOdupJgBZi" title="Concentrations of risk percentage">11</span>% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--VendorThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z5nPU0oXBI5k" title="Concentrations of risk percentage">17</span>% of the Company’s total purchases, respectively. For the six months ended June 30, 2022, two vendors accounted for approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zmCW89xpMFt5" title="Concentrations of risk percentage">46</span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zd82PAUU45Ac" title="Concentrations of risk percentage">43</span>% of the Company’s total purchases, respectively. For the three and six months ended June 30, 2021, one vendor accounted for <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zImyrfTNS1f6"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z6XC7a6fpjVi">100</span></span>% of the Company’s total purchases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2022, three vendors accounted for approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zKHIKKTTgDQe" title="Concentrations of risk percentage">36</span>%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z3oO3RWQh7b8" title="Concentrations of risk percentage">40</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--VendorThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zS4pxo77Sjhk" title="Concentrations of risk percentage">20</span>% of the Company’s total balance of accounts payable, respectively. The vendor which accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--VendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zFhDLFGFLDv" title="Concentrations of risk percentage">40</span>% of the Company’s total balance of accounts payable is a related company, i.e. CTA Nutriceuticals (Asia) Sdn Bhd. As of December 31, 2021, one vendor accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--OneVendorMember_zYcOJ9OEpQxg" title="Concentrations of risk percentage">100</span>% of the total balance of accounts payable. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17. CONCENTRATIONS OF RISKS (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Commission Expenses to Sales Distributors and Stockists</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended June 30, 2022, one sales distributor accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__srt--MajorCustomersAxis__custom--OneSalesDistributorMember_zZlXKOIbaRsd" title="Concentrations of risk percentage">10</span>% of the Company’s commission expense. For the three months ended June 30, 2021, one sales distributor accounted for approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__srt--MajorCustomersAxis__custom--OneSalesDistributorMember_zSQoBuXFlt7h" title="Concentrations of risk percentage">21.9</span>% of the Company’s commission expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2022, no sales distributor accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__srt--MajorCustomersAxis__custom--NoSalesDistributorMember_zqLGs6HFESsb">10</span>% or more of the Company’s commission expense. For the six months ended June 30, 2021, one distributor accounted for approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__srt--MajorCustomersAxis__custom--OneSalesDistributorMember_ztcrYL7LtQV1">16.2</span>% of the Company’s total purchases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) Credit risk</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. As of June 30, 2022, and December 31, 2021, $<span id="xdx_907_eus-gaap--Deposits_iI_pp0p0_c20220630_ztjwpMEq8Vv3" title="Deposits">666,779</span> and $<span id="xdx_907_eus-gaap--Deposits_iI_pp0p0_c20211231_zSprDDSuAMBb" title="Deposits">554,864</span> were deposited with financial institutions, respectively, $<span id="xdx_903_ecustom--DepositForInsurance_iI_pp0p0_c20220630_zbKqHK0YzJ76" title="Deposit for insurance">319,994</span> and $<span id="xdx_907_ecustom--DepositForInsurance_iI_pp0p0_c20211231_zNwd61jeumZ" title="Deposit for insurance">295,761</span> of these balances are not covered by deposit insurance, respectively. While management believes that these financial institutions are of high credit quality, it also continually monitors their credit worthiness.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its account receivable is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. Historically, the Company did not have any bad debt on its account receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) Exchange rate risk</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company cannot guarantee that the current exchange rate will remain steady; therefore, there is a possibility that the Company could post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually post higher or lower profit depending on exchange rate of RM and HK$ converted to US$ on that date. The exchange rate could fluctuate depending on changes in political and economic environments without notice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.10 0.10 0.10 0.10 1.000 0.70 0.11 0.17 0.46 0.43 1 1 0.36 0.40 0.20 0.40 1 0.10 0.219 0.10 0.162 666779 554864 319994 295761 <p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zG2Ri1vjy1Dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18. <span id="xdx_824_z6Qo9TOQyvke">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Lease commitments</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 1, 2020, the Company adopted ASC 842 for ASL’s office space lease and sales and training center as the lease commencement date upon the acquisition of ASL. The Company recognized lease liabilities of approximately $<span id="xdx_90F_eus-gaap--OperatingLeaseLiability_iI_c20200401__us-gaap--BusinessAcquisitionAxis__custom--AgapeSuperiorLivingMember_z2UO4mOOJfKc" title="Operating lease liability">490,000</span>, with a corresponding right-of-use (“ROU”) asset in the same amount based on the present value of the future minimum rental payments of the lease, using an effective interest rate of <span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20200401__us-gaap--BusinessAcquisitionAxis__custom--AgapeSuperiorLivingMember_zn9t9O1tVpGc" title="Operating lease effective interest rate">5.5</span>%, which was determined using the Company’s estimated incremental borrowing rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 31, 2021, the Company entered into two separate two-year leases extension with the modified lease expiring <span id="xdx_90C_ecustom--LeaseExpirationTerm_dd_c20210530__20210531_zuJSmps3B2V5" title="Lease expiration term">May 31, 2023</span> for its office space and expiring <span id="xdx_90D_ecustom--LeaseExpirationTerm_dd_c20210530__20210531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TrainingCenterMember_zgo00piLMVCd" title="Lease expiration term">August 31, 2023</span> for its training center. The lease modification required the Company to re-measure the ROU assets and lease liabilities based on the modified leases. The Company recognized a reduction of $<span id="xdx_90A_ecustom--IncreaseDecreaseInROUAssetsAndLiabilities_iI_c20210531_z58yP16DZNJh" title="Reduction in ROU assets and liabilities">3,250</span> in ROU assets and lease liabilities upon lease modifications based on the present value of the future minimum rental payments of the lease, using an effective interest rate of <span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20210531__us-gaap--BusinessAcquisitionAxis__custom--AgapeSuperiorLivingMember_zZwMD91E0GJ7" title="Operating lease effective interest rate">5.5</span>%, which was determined using the Company’s estimated incremental borrowing rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted remaining term of the lease is approximately <span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--BusinessAcquisitionAxis__custom--AgapeSuperiorLivingMember_zkBUHFYjERF4" title="Operating lease, weighted average remaining lease term">1.17</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18. COMMITMENTS AND CONTINGENCIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zR7wjrm2eTG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The five-year maturity of the Company’s operating lease liabilities is as follow:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_z0SDbBrVlhQe" style="display: none">SCHEDULE OF LEASE COMMITMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20220630_zqGiNwByhZpf" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Twelve Months Ending June 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating lease<br/> liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzA1T_zGU5fq4vdPd9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">155,474</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzA1T_zR1apq1TDgSb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,898</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pp0p0_maLOLLPzA1T_zUpzmhrDi5I" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1667">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzA1T_zyLgF8YRlDLb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">166,372</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zuDBsLsOEqal" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,987</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">161,385</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zaqA8odxZFBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also leases one office and operation center, and one shophouse with an expiring term of twelve months or less, which were classified as operation leases. Since the lease terms for these leases were twelve months or less, a lessee is permitted to elect not to recognize lease assets and liabilities. The Company has elected not to recognize lease assets and liabilities on these leases. As of June 30, 2022, the Company’s commitment for minimum lease payment under these operating leases within the next twelve months were $<span id="xdx_90C_eus-gaap--OperatingLeasePayments_c20220101__20220630_z4zzS6bvnAO1" title="Operating lease payments">11,416</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent expense for the three months ended June 30, 2022 and 2021 was $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_pp0p0_c20220401__20220630_zbXwyFqRDLP6" title="Operating lease, expense">54,237</span> and $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_pp0p0_c20210401__20210630_zix08x2Ssx92" title="Operating lease, expense">45,560</span>, respectively. Rent expense for the six months ended June 30, 2022, and 2021 was $<span id="xdx_909_eus-gaap--OperatingLeaseExpense_pp0p0_c20220101__20220630_zs5NXhYZRYRj" title="Operating lease, expense">98,312</span> and $<span id="xdx_90A_eus-gaap--OperatingLeaseExpense_pp0p0_c20210101__20210630_zUAt2ib9Aex3" title="Operating lease, expense">91,521</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contingencies</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company is party to certain legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued, as well as the total amount of reasonably possible losses with respect to such matters, individually and in the aggregate, are not deemed to be material to the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COVID-19</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since the declaration of the COVID-19 pandemic on March 11, 2020 by the World Health Organization or WHO, Malaysia has been put through various stages of lockdowns such as (1) full movement control orders (“MCO”), under which, quarantines, travel restrictions, and the temporary closure of stores and facilities in Malaysia were made mandatory, (2) MCO were eased to a Conditional Movement Control Order (“CMCO”) where most business sectors were allowed to operate under strict rules and Standard Operating Procedures mandated by the government of Malaysia and (3) CMCO were further relaxed to Recovery Movement Control Order (“RMCO”). On January 12, 2021, due to a resurgence of COVID-19 cases, the Malaysian government declared a state of emergency nationwide to combat COVID-19. Intermittent lockdowns were imposed in various states and districts in the country. February 2021 marked a significant month for Malaysia as all frontline staff of the country, which comprised those in healthcare, police, the Volunteers Department of Malaysia, the Fire and Rescue Department of Malaysia and civil defense sectors were vaccinated. On February 16, 2021, Prime Minister Tan Sri Muhyiddin Yassin announced that a National COVID-19 Immunization Plan will be implemented for one year after February 2021, which 80% of the Malaysia population will be vaccinated to achieve herd immunization. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE ATP CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency expressed in United States Dollars (“US$”), except for number of shares)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18. COMMITMENTS AND CONTINGENCIES (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 5, 2021, lockdowns in most part of the country was eased to a CMCO, nevertheless, COVID-19 cases in the country continue to rise. <span id="xdx_900_eus-gaap--UnusualRiskOrUncertaintyImpact_c20220101__20220630__us-gaap--UnusualRiskOrUncertaintyByNatureAxis__custom--COVIDNineteenImpactMember_zRnbkNLKkdEa" title="COVID-19 impact description">On May 12, 2021, Malaysia was again put under a full lockdown nationwide, until the earlier of (i) daily COVID-19 cases infection of the country fall below 4,000; (ii) intensive Unit Care, or ICU, wards start operating at a moderate level; or (iii) 10% of the Malaysian population is fully vaccinated. The country was administering over 400,000 doses of COVID-19 vaccines daily. On July 17, 2021, the full lockdown was slightly eased as 13.9% of the Malaysian population was fully vaccinated, with another 30% having received at least one dose of the vaccine. The COVID-19 situation in the country showed no sign of abating. Kuala Lumpur and Selangor remained the epicenter of the latest wave of infections. Total COVID-19 cases in the country surpassed the one million mark on July 25, 2021, and daily cases hit a record high of 24,599 on August 26, 2021. Despite the deteriorating COVID-19 state, the government lifted Kuala Lumpur from Enhanced Movement Control Order (“EMCO”) ahead of schedule and ended the nationwide state of emergency on August 1, 2021. Parliament met for the first time this year on July 26, 2021. Malaysia pressed on with its National COVID-19 Immunization Plan, fast inoculating of its residents. COVID-19 infections started to drop below the 10,000 mark daily, beginning October 3, 2021. Effective October 11, 2021, interstate and international travel restrictions were lifted for residents who had been fully vaccinated against COVID-19 as the country achieved its target of inoculating 90% of its adult population</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia officially transitioned to the endemic phase of COVID-19 effective April 1, 2022. Restrictions on businesses and people are minimal. Meanwhile, the government continues to encourage inoculation for those between the ages of 5 to 11 years and its adolescent group which comprised those between the ages 12 to 17. Adults who have been fully vaccinated, i.e. received two doses of the COVID-19 vaccine are encouraged to take booster shots.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially, affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact, almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">temporary closure of offices, travel restrictions, financial impact of the Company’s customers or suspension supplies may be negatively affected, and could continue to negatively affect the demand for the Company’s product;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company may have to provide significant sales incentives to its customers during the outbreak, which may in turn materially adversely affect its financial condition and operating results; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any disruption of the Company’s supply chain, logistics providers or customers could adversely impact its business and results of operations, including causing the Company or its suppliers to cease manufacturing for a period of time or materially delay delivery to its customers, which may also lead to loss of its customers.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the COVID-19 cannot be reasonably estimated at this time. There is no guarantee that the Company’s total revenues will grow or remain at similar levels year over year in 2022 and beyond.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 490000 0.055 2023-05-31 2023-08-31 3250 0.055 P1Y2M1D <p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zR7wjrm2eTG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The five-year maturity of the Company’s operating lease liabilities is as follow:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_z0SDbBrVlhQe" style="display: none">SCHEDULE OF LEASE COMMITMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20220630_zqGiNwByhZpf" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Twelve Months Ending June 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating lease<br/> liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzA1T_zGU5fq4vdPd9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">155,474</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzA1T_zR1apq1TDgSb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,898</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pp0p0_maLOLLPzA1T_zUpzmhrDi5I" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1667">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzA1T_zyLgF8YRlDLb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">166,372</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zuDBsLsOEqal" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,987</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">161,385</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 155474 10898 166372 4987 161385 11416 54237 45560 98312 91521 On May 12, 2021, Malaysia was again put under a full lockdown nationwide, until the earlier of (i) daily COVID-19 cases infection of the country fall below 4,000; (ii) intensive Unit Care, or ICU, wards start operating at a moderate level; or (iii) 10% of the Malaysian population is fully vaccinated. The country was administering over 400,000 doses of COVID-19 vaccines daily. On July 17, 2021, the full lockdown was slightly eased as 13.9% of the Malaysian population was fully vaccinated, with another 30% having received at least one dose of the vaccine. The COVID-19 situation in the country showed no sign of abating. Kuala Lumpur and Selangor remained the epicenter of the latest wave of infections. Total COVID-19 cases in the country surpassed the one million mark on July 25, 2021, and daily cases hit a record high of 24,599 on August 26, 2021. Despite the deteriorating COVID-19 state, the government lifted Kuala Lumpur from Enhanced Movement Control Order (“EMCO”) ahead of schedule and ended the nationwide state of emergency on August 1, 2021. Parliament met for the first time this year on July 26, 2021. Malaysia pressed on with its National COVID-19 Immunization Plan, fast inoculating of its residents. COVID-19 infections started to drop below the 10,000 mark daily, beginning October 3, 2021. Effective October 11, 2021, interstate and international travel restrictions were lifted for residents who had been fully vaccinated against COVID-19 as the country achieved its target of inoculating 90% of its adult population <p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zwUhh31AtLJ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19. <span id="xdx_820_zJp8RlH8oaGj">SUBSEQUENT EVENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 19, 2022, Greenpro Capital Corp. filed a certificate of change with the Secretary of State of Nevada to effect a reverse split of <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20220718__20220719__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4vqmZdqpH54" title="Stockholders equity reverse stock split">the company’s common stock at the ratio of 10-for-1 effective July 28, 2022. Under the reverse stock split, each 10 pre-split share of common stock outstanding will automatically combine into 1 new share of common stock of the company</span>. As at June 30, 2022, the Company has an investment of <span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220630__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zjm0gBGXSW4e" title="Investment owned, balance shares">116,646</span> common stock of Greenpro Capital Corp. valued at $<span id="xdx_901_eus-gaap--InvestmentOwnedAtFairValue_iI_pp2d_c20220630__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zd5CYQKf5T5j" title="Investment owned, fair value">24,853.45</span>. The Company’s investment of <span id="xdx_909_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220630__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_z3HydqEBWCEb" title="Investment owned, balance shares">116,646</span> common stock of Greenpro Capital Corp. shall be reduced to <span id="xdx_90E_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220719__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zNN9GBEK4Sjk" title="Investment owned, balance shares">11,665</span> as a result of the reverse stock split. However, the value of the Company’s investment in Greenpro Capital Corp. as at June 30,2022 remained unchanged despite the reduction in the number of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> the company’s common stock at the ratio of 10-for-1 effective July 28, 2022. Under the reverse stock split, each 10 pre-split share of common stock outstanding will automatically combine into 1 new share of common stock of the company 116646 24853.45 116646 11665 EXCEL 88 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

>=GC_F!@KSQJ,797,7;A03[+ MQCB9R%"G$?&(=GBK"K1;:H0Y.# W @WZ;!OH)AX9ID?> 0:-]_U5+O;!7%PL MXO%4UIR5 WR_% 77^F,ASZ9AZ@5$ M_)1S_:2RJBDX6E#

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ˮ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ː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�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�[25BWID.FE]>!(,N)N:=*;5WL�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end XML 89 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 90 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 91 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 304 314 1 false 96 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://agapeatp.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://agapeatp.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://agapeatp.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://agapeatp.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND Sheet http://agapeatp.com/role/OrganizationAndBusinessBackground ORGANIZATION AND BUSINESS BACKGROUND Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - VARIABLE INTEREST ENTITY (???VIE???) Sheet http://agapeatp.com/role/VariableInterestEntityVie VARIABLE INTEREST ENTITY (???VIE???) Notes 9 false false R10.htm 00000010 - Disclosure - CASH AND CASH EQUIVALENTS Sheet http://agapeatp.com/role/CashAndCashEquivalents CASH AND CASH EQUIVALENTS Notes 10 false false R11.htm 00000011 - Disclosure - ACCOUNTS RECEIVABLE Sheet http://agapeatp.com/role/AccountsReceivable ACCOUNTS RECEIVABLE Notes 11 false false R12.htm 00000012 - Disclosure - INVENTORIES Sheet http://agapeatp.com/role/Inventories INVENTORIES Notes 12 false false R13.htm 00000013 - Disclosure - PREPAYMENTS AND DEPOSITS Sheet http://agapeatp.com/role/PrepaymentsAndDeposits PREPAYMENTS AND DEPOSITS Notes 13 false false R14.htm 00000014 - Disclosure - PROPERTY AND EQUIPMENT, NET Sheet http://agapeatp.com/role/PropertyAndEquipmentNet PROPERTY AND EQUIPMENT, NET Notes 14 false false R15.htm 00000015 - Disclosure - INTANGIBLE ASSETS, NET Sheet http://agapeatp.com/role/IntangibleAssetsNet INTANGIBLE ASSETS, NET Notes 15 false false R16.htm 00000016 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES Sheet http://agapeatp.com/role/InvestmentInMarketableSecurities INVESTMENT IN MARKETABLE SECURITIES Notes 16 false false R17.htm 00000017 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES Sheet http://agapeatp.com/role/InvestmentInNon-marketableSecurities INVESTMENT IN NON-MARKETABLE SECURITIES Notes 17 false false R18.htm 00000018 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES Sheet http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities OTHER PAYABLES AND ACCRUED LIABILITIES Notes 18 false false R19.htm 00000019 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS Sheet http://agapeatp.com/role/RelatedPartyBalancesAndTransactions RELATED PARTY BALANCES AND TRANSACTIONS Notes 19 false false R20.htm 00000020 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://agapeatp.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 20 false false R21.htm 00000021 - Disclosure - NON-CONTROLLING INTEREST Sheet http://agapeatp.com/role/Non-controllingInterest NON-CONTROLLING INTEREST Notes 21 false false R22.htm 00000022 - Disclosure - INCOME TAXES Sheet http://agapeatp.com/role/IncomeTaxes INCOME TAXES Notes 22 false false R23.htm 00000023 - Disclosure - CONCENTRATIONS OF RISKS Sheet http://agapeatp.com/role/ConcentrationsOfRisks CONCENTRATIONS OF RISKS Notes 23 false false R24.htm 00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://agapeatp.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 24 false false R25.htm 00000025 - Disclosure - SUBSEQUENT EVENT Sheet http://agapeatp.com/role/SubsequentEvent SUBSEQUENT EVENT Notes 25 false false R26.htm 00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 26 false false R27.htm 00000027 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Tables) Sheet http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables ORGANIZATION AND BUSINESS BACKGROUND (Tables) Tables http://agapeatp.com/role/OrganizationAndBusinessBackground 27 false false R28.htm 00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies 28 false false R29.htm 00000029 - Disclosure - VARIABLE INTEREST ENTITY (???VIE???) (Tables) Sheet http://agapeatp.com/role/VariableInterestEntityVieTables VARIABLE INTEREST ENTITY (???VIE???) (Tables) Tables http://agapeatp.com/role/VariableInterestEntityVie 29 false false R30.htm 00000030 - Disclosure - ACCOUNTS RECEIVABLE (Tables) Sheet http://agapeatp.com/role/AccountsReceivableTables ACCOUNTS RECEIVABLE (Tables) Tables http://agapeatp.com/role/AccountsReceivable 30 false false R31.htm 00000031 - Disclosure - INVENTORIES (Tables) Sheet http://agapeatp.com/role/InventoriesTables INVENTORIES (Tables) Tables http://agapeatp.com/role/Inventories 31 false false R32.htm 00000032 - Disclosure - PREPAYMENTS AND DEPOSITS (Tables) Sheet http://agapeatp.com/role/PrepaymentsAndDepositsTables PREPAYMENTS AND DEPOSITS (Tables) Tables http://agapeatp.com/role/PrepaymentsAndDeposits 32 false false R33.htm 00000033 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) Sheet http://agapeatp.com/role/PropertyAndEquipmentNetTables PROPERTY AND EQUIPMENT, NET (Tables) Tables http://agapeatp.com/role/PropertyAndEquipmentNet 33 false false R34.htm 00000034 - Disclosure - INTANGIBLE ASSETS, NET (Tables) Sheet http://agapeatp.com/role/IntangibleAssetsNetTables INTANGIBLE ASSETS, NET (Tables) Tables http://agapeatp.com/role/IntangibleAssetsNet 34 false false R35.htm 00000035 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Tables) Sheet http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables INVESTMENT IN MARKETABLE SECURITIES (Tables) Tables http://agapeatp.com/role/InvestmentInMarketableSecurities 35 false false R36.htm 00000036 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Tables) Sheet http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables INVESTMENT IN NON-MARKETABLE SECURITIES (Tables) Tables http://agapeatp.com/role/InvestmentInNon-marketableSecurities 36 false false R37.htm 00000037 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES (Tables) Sheet http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesTables OTHER PAYABLES AND ACCRUED LIABILITIES (Tables) Tables http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities 37 false false R38.htm 00000038 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables) Sheet http://agapeatp.com/role/RelatedPartyBalancesAndTransactionsTables RELATED PARTY BALANCES AND TRANSACTIONS (Tables) Tables http://agapeatp.com/role/RelatedPartyBalancesAndTransactions 38 false false R39.htm 00000039 - Disclosure - NON-CONTROLLING INTEREST (Tables) Sheet http://agapeatp.com/role/Non-controllingInterestTables NON-CONTROLLING INTEREST (Tables) Tables http://agapeatp.com/role/Non-controllingInterest 39 false false R40.htm 00000040 - Disclosure - INCOME TAXES (Tables) Sheet http://agapeatp.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://agapeatp.com/role/IncomeTaxes 40 false false R41.htm 00000041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://agapeatp.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://agapeatp.com/role/CommitmentsAndContingencies 41 false false R42.htm 00000042 - Disclosure - SCHEDULE OF SUBSIDIARIES AND ASSOCIATES (Details) Sheet http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails SCHEDULE OF SUBSIDIARIES AND ASSOCIATES (Details) Details 42 false false R43.htm 00000043 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative) Sheet http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative) Details http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables 43 false false R44.htm 00000044 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details) Sheet http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details) Details 44 false false R45.htm 00000045 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET (Details) Sheet http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET (Details) Details 45 false false R46.htm 00000046 - Disclosure - SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES (Details) Sheet http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES (Details) Details 46 false false R47.htm 00000047 - Disclosure - SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES (Details) Sheet http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES (Details) Details 47 false false R48.htm 00000048 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables 48 false false R49.htm 00000049 - Disclosure - SCHEDULE OF VARIABLE INTEREST ENTITY (Details) Sheet http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails SCHEDULE OF VARIABLE INTEREST ENTITY (Details) Details 49 false false R50.htm 00000050 - Disclosure - VARIABLE INTEREST ENTITY (???VIE???) (Details Narrative) Sheet http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative VARIABLE INTEREST ENTITY (???VIE???) (Details Narrative) Details http://agapeatp.com/role/VariableInterestEntityVieTables 50 false false R51.htm 00000051 - Disclosure - CASH AND CASH EQUIVALENTS (Details Narrative) Sheet http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative CASH AND CASH EQUIVALENTS (Details Narrative) Details http://agapeatp.com/role/CashAndCashEquivalents 51 false false R52.htm 00000052 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY (Details) Sheet http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY (Details) Details 52 false false R53.htm 00000053 - Disclosure - SCHEDULE OF INVENTORIES (Details) Sheet http://agapeatp.com/role/ScheduleOfInventoriesDetails SCHEDULE OF INVENTORIES (Details) Details 53 false false R54.htm 00000054 - Disclosure - INVENTORIES (Details Narrative) Sheet http://agapeatp.com/role/InventoriesDetailsNarrative INVENTORIES (Details Narrative) Details http://agapeatp.com/role/InventoriesTables 54 false false R55.htm 00000055 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND DEPOSITS (Details) Sheet http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails SCHEDULE OF PREPAID EXPENSES AND DEPOSITS (Details) Details 55 false false R56.htm 00000056 - Disclosure - SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) Sheet http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) Details 56 false false R57.htm 00000057 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details) Sheet http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details) Details 57 false false R58.htm 00000058 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative) Sheet http://agapeatp.com/role/PropertyAndEquipmentNetDetailsNarrative PROPERTY AND EQUIPMENT, NET (Details Narrative) Details http://agapeatp.com/role/PropertyAndEquipmentNetTables 58 false false R59.htm 00000059 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, NET (Details) Sheet http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails SCHEDULE OF INTANGIBLE ASSETS, NET (Details) Details 59 false false R60.htm 00000060 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative) Sheet http://agapeatp.com/role/IntangibleAssetsNetDetailsNarrative INTANGIBLE ASSETS, NET (Details Narrative) Details http://agapeatp.com/role/IntangibleAssetsNetTables 60 false false R61.htm 00000061 - Disclosure - SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES (Details) Sheet http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES (Details) Details 61 false false R62.htm 00000062 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Details Narrative) Sheet http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative INVESTMENT IN MARKETABLE SECURITIES (Details Narrative) Details http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables 62 false false R63.htm 00000063 - Disclosure - SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES (Details) Sheet http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES (Details) Details 63 false false R64.htm 00000064 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Details Narrative) Sheet http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative INVESTMENT IN NON-MARKETABLE SECURITIES (Details Narrative) Details http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables 64 false false R65.htm 00000065 - Disclosure - SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES (Details) Sheet http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES (Details) Details 65 false false R66.htm 00000066 - Disclosure - SCHEDULE OF RELATED PARTIES (Details) Sheet http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails SCHEDULE OF RELATED PARTIES (Details) Details 66 false false R67.htm 00000067 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://agapeatp.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://agapeatp.com/role/StockholdersEquity 67 false false R68.htm 00000068 - Disclosure - SCHEDULE OF NON CONTROLLING INTEREST (Details) Sheet http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails SCHEDULE OF NON CONTROLLING INTEREST (Details) Details 68 false false R69.htm 00000069 - Disclosure - SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX (Details) Sheet http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX (Details) Details 69 false false R70.htm 00000070 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAX (Details) Sheet http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails SCHEDULE OF PROVISION FOR INCOME TAX (Details) Details 70 false false R71.htm 00000071 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details) Sheet http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails SCHEDULE OF DEFERRED TAX ASSETS (Details) Details 71 false false R72.htm 00000072 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://agapeatp.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://agapeatp.com/role/IncomeTaxesTables 72 false false R73.htm 00000073 - Disclosure - CONCENTRATIONS OF RISKS (Details Narrative) Sheet http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative CONCENTRATIONS OF RISKS (Details Narrative) Details http://agapeatp.com/role/ConcentrationsOfRisks 73 false false R74.htm 00000074 - Disclosure - SCHEDULE OF LEASE COMMITMENTS (Details) Sheet http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails SCHEDULE OF LEASE COMMITMENTS (Details) Details 74 false false R75.htm 00000075 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://agapeatp.com/role/CommitmentsAndContingenciesTables 75 false false R76.htm 00000076 - Disclosure - SUBSEQUENT EVENT (Details Narrative) Sheet http://agapeatp.com/role/SubsequentEventDetailsNarrative SUBSEQUENT EVENT (Details Narrative) Details http://agapeatp.com/role/SubsequentEvent 76 false false All Reports Book All Reports form10-q.htm aatp-20220630.xsd aatp-20220630_cal.xml aatp-20220630_def.xml aatp-20220630_lab.xml aatp-20220630_pre.xml ex31-1.htm ex31-2.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 94 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 22, "contextCount": 304, "dts": { "calculationLink": { "local": [ "aatp-20220630_cal.xml" ] }, "definitionLink": { "local": [ "aatp-20220630_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "aatp-20220630_lab.xml" ] }, "presentationLink": { "local": [ "aatp-20220630_pre.xml" ] }, "schema": { "local": [ "aatp-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 549, "entityCount": 1, "hidden": { "http://agapeatp.com/20220630": 22, "http://fasb.org/us-gaap/2022": 109, "http://xbrl.sec.gov/dei/2022": 4, "total": 135 }, "keyCustom": 62, "keyStandard": 252, "memberCustom": 68, "memberStandard": 27, "nsprefix": "AATP", "nsuri": "http://agapeatp.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://agapeatp.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - CASH AND CASH EQUIVALENTS", "role": "http://agapeatp.com/role/CashAndCashEquivalents", "shortName": "CASH AND CASH EQUIVALENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - ACCOUNTS RECEIVABLE", "role": "http://agapeatp.com/role/AccountsReceivable", "shortName": "ACCOUNTS RECEIVABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - INVENTORIES", "role": "http://agapeatp.com/role/Inventories", "shortName": "INVENTORIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:PrepaymentsAndDepositsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - PREPAYMENTS AND DEPOSITS", "role": "http://agapeatp.com/role/PrepaymentsAndDeposits", "shortName": "PREPAYMENTS AND DEPOSITS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:PrepaymentsAndDepositsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - PROPERTY AND EQUIPMENT, NET", "role": "http://agapeatp.com/role/PropertyAndEquipmentNet", "shortName": "PROPERTY AND EQUIPMENT, NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - INTANGIBLE ASSETS, NET", "role": "http://agapeatp.com/role/IntangibleAssetsNet", "shortName": "INTANGIBLE ASSETS, NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:InvestmentInMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES", "role": "http://agapeatp.com/role/InvestmentInMarketableSecurities", "shortName": "INVESTMENT IN MARKETABLE SECURITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:InvestmentInMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:InvestmentInNonMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES", "role": "http://agapeatp.com/role/InvestmentInNon-marketableSecurities", "shortName": "INVESTMENT IN NON-MARKETABLE SECURITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:InvestmentInNonMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES", "role": "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities", "shortName": "OTHER PAYABLES AND ACCRUED LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS", "role": "http://agapeatp.com/role/RelatedPartyBalancesAndTransactions", "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://agapeatp.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "lang": null, "name": "us-gaap:NotesReceivableRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "role": "http://agapeatp.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - NON-CONTROLLING INTEREST", "role": "http://agapeatp.com/role/Non-controllingInterest", "shortName": "NON-CONTROLLING INTEREST", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - INCOME TAXES", "role": "http://agapeatp.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - CONCENTRATIONS OF RISKS", "role": "http://agapeatp.com/role/ConcentrationsOfRisks", "shortName": "CONCENTRATIONS OF RISKS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://agapeatp.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - SUBSEQUENT EVENT", "role": "http://agapeatp.com/role/SubsequentEvent", "shortName": "SUBSEQUENT EVENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Tables)", "role": "http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables", "shortName": "ORGANIZATION AND BUSINESS BACKGROUND (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:VariableInterestEntityDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - VARIABLE INTEREST ENTITY (\u201cVIE\u201d) (Tables)", "role": "http://agapeatp.com/role/VariableInterestEntityVieTables", "shortName": "VARIABLE INTEREST ENTITY (\u201cVIE\u201d) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:VariableInterestEntityDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "AATP:VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://agapeatp.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "AATP:VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - ACCOUNTS RECEIVABLE (Tables)", "role": "http://agapeatp.com/role/AccountsReceivableTables", "shortName": "ACCOUNTS RECEIVABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - INVENTORIES (Tables)", "role": "http://agapeatp.com/role/InventoriesTables", "shortName": "INVENTORIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "AATP:PrepaymentsAndDepositsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - PREPAYMENTS AND DEPOSITS (Tables)", "role": "http://agapeatp.com/role/PrepaymentsAndDepositsTables", "shortName": "PREPAYMENTS AND DEPOSITS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "AATP:PrepaymentsAndDepositsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)", "role": "http://agapeatp.com/role/PropertyAndEquipmentNetTables", "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - INTANGIBLE ASSETS, NET (Tables)", "role": "http://agapeatp.com/role/IntangibleAssetsNetTables", "shortName": "INTANGIBLE ASSETS, NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "AATP:InvestmentInMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Tables)", "role": "http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables", "shortName": "INVESTMENT IN MARKETABLE SECURITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "AATP:InvestmentInMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "AATP:InvestmentInNonMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:NonMarketableSecuritiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Tables)", "role": "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables", "shortName": "INVESTMENT IN NON-MARKETABLE SECURITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "AATP:InvestmentInNonMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:NonMarketableSecuritiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES (Tables)", "role": "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesTables", "shortName": "OTHER PAYABLES AND ACCRUED LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)", "role": "http://agapeatp.com/role/RelatedPartyBalancesAndTransactionsTables", "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:MinorityInterestDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:ScheduleOfNonControllingInterestTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - NON-CONTROLLING INTEREST (Tables)", "role": "http://agapeatp.com/role/Non-controllingInterestTables", "shortName": "NON-CONTROLLING INTEREST (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:MinorityInterestDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:ScheduleOfNonControllingInterestTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "role": "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "lang": null, "name": "us-gaap:SalesCommissionsAndFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - INCOME TAXES (Tables)", "role": "http://agapeatp.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://agapeatp.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-06-30_custom_SubsidiaryCompanyMember", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:NameOftheCompany", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - SCHEDULE OF SUBSIDIARIES AND ASSOCIATES (Details)", "role": "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails", "shortName": "SCHEDULE OF SUBSIDIARIES AND ASSOCIATES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-06-30_custom_SubsidiaryCompanyMember", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:NameOftheCompany", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-05-072020-05-08_custom_ShareExchangeAgreementMember_custom_MrHowKokChoongMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative)", "role": "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative", "shortName": "ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-05-072020-05-08_custom_ShareExchangeAgreementMember_custom_MrHowKokChoongMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "AATP:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-06-30_us-gaap_ComputerEquipmentMember_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)", "role": "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails", "shortName": "SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "AATP:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-06-30_us-gaap_ComputerEquipmentMember_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "AATP:ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock", "us-gaap:IntangibleAssetsFiniteLivedPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-06-30_us-gaap_ComputerSoftwareIntangibleAssetMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET (Details)", "role": "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails", "shortName": "SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "AATP:ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock", "us-gaap:IntangibleAssetsFiniteLivedPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-06-30_us-gaap_ComputerSoftwareIntangibleAssetMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "AATP:ScheduleOfDisaggregatedInformationOfRevenuesTableTextBlock", "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES (Details)", "role": "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails", "shortName": "SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "AATP:ScheduleOfDisaggregatedInformationOfRevenuesTableTextBlock", "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30_custom_PeriodEndMYRMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES (Details)", "role": "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails", "shortName": "SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_custom_PeriodEndMYRMember", "decimals": "INF", "lang": null, "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "p", "AATP:PrepaymentsAndDepositsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "AATP:AllowanceForDoubtfulAccountsReceivablesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "AATP:PrepaymentsAndDepositsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "AATP:AllowanceForDoubtfulAccountsReceivablesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - SCHEDULE OF VARIABLE INTEREST ENTITY (Details)", "role": "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails", "shortName": "SCHEDULE OF VARIABLE INTEREST ENTITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "us-gaap:VariableInterestEntityDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember", "decimals": "0", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "role": "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-03-31_us-gaap_RetainedEarningsMember", "decimals": "0", "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:VariableInterestEntityDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30_custom_SubsidiaryCompanyThreeMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - VARIABLE INTEREST ENTITY (\u201cVIE\u201d) (Details Narrative)", "role": "http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative", "shortName": "VARIABLE INTEREST ENTITY (\u201cVIE\u201d) (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - CASH AND CASH EQUIVALENTS (Details Narrative)", "role": "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative", "shortName": "CASH AND CASH EQUIVALENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY (Details)", "role": "http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails", "shortName": "SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - SCHEDULE OF INVENTORIES (Details)", "role": "http://agapeatp.com/role/ScheduleOfInventoriesDetails", "shortName": "SCHEDULE OF INVENTORIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - INVENTORIES (Details Narrative)", "role": "http://agapeatp.com/role/InventoriesDetailsNarrative", "shortName": "INVENTORIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "AATP:PrepaymentsAndDepositsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "AATP:ReceivablesFromSalesDistributors", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND DEPOSITS (Details)", "role": "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails", "shortName": "SCHEDULE OF PREPAID EXPENSES AND DEPOSITS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "AATP:PrepaymentsAndDepositsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "AATP:ReceivablesFromSalesDistributors", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "AATP:ScheduleOfChangesInAllowanceForDoubtfulAccountsTableTextBlock", "AATP:PrepaymentsAndDepositsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details)", "role": "http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails", "shortName": "SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "AATP:ScheduleOfChangesInAllowanceForDoubtfulAccountsTableTextBlock", "AATP:PrepaymentsAndDepositsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)", "role": "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)", "role": "http://agapeatp.com/role/PropertyAndEquipmentNetDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT, NET (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CapitalizedComputerSoftwareGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, NET (Details)", "role": "http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails", "shortName": "SCHEDULE OF INTANGIBLE ASSETS, NET (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CapitalizedComputerSoftwareGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://agapeatp.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "0", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSoldAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)", "role": "http://agapeatp.com/role/IntangibleAssetsNetDetailsNarrative", "shortName": "INTANGIBLE ASSETS, NET (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "AATP:InvestmentInMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InvestmentOwnedAtCost", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000061 - Disclosure - SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES (Details)", "role": "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails", "shortName": "SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "AATP:InvestmentInMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "AATP:InvestmentsIncomeDividend", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "AATP:InvestmentInMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InvestmentOwnedAtCost", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000062 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Details Narrative)", "role": "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative", "shortName": "INVESTMENT IN MARKETABLE SECURITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "AATP:InvestmentInMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2018-10-16_custom_GreenproCapitalCorpMember", "decimals": "0", "lang": null, "name": "us-gaap:InvestmentOwnedAtCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "AATP:InvestmentInMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InvestmentOwnedAtCost", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000063 - Disclosure - SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES (Details)", "role": "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails", "shortName": "SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "AATP:NonMarketableSecuritiesTableTextBlock", "AATP:InvestmentInNonMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30_custom_PhoenixPlusCorpMember", "decimals": "0", "lang": null, "name": "us-gaap:InvestmentOwnedAtCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "AATP:InvestmentInMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InvestmentOwnedAtCost", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000064 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Details Narrative)", "role": "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative", "shortName": "INVESTMENT IN NON-MARKETABLE SECURITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "AATP:InvestmentInNonMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2019-04-03_custom_PhoenixPlusCorpMember", "decimals": "INF", "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "AATP:ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000065 - Disclosure - SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES (Details)", "role": "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails", "shortName": "SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "AATP:ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableRelatedPartiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000066 - Disclosure - SCHEDULE OF RELATED PARTIES (Details)", "role": "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails", "shortName": "SCHEDULE OF RELATED PARTIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:DueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000067 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "role": "http://agapeatp.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-06-30_custom_ShareForfeitureAgreementsMember", "decimals": "INF", "lang": null, "name": "AATP:ReductionInCommonStockOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "AATP:ScheduleOfNonControllingInterestTableTextBlock", "us-gaap:MinorityInterestDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "AATP:NonControllingInterestPaidinCapital", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000068 - Disclosure - SCHEDULE OF NON CONTROLLING INTEREST (Details)", "role": "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails", "shortName": "SCHEDULE OF NON CONTROLLING INTEREST (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "AATP:ScheduleOfNonControllingInterestTableTextBlock", "us-gaap:MinorityInterestDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "AATP:NonControllingInterestPaidinCapital", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000069 - Disclosure - SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX (Details)", "role": "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails", "shortName": "SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND", "role": "http://agapeatp.com/role/OrganizationAndBusinessBackground", "shortName": "ORGANIZATION AND BUSINESS BACKGROUND", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000070 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAX (Details)", "role": "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails", "shortName": "SCHEDULE OF PROVISION FOR INCOME TAX (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000071 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)", "role": "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails", "shortName": "SCHEDULE OF DEFERRED TAX ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "lang": null, "name": "AATP:DeferredTaxLiabilitiesDepreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:TaxRateDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000072 - Disclosure - INCOME TAXES (Details Narrative)", "role": "http://agapeatp.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AATP:TaxRateDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Deposits", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000073 - Disclosure - CONCENTRATIONS OF RISKS (Details Narrative)", "role": "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative", "shortName": "CONCENTRATIONS OF RISKS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:Deposits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000074 - Disclosure - SCHEDULE OF LEASE COMMITMENTS (Details)", "role": "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails", "shortName": "SCHEDULE OF LEASE COMMITMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000075 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-05-302021-05-31", "decimals": null, "lang": "en-US", "name": "AATP:LeaseExpirationTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30_custom_GreenproCapitalCorpMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:InvestmentOwnedBalanceShares", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000076 - Disclosure - SUBSEQUENT EVENT (Details Narrative)", "role": "http://agapeatp.com/role/SubsequentEventDetailsNarrative", "shortName": "SUBSEQUENT EVENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30_custom_GreenproCapitalCorpMember", "decimals": "2", "lang": null, "name": "us-gaap:InvestmentOwnedAtFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - VARIABLE INTEREST ENTITY (\u201cVIE\u201d)", "role": "http://agapeatp.com/role/VariableInterestEntityVie", "shortName": "VARIABLE INTEREST ENTITY (\u201cVIE\u201d)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 96, "tag": { "AATP_ATPRMITOPlusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ATPR Mito+ [Member]", "label": "ATPR Mito+ [Member]" } } }, "localname": "ATPRMITOPlusMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "AATP_AccruedPromotionExpensesCurrent": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "AATP_OtherAccountPayableAndAccruedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued promotion expenses, current.", "label": "Promotion expenses" } } }, "localname": "AccruedPromotionExpensesCurrent", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "AATP_AccruedTaxPenaltyCurrent": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "AATP_OtherAccountPayableAndAccruedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued tax penalty, current.", "label": "Tax penalty" } } }, "localname": "AccruedTaxPenaltyCurrent", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "AATP_AgapeATPAsiaLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agape ATP Asia Limited [Member]", "label": "Agape ATP Asia Limited [Member]" } } }, "localname": "AgapeATPAsiaLimitedMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "AATP_AgapeATPInternationalHoldingLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agape ATP International Holding Limited [Member]", "label": "Agape ATP International Holding Limited [Member]" } } }, "localname": "AgapeATPInternationalHoldingLimitedMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_AgapeSuperiorLivingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ASL [Member]", "label": "ASL [Member]" } } }, "localname": "AgapeSuperiorLivingMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Allowance for doubtful accounts receivable exchange rate effect.", "label": "Exchange rate effect" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableExchangeRateEffect", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "AATP_AllowanceForDoubtfulAccountsReceivablesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Allowance for doubtful accounts,", "label": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivablesCurrent", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "AATP_BetaMaxxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beta Maxx [Member]", "label": "Beta Maxx [Member]" } } }, "localname": "BetaMaxxMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "AATP_COVIDNineteenImpactMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "COVID-19 Impact [Member]", "label": "COVID-19 Impact [Member]" } } }, "localname": "COVIDNineteenImpactMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_CTANutriceuticalsSdnBhdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CTA Nutriceuticals Sdn Bhd [Member]", "label": "CTA Nutriceuticals Sdn Bhd [Member]" } } }, "localname": "CTANutriceuticalsSdnBhdMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "AATP_ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Changes in right of use assets and lease liabilities due to lease modifications.", "label": "Changes in right-of-use assets and lease liabilities due to lease modifications" } } }, "localname": "ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "AATP_ComputerAndOfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer and Office Equipment [Member]", "label": "Computer and Office Equipment [Member]" } } }, "localname": "ComputerAndOfficeEquipmentMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "AATP_DSYBeautySdnBhdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DSY Beauty Sdn Bhd [Member]", "label": "DSY Beauty Sdn Bhd [Member]" } } }, "localname": "DSYBeautySdnBhdMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "AATP_DSYBeautySdnBhdOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DSY Beauty Sdn Bhd [Member]", "label": "DSY Beauty Sdn Bhd [Member] [Default Label]", "verboseLabel": "DSY Beauty Sdn Bhd [Member]" } } }, "localname": "DSYBeautySdnBhdOneMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "AATP_DSYWellnessAndLongevityCenterSdnBhdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DSY Wellness & Longevity Center Sdn Bhd [Member]", "label": "DSY Wellness & Longevity Center Sdn Bhd [Member]" } } }, "localname": "DSYWellnessAndLongevityCenterSdnBhdMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "AATP_DSYWellnessAndLongevityCenterSdnBhdOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DSY Wellness & Longevity Center Sdn Bhd [Member]", "label": "DSY Wellness & Longevity Center Sdn Bhd [Member] [Default Label]", "verboseLabel": "DSY Wellness & Longevity Center Sdn Bhd [Member]" } } }, "localname": "DSYWellnessAndLongevityCenterSdnBhdOneMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DSY Wellness and Longevity Center Sdn Bhd [Member]", "label": "DSY Wellness and Longevity Center Sdn Bhd [Member] [Default Label]", "verboseLabel": "DSY Wellness and Longevity Center Sdn Bhd [Member]" } } }, "localname": "DSYWellnessAndLongevityCenterSdnBhdThreeMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "AATP_DSYWellnessandLongevityCenterSdnBhdTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DSY Wellness and Longevity Center Sdn Bhd [Member]", "label": "DSY Wellness and Longevity Center Sdn Bhd [Member]" } } }, "localname": "DSYWellnessandLongevityCenterSdnBhdTwoMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "AATP_DSwissIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DSwiss Inc. [Member]", "label": "DSwiss Inc. [Member]" } } }, "localname": "DSwissIncMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_DeferredTaxLiabilitiesDepreciation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities, depreciation.", "label": "DeferredTaxLiabilitiesDepreciation", "verboseLabel": "Depreciation" } } }, "localname": "DeferredTaxLiabilitiesDepreciation", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "AATP_DefinedContributionPlanPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Contribution Plan [Policy Text Block]", "label": "Defined contribution plan" } } }, "localname": "DefinedContributionPlanPolicyTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "AATP_DepositForInsurance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deposit for insurance.", "label": "Deposit for insurance" } } }, "localname": "DepositForInsurance", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "AATP_DepositsToSupplier": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails": { "order": 2.0, "parentTag": "AATP_PrepaidExpensesGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deposits to supplier.", "label": "Deposits to suppliers" } } }, "localname": "DepositsToSupplier", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails" ], "xbrltype": "monetaryItemType" }, "AATP_DisclosureInvestmentInMarketableSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Marketable Securities", "verboseLabel": "Schedule Of Investment In Marketable Securities" } } }, "localname": "DisclosureInvestmentInMarketableSecuritiesAbstract", "nsuri": "http://agapeatp.com/20220630", "xbrltype": "stringItemType" }, "AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Non-marketable Securities" } } }, "localname": "DisclosureInvestmentInNonmarketableSecuritiesAbstract", "nsuri": "http://agapeatp.com/20220630", "xbrltype": "stringItemType" }, "AATP_DisclosurePrepaymentsAndDepositsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepayments And Deposits", "terseLabel": "Schedule Of Changes In Allowance For Doubtful Accounts", "verboseLabel": "Schedule Of Prepaid Expenses And Deposits" } } }, "localname": "DisclosurePrepaymentsAndDepositsAbstract", "nsuri": "http://agapeatp.com/20220630", "xbrltype": "stringItemType" }, "AATP_ECommerceCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "E-commerce [Member]", "label": "E-commerce [Member]" } } }, "localname": "ECommerceCompanyMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_EmployeesProvidentFundMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees Provident Fund [Member]", "label": "Employees Provident Fund [Member]" } } }, "localname": "EmployeesProvidentFundMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_EmploymentInsuranceSystemMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employment Insurance System [Member]", "label": "Employment Insurance System [Member]" } } }, "localname": "EmploymentInsuranceSystemMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_EnergizedMineralConcentrateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Energized Mineral Concentrate [Member]", "label": "Energized Mineral Concentrate [Member]" } } }, "localname": "EnergizedMineralConcentrateMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails": { "order": 4.0, "parentTag": "us-gaap_MarketableSecuritiesNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exchange rate effect.", "label": "Exchange rate effect [Default Label]", "verboseLabel": "Exchange rate effect" } } }, "localname": "ExchangeRateEffectOnInvestmentInMarketableSecurites", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "AATP_ForeignCurrencyExchangeRateAverage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign currency exchange rate period average.", "label": "Foreign currency exchange rate period average" } } }, "localname": "ForeignCurrencyExchangeRateAverage", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" ], "xbrltype": "pureItemType" }, "AATP_ForfeitedCouponIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Forfeited coupon income.", "label": "Value of coupons" } } }, "localname": "ForfeitedCouponIncome", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "AATP_GreenproCapitalCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Greenpro Capital Corp. [Member]", "label": "Greenpro Capital Corp. [Member]" } } }, "localname": "GreenproCapitalCorpMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_HealthAndWellnessServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health and Wellness Services [Member]", "label": "Health and Wellness Services [Member]" } } }, "localname": "HealthAndWellnessServicesMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails", "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_HostastaySdnBhdHostastayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hostastay Sdn. Bhd. (\u201cHostastay\u201d) [Member]", "label": "Hostastay Sdn. Bhd. (\u201cHostastay\u201d) [Member]", "verboseLabel": "Hostastay Sdn. Bhd. (\u0093Hostastay\u0094) [Member]" } } }, "localname": "HostastaySdnBhdHostastayMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "AATP_HostastaySdnBhdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hostastay Sdn. Bhd. (\u201cHostastay\u201d) [Member]", "label": "Hostastay Sdn. Bhd. (\u0093Hostastay\u0094) [Member]" } } }, "localname": "HostastaySdnBhdMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "AATP_HowKokChoongMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "How Kok Choong [Member]", "label": "How Kok Choong [Member]" } } }, "localname": "HowKokChoongMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "AATP_HowKokChoongTalentLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "How Kok Choong Talent Limited [Member]", "label": "How Kok Choong Talent Limited [Member]" } } }, "localname": "HowKokChoongTalentLimitedMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_HumanResourceDevelopmentFundMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Human Resource Development Fund [Member]", "label": "Human Resource Development Fund [Member]" } } }, "localname": "HumanResourceDevelopmentFundMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_HyaluronicAcidSerumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hyaluronic Acid Serum [Member]", "label": "Hyaluronic Acid Serum [Member]" } } }, "localname": "HyaluronicAcidSerumMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "AATP_IncreaseDecreaseInROUAssetsAndLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reduction in ROU assets and liabilities.", "label": "Reduction in ROU assets and liabilities" } } }, "localname": "IncreaseDecreaseInROUAssetsAndLiabilities", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "AATP_InvestmentInMarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment in Marketable Securities [Text Block]", "label": "INVESTMENT IN MARKETABLE SECURITIES" } } }, "localname": "InvestmentInMarketableSecuritiesTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/InvestmentInMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "AATP_InvestmentInNonMarketableSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in non marketable securities noncurrent.", "label": "Investment in non-marketable securities", "verboseLabel": "Cost of investment" } } }, "localname": "InvestmentInNonMarketableSecuritiesNoncurrent", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/BalanceSheets", "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "AATP_InvestmentInNonMarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment in Non Marketable Securities [Text Block]", "label": "INVESTMENT IN NON-MARKETABLE SECURITIES" } } }, "localname": "InvestmentInNonMarketableSecuritiesTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/InvestmentInNon-marketableSecurities" ], "xbrltype": "textBlockItemType" }, "AATP_InvestmentsIncomeDividend": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_MarketableSecuritiesNoncurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Dividend income .", "label": "Dividend income", "negatedLabel": "Dividend income from Greenpro Capital Corp." } } }, "localname": "InvestmentsIncomeDividend", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "AATP_IonizedCalMagMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ionized Cal-Mag [Member]", "label": "Ionized Cal-Mag [Member]" } } }, "localname": "IonizedCalMagMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "AATP_IronMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Iron [Member]", "label": "Iron [Member]" } } }, "localname": "IronMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "AATP_LabuanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Labuan [Member]", "label": "Labuan [Member]" } } }, "localname": "LabuanMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_LeaseExpirationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease expiration term.", "label": "Lease expiration term" } } }, "localname": "LeaseExpirationTerm", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "dateItemType" }, "AATP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "AATP_LipomaskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lipomask [Member]", "label": "Lipomask [Member]" } } }, "localname": "LipomaskMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "AATP_MYRCurrencyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MYR Currency [Member]", "label": "MYR Currency [Member]" } } }, "localname": "MYRCurrencyMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_MarketableSecuritiesUnrealizedHoldingGainLoss": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_MarketableSecuritiesNoncurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrealized holding (loss) gain.", "label": "Unrealized holding (loss) gain", "negatedLabel": "Unrealized holding loss" } } }, "localname": "MarketableSecuritiesUnrealizedHoldingGainLoss", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "AATP_MonthlySalary": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Monthly salary.", "label": "Monthly salary" } } }, "localname": "MonthlySalary", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "AATP_MousseFacialCleanserMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mousse Facial Cleanser [Member]", "label": "Mousse Facial Cleanser [Member]" } } }, "localname": "MousseFacialCleanserMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "AATP_MrHowKokChoongMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr.How Kok Choong [Member]", "label": "Mr.How Kok Choong [Member]" } } }, "localname": "MrHowKokChoongMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_NameOftheCompany": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the company name.", "label": "Subsidiary company name" } } }, "localname": "NameOftheCompany", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails" ], "xbrltype": "stringItemType" }, "AATP_NetOperatingLossCarryForwardsExpirationDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net operating loss carry forwards expiration, description.", "label": "Net operating loss carry forwards expiration, description" } } }, "localname": "NetOperatingLossCarryForwardsExpirationDescription", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "AATP_NoCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No Customer [Member]", "label": "No Customer [Member]" } } }, "localname": "NoCustomerMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_NoSalesDistributorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No Sales Distributor [Member]", "label": "No Sales Distributor [Member]" } } }, "localname": "NoSalesDistributorMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_NonControllingInterestAccumulatedDeficit": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails": { "order": 2.0, "parentTag": "AATP_NonControllingInterestNonControllingInterestGross", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non controlling interest accumulated deficit.", "label": "Retained earnings (Accumulated deficit)" } } }, "localname": "NonControllingInterestAccumulatedDeficit", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails" ], "xbrltype": "monetaryItemType" }, "AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails": { "order": 3.0, "parentTag": "AATP_NonControllingInterestNonControllingInterestGross", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non controlling interest accumulated other comprehensive income.", "label": "Accumulated other comprehensive (loss) income" } } }, "localname": "NonControllingInterestAccumulatedOtherComprehensiveIncome", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails" ], "xbrltype": "monetaryItemType" }, "AATP_NonControllingInterestAsl": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non controlling interest ASL.", "label": "ASL" } } }, "localname": "NonControllingInterestAsl", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails" ], "xbrltype": "monetaryItemType" }, "AATP_NonControllingInterestNonControllingInterestGross": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-Controlling interest non controlling interest gross", "label": "NonControllingInterestNonControllingInterestGross", "totalLabel": "Non Controlling interest Gross" } } }, "localname": "NonControllingInterestNonControllingInterestGross", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails" ], "xbrltype": "monetaryItemType" }, "AATP_NonControllingInterestPaidinCapital": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails": { "order": 1.0, "parentTag": "AATP_NonControllingInterestNonControllingInterestGross", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non controlling interest paid in capital.", "label": "Paid-in capital" } } }, "localname": "NonControllingInterestPaidinCapital", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails" ], "xbrltype": "monetaryItemType" }, "AATP_NonMarketableSecuritiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non Marketable Securities [Policy Text Block]", "label": "Investment in non-marketable equity securities" } } }, "localname": "NonMarketableSecuritiesPolicyTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "AATP_NonMarketableSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non Marketable Securities [Table Text Block]", "label": "SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES" } } }, "localname": "NonMarketableSecuritiesTableTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "AATP_NoncontrollingInterestPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-controlling Interest [Policy Text Block]", "label": "Non-controlling interest" } } }, "localname": "NoncontrollingInterestPolicyTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "AATP_OmegaBlendMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Omega Blend [Member]", "label": "Omega Blend [Member]" } } }, "localname": "OmegaBlendMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "AATP_OneIndividualCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Individual Customers [Member]", "label": "One Individual Customers [Member]" } } }, "localname": "OneIndividualCustomersMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_OneSalesDistributorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Sales Distributor [Member]", "label": "One Sales Distributor [Member]" } } }, "localname": "OneSalesDistributorMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_OneVendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Vendor [Member]", "label": "One Vendor [Member]" } } }, "localname": "OneVendorMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_OrganicYouthCarCleansingBarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organic Youth Care Cleansing Bar [Member]", "label": "Organic Youth Care Cleansing Bar [Member]" } } }, "localname": "OrganicYouthCarCleansingBarMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "AATP_OtherAccountPayableAndAccruedLiabilities": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.", "label": "OtherAccountPayableAndAccruedLiabilities", "totalLabel": "Total" } } }, "localname": "OtherAccountPayableAndAccruedLiabilities", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "AATP_OtherPayablesRelatedPartyCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other payables - related party, current.", "label": "OtherPayablesRelatedPartyCurrent", "verboseLabel": "Other payables and accrued liabilities" } } }, "localname": "OtherPayablesRelatedPartyCurrent", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "AATP_OthersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Others [Member]", "label": "Others [Member]" } } }, "localname": "OthersMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "AATP_ParticularsOfIssuedCapital": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Particulars of issued capital.", "label": "Particulars of issued capital" } } }, "localname": "ParticularsOfIssuedCapital", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails" ], "xbrltype": "stringItemType" }, "AATP_PeriodAverageHKDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period-average HKD [Member]", "label": "Period-average HKD [Member]" } } }, "localname": "PeriodAverageHKDMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" ], "xbrltype": "domainItemType" }, "AATP_PeriodAverageMYRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period-average MYR [Member]", "label": "Period-average MYR [Member]" } } }, "localname": "PeriodAverageMYRMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" ], "xbrltype": "domainItemType" }, "AATP_PeriodEndHKDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period-end HKD [Member]", "label": "Period-end HKD [Member]" } } }, "localname": "PeriodEndHKDMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" ], "xbrltype": "domainItemType" }, "AATP_PeriodEndMYRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period-end MYR [Member]", "label": "Period-end MYR [Member]" } } }, "localname": "PeriodEndMYRMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" ], "xbrltype": "domainItemType" }, "AATP_PhoenixPlusCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Phoenix Plus Corporation [Member]", "label": "Phoenix Plus Corporation [Member]" } } }, "localname": "PhoenixPlusCorpMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "AATP_PlaceAndDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Place and date of incorporation.", "label": "Place and date of incorporation" } } }, "localname": "PlaceAndDateOfIncorporation", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails" ], "xbrltype": "stringItemType" }, "AATP_PrepaidExpensesGross": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid expenses gross.", "label": "Prepaid expenses gross", "totalLabel": "Subtotal" } } }, "localname": "PrepaidExpensesGross", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails" ], "xbrltype": "monetaryItemType" }, "AATP_PrepaidTaxesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid Taxes [Policy Text Block]", "label": "Prepaid taxes" } } }, "localname": "PrepaidTaxesPolicyTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "AATP_PrepaymentsAndDepositsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayments and Deposits [Policy Text Block]", "label": "PrepaymentsAndDepositsPolicyTextBlock", "verboseLabel": "Prepayments and deposits" } } }, "localname": "PrepaymentsAndDepositsPolicyTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "AATP_PrepaymentsAndDepositsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayments and Deposits [Text Block]", "label": "PREPAYMENTS AND DEPOSITS" } } }, "localname": "PrepaymentsAndDepositsTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/PrepaymentsAndDeposits" ], "xbrltype": "textBlockItemType" }, "AATP_PrincipalActivities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Principal activities.", "label": "Principal activities" } } }, "localname": "PrincipalActivities", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails" ], "xbrltype": "stringItemType" }, "AATP_ProductHealthTherapiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Others - Products for the Provision of Complementary Health Therapies [Member]", "label": "Others - Products for the Provision of Complementary Health Therapies [Member]" } } }, "localname": "ProductHealthTherapiesMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "AATP_ReceivablesFromSalesDistributors": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails": { "order": 1.0, "parentTag": "AATP_PrepaidExpensesGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables from sales distributors.", "label": "Receivables from sales distributors" } } }, "localname": "ReceivablesFromSalesDistributors", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails" ], "xbrltype": "monetaryItemType" }, "AATP_ReductionInCommonStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reduction in common stock outstanding during period.", "label": "Reduction in outstanding shares" } } }, "localname": "ReductionInCommonStockOutstanding", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "AATP_RelatedPartiesNatureDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related parties nature, description.", "label": "Nature" } } }, "localname": "RelatedPartiesNatureDescription", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "AATP_RelatedPartiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Parties [Policy Text Block]", "label": "Related parties" } } }, "localname": "RelatedPartiesPolicyTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "AATP_RelatedPartiesRelationshipsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related parties, relationships, description.", "label": "Relationship" } } }, "localname": "RelatedPartiesRelationshipsDescription", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "AATP_RelatedPartyOfficeRentalExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related party office rental expenses.", "label": "Office rental expense" } } }, "localname": "RelatedPartyOfficeRentalExpenses", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "AATP_RelatedPartyOtherIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Other income" } } }, "localname": "RelatedPartyOtherIncome", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Other purchases" } } }, "localname": "RelatedPartyTransactionOtherPurchasesFromRelatedParty", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "AATP_SEATechVenturesCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SEATech Ventures Corp. [Member]", "label": "SEATech Ventures Corp. [Member]" } } }, "localname": "SEATechVenturesCorpMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_SalaryPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Salary percentage.", "label": "Salary percentage" } } }, "localname": "SalaryPercentage", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "AATP_SalesCommissionsAndFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Commission expense.", "label": "Commission" } } }, "localname": "SalesCommissionsAndFee", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "AATP_SalesCommissionsAndFees1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).", "label": "Commission expenses [Default Label]", "verboseLabel": "Commission expenses" } } }, "localname": "SalesCommissionsAndFees1", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "AATP_ScheduleOfChangesInAllowanceForDoubtfulAccountsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Changes in Allowance for Doubtful Accounts [Table Text Block]", "label": "SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS" } } }, "localname": "ScheduleOfChangesInAllowanceForDoubtfulAccountsTableTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/PrepaymentsAndDepositsTables" ], "xbrltype": "textBlockItemType" }, "AATP_ScheduleOfDisaggregatedInformationOfRevenuesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Disaggregated Information of Revenues [Table Text Block]", "label": "SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES" } } }, "localname": "ScheduleOfDisaggregatedInformationOfRevenuesTableTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "AATP_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Estimated Useful Lives of Intangible Assets Net [Table Text Block]", "label": "SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET" } } }, "localname": "ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "AATP_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Estimated Useful Lives of Property and Equipment [Table Text Block]", "label": "SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT" } } }, "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "AATP_ScheduleOfNonControllingInterestTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Non Controlling Interest [Table Text Block]", "label": "SCHEDULE OF NON CONTROLLING INTEREST" } } }, "localname": "ScheduleOfNonControllingInterestTableTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/Non-controllingInterestTables" ], "xbrltype": "textBlockItemType" }, "AATP_ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Other Payables and Accrued Liabilities [Table Text Block]", "label": "SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES" } } }, "localname": "ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "AATP_ShareExchangeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Exchange Agreement [Member]", "label": "Share Exchange Agreement [Member]" } } }, "localname": "ShareExchangeAgreementMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_ShareForfeitureAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Forfeiture Agreements [Member]", "label": "Share Forfeiture Agreements [Member]" } } }, "localname": "ShareForfeitureAgreementsMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_ShippingAndHandlingPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shipping and Handling [Policy Text Block]", "label": "Shipping and handling" } } }, "localname": "ShippingAndHandlingPolicyTextBlock", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "AATP_SocialSecurityOrganizationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Social Security Organization [Member]", "label": "Social Security Organization [Member]" } } }, "localname": "SocialSecurityOrganizationMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_SubsidiaryCompanyFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subsidiary Company Five [Member]", "label": "Subsidiary Company Five [Member]" } } }, "localname": "SubsidiaryCompanyFiveMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative", "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails" ], "xbrltype": "domainItemType" }, "AATP_SubsidiaryCompanyFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subsidiary Company Four [Member]", "label": "Subsidiary Company Four [Member]" } } }, "localname": "SubsidiaryCompanyFourMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails" ], "xbrltype": "domainItemType" }, "AATP_SubsidiaryCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subsidiary Company [Member]", "label": "Subsidiary Company [Member]" } } }, "localname": "SubsidiaryCompanyMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails" ], "xbrltype": "domainItemType" }, "AATP_SubsidiaryCompanyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subsidiary Company One [Member]", "label": "Subsidiary Company One [Member]" } } }, "localname": "SubsidiaryCompanyOneMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails" ], "xbrltype": "domainItemType" }, "AATP_SubsidiaryCompanyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subsidiary Company Three [Member]", "label": "Subsidiary Company Three [Member]" } } }, "localname": "SubsidiaryCompanyThreeMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails", "http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_SubsidiaryCompanyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subsidiary Company Two [Member]", "label": "Subsidiary Company Two [Member]" } } }, "localname": "SubsidiaryCompanyTwoMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative", "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails" ], "xbrltype": "domainItemType" }, "AATP_SurvivorSelectMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Survivor Select [Member]", "label": "Survivor Select [Member]" } } }, "localname": "SurvivorSelectMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "AATP_TaxRateDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax rate description.", "label": "Tax rate description" } } }, "localname": "TaxRateDescription", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "AATP_TrainingCenterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Training Center [Member]", "label": "Training Center [Member]" } } }, "localname": "TrainingCenterMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_TrimPlusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trim+ [Member]", "label": "Trim+ [Member]" } } }, "localname": "TrimPlusMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "AATP_UnutilizedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unutilized [Member]", "label": "Unutilized [Member]" } } }, "localname": "UnutilizedMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "VIE consolidated amount of cash and cash equivalents.", "label": "VIE consolidated amount of cash and cash equivalents" } } }, "localname": "VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "AATP_VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "VIE consolidated amount of other payables and accrued liabilities.", "label": "VIE consolidated amount of other payables and accrued liabilities" } } }, "localname": "VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "AATP_VariableInterestEntityConsolidatedAmountOfPrepaidTaxes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "VIE consolidated amount of Prepaid taxes .", "label": "VIE consolidated amount of prepaid taxes" } } }, "localname": "VariableInterestEntityConsolidatedAmountOfPrepaidTaxes", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "AATP_VehicleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vehicle [Member]", "label": "Vehicle [Member]" } } }, "localname": "VehicleMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "AATP_VendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor [Member]", "label": "Vendor [Member]" } } }, "localname": "VendorMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_VendorOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor One [Member]", "label": "Vendor One [Member]" } } }, "localname": "VendorOneMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_VendorThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor Three [Member]", "label": "Vendor Three [Member]" } } }, "localname": "VendorThreeMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_VendorTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor Two [Member]", "label": "Vendor Two [Member]" } } }, "localname": "VendorTwoMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "AATP_YoungFormulaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Young Formula [Member]", "label": "Young Formula [Member]" } } }, "localname": "YoungFormulaMember", "nsuri": "http://agapeatp.com/20220630", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "country_HK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "HONG KONG" } } }, "localname": "HK", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative", "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails" ], "xbrltype": "domainItemType" }, "country_MY": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MALAYSIA" } } }, "localname": "MY", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative", "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails", "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative", "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r586" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r584", "r586", "r587" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r585" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r586" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r586" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative", "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails", "http://agapeatp.com/role/SubsequentEventDetailsNarrative", "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r593" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative", "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails", "http://agapeatp.com/role/SubsequentEventDetailsNarrative", "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r586" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r582" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r583" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r592" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agapeatp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative", "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails", "http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r170", "r302", "r306", "r539" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r229", "r230", "r231", "r232", "r250", "r271", "r312", "r315", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r536", "r540", "r570", "r571" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative", "http://agapeatp.com/role/IncomeTaxesDetailsNarrative", "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r229", "r230", "r231", "r232", "r250", "r271", "r312", "r315", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r536", "r540", "r570", "r571" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative", "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r170", "r302", "r306", "r539" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r167", "r230", "r231", "r302", "r304", "r487", "r535", "r537" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails", "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r167", "r230", "r231", "r302", "r304", "r487", "r535", "r537" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails", "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r217", "r229", "r230", "r231", "r232", "r250", "r271", "r309", "r312", "r315", "r338", "r339", "r340", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r536", "r540", "r570", "r571" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative", "http://agapeatp.com/role/IncomeTaxesDetailsNarrative", "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r217", "r229", "r230", "r231", "r232", "r250", "r271", "r309", "r312", "r315", "r338", "r339", "r340", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r536", "r540", "r570", "r571" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative", "http://agapeatp.com/role/IncomeTaxesDetailsNarrative", "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r119", "r124", "r228", "r313" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative", "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails", "http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r168", "r169", "r302", "r305", "r538", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative", "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails", "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r168", "r169", "r302", "r305", "r538", "r555", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative", "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails", "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r119", "r124", "r228", "r313", "r473" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r171", "r464" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilities": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": { "order": 6.0, "parentTag": "AATP_OtherAccountPayableAndAccruedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.", "label": "Others" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts payable \u2013 intercompany" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts Payable [Member]" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableOtherCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Other payable \u2013 a related party", "verboseLabel": "Amount due to a Related Party" } } }, "localname": "AccountsPayableOtherCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets", "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r43", "r108", "r463", "r465" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable \u2013 a related party", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets", "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r11", "r43" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r6", "r27", "r172", "r173" ], "calculation": { "http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r172", "r173" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable", "totalLabel": "Total accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets", "http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "AATP_OtherAccountPayableAndAccruedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Payroll" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "AATP_OtherAccountPayableAndAccruedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalesCommissionCurrent": { "auth_ref": [ "r10", "r46" ], "calculation": { "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "AATP_OtherAccountPayableAndAccruedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Commissions" } } }, "localname": "AccruedSalesCommissionCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r19", "r213" ], "calculation": { "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r32", "r55", "r56", "r57", "r522", "r545", "r546" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r54", "r57", "r64", "r65", "r66", "r111", "r112", "r113", "r403", "r458", "r541", "r542" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r30", "r470" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Paid in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r111", "r112", "r113", "r343", "r344", "r345", "r421" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": { "auth_ref": [ "r283", "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.", "label": "Adjustments to Additional Paid in Capital, Stock Split", "verboseLabel": "Additional paid in capital" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r347" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "verboseLabel": "Advertising costs" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": { "auth_ref": [ "r178" ], "calculation": { "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.", "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables", "negatedLabel": "Less: Provision for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r36", "r178", "r186", "r187", "r190" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r36", "r178", "r186" ], "calculation": { "http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts receivable, allowance for credit loss", "negatedLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails", "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable.", "label": "Addition" } } }, "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Write off" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r89", "r199", "r205" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IntangibleAssetsNetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Potentially dilutive securities outstanding" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StockholdersEquityDetailsNarrative", "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative", "http://agapeatp.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r22", "r103", "r156", "r159", "r165", "r184", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r396", "r404", "r429", "r468", "r470", "r504", "r521" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r42", "r103", "r184", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r396", "r404", "r429", "r468", "r470" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total current assets", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets", "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r103", "r184", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r396", "r404", "r429", "r468" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total Other Assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER ASSETS" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r311", "r314", "r388" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r311", "r314", "r386", "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r3", "r110", "r151" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "ORGANIZATION AND BUSINESS BACKGROUND" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/OrganizationAndBusinessBackground" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r572" ], "calculation": { "http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Computer software" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r17", "r470", "r548", "r549" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r17", "r91" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents (Included $7,626 and $17,493 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of June 30, 2022 and December 31, 2021, respectively)", "terseLabel": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets", "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative", "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.", "label": "CASH AND CASH EQUIVALENTS" } } }, "localname": "CashAndCashEquivalentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CashAndCashEquivalents" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r86", "r91", "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "CASH AND CASH EQUIVALENTS, end of period", "periodStartLabel": "CASH AND CASH EQUIVALENTS, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r86", "r434" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "DECREASE IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommissionsExpensePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commissions incurred in relation to revenue generating activities or operations.", "label": "Commission expenses" } } }, "localname": "CommissionsExpensePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r225", "r226", "r227", "r233", "r557" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r111", "r112", "r421" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheetsParenthetical", "http://agapeatp.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheetsParenthetical", "http://agapeatp.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r26", "r283" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheetsParenthetical", "http://agapeatp.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r26", "r470" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, par value $0.0001; 1,000,000,000 shares authorized, 75,452,012 and 290,460,047 shares issued and outstanding as of June 30, 2022 and December 31, 2021 respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r59", "r61", "r62", "r72", "r513", "r531" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "COMPREHENSIVE LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r59", "r61", "r71", "r394", "r395", "r413", "r512", "r530" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Less: Comprehensive loss attributable to non-controlling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r59", "r61", "r70", "r393", "r413", "r511", "r529" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "TOTAL COMPREHENSIVE LOSS" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r200", "r203", "r389" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r145", "r146", "r170", "r426", "r427", "r556" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r145", "r146", "r170", "r426", "r427", "r547", "r556" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r145", "r146", "r170", "r426", "r427", "r547", "r556" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "CONCENTRATIONS OF RISKS" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisks" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r145", "r146", "r170", "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentrations of risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r143", "r145", "r146", "r147", "r426", "r428", "r556" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r145", "r146", "r170", "r426", "r427", "r556" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r96", "r398" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r291", "r292", "r303" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Customer deposits" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r78", "r487" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "negatedLabel": "COST OF REVENUE", "verboseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSoldAmortization": { "auth_ref": [ "r76" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.", "label": "Amortization" } } }, "localname": "CostOfGoodsAndServicesSoldAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsTotalMember": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation.", "label": "Cost of Goods and Service Benchmark [Member]" } } }, "localname": "CostOfGoodsTotalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of revenue" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current:" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r104", "r369" ], "calculation": { "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "negatedLabel": "- Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r104", "r369", "r376" ], "calculation": { "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current State and Local Tax Expense (Benefit)", "negatedLabel": "- Local" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r144", "r170" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r49", "r102", "r109", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r284", "r285", "r286", "r287", "r444", "r445", "r446", "r447", "r519" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "verboseLabel": "Deferred offering costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCosts": { "auth_ref": [ "r21", "r503", "r520" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.", "label": "Deferred offering costs" } } }, "localname": "DeferredCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "SCHEDULE OF PREPAID EXPENSES AND DEPOSITS" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/PrepaymentsAndDepositsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred:" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r104", "r370", "r376" ], "calculation": { "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "negatedLabel": "- Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r89", "r104", "r370", "r376", "r377", "r378" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred tax provision (benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r351", "r352" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r104", "r370", "r376" ], "calculation": { "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "negatedLabel": "- Local" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r362" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "negatedLabel": "Deferred tax liabilities, net" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "auth_ref": [ "r367", "r368" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.", "label": "Net operating loss carry forwards in Malaysia" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r361" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred tax valuation allowance", "negatedLabel": "Less: valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative", "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined contribution plan expense" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Deposits": { "auth_ref": [ "r508" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.", "label": "Deposits" } } }, "localname": "Deposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r89", "r211" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/PropertyAndEquipmentNetDetailsNarrative", "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r28", "r108", "r237", "r239", "r240", "r244", "r245", "r246", "r462", "r507", "r527" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due from related parties" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r73", "r116", "r117", "r118", "r119", "r120", "r125", "r127", "r130", "r131", "r132", "r135", "r136", "r422", "r423", "r514", "r532" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and diluted" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LOSS PER SHARE" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING" } } }, "localname": "EarningsPerShareBasicOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r133", "r134" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings (loss) per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r434" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective income tax rate reconciliation, percent" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r106", "r354", "r380" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Tax percentage" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r64", "r65", "r66", "r111", "r112", "r113", "r115", "r121", "r123", "r138", "r185", "r283", "r288", "r343", "r344", "r345", "r372", "r373", "r421", "r435", "r436", "r437", "r438", "r439", "r440", "r458", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Proportional of ownership interest and voting power held", "terseLabel": "Equity interest percentage", "verboseLabel": "Ownership interest percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative", "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails", "http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair value of financial instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Estimated useful lives of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r20", "r204" ], "calculation": { "http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Less: accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r200", "r201", "r204", "r206", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r200", "r203" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r204", "r488" ], "calculation": { "http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyExchangeRateTranslation1": { "auth_ref": [ "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.", "label": "Foreign currency exchange rate, translation" } } }, "localname": "ForeignCurrencyExchangeRateTranslation1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" ], "xbrltype": "pureItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r430", "r431", "r432", "r433" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Exchange loss, net" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign currencies translation and transaction" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails", "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "negatedLabel": "GENERAL AND ADMINISTRATIVE" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r77", "r103", "r156", "r158", "r161", "r164", "r166", "r184", "r234", "r235", "r236", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r429" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross profit", "totalLabel": "GROSS PROFIT" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails", "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r89", "r210" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of long-lived assets" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r208", "r215" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment for long-lived assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r105", "r379" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Local \u2013 United States" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r68", "r156", "r158", "r161", "r164", "r166", "r502", "r509", "r515", "r533" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Loss before income tax", "totalLabel": "LOSS BEFORE INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails", "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r105", "r379" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Foreign \u2013 Hong Kong" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r106", "r355", "r359", "r364", "r374", "r381", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationDescription": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.", "label": "Income tax examination, description" } } }, "localname": "IncomeTaxExaminationDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": { "auth_ref": [ "r348", "r357" ], "lang": { "en-us": { "role": { "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.", "label": "Income tax examination, likelihood of unfavorable settlement" } } }, "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": { "auth_ref": [ "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.", "label": "Income tax examination, penalties and interest expense" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r122", "r123", "r155", "r353", "r375", "r382", "r534" ], "calculation": { "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "PROVISION FOR INCOME TAXES", "negatedTotalLabel": "Provision for income tax" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails", "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r63", "r349", "r350", "r359", "r360", "r363", "r371" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r88" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Accounts Payable, Related Parties", "verboseLabel": "Accounts payable \u2013 a related party" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r88" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivables" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r88" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Income tax payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r88", "r482" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Customer deposits" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent": { "auth_ref": [ "r88" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in related party receivables classified as other, due within one year or operating cycle, if longer.", "label": "Increase (Decrease) in Due from Other Related Parties, Current", "negatedLabel": "Amount due from related parties" } } }, "localname": "IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent": { "auth_ref": [ "r88" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in related party payables classified as other, due within one year or operating cycle, if longer.", "label": "Amount due to a related party" } } }, "localname": "IncreaseDecreaseInDueToOtherRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r88" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r88", "r453" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "verboseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayable": { "auth_ref": [ "r88" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Increase (Decrease) in Other Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r88" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Other payables and accrued liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "auth_ref": [ "r88" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Expenses, Other", "negatedLabel": "Prepayments and deposits" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "auth_ref": [ "r88" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Taxes", "negatedLabel": "Prepaid taxes" } } }, "localname": "IncreaseDecreaseInPrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "INTANGIBLE ASSETS, NET" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IntangibleAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r97", "r203", "r484", "r485", "r486", "r488" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "verboseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r198", "r202" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r41", "r470" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r12", "r39", "r98", "r137", "r192", "r194", "r195", "r483" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r193" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory write-downs", "verboseLabel": "Inventories write-down" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/InventoriesDetailsNarrative", "http://agapeatp.com/role/StatementsOfCashFlows", "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r80", "r154" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtCost": { "auth_ref": [ "r550" ], "calculation": { "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_MarketableSecuritiesNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of the investment.", "label": "Cost of investment", "verboseLabel": "Investment amount" } } }, "localname": "InvestmentOwnedAtCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails", "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtFairValue": { "auth_ref": [ "r550", "r553", "r554" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.", "label": "Investment owned, fair value" } } }, "localname": "InvestmentOwnedAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedBalanceShares": { "auth_ref": [ "r551", "r552" ], "lang": { "en-us": { "role": { "documentation": "Balance held at close of period in number of shares.", "label": "Investment in securities, shares", "terseLabel": "Investment owned, balance shares", "verboseLabel": "Shares purchased during period" } } }, "localname": "InvestmentOwnedBalanceShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails", "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "SCHEDULE OF LEASE COMMITMENTS" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r456" ], "calculation": { "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r456" ], "calculation": { "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r456" ], "calculation": { "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r456" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r45", "r103", "r160", "r184", "r234", "r235", "r236", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r397", "r404", "r405", "r429", "r468", "r469" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r35", "r103", "r184", "r429", "r470", "r506", "r525" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r9", "r48", "r103", "r184", "r234", "r235", "r236", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r397", "r404", "r405", "r429", "r468", "r469", "r470" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Total current liabilities", "negatedLabel": "Current liabilities", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets", "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r14", "r15", "r16", "r23", "r24", "r103", "r184", "r234", "r235", "r236", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r397", "r404", "r405", "r429", "r468", "r469" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total Non-current Liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CURRENT LIABILITIES" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.", "label": "ACCOUNTS RECEIVABLE" } } }, "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/AccountsReceivable" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 }, "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Investment in marketable securities", "totalLabel": "Investment in marketable securities" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets", "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Investment in marketable equity securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r75" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Unrealized holding loss on marketable securities", "negatedLabel": "Unrealized holding loss on marketable securities" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows", "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r52", "r103", "r184", "r234", "r239", "r240", "r241", "r245", "r246", "r429", "r505", "r524" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "NON-CONTROLLING INTERESTS", "verboseLabel": "Total" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets", "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of noncontrolling interest which might include background information, terms of the ownership arrangement, and type and terms of equity interest owned by the noncontrolling interest holders.", "label": "Noncontrolling interest, description" } } }, "localname": "MinorityInterestDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestDisclosureTextBlock": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "NON-CONTROLLING INTEREST" } } }, "localname": "MinorityInterestDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/Non-controllingInterest" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r86", "r87", "r90" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r58", "r60", "r66", "r69", "r90", "r103", "r114", "r116", "r117", "r118", "r119", "r122", "r123", "r128", "r156", "r158", "r161", "r164", "r166", "r184", "r234", "r235", "r236", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r423", "r429", "r510", "r528" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income (loss)", "totalLabel": "NET LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails", "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r58", "r60", "r66", "r122", "r123", "r400", "r412" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "LESS: NET INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r116", "r117", "r118", "r119", "r125", "r126", "r129", "r132", "r156", "r158", "r161", "r164", "r166" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "NET LOSS", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows", "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity", "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL NON-CASH FLOWS INFORMATION" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Abstract]" } } }, "localname": "NoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r111", "r112", "r113", "r288", "r391" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r81" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "TOTAL OTHER EXPENSES, NET" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER (EXPENSES) INCOME" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NotesReceivableRelatedPartiesCurrent": { "auth_ref": [ "r29", "r108", "r462" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).", "label": "Amount due from related parties" } } }, "localname": "NotesReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "negatedTotalLabel": "TOTAL OPERATING EXPENSES" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r156", "r158", "r161", "r164", "r166" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "LOSS FROM OPERATIONS", "verboseLabel": "Profit (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails", "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r450" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating lease, expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r449" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Present value of lease liabilities", "verboseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r449" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r449" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r451", "r453" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r448" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r89" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization of operating right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r455", "r457" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating lease effective interest rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r454", "r457" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating lease, weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net operating loss carryforward" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.", "label": "Other payables and accrued liabilities ($787 and $1,548 are included in the consolidated VIE that are without recourse to the credit of Agape ATP Corporation as of June 30, 2022 and December 31, 2021, respectively)" } } }, "localname": "OtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r393", "r394", "r402" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "verboseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER COMPREHENSIVE LOSS" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]" } } }, "localname": "OtherLiabilitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "OTHER PAYABLES AND ACCRUED LIABILITIES" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income (expenses), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r84" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Deferred offering costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMachineryAndEquipment": { "auth_ref": [ "r83" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for acquisition of machinery and equipment.", "label": "Payments to Acquire Machinery and Equipment", "negatedLabel": "Purchase of equipment" } } }, "localname": "PaymentsToAcquireMachineryAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of interest-bearing domestic time deposit liabilities to total deposit liabilities.", "label": "Percentage of Interest-Bearing Domestic Deposits to Deposits, Time Deposits" } } }, "localname": "PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r25", "r269" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheetsParenthetical", "http://agapeatp.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r25", "r269" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheetsParenthetical", "http://agapeatp.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheetsParenthetical", "http://agapeatp.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r25", "r470" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.0001 par value; 200,000,000 shares authorized; None issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepayments and deposits", "totalLabel": "Total" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets", "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r7", "r196", "r197" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid taxes (Included $1,744 and $1,357 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of June 30, 2022 and December 31, 2021, respectively)", "verboseLabel": "Prepaid taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets", "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Advances to related parties" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails", "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r58", "r60", "r66", "r85", "r103", "r114", "r122", "r123", "r156", "r158", "r161", "r164", "r166", "r184", "r234", "r235", "r236", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r393", "r399", "r401", "r412", "r413", "r423", "r429", "r515" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "NET LOSS" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails", "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r216", "r558", "r559", "r560" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT, NET" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/PropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Estimated Useful Lives of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r18", "r212" ], "calculation": { "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Subtotal" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails", "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r214", "r470", "r517", "r526" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 }, "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets", "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r214", "r558", "r559" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "SCHEDULE OF PROPERTY AND EQUIPMENT, NET" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/PropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails", "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Estimated Useful Life of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r74", "r188" ], "calculation": { "http://agapeatp.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision for doubtful accounts", "negatedLabel": "PROVISION FOR DOUBTFUL ACCOUNTS" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows", "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r310", "r461", "r462" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails", "http://agapeatp.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Purchases" } } }, "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r310", "r461", "r465", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails", "http://agapeatp.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r459", "r460", "r462", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY BALANCES AND TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/RelatedPartyBalancesAndTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r31", "r288", "r470", "r523", "r544", "r546" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r111", "r112", "r113", "r115", "r121", "r123", "r185", "r343", "r344", "r345", "r372", "r373", "r421", "r541", "r543" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r152", "r153", "r157", "r162", "r163", "r167", "r168", "r170", "r301", "r302", "r487" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "REVENUE", "terseLabel": "Operating revenues", "verboseLabel": "Revenue from contract with customer excluding assessed tax" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails", "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r145", "r170" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r99", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r307" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "verboseLabel": "Customer deposits" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r99", "r100" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r67", "r103", "r152", "r153", "r157", "r162", "r163", "r167", "r168", "r170", "r184", "r234", "r235", "r236", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r429", "r515" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Total revenues - products and services" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SalesCommissionsAndFees": { "auth_ref": [ "r79" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).", "label": "Sales Commissions and Fees", "negatedLabel": "COMMISSION" } } }, "localname": "SalesCommissionsAndFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/AccountsReceivableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "SCHEDULE OF PROVISION FOR INCOME TAX" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "SCHEDULE OF DEFERRED TAX ASSETS" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r200", "r203", "r488" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r200", "r203" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "SCHEDULE OF INTANGIBLE ASSETS, NET" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.", "label": "SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES" } } }, "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r12", "r38", "r39", "r40" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "SCHEDULE OF INVENTORIES" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails", "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails", "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r463", "r465" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "SCHEDULE OF RELATED PARTIES" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/RelatedPartyBalancesAndTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r218", "r219", "r220", "r221", "r222", "r223", "r224" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership.", "label": "SCHEDULE OF SUBSIDIARIES AND ASSOCIATES" } } }, "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "auth_ref": [ "r406", "r407", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "SCHEDULE OF VARIABLE INTEREST ENTITY" } } }, "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/VariableInterestEntityVieTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingExpense": { "auth_ref": [ "r79" ], "calculation": { "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services.", "label": "Selling expenses", "negatedLabel": "SELLING" } } }, "localname": "SellingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Purchased price per shares", "verboseLabel": "Shares Issued, Price Per Share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Shares, Outstanding, Ending Balance", "periodStartLabel": "Shares, Outstanding, Beginning Balance" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShippingAndHandlingMember": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Packing and transport of product.", "label": "Shipping and Handling [Member]" } } }, "localname": "ShippingAndHandlingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r95", "r110" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r50", "r64", "r65", "r66", "r111", "r112", "r113", "r115", "r121", "r123", "r138", "r185", "r283", "r288", "r343", "r344", "r345", "r372", "r373", "r421", "r435", "r436", "r437", "r438", "r439", "r440", "r458", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative", "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative", "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails", "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails", "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails", "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails", "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity", "http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r111", "r112", "r113", "r138", "r487" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative", "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative", "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative", "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails", "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails", "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails", "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails", "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity", "http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r25", "r26", "r288" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock issued during period acquisitions, shares" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares (or other type of equity) forfeited during the period.", "label": "Number of shares forfeited", "negatedLabel": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity", "http://agapeatp.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": { "auth_ref": [ "r342" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Forfeiture of common stock" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r26", "r33", "r34", "r103", "r180", "r184", "r429", "r470" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Net deficit", "totalLabel": "TOTAL AGAPE CORPORATION STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets", "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r65", "r103", "r111", "r112", "r113", "r115", "r121", "r184", "r185", "r288", "r343", "r344", "r345", "r372", "r373", "r391", "r392", "r411", "r421", "r429", "r435", "r436", "r440", "r458", "r542", "r543" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "TOTAL EQUITY" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets", "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r101", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r288", "r290", "r420" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders equity reverse stock split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r441", "r472" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r441", "r472" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r441", "r472" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r441", "r472" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r471", "r474" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENT" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL CASH FLOWS INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://agapeatp.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Income tax payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TimeDepositLiabilityUninsured": { "auth_ref": [ "r589" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of uninsured time deposit liability. Excludes uninsured time deposit liability in excess of Federal Deposit Insurance Corporation (FDIC) insurance limit or similar state deposit insurance regime in United States of America (US).", "label": "Time deposit uninsured" } } }, "localname": "TimeDepositLiabilityUninsured", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TimeDeposits": { "auth_ref": [ "r508", "r518" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of time deposit liabilities, including certificates of deposit.", "label": "Time Deposits" } } }, "localname": "TimeDeposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r174", "r175", "r176", "r177", "r179", "r182" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "verboseLabel": "Accounts receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradingActivitiesGainLossByTypeTable": { "auth_ref": [ "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Schedule of gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance by statement location, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit).", "label": "Trading Activities, Gain and Losses, by Type, by Income Statement Location [Table]" } } }, "localname": "TradingActivitiesGainLossByTypeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TradingActivityByTypeAxis": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Information by type of trading activity.", "label": "Trading Activity [Axis]" } } }, "localname": "TradingActivityByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TradingActivityByTypeDomain": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit)." } } }, "localname": "TradingActivityByTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradingActivityGainsAndLossesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Trading Activity, Gains and Losses, Net [Line Items]" } } }, "localname": "TradingActivityGainsAndLossesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative", "http://agapeatp.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualRiskOrUncertaintyByNatureAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by nature of risk and uncertainty, for example, but not limited to, threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.", "label": "Unusual Risk or Uncertainty, Nature [Axis]" } } }, "localname": "UnusualRiskOrUncertaintyByNatureAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualRiskOrUncertaintyImpact": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Describes the potential impact of the occurrence of the defined risk or adverse resolution of an uncertainty on the entity's financial statements, including a range of potential loss if reasonably estimable.", "label": "COVID-19 impact description" } } }, "localname": "UnusualRiskOrUncertaintyImpact", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualRiskOrUncertaintyNatureDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Describes the nature of the unusual risk or uncertainty, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost." } } }, "localname": "UnusualRiskOrUncertaintyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r139", "r140", "r141", "r142", "r148", "r149", "r150" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableIncomeInterestRateMember": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Trading in derivative and nonderivative instrument that provides fluctuating return in form of periodic payment of interest based on movement of benchmark rate and return of principal at maturity.", "label": "Variable Income Interest Rate [Member]" } } }, "localname": "VariableIncomeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableInterestEntityDisclosureTextBlock": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.", "label": "VARIABLE INTEREST ENTITY (\u201cVIE\u201d)" } } }, "localname": "VariableInterestEntityDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/VariableInterestEntityVie" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles [Member]" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r125", "r132" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/subtopic&trid=2196772" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "https://asc.fasb.org/topic&trid=2122478" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "c(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121825205&loc=d3e27249-109313" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r385": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r414": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "184", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5634876-113961" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521" }, "r443": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r467": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r474": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.12)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r573": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r574": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r575": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r576": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r577": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r578": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r579": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r580": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r581": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r582": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r583": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r584": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r585": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r586": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r587": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r588": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r589": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(f)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(2)" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r590": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r591": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r592": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r593": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" } }, "version": "2.1" } ZIP 95 0001493152-22-022006-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-022006-xbrl.zip M4$L#!!0 ( "EH"U7OS415"Q8 +3S 1 86%T<"TR,#(R,#8S,"YX MMSVSB2_WQ7=?\#SU=UEZT[Q78RR4PRR6[1$FVSHM>*M&>R7[9@$I)0 MH4@-0,K6_/77X$/B P0IQ;D@1TWMSLA ^CN'QZ-;A#X\+>GE:=M,&4D\#^> M7;Z\.-.P[P0N\1MHUP9[[7AL$3L_T MY\&OVABM\'OM!ON8HC"@OVKWR(MX2G!-/$RU?K!:>SC$D)&T]%Y[\_+RS8/6 MZ[6H]Q[[;D#O9N:NWF48KMG[\_/'Q\>7?K!!CP']PEXZP:I=A5:(PHCM:KMX MNDC_:5=\1)BS*_SN[6C-?GZ:D=\7V/\E&B#_D?V&_MOL/TS?_?GF'[]$^,MR M\]O5GP^?O;>#[9?HXN_WG_K;3^]&EK\RK=%5TN0'YBSQ"FD AL\^GG'Y4O$> M7[\,Z.+\U<7%Y?GOHZ$5TYTEA.^?/.)_$9%?OGOW[CS.S4@KE$\/U,NJ?GW. MLQ\0P[N:(9=(Z(G/0N0[!7HWW!7($[\Y3S(+I$1(^C8A)1FIBTMT##LO%\'F M'#* _M6KC#!BO05"ZQWQ'+&'N-(THT#,:%@EA,0R42_SZ\NLY*Z;D]WA= "K3$*U[PWQ_5?O'W-QZ2'5]@/KP.Z M&N YBCP0X8\(>61.L'NFA8@N<,B[)ULC!S?4EO5QY/L!# 48CVD*3UNO"?1U M2/B7#[Q3O*>!AVU@7.,_8!"*Z^:9Y_T )I(SC;@?SY*?O!:H,Z['Q7/BD[BQ M=+1=:CT^MB(N&/R,BWPX+Q/GJH@8=B?^7^/?:XH9E(NY'T)"6C EJ2GD(,^) MO,/*[%D1%DD3,BT=I;!BP=, ?0R^'[J1U\^_:T8*[M6]20 M[VJ%-C7>:.>'6QZ?_A+Y"\Q,WPH#Y\LR\%RP"HT_(A)NJV#*B.5(OCD&R;0Y MC?A:OL'_TI(F3SCFH4%L>>T%CX(AN,^28_3V*(R@3/F"^8 M[*XB1GS,V!5ROBQH$/EN DTSF1RFG[FI!ML>+V 1Q?#'9':CC\U_Z+8Y&6OZ M>*!=W5GFV+ L[4KO?[J93>[&@TX"8D6K%:+;R=PB"Q^LXXH.,0MM13 MZ-$.P=F :4VIO?[ (IMCF^TZ61H M]DW#ZB1 ]X@2].!ATP\QB!4:H.QP>T]P@DE]MAR&=V48[O69J5\-# M%(++BS($?=VZC2>G^(?Q]SOS7A\""MWL^.G,PF;8P:!1Z..)K@7IGTG-6SZ&Q EH+L)/I\@U^FKLD[-\3WTU,FLJ]/TE.(UVL8F M'TP$ [P.&,EFAYH\N89?ES4\G1E3_?.(SP?Q)#$PIA/+[.CD,*4!;&'#+>B3 M3[AKKMPQ#C-]BS/E"O^IJO#)U)C!"LBUS6?C*5?^_VACP^ZDSL'$@+TF@0E7 M9PR';*=O489MCV],;G_HEF785I?5O $[CO=9TQ\A^@6'?(VSL!-1 M:#@_54NIY "\%#7[NJ\GM?S./![JU:(U%+* M4:EL6XNHC"?CW@F9G2LA7&(Z15NN8;ZN@EU((^P.83M$O!PN+>CDJ%1VK!/[ MUIAIL!AS&)+%&$S*V9TQT(:PAS*'W05EACWN )LB6'[3B '7N4V1SY 3>YP3 M5-H0RF&I[&!GQE"W 8.ISA?M*WVHC_LI//9,'UMZGWM_NHE+O>?Z,"?UJ\JF MU;(G_4^WD^' F%G:62;1=ERE7>67_ MRM>!_F1LSR;#(?>/91Z;3BK<].$GMM'3?AW>)\@5*]C$]BA?R:QP[RG9G6IZ[J>K4B8>85 M /5R)SKV]^YV&8%<[Y6M+'3KD6GO?0=\]H"9PQAWUJUN10\,_Q&!. ;W>64! MCF*B7,N53:QU=V7!TL>M=8-[PSJJV#9!HF,"2^T"3*\J6]OV 2;M1=9&-T,< MC6%7.]Y$M8S1IL1RM(Z*U&HODKJ[B5*[T9*'ZJ 2UU(*N=HK^^>Z$&77,1"&(XL@R$CD* @"Q;5QRVX#(8A3%F>=NFPY )7= MMCB8V77=R^.5Y>F_!:T<%4&(N3'">8*H*8!9!U,#O1RJAF!T;=BSVW UQS4+ MN_6VU'*HJMOU5K'0;B/5(M:9AZH]N1RKRE:]98"TVV#5Q.CR ,E)Y*!4]NAU MP;QNHY +XA67G'*R5-L_57;@^0A?MS4LB2[E-=Y,)D>@LC67AJ*Z#0F_+,&- M/#R9\T 4<0GB'A"^6#,6. 06!38 XMXF5NW/;T#5&0%+MC!'E8?,-;ADXJ123HU=Q +0+ MH:2M:+MFN@GB?A 9+"0K;GG=,3R/O"&HA$WF(M=,S2@\O (YL!7'0GY8@HE@ MCF)S[LXRKN^&8&[#IHGGB/T_'1^K32@)G#\'H2PI+P>Y>HJ@%6BPH7G"D^&U(=!6S.YG/\ ;[4>U2>D!).;#5FU=-O;F;&38RN M.;Z>S$;)A,T/1?'C(W>=7U_WH%P'%).%WX\H36U/OAE..#:>G/@.A)G$/CJX MO!S:BA<+*K2L!4?9Z@9HW)B.6P5KTI^0-:?@NCTV*L]:R(>;NW)I5"]J;AD M#CND.& &+F6M'+8JGZ7*/1^Y84@UB @HY.!7?31Z1ERTR-? =5%:.I-0ADFR*+7[>0Q\.)[_Q MT#3?2FN#R=V5S5U?NZ7J!&LVLH2'!FO'H91:#IW4X2$];]AIK.0Z+RUA;8GE M2%4<&&W0.2UO>P.N;1C@6(?_&ZFOXN36;W=NM\X*;":4@O-6<&!$"LAIY.2W M/K)#NY(=4YMB4 M8REUI[0]S-_IH;G').>+KP=.3"0'2>HIR?OF3VA4+S"K.2W03"?'I.H"J;WX M[#3O588*K$3]ZA<3-4-&3BR'J7J (S=TN+4A_M:BVV-H[^T-5NO 3YY$2;ZU M #VR*SP/*-Y]>U'G*3ZDK!Q$J8ND/QE-)^,XTAR;D_R#CO,7PXEE_46[,OCI MJ]Q7'B=D]^[?#>%/65X'M E)*:T4N9^KUT,6'<7WIL4/P7''_@FDZJE5/,>4 M8A?4G3BPZLZHUM')P9%Z20;&M3&;@5W! 4E<71W')?>Q6=U6JYY CH3TYLF3 M^2"[C;+FC%,K4CDH;6^K/.%3F;B&&#&<^U2P9MZJ(Y/C(OT,9FCHEE'XJ+#; MDY;D>\VZD=.^@!RGBFNAX5//TRA*S\ 7+AVM.^PN)Y(C([@2LWA3Z?]O,/B_ M^&/A,SS7XD?&WX>0__&,$?[,^UF:MJ1X_O$, 3:][.7I?X)H+Y]67D;"JY8\ M,A[#6=9&VG!6!:).I9;*(^A027P6 ,;@><9\5D%(0EY\FFM&X^W 9'O^'")[ MZ.%0D:$(]KZAK$->_[,*";WO4"%+'?8;B=K?M_*L L/0.53@XFC[1O(.=HWD MQ4W?=C_?/^Z>_EU^ /X#"![04/,K+\E7A2(^"_GYM3.-@4&R0L/ B:N2%.%_ M];)R/9[4NWS5>WWY\HFY>TX/86*OAL.8R,H=P41<&\/.RT6P 5#).>\4XO99 M'3G_$7>FMHW.$7N(18A8;X'0NDVCPC+GV M9EG(T"WR8L*_G(:[F("8*<+HA M/>=5\$HO>A>7O5>7]>PTE8S_9D=U@OC0)MT>TA'R1;(_CD.#T? @(#+Z! 3X MZ^AFC^@%U<9KNP#VDC>AX_MB=7OZ3YU;>O C]E_[<3/(NPT\%^SK(5GQ-Z!' M>/6 Z5G,-Y0ZH #Q/!X)_'@6THC/J< U>0]S+0E<.UX2W"C9"Y]IR1(!/2CA M_;T;K!#QS1"O."5H DQ+F(TC3GU#@VC]\2RI#AIP[ M&F0HD"@I1(, :C,_\9L R%,H*8(-]F^3$$4:)<6X#B+:-!;R)"H(<8N1%_)O M37_#GL?O-+(PW1 'LZ(@S60J"&/Q*[2\]-#4-G]I4PF69CH5Q!E]GJ777Y1F M*%&&"@P;L*<-MABS.!SI0MYUY)=,I@8:=<1(SN,Q: YVDM:602&1)#(R%82Y MC5;(GV$&$X^#!WB#O2#^3J6*3"M*%42R(IA[-@&U(,+TA7@=TK M'*(1>GHJ,EM)58%5DY;7V4**"BQ^#B)_<1W05>2A(JO"'!583JP3!_@+EWU$ M^QY&/B/^X@J5;,TVA"H(!/^?C4Q[,O6BDI$IS%&!Y2%90U7L2Y'=2JH*K-YN MD1?!L"..[A 7K/2H9+7("%008!1$C.%KQ"WTI _C4D>74J@@@DW)JMJ[*ZDJ ML I&N!LY8;*]LY=@;:Q)>>_70*."&/&G%B6V2VDJL#F-FS/ Q/@\*^E8E*,4 MR[>?!C4LYW/485G?0$==X!I-"W*58[U&XX)<%5CG#JXHQ%3WWTB,*&95;*35M>=#&2^.%!98%:2KP.XXZ$HE# =BV!"@*, SG_DGP5V(_](%84MTJ' M,!.7]QLR A4$L"G4 TPE.X9RN%.8IP+;_TC)#OQ$=%P=QCGP$*-@B9?V859UD/R[CD(C!](F$F?Y*T"T"6BV^=8"(2/ M&O4#GP4>=0['Y#U>T>DIB1Q1*$N6/I)=W<6\3O!.4%SI?]H:$FLJ]82,.LFF>%KNER['H0VY=4#LXFUBO M'E) :8C!V!%=M-P.Y<;"2@-=8_Y)L6Y11A&X\W9)_*;L5CP[U9*H)$=E"I5) MU()8$=EJ>E.-<*VI%9'.6A)^#MWF!D,!B)7XTS>:,5\?><]3T@VA%\,S2<4II4Y%R.@$;#BT6%"^X.*8_#^@J M;I]?];_!?@1F3(,RCJA!.2VT>A>R21''5:*(+NIL6*',;8D5D>V0=T>:0#ZB M!N6T('Z1H$GREJ44D78,W$_F %9Z!F'7=:OIWWO[";:?@_G.!";0Y+$!N@ZR M%M,MC)3DNPO [2)^T2/EJR!C$?^Z/?ZB8L>_C.*[LP_U.&2-8(X.R:;@S19G M?6^&85G!9.%G]YQD%Y+-H'.D7T!E_+>B/%*<-??[/$.D5[)8SK"#R2:>:OO% MB-W!I50-)*2'%_EN,%H'?G()?PX^8::RSO[X3$%\!S?C+V[P!?(:8W:Y6TWJ M\X^7Z=L&R8!EJ&C*C[.!?;\?6H+TKUCZUDD]S\#O"-;HI;=-V,N8+2>JJNR" M=97;=6]+P[\%G:H#/C<[7=-@53Z%LUMZ6M I&E;>1;0"*UJO/9([52_*452* MU ]N/*VQSS"#LBQG%@CS%)6DW5J9MPV,^1P[!ZZUPO*JSC/[Z U+%M4!B2]< MR)/V(*2T; "V=S5-E^;B13%>B459&+$97X+[X?6)(U&V#F4++.NS]:4W_OG7F1T3'B'Z4URB,B4TB0K4V1 MSY 3^_1CNSNB,&&RQ"[-$PK$.ZBPJM:">-Z\D],S.^A?6R-4 $ M8PW=#R$B[W9%OTI]MK*>E1GF%XT1[@3B?2WPXR>@)U'(IV]NH^UE:R8\=G;A M7]NRYPDV"4()4]A2$;_D.6Y'JNHR)^8>5NJ(7Z8)79 ?!7%(*)=62/_#BAP/ M.!Y]H7@)\PC9X.+@_)H*?BREB%,+GH9C"OY82M!9PUA/"%05*O=XRRP984YW]M\'>-P LTA_OHG=UST$:7;ZX ^(NHRL%]( MTKI G*-*?F]Q4[]J_,!Y>MU^R>5:RE+4>3'$C&&\UW_^ZY?M-#W#.XBP/H>I MX3-&_-OQ3- CRZHZX&+^]_W-QG2UEU24=60?Y)]D/8M#%?0!; UP\E_3GTWN M]I\Q57T8AQ3X_AA].$]>6(.?_PM02P,$% @ *6@+5=FM9O/B&0 ,TX! M !4 !A871P+3(P,C(P-C,P7V-A;"YX;6SM76USXS:2_GY5]Q]XWJJM2=5J M_#*923*3N2U9HCVJR))6E"?)?4G1%&1CAR(=@O)+?OT!)"63(@@T*)* KRZU MF\S80+.['P#]@@;P\S^?UK[U@"*"P^#ST>G;DR,+!5ZXQ,'MYZ-KI]=W!J/1 MD45B-UBZ?AB@ST=!>/3/__[/_[#H/S__5Z]G76#D+S]:P]#KC8)5^,F:N&OT MT;I$ 8K<.(P^65]=?\-^$EY@'T76(%S?^RA&]!?IAS]:[]^>OK^Q>CT W:\H M6(;1]7RTHWL7Q_?DX_'QX^/CVR!\3K)_DF[ M_^SCX-M']J\;ER"+ZBL@'Y\(_GS$OIM]]O'=VS"Z/3X[.3D]_NUJ['AW:.WV M<,#TYJ&C;2]&A=?O]*>??CI.?KMM6FKY=!/YVV^\.]ZRLZ-,?XL%[7.<$/R1 M).R-0\^-$]BEG[$J6["_];;->NQ'O=.SWKO3MT]D>;15?J+!*/31'*TL]E^* MWNZK[JU[C]SXG@%VS'YY/ CI@*2<)MWN(K3Z?.32!I3ZV=G)AWS[W,8M\#%S(Q3$=RC&GNLK,<7MV0R' M;,J@-:5.IJOI/9OF=!R1?K!D4SM"=R@@^ &-0R)5HSJEYB48W+G!+2*CP(E# M[]M=Z"_ILF3_N<'QLPK[ #(M\.Z2NPL_?%12=*E3,WQ-HULWP'\E$%($SS<$ M!XB0<]?[=AN%FV IXQ%,H"$];M9K-WJ>KAQ\&^ 5G29!W/<\^J&8FK]9Z&,/ M([EBE:@TP_E7-\+NC8]&08PB1&*;?BM^_HJ1C%EIQV;X8P.,S6'Z'S8!'ER? M#3SIDB[LU0QG&3)DCCQ$OW#C2U56W:,9CD;! Q4SC !#C=.T&1YF$;IWGY/5 M@0(P1/?6V"8CEKPFY-(4=]JEM,1T2?$&IP M 7P)NC0WFDC,Q!T%5V[T#<5LQ#K(VT0X!@XQ2/_FN9V$06]](,I4 M13/WF7V#C7RZ0D0;M!S3E17[()[A%)KA>(Y\:OV7U".,GS,?D7UV$;D!<;W$ MY9*QK$"B*2]'W1EKU^]BH\L+@YC^A?:\W=I0&5N2;DW-)/I'M'"?(!.FU+0A MJQ_204'E3'WXZ6J.R3>YT1=U:HJO]1K'6SM%/\@<,Q1 G#M UZ9\T1N"_MS0 M#]G,QLN=3F[S+OWB9OWC=OQD:4"Q2%;@@^.2(IDN48 )4(=6RY$*C'%@][9B M QB3LGZ-QPDPMBH[M!DSP%B#]&TU?H"R">C<6BP!15G2L9NX CXDX52ZBS'4 MN8=1ZBK> )HQ13J=Q1XP]I4)M>KUPW@&=6X\ H .YXH.K7O=,/[ !!KRM[P[ MM-SXB#I)U+G&2^PRR\FF"2&AA^G0(T,ZV[$O][:4*77D[69?G;@1"[<>I*G/ MV@2;1L0F,5ZSR7]-T&KCC^FG:*C(,\_*$-4FW8V,'//>D(ARRDU+.,2DY][> M1NB6,<.VX*-U,K9HU(^HK[JI,.54>/XH$FY8GERA09KVZ;^-9#]5! NC:M":3O 9>VD_W*" HG]M05BR8 M5-,R[,I8^KX?/K(HB]JA8;BYB:GOL!VIRN+4H=H\.MQT3@UH('1:S5^IS@5% M,LVO,(=[L5WYJ]7?45AYP"3:6,M%&;9:"[P"P6ZRC75,01UZ;:(S"9L'"$:S MN[SJ(3BITFP:*WFV5!DJ99)-RY1S*NOP+^S>5M6'I>7PVJ+7A]#YB=,J$.9WU)(%0: MSY>A%8HBM*1?2OT(]>R8A$+C.P_J"[ZT:XNU2J"G& 5+M#L+P5B&'J:* M<.PRW82JF?\Q:ML8)_\14@:,SRL;NH$K"$J4?$+1D?R*ACY?, M_[ R2E9*RGIS';B;)::_^6Y[Y&S+OA]Z!99]=N8MW#M MMB&]6]>]/V;8'B,_)MN?)&@G2&<_^"-=6],\_:X6SW=OD)]\\8^LW5ZS8RV\ M\E.G_7A Q^GV^^XD5<8/.5SAEF+ M8\+V#QB9'L5[O>V_BL*U2-696L,ZHN0AH5P<68\(W][%"?=Z("RGBR3\-MN(#SG3NF4<2JV M@N'QO58\>'*9I/=LZZ-P0J&L]V(KF-[?:]4[3RX#]9YM.5'3F.2K@,X-J#,, MI0\FH 31@DG@93L--$*%N:'YEKJ&6[HG-?-9#0C_H"9OG(EZF>%WEE$HC3&Y MZ"8-+LZ&EOWD^1MV3^++"2DMQD>J!0Z%568!&%VN49PFZ2!YHR; MZ>J:I%)48R?I9H;[*04-)+Q):/%V\2!KNZR?&>ZI%"^8^ T"QCG4U5_,_@#L MK0I18404:9CAR%8C5$,D\Z;7=E]D$))8$&+L-3/#>Y5.'JYP)FD_E4/FH)KB MS%4EH^H'!'H\&Z$<9D_77(&$- [EM=6;ILT*/A:1NT3@+"VWD^X)48U#1:96 M(+I)XVN/7<5$+:RW[D6@+G:O)EN;U,RX7OPKCN\&&Q*':Q1MA7Z6@@CKK3O< M 8.HH@R30"P&:G#X9/UTQSU@X& *, JR)#U:7#2$5UIQT(.3T!T>P8%458M) MF.[QG+G73'3G7-'T]TDY!*-I,R7J4(<1O#D/E!/S("44U")"8E%F7YI1T-BE[ ^2^)%DP"#N0E MU?"#.IE+%3 (UG4CLV1*$IF]#E1?A%H>5;RVVLI/THF;L"2I0^4VUCTI!!?0 MEFI,JD0U:1RQ"OPP@,!1;JE[.H.QJ!+2)"#ZRR5F(KO^S,74L W<>QR[@I*+ MR@ZZ,UA@6"0BFX3.G)WP"-#2=J. >HR$AI";]29)FU)?!'M8X'E!^NI.7H$Q M@RO")/AR7*;1?O[EF=2)9._/4-=QNJ+>I# !HD9(=S(+/AGKJ<@DE,NR4K[3 MLJU9&"4JC^,(WVR20H9%R#R\ZDO;(7Y4/?KF^3"'Z&EO',ENZ#=CJ%SA((P2 MP66@EUN:Y_8T"%^58DP"+Q>D]8.E2B0D[ZE[;D)EJXY;7TT(KB)?PV->J)J? MC_'GI^UWA2^\EV+QX%KO/Q7D/5[F*POG['"E?7R M(M'R.=+]*.NE/ M4+" &C )M/PM8?N7VXKVLD2]=&=_H7!!9#<)JYU<+_E+@-7,-S;&$I4EV)]* M'(?'R P 7*3J86F28S8)@[ HDG3]%G316.!;0Q!9/]W31RH2KZ)7WLF@)2Y_ M3I.Q*D]H5_?0O3*HHB63W22<> =HKX,(N3[^"RTO71R(K1.TOV[/3Q5#-;V8 MA&CQZ9[GW!MU6Z[32W"%23$E(KK=1%5L:VC()(!?_)-M<@\'&RKZ2X)Y[Y9C M1.PG&L!0''#@1L\CJDNBNL? M7%RNRRFK?9@,F@X%"0XK3JM!2O<4@N!76T-&S2].,>6VD++9$L7&/V3"O'AP ML9]RF2ODSXJ!SEV"/>BL !#2O::U-%*$LPJL7Y.6SJHBY>J@<_N0?(;F\M^; M-'FTU2]7K6FME"0#VAT;NI?L;H:G%FQ-&MP"-==:^XU>URKK<]H9:J\#YM;< M@-?A&C8Z7!IT&[NM#<[7S^Y>UQ743!>*9]_7*9[-OF+AP,I_Y^_N?4@^6>GG M"O6SW10/LP=<+OSPL:).^$,M42E-*R&JOR"8/7)"V4GJ*ZB&SI^O";O<8)>] M[%,C]R"Y.T"%QO][]9UG*A3Q_;_GL \179\]G&BK&MIB*]UFZ&#<>$*;!$IU M$71_S7RKOR1P0?MKWY8^%$@U19D$L?!B_#SS\FH?94K:=ZP/A;VN\DP: &:5 MGK1WU/U@L ^N1=&78"Y=B 7=7Y-VU'VK8P,F&*0:DV;L[O6V7^D@1,/P46"! M>6UUW_=X,&;5"C ))GU' 7XT%[K7=D: +@L1L^U#E/YW%)3?(!66)P!ZPT#] MR5Q0591DE%TL,SY,S^HF6PR*KP#4(@9,/9R\)O#!.C1\+&S-C#"O)ND&Q-?@ MW!)(+X8C"7M/5M8/B*7!^2:89EX'F-M37\DR4P/4O?Y < W.0:EIRG"0>8\G MJ(#,[P\$V>",DYJF7H:NC,;?N$+12KP2P@!X3GQL@@MDQ/DQ?941K[R4MJ_^=4"_9JA3S1 M\9*.^="]HNC1>[D$7-6Q-/*&$Y.5*?)K#E!F>WM*)BM3M"8;M*BFHDU7>7&G MP4&*W:EPB,E]2%S_,@HW][0'_;N77O&"EB\WO%0OM";PIKN&VX@A;@(0D*G3 M[?G$:73K!ED!/&7\?$-H9$?(N>M]NZ7"!"\WZ1>.Z_U@]2PFI!^2383H7Z;S MR_YD]#_]Q6@ZL?J3H75^[8PFMN-8Y_W!+Y?SZ?5DV.9)0S80H^?IRL&W 5YA MSPWB+.V:G#'VL9=?NPJR_+@OBW-]==6?_VY-+RQG=#D978P&_;O?_OQ[.SDT]>1G?SI]%.;1T"S*;0W<;@RG)[LRS#H.U^2 MP93\P?[7]>AK?TS%:%/O@JK( K.G^\QFP\.QYO; IHQ2W;?()J^^J\#?V3Y_ MH\E7JKKIO-UAFY2SI $96P<1719Q%=[O]EFU9__39U1JW!3 MCX>NSW$AE95_?KS \/=EAJTXG%>.6C<\98_X?UL1>M(I]3 T89EM)[ P3 MJ>3W?7D,+/J3RQ%;%OJ.8R^<]EE]N=^7=S:'S_<'WMAU%DRW](\679Q_L1?) MXN;8@^OY:-'NF,X+,:&^SAHL2,E,%@693">]KH5)=I^RS0$_G*UT"Y]?VT!I3RS,:MRU)/MV3O95&MI?(I%?*5(A2LI5S>]Q? M4+YG?3:7S_OC_F20B;28]R=.?\#G M/WQ*%J+%[RURRR:!Z *. LLE0\E&_6 Z6+?OQF>28RT' MTRO;6O1_:W4,#T(Z:H,X"Q"FJSDFWRI8+%E+JL,!74CFB<_M,&]U/G)^:9?; M]1K'6^.>WG1ZBX)*U_JL9#"I4J]&BQ<+S\8!'0/VI&5OVMG<$/3GAG)N/^0W MJPKI"1;O>4&!)U(M ,BT"X$K Q%13(=%)!V(54YT!.(\ZYD>#GA7A="J8+ ;]KE1H8A_3C!;&1MV,U!*0:*(_9*EYH>* M70UQ401I4BRLED'Q95=" 8(,$62 ME:PZ,,SL0K2*"$XD3LF@5\5QW3Y"8$N.0QY8NAJ,KI(U[]JQ+Z['= 6G9HO] MAN\==8*V3 4K4PU0OGON[6V$;ID:1L$JC-(-?59-1R.- MC61:EU,..=F'(Z?7O[R) D:3B^G\*IT,+%G%4BK7';BFG3J-VB3M@\6Z$3^SY.9;=_&WRAR-O6O+,%#I:B@*UR M!R4K-*UU_ R&$.&2NY-'N#J7T0&8E>D8$'[O2SZ16F*F4P3YU0,P.E2<[)13BD!>!JN6JKVR]*P*47:24-Q+3_UAF:?D M*>\:LA3[Z2Z:AB"T5V4'4X5)Q:-]WP\?66S/N>WN10HYEFID=)=PUX&VCJ+, M>HQAM_+FTNC"1;84TN47V4).O0/#7V9:8@(Y2=TRQUT;O;T+CW+; T(DA%%6 MLE_OYC]L2=&LLIQ5@?6EM^T MUFI7P4S.@6"'HASJ)Q&JK/3-E#"J8DS>39L%JM9;<6V"B=&XU:G 8;?1%3J; M^WL?CB2=([7DH,ZZ73,%"?/P"6$V M"$"1KT%E6./-FFR%SDW_>NZ9D*!N1ZT&T(>*;+3GMGM$2R2>T),0YBS3U)S# M-E7[X_'T5[9%QQ)ZUG!Z?;Y@"=Q=:-UMWK*B)$$HJ3!+*:Q/T)L9V,HZ\UF> MDE^9SST!+^BE[5P_GZVF*!K-5=Q_&*VZ3O MA1LJTLU0+0O !0[HH&?;PDO!F:ORM);UTW7UR#V.TX>0V$NKFQA%3KB*']T( M2:R1O*=N>P1#:O]!.*!"3+)) D%SZRGLY;\ZM'3;F5I UU>:43:E>L45VY,/ MG#(XX7+;O2D15_R*[,J'TC[O?HI>6OZKU\CP!&8/7,O25+)^^MX]2Z&>REH07O=B[R: M^B7"@!;R)@ 0OSWY)?3933&"MSH9$44:NN^N4@>JEI(Z *]\C= T$)HE;K*9 MD:I%2?<-3>I 'J PD^X_ KH>$@>+>]D*U._0Z6U1C)4=+FE-1.%3?4U!\HH+UAW?7EG%FG,RB<(4( M>X'5]2\0X'D%63^M91RJF)73Q "=M.]?O_"Q#M/# ND>>C4XK)NTE]:JC[K0 M@"0S+WFV9=E]9N<>D].#X*G%ZZ/-_6YP6E7KPD#DDM*NY$QELA) P:OJILWK M;@X_L48Z6Q7I^)DANC+'SZ#ED-,?_5%087X-.D[:+_Z&9BY<"[:XW(6L2M6E4&@)=85U:% M$:$[&D;2A3C=QZF+9C4]K4%;-_#*E&FFK\(8#H/T*:>47VKJR#E:A1':W?.HXWUGG-KNS(7<[4/?%W0^8Q6\78002 M]8?R1<#%TNZO(X?=-<$JU[E2:2H.R$3+ED8=,J+BQH5W:46:J#6T9")"&>CLC:VLOZZZR[JH0K3BIE>WE8&RG9: MQ2ITPNGP1EI'X0OB[0]95*O!<'8&) 7R#0 MEE4;LY?A6\.+"L=UW[,*MFYI=YS&BDP7M7@I-)-UFH9^WKQT/-[QX M.2,!IZ!GR8?R-Z'#8_&(_ =T18/@.\%617V*NEUP5;3W[,2AJC3)$X#*\CMR MH\5C>/AHV!'2[<9W- CV%-=^+A#*6'\5HZ@:5D:K'BG=KGQ=8.M+;)Y#*+@8 M&^:,E$H4)5=D=^N2%)\;@DG$>;ZG^/Q0M1 9=NQ?-W1 T)_\+U!+ P04 M" I: M5/)SBFALR "\Y ( %0 &%A=' M,C R,C V,S!?9&5F+GAM;.U] MZW/;.+;G]ZW:_T&;J9KJJ;KNQ$F<1_?TWJ)EVN&-+&DDV3W9+RJ$@B1.*$+# MAVW-7[\ *=FBR . %$F W;HU=\9V /"<\\/CO'#P]_]^6KF=!^P'#O%^>W7^ M\YM7'>S99.9XB]]>W8W/C''7LEYU@A!Y,^02#__VRB.O_OO__N__U:'_]_?_ M(0TW](/OQ+Y^+G\XOOG;,SB7'OL3AYW&8;KX)?7KQ\?'W_VR -Z M)/Z/X&>;K.0&'(M_WO;&]A*OT)GC,;G9^-6N%QLEK]_YY\^?7\?_ MNFN::?GTW7=WWWCW>D?.\\CT7V?AODW_<;^IPAMXC.G!^"6).>L1& M83Q#A!1UP!;LM[-=LS/VI[/SMV?OSG]^"F:O=CC%PO:)BT=XWF'_2X%^_BI: MH#5&X9IA^YK]X^LNH7.74AIW6_IX_MLK1!O0T=^^??/AW1LV]E]2C<+-FL[A MP&%3\%7G=U5#(5A=> MT=&#P7RP9CL"G4>!X@NT3> @>6-PZ)_6-) MW!G=P#@( M+I']8^&3R)N):)0>H"(Y1JL5\C>#^=A9>,Z<+A,O-&R;?BBD)^60N([M8+%@ M"XU2#>7WR'?0=Q=;7HA]'(0F_5:XN7>PB%AAQVKH8Q.,K6'Z/VP!/""733SA MEL[M50UE6V2"$;8Q_<)W5R@RN$ V63^!)3+:=I-30,?;Q&FWAWH !< MX34)'#%>_%Y544;HJ1!NZ ?8G%BSK_5Q*":-VZTJY*A.M7#HC#""@!ZX$G1Q MNE0WFX*0L6MYM\C_@4,V8\?8CGPGE)QB,OVKI[9/O+/5D12+QJCHG*-*E3]$ M&_8--O/I#N%'>-:C.ZOC2M$L/T(U%(^P2T__&=4(P\U61V2?G?C("Y =JUPB MD@L,49664UP9JU?O8K/+)EY(?Z$]%[LS5$26H%M5*XG^B"?H26;!9)I6=.H3 M.BDHGXD./YB/G."'^-#G=:J*KM7*"7?G%/T@4\RP)Z/<272M2A?]'N!_1_1# M)COCQ4IG;O,F]>)J]>-Z]&2A03&)=^"C[9+T,$VB(,= F;%JME3D")?L7I=M M($>DJ%_E=H(<66"'.FT&.=)D^M9J/\B2*=&Y-EM"%F5!QV;L"ODI*3]*KE1FK*WI \Q@J.TYCM(4=^X8%JU?KE:);J7+D%(#N=@0ZU:]UR]$D/4)&^ M92_Q+'(Q59*HI9D[7W@[-]Y;3P_"DX8-7\[#D*"I,.]ZW-^W45BPTD-5S<-S&HOANN2165GT'+HBT?>0Z@Z[F5J8G3*C5H].KCNG!#0R MX]3JORJZ%@H.4_T.<[P6VY2^"G^GP,XC/40=>SG/PU9J@R\P8#/>QC)'09GQ MZD2G3ZH'2&[,YORJQ^!4=,RJL1)[2PM#57C(JGG:4RK+T,_M7E?61V$+4WJ$ MJJ5+9VPWZ^LM+&6I82K7^LAJ3;PD/3AQ#+LD""[QG/CXV5%<7.LK,6H-6M^# MPRZD4(6S/"#8(#:HS[%I5UXJ%IRL8J[.*6Z\VA%OKTC-Z_Q_O>!FUF[ M"V+L2M9%3-:2#N';T7=\-G-6[%H-\5YUMA_:E\?S*(X7OJ9-7V_;O,X=H'ZZ MGS]V-B,KY!0D.MN[ 8KC+YVM\.H[NZ)6B-QTU_II1:Y;C,*X0_UT>20TBI*V MZ]/HG,1S%+EAZ4FYZYZFF?[9\1QVRO3HKRFZ\5.(O1E^O@K%!I2]2QDZ(6N\ MO0E[WCECUV8CML/2'[SE67S[3 M(?/.RX\N\1.,>RR2]S$S^YCP6X#FJ/@>[P+1<'9 J'U:Z:LO,9N&.S^$JLO\;ZV M_KO6S]N4]60E%NQ4:X'.S+EA+RJD-\.JM^ M>W7^YH46:GGCV6^O0C_*8;EA@))Y_N(=,)X(G)GE==':"9$K H3;K89%53DZ8@9 J)1A-6*.,P_/3.1[CK<(1"#EMY_F M[=B:H<.A'#R'U"TAVXY641P(C..9*=LM\><+EY/L$-.\[5HS\(HQ YY+RO#L M$R_GAHH(0EZOZ7O]41/2#P'U7AE06;\$G5UN-(OSIOU8LF'H.]^C.&%B0O)9 MY)E958P__:@&_ *VC)>($C>(PKBT(R67@_9A4_V!RZ48/""5[:SKY+%#@V9XLM-I#V^)7A!SPN5:$+'?&,I_1]G MQ=3=-=7D[HXQ^U>49+E1D0SF$_0$3X)ZOJ?]7*F1;?!@5WJN6T$0X=E5Y+-C M"/L.F<65:^,]CRX''$=CJ"1BSJ@$YIB%!P2'>;E!M9\D8W;B09N)K,J7 M-RY-+I?;T:# MN_Y5C?'A8K5=4ZQ\.F1E?'=[:XR^=0;7G;%UT[>NK:[1GW2,;IDI$^^=7[ZZU\^O7W[ MYM=[RXQ_.O^UQLDE*!2[S\+YFT,6NL;X2SR3XA_,?]Q9]T:/Y%=@),C/Z-Q38$8SPV)^/:*96L3ILB^T/>O!U/F&3ICQVZ*7\U)_&N M-C:[=R-K4NM\+E2O-L5'YG!,\]$?],\:YJ5 '=L4)YFS<3#Y8HXZ=*DRTI.E M2O>^T9UYU>G1 \?JUJV*4XR)^3([!D32O;08,OXTN@9_>Z6H\G(Z(^- M+E-E:F1%,GWM;>9@'$\&W:]?!KTK04:QCCYEZ.K+&7VLE5EQ4-T5RYIBD(KVU)B_'.IL$= *8_7JU9ZCJ;HK8 MS"$YOKLT*1O@3*Z><8J;S#$.66V-K"4;*'F\3_+[S%F];\0U0";'0.*1G3FT MN692$VIM\4+(*88RA_JX^\6\NJ/;%--JJ5EE75E&K)+$:WT\'G0MNE H:]MA M3]?G3M?G8K'I>WTN\,,]<.AO+\#07Z9[59QC7]XM#I=D]J(39/^*,7L!&;A1 M1X<\;D1-+]L=S1QNN4^>23%Y/[UVF']HI^P,.(.E_J%OZUR3RBPG_I4?CN;'5R/Z 4CT'VL7O?-0<-Z_])A^ M;J?HTPQ HO]@9E8-YN,1;,@!Y'S:;GBNZ,BVVWV%R(9E6K"(.761C%I*B ME"8E;?TU2;(N .ER>F@N:"'E#:F*<;EI.W*1SZH(QRG_V_(%D,C!#KI+7$ X MJ"16+'#?\6QGC5S##IV'5!K?H:2S+747,40Q:&2JK?=S:%T/'CWL!TMG/<0^ MR_A""XZG5GH(C4$KQPJHUJNYW5/^(<54/"23)2"7OK0=O/,\^BDL<@J+Y*RQ M4UCD%!8YA45.81&MH3N%19H.BQA,G:$_Q,D^'DK*R'TA+BO!TG-6["(QUY\C MW;\5H9-"W*@*IASAU&]G,"5-O[)@RE&^S:9KW57NV]2SOMV$CCV8&]3T\1;Q M/LXO-@TTUU3!XQ-=M;_H^-J1+Q2R-, ^W3M?_K*?'BNL(%ET(#4%J?FXD.-8 M:DC#:P&\6NJ$]4^!9I-C6$T=\\F.WZ\P%CZ.B>(?=IPNJHHFEUUEI !;H-;7 MJ-4\8:Y#%K>9.0_.+$(N[/L FFIZYL$$-^/#+RKWWYUP&=\(8=-JZ:PG)+G^ MR+.!"P_2O#^#CP$'*SEYJ/9 MT\;/JR-6#I%@!3RCE-D&C<8[+_XPX@1MHN3R4!XN[X+24A-/KV)27VZ8,X/O/I7JK,ZP+(H5*D9/JK,:Y6@0-21RS$M')O5HWD%J:GTV K>^+@>LHQ/XSQ1+O!N9U M4/1Z8)%5EGE+$.)#N]WU.O*I'*DJ2SF\=I[83\+P!MQ'U6MUY;$2\%)Y*/YH MP'H8!9C51[56:Y\\)*$ $6*<3JI>.RL/F8@9"#-U3Y_=XZ5CN^*%E6ZGRC-0 M'ID<^B$P+AH-)HWB6!<80-K[Y];I]FGRP?VJ<6F# 1LG-^SSG>3XG.JM[7*NWEE.5)NU 42'A>/*,$IGG#_''0!;EK M69@JIZ Q-TJ5+>(O%:6"ZAZKC5)=,R%C)HG9H1PR$R/'62'56W6DBD.E=*Q* M/(8VT:HBD(+Q*EF9:1^QXC!RN;E%_R)^UT5!P(]<%1I$ RM7&CU2GDW]O*TP M]2^T-V5Q0_*[MR\V-I0@Y;M-?+&.$RO55%VX[0WJ39DC#$U1AHU*PZ0XN%CQ?, M2K.\.?%7<4;S8#["#]B+!(\"9!\HVS/-KJSQF7%S,S)O8OO,ZE\/1K=)>1SV MKAU[?^U._?L U-R>17:XQ[N$'<;MI-K\RA)7)$,POZLVQI8$7+R<0)Y@M"RN MLZ5YX(^Q_^#8G+A??DL-C".1V(F A68.0SD,2@DTSQZ08E6_6B!Y1./O_R?&U"+7W-)'M(*:W<52_$;B;S% M-;4"(A=QI9EM.'VK^\$%T0Q*M^JS*BEL;%,ZPF47^5T7(ZJ3>HM+Q']>0]AO M^E;W@TR2!1"*J@\V^O^C6VLR&+H1G"<=5S#,-)R^T_UP@V@&+8^JC[>>LZ;$ M!3^XDDTWFK[3_7C+HQ>4:-7'VY<-9R%I . M&A95GX6W) H"?(ULA]HX\7Z%^=LTW&'Z7O>S440[*/6JS\B)[ZR$FW*ZT?2] M[J=?'KV@1*L^ZK:4?L'(#9>3)379UP[GRHYBOA_![33_H?C!*,0""H.X2Z"X[ )[^NQ;3CTW7TBX=*4Z3#$E= M>=+&-?&QL_"ZD>]CSZ9G3UPJ-:E$MRN%.D*A('7C(R]UXWHP,JV;?J=[-QJ9 M_:YECCN3D=$?]Y+T#?.?W2]&_\;LC(R)^@R.*_R=HAR$5).7J_8$=E"SEM+D M"'(UU59-$#@H6EK^^R>#'0:!E&L:Q,#6:@Y$4KS2]V>VW$=_BSC14E$?-F==$ M1&[5.Y!(J%^^7LD)];FAJASF@E)-TPMN*[7(U7C /EI@N0E[V%A5>9\B\LVE M&?3&U2ECN?E[V+CQI)7R,D[3#,FXM,/S^$L3*4-MLV^;[9ELY_"9*3G ]%R1 MB5U,W2_$C83U7<6"X="TG63 XA%WU!V5(EQ('+V-^D*BU0KYF\%\3(EWYH[- M*B78-HF\D)7T)J[#W")R[SA_ROA![FYOC=$WY@896S=]Z]KJ&OU)Q^AV!W?] MB=6_Z0P'/2OVB6CSFO/I$LOI$HM*Q\GI$LOI$LOI$LOI$DO;+K'4$W5LNN)4 MU4%'7DVIC\JLJ?'26:^I>D?I_H*\&1T:OI"QV[ZA+M-S!97XBH;C!=2#)THU M3QL&V/YY01Y>S["3H$-_> &%_C+MX05RDT>O@ .=MLHT:L]9GD<]>(8T(W+! M*W>TB=*7"#D2(P"%]1[*54M4RT.WL-2;O2=*6-+G&-N13PE($O7_$R\Z_IU1 M0;?I>=,%Q:&I2XH2#6[%VFYTTK M-A(B%Q,,BKNT*L,5-UNCEA=$/O)L/-X$U*B7D#C8:WK>M#]>6N@"FD&Y5YV! M_"5:(6^$ Q+Y-K["#]@E<;U4X607=VS^+I^$]&7)AH]693J\\8C\&7MY@9\R M<]"L/2IC/OW@4:O.E$(^OD0!GK&*9%0(*!'FRW/LEYN7-D,4+_68J1?.O!DK M4"Q3Z:^>KZE)W\E']M!NJT^Z.F7_M'\6::G.*YYIS3X$_FVTBSWR[[X=MFN^ M7$$3BYL(.0:5J@_*GFSB-W&XP-1MC&S@,[*1-F0LZ9 M7V28Z5MU;[,5C-R5X L"6=E.SUX]]^BPF]^I74LG[2-GG\ZV;1%8$/%51^^@ ML@%2\19QZ=AMF7ARB:^< M8,T"](,Y9WG)#M$&8,OQ5+4Y!:>&S3'=!>A!'ZV)9WDV67&RP;)MVX" @'A( MU._5E1@/Z"2Y(62V'T8;$W<&+QFX3QL0DF0"0NI"\0W1:\IZE[#Z?7;XNQ,N MNU$0TNGEFT^V&\U8=).N<_J?V00]P1"6&*Q%V);F#@+]@S*7 ';I< OSB5E& MO&2]5+L6095'.(3"1V46V>P!^Z$3R""1;=LB-"#B(40^51S:1$SC)*N5$S"7 M#]N8KS$.\A+ZX^@@T+P- A?3#\G\L[IKU52 3*FA.ZKS/6+L,;?+-F#HLYQO M'[._(G^SW\A8,:,"7C''C=L&L"MD%#280#HSF<^H97C;;GZ@5UG2:V! MP?S.FZ,'XC/WQQB'81)?X/GG2@S7!D"/YP_$7EF@-H^9(?:0&SJ8G;^6%V(? M!Z%0S2LX4,OQ%G(&(JW,L7'K>(0EC>W(O<+T='76X5YZ0A953J<6(2CD D1+ MF7/#\$)GYK@1N_*W3?>CLRTQU/$L,>394V_;M[1,Y'O41@GH 1['!D4J9B7# MMV@&5,@O'"!57;9K=\']>4-*TKQX-;H^\VITW1LCRV"O6UO]B3DRQY..V9]8 MDV^JRW%-?!0[JVR*)F7PALX8M@_W"/->969"=O++]E>S\M/4T5G*Z&.T76Y8 M;%]P256NMS;W5(M!>;"HBTA*^W)?!Y)(6. G,7*Z*$MH+(0)#\X<"6A4&BR7 M5E&"&;>3FFQ#L!XC&BW62:)%N+\O/UFC5]QKD(AR7( 8:%L#?7H]''<^&06 I)M MVTI4 #:T6R;CD-@_EL2E5 3FOR/*)R>\G6G;2F@ -D!%0EE2$ I8-0/V/XS, M!^2R/&PC["+?WU#N[Y$;<8PRJ>ZM!%">,U"=4/?( EXCAZ6Z\(K,[[=J)4(9 M!B @E#FF=TFV0[1AJ@WE+'ZD@_Z9FN.S(@=6T9%:"6@I)B'0R_JW><_%; D+ M1MBE>NELB/QPPT\H%W5K%T[2'$&@*$NN4YY1V2JA M##"I9JV$),L!"(:B&KWYX]!.F\ E+/:,BR./4S7A2$'AT)=,@L07 MZSA9!2>KH")M8\3J3L$J_MX_ MZZNO9WA0K'S']("'_8[@78/FU>JLO$@^:7HHQ$7$J:NJ*RGR)E/S!%*_I2); M17#M8=HFU:1Q#0>8K(1#'CB?&]T>;M&34++[3:9-OP,GEFR&/'#.*M/N_\A) M/=**R/$)/,I",8QF/CRMD+Z>R8@3>JA=X34)G)!W V6OE?;"SA +;O;*4M*> M;>C!?!?5NL3(I^OPBJSH+XZ]8V!"GG^20NKHH;6'MQH.P6-*@X6XR^W:W'D. M>Q4!@BG]VK\2R^.ZIR2H6?["6"\Z[@7;WG7<;?OPXX[([-K M6O[$\&H_WG M;FND/DNSP/WW_I#X/(+W'7X-"'Z;U+NM.,&2.G:;&!>'"QX.PY$Y-*RKCOG/ MH=D?4]Z8A_/*' [&UJ019%[8Z\9O1 >6QZO)R^7T X_3[A>C?T,9M/H=H]<; M_&[TNV;G>C#J7 WN+B?7=[V7I=8HVT.?K#'=(BB<3!>/GUSIXY#+Z$<^I(.A MR78%!B7S4P]OZX(VCB]Y:'D/3DM(2WM[_"#;,CL U VDED&%)L!N-&7_ M(DN)%.-&NXWT.O*I-*F"RBKZ.D_L)_@!]&TGN(^J5)D2B,GQTE#4J0!@/8P" MS"YF6ZNU3QZ2=Z=$B'$Z3=^W#3(1,Z #JN+2N/=XZ=@N/S,PU6:JZ-VRDOM9 MEG9(LA_TTP/CVV0E-(>XW_2\>JWA.*1$!IL,/]J%"0W;CE91[("]PFL?VTY< MY)'^[,:UQ2D?QHKXX?8=;9!'&.:JOM"^"5$MY]JI+2"]?[8-8S(U$ M&+7)4 S?BRIP]G\Z=*?*N% ;=OY;7HB\A<-J/\3UID0N8FZ-5ZL_,?HW%KOV M:(S'YF1\Z!VN,1 #L<''Z$/FXJ: A\;AV>7&6]XM\G]0(N)*\+NBPSRL/F1R MS0\C9>,)FW\L='%KC+Z:D_C"ZMCLWHVL28,1- D&!2AF0IU%N#OEUY_RZW7/ MKP^P_?."/+R>82?!AO[P @G]A1K9"^0FM]:!T !ME6FD:99]'JFU*G1B^2:D M@.Y=VB3=HF%G/$=B!*"P7L]ZU1+5TBM>6.J-NKAO?(R]M4^Z:.V$R.T2?\WU M_(#MFW9J0U.52-):]58!R/=J_.@$@>797*D>M&H\O5Y"F'DD@I.T8B&.36." M[>4]75_,D2V;VTSPX5 M$J^=#_* 8B-DCRU+HY,T;QLL>U1KY]A+YHH5!!&>#7W'QKN'?C@V$=1%>USX ME&OFO*,.GXQ=G0'XC=*2#;A(]N1D*6W## M)<&>\S1T(['UEMM60_<"2*=VVFFZ+B.2ZA/](_V]S"](7& MT!>2+(+VFT7G(K^GHK^GHK^GHK^ MGHK^ZE/TMW5F5ZDRO^TQQ)ZW_(1)=K6*>.R>!_^FKJ";IB>8'/$2X0 5-9B? MR11=U@2:J[EG*R?KO#++ +\ZW:FM A@MCZ"JP=/T-6U*Y8IX\0NLHHM]F:8U MX";EZN O#B)!-'@&_3F*S&OKHBK%2=6>1!V3<71'3$B\=EK?R?VNEX97:3*. M[KCP*0>U!-7).*GW;-FMSLQKP]Q<'&[AN<'DBSGJ#(UO245#=M'.Z'9'=^95 MIV<9EU:OL9M-+_SN56P4\<8M-;=?G%&#?*+]0I03'WD!LK=R$T41Q#U55UP# M* PN-ZE_D2V_5F@X;2(4L@"#E=A*2%'[LFQR//%]/D7&T*!(6QD8#Y^U+BHT MC52\5,%=@6,BKZT:=U$)D<.8Z>LX.@X M7T@0(OJ?C<3$SVT[/==ZEG-H!F5<]9R66&D#CU]QKL@0T_-/.B-2G!40J$_5 M W6)413*+(;HAE46TO7Q!0O!@3 /WDDLHM!.,3TG=;'0'%6 M8-VTWL4@L4/E-I^^:_K2^3%+XH!L4-BE[Y^#Q_#C5_*CNR1T!@C.X,.&T_=: M[SD0P:!"6>.& YTWXK?@BPTR?:^H)FQE)W"&&1"NTE5BY132YU^+:*8'G:87 M6I\!,L1#XK^H>M=/!V+BWYA'9>FL@RL7FAP(L@XZXNR M!(%4L=9WJT!L3!/ MH'FB"LRK"%]3*:1)AM'+;=XVN#A,@(JR)HLMSJ.P9':AFTY_D 5LC;M9)^X)*&I )8'Y[S\6*U!\T@. M(3P_5%Q\$+FL*M]JY00L9LLLQFN35;0(@!:MU?\ASQ 4O^L*&N673EA M+T=A/TCN,\B5I<@^Y3L9=+]^&?2NS-'XKW_Y]/;\XZ_Q$Q1[SWPKKT31)2Z= M;B2AP:"T>(ODJ2RZ3[%Z(L _[V?'9(#/NX!4Y5=49ZI6P(UT&FMUW](FQ[6. M*0?FPU:-E?;)LA,Z]F"^QPH_+Q9HKD$*;.7($1G&]?/R93A'^ AUMA@Y/=2 M]7ANV;5&BG$&KE M[B+\26Z?U'ST5G$U15F@YG0UY70UY70UY:B$M ERXYO6 MXFQ\02]59V'Q3#6(>' )*=O?AG08[/MX%KO!DNON1A0NB>_\Y\6%EO=J+J^? MJDS/$6Q=#= MZ_@G@_B0<^VTT+WB6/);-*?3'QA?$=>@!J0-MJ*=&>CP9\)48D]6EHB4(59J M0^;U^C,A*[L5ETT[JJ (+:4UF7]7D4_)'&+?(;.$^OB_+U& 9ZSH(;4%XW3O MK0^,MZ:/&?4//#V.%@LT?2K. MD]W![7#0-_N3_ZUS:5X/1N;VCYV)\4_51?U.CP&='@.J MZC&@':DWF"Q\M%ZRNDB4G[,/^0,2/&F7=BU!$/F4^@C2K?C(7\3"ROVB60L_4IGB.Q'_Y!3J!CS M$B%?-0ZAH4\>G"!Q;$NY2CZ^X;E*AJ/!O36V!OW.]6"4[Q5IP!]TM8W!4U:, M(, A]\F&C^<\AJ[,:W,T,J]B)HSQV)PH?[;AY.$Y>7A.'IZ3A^?DX=$3B).' MITEGQ-T8=D;M65*G/K.DL^7(^,SUO?V44TZV!X2V8[=%% MOK^A9L8C\F=BD[[X6*I"]]*:4TF6M//@9/BX1VX4VY&&ZY)']B1F 5RSG=L' M),!#U;L>5&3YA9S4&X5K']L.XI0E%7?4%XH"]$MX)Q0OH#WJ^YCCQ1)TU!>M M O2#VI<:7]*^8UVFLM''MX?^EA%^7V>HJHI #47IE;1Q:(/#\^Q+9V(9Y]0D47S.$> M:FH "$0MPD7?6__50:.E(ZA*^!IP!I4.-<1OA]C(_9_(=X*9$V> BZH>"3HJ M>K]2N'ARP@]\)K3;#K?6?'?KOA' E->ZAK56!S@@Z2 DS<8BVA\/*J@XE L0 M56L8GP)$IP"1JAK1<2IJTHF*?(F'3$" MJ=^B)V<5K7AR3S5I/"0'3%;"(0^2[$;MFAOYC);=SDF M$1!;DNZ\8(UM9^[@&=<.A)LK-,ASY4IDB-9C=Z\*!%UW_J.!:K0@[YT7A8[+ MJN!Q[<;#9M-S%=F$PJE-1!2#6KFZU$)S/L M!]I%MF#^RB3:M DF26::";'HE+S;/@REN6K&C7+TJ9AWP;?HX9]36?B]I0?S$=. M\$/R)L>[PYL;7SX3ZJW@ X MH$AP.V6!&X&<"9?J M9IPQ K'WT0H/YBGR>'$"3O/F@S4[CW/# M-(?-%%31$,]JPJ>WZLT'D.B GE/>S'EP9A$UT7:3@"M=7A<5%6D+B5I(/.@@ M*NLA @1_3W5//H!3TV%4_EY-N31R(AT>=6*C)42T@T M32_H.:E'HK2-S"S=:Z#Q5?6JIWN- MA#@/6DW/=5_VN02#0OU0-D %"W6,7!Q<.4'H.]]97H!(O/GMF_>)E1 TCW10 MY!\K%GF?%)(XU'QZ_EES@?,I!^7]6>$+I <^A,O-)?;LY0KY/_A5*<0]-7>, M2/,!6NKZ@+8C6%0-0=Q33<$*:1!$V.4+0J<2%O6!IZ4/IEZ -2UR,<(/V(OP MKEZ]C^SP=R=<"OT[V_Y2W145O)!>T;=T(=AQ&'"= SI7PE#=&F MR#)*-6_^4D(UBRB'"= :>*N18KF9T,\5-@1>.K76!CCD6Z.\V2QK]&.%EH?"53+%/SR8&JJUN^TU0SE0EV#WU$753YG-9&B?&BW M6XZC]=IU2H FZ*B-IBA$38814%NL!+==A9@9=A+(Z \O2-%?ICV\0*[IA7 Q M7-HJTTAS[2*/9-!P:D;."2G@&42;I%LTK!EP)$8 "NL]]JN6J)9'>&&I-YH7 M9;++%71E8OJ_:^3!%4A9Z_S&C7M>H%E*I"@%]PA]#,,AH]P+T0*?%U!E]WI- MW^KB#>L536?.< 'AI?"-FS4)G)!CM.]:M >&-,6@\Z3JQVGBC\;OKP:1#]PO M3EYSR;1L@6RYE$NXXM6\B]O#*&#;YLI)[FEQ7Y!]SWM!MF<:8[/3'=S>6I-; MLY]Z/_:%R8H9V:/<\&;)==X%]FQ']I&6B^S5GA<&C/X5N^HSL?HW9K]KZ?1J MRP@'H1_98>13AIGKFK)/_X;]!YR9H7E1,9G>BHS,Y[F9HC*FT$4AGC%Z16^X M%!I$F^M!14 ]-$R+2TW-[:$",^$R"BC706#8_XZ<( &$ZSX'.R@S;LO 0N1X MJOK8K@4N]J./A8Y:B:YJ_.HBZ8NQRI6 3I[U.F'3TD2O!]I&[7B#*4+CB.Y# M#O%[S@/=4KBF/-A>D;M9H41) M$%STS6O:^ /O)=8,D6 !7%[*CKX[+PHBY#)OV<"_\VS*+:4]W%QN^H@>%8*S M3ZYWBP^_(N+1*/@/D9T0+=HUY7JK.?\* 2*'99Y0=#H!ZP=3YS.P9L ;/06[ M@WOKJD^MJ1!CSUJMD1URCT*P/:5:S8%8: T1:4Y@)Z<&19)9U&7WY/T&7FA M!V69VT6PH[AS3]%*F<(+]%; UYK1L%1I<'JKVI@#2MCS;9R11_+6\TN$N*:;.W MFK?+WL%Y!@ ;0+I_ZY IR)EV^C]WD8_P*C%/XW]DLXZ3RU1TI%9!?12/$.C* MJHZGV1BB39QJ(0OMKGW[ 4QS L&DK+9XFEBZ_5-#B9,=D=N\_2"E&($P4E8U M'#)S$LNEN+&=]&LC:C(<0?#ME0%O-&$N^A[@?T=T"S ?Z'_)Y99]R*3+W5V. MS7_/9%TA9BHZ\'OTIX=/;5 M5P2AIM>@#^@5WZ/-::XHATN\6KC0-)2Z]8>[+BMSUA2Y+%M)-M7ILNSILNP? M[K+LC8^QM_;)\[MD_IH;607;UR#[HZ_,\HD%MV1UVBA[)FQ)7$I&P#*FP@TK M@^<'6.:A-8G.J@K*%;7T)#G1+J!J>0\X>0IN\.CAV25RV>7(\1+YN:&@;3=> MKY8@)F1!.\/O@&(CO$:.SU["Y?A3X#[MA.F0 0GM"7)';O_._NL["C#]R_\' M4$L#!!0 ( "EH"U44.X+9W'L 'NG!@ 5 86%T<"TR,#(R,#8S,%]L M86(N>&UL[+U[/P%2E(O7'M!%.)_^R*, MOOB?_^.__3^(_.]?_]_K:W3GXV#]$[J-5M?C#O^$WN,0QUX:Q3^C MCUZ0T=]$=WZ 8S2,=OL IYA\D'_Q3^C/7[_[\Q.ZOC9H]R,.UU'\.!]7[6[3 M=)_\],TWKZ^O7X?1B_<:Q;\G7Z^BG5F#B]1+LZ1J[=NW;XO_Y>K_&OCA[S_1 M/YZ\!"/RO,+DI[?$_[0)/Y/"8-W M'ZV\E'6[]FN05(+^Z[H4NZ:_NG[WW?7W[[Y^2]9?E ^?/<$X"O <;Q S\Z?T ML"=42GS*A"^*WVUCO!&#">+X&ZK_38B?O12OZ1?]2+_HW5_H%_VA^/6]]X2# M+Q"5)/R0VO5CJZU"Z1O;8&1'8*0^Y]^,5/]> _O*>_-2"B-]2,H'A M=0F2-J$8@=DWL(FA:+MJ/5JUV@WH:![%O.UT9F1M;KSDB36<)=?/GK_*3\+F;HOWUA MJ/--UQ"J/8A+:[QXI7DDA<0WJXA,:/OT.L@??JZ^B:.=,93B^46&"K\%3]7W MY ^=0)$8U!*+<1)E\0KWZO.F57V><(%R%Q MZL3A\/IQ\<7_R$51+8O^3J7_ MXU^_J;_!"<4(HET4+M)H]?L#WCWA6&*T0,XFE:0PF_3AA,!01H:L2Y-<#C%! M]/=GZ(UR,O#LDZ.%'23"9LDU]JP$UBB27!,$H)KTNE4AB5 MTG 8-%BMLET64 =VFFYQ3&?=&&]QF/@O>!RNHAU6CUWF^E;'L;YFM<8T4V4P M;.R+F!OKIL,Q&J1I[#]EJ?<48)1&9-2+B?<%AZH3TNU1F)*'05I]'HTQ^8"]4Z.6.ZXVI!F KL:Q53"SDEEBK!+ M+*:"2AU4*;EU_Y9^2F?^<;CV7_QUY@42OTXB9\MA4\(L/3&AD'.^Z)!U><)D M4;1!M?1E1Y2'^$/T^DOT^W ;1>&S?"01RUD;050PJY%#).2< 3ID708\Q%\3 M642$42Y]MB%"-J=D3XF_]KV8'5)YX6'Y&BEF%(6TO?E$"[F>3:2B,)BAQU+) B<(!-&#*'?-0+5.E!TW<4\24 M'J"IT9<6MADQ#?N,'0UI=[S@(,NI48D"94<7GP%!B(I]-X2(]Z%)2]ZA*\+# M5C@CM3!0LO (31P2JF3?)2&/H8]+TA!WZ))PH!4N224+E"P<0!.7A.BXW069 MQ=$Z6Z73>('C%W\E.]P2B]G: U&!++= 1#+.F:(!UF5(( MD&X'X?I7' 0A3I+B6\4A168JUH830_#5D**1=TZ6'B"[Q,FU&&]*O9) @**. M%EM_O_?#9V+=!P*5-"W>O&:GI(KPA$Z,E8C6D7P6E&K30'G?%&AXB)8J RB M0A<^Y/LT'V9QC,.58C-6(&3O>$\&L#[;ZTHX[V@E+.Y4[],JF?I/[*"] #]HA? M5$1>7W# T'3T@Q_ZNTSL7@L^M]7A0EAEI[<^!-'Q(D3/WAOZNYN M?VZMNT6PJNYN?@BCNP6(N.[.9>#XI7=9'/HI&7*(EW/GO]&?U+DJ5 HVG0(] M\*9?()=V3AUCB%TN50KLU*]4@4.M>S*7X6T4K,>[?1R]L$E-S2VEADUR&4!O MLDLA#H9>>HS\F6*A@9HJ$L+KT*(7@ M$.*.^%(I9HOO<9@6JV^V^$YN#@_>?T;Q,/ 25=K!7BU8G>WZF]::_LS5P9"P M/V9N@F0M%+LQ=1OY?DR"G@Z(-8-8.]#V9Q;1)GWU8MRQW6BW1J/K8N_&R!S1 M3HY2$0Q9^Z"5[O*4RE<<62\?JAZ_^"]1O, !7JFNZPOE+ :GRV$VHM)Y(><\ MT2'CX]!S493+7OR -<3QL_]/O'[P:<+]8$@[(DQC+U5<<#%0LG?(:FI ?XLJ^4,P:910@*Y((9�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